INSERT INTO `questionnaire_part_item` VALUES (23625,183,2082,22,'職業病 (GRI403-10)\n所有員工之職業傷害相關統計 ','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u8077\\u696d\\u75c5\\u6240\\u9020\\u6210\\u7684\\u6b7b\\u4ea1\\u6578\\u91cf\\u8207\\u6bd4\\u7387\\uff1b\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"\\u53ef\\u8a18\\u9304\\u4e4b\\u8077\\u696d\\u75c5\\u7684\\u6848\\u4ef6\\u6578\\u91cf\"},{\"type\":\"1\",\"title\":\"\\u8077\\u696d\\u75c5\\u7684\\u4e3b\\u8981\\u985e\\u578b\"}]}','1',5,1696990330,1696998698,'0'),(23626,183,2082,23,'職業病 (GRI403-10)\n所有非員工但其工作及/或工作場所受組織所管控之工作者相關統計','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u8077\\u696d\\u75c5\\u6240\\u9020\\u6210\\u7684\\u6b7b\\u4ea1\\u6578\\u91cf\\u8207\\u6bd4\\u7387\\uff1b\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\" \\u53ef\\u8a18\\u9304\\u4e4b\\u8077\\u696d\\u75c5\\u7684\\u6848\\u4ef6\\u6578\\u91cf\\uff1b\"},{\"type\":\"1\",\"title\":\"\\u8077\\u696d\\u75c5\\u7684\\u4e3b\\u8981\\u985e\\u578b\\u3002\"}]}','1',4,1696990330,1696998698,'0'),(23627,183,2082,24,'職業病 (GRI403-10)\n造成疾病風險的職業危害，','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u5982\\u4f55\\u6c7a\\u5b9a\\u9019\\u4e9b\\u5371\\u5bb3\\uff1b\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5831\\u5c0e\\u671f\\u9593\\u5167\\uff0c\\u4f55\\u7a2e\\u5371\\u5bb3\\u9020\\u6210\\u6216\\u4fc3\\u6210\\u75be\\u75c5\\u6848\\u4f8b\"},{\"type\":\"1\",\"title\":\"\\u4f7f\\u7528\\u5206\\u7d1a\\u7ba1\\u63a7\\uff0c\\u6d88\\u9664\\u9019\\u4e9b\\u5371\\u5bb3\\u4e26\\u5c07\\u98a8\\u96aa\\u964d\\u81f3\\u6700\\u4f4e\\uff0c\\u6240\\u63a1\\u53d6\\u6216\\u5373\\u5c07\\u63a1\\u53d6\\u7684\\u884c\\u52d5\"}]}','1',3,1696990330,1696998698,'0'),(23628,183,2082,25,'職業病 (GRI403-10)\n此揭露項目是否排除任何工作者，並說明其原因（如有排除），包括所排除工作者之類型。','TextLong','0','',NULL,'[]','1',2,1696990330,1696998698,'0'),(23629,183,2082,26,'職業病 (GRI403-10)\n請說明上述邊賄數據之背景資訊、標準、假設或方法學。','TextLong','0','',NULL,'[]','1',1,1696990330,1696998698,'0'),(23630,184,2083,1,'請提供三個貴公司曾經因為採用外部資源來協助內部研發團隊，且成功獲利的創新案例: \n針對每個案例，請說明具體事實(人事時地物，以及量化指標) 並提供佐證文件 ','DynamicForm','0','以下提供 開放式創新的案例，請從下方選出三個案例:\n1) R&D 研發 -與外部企業夥伴合作\n2) 引進 企業投資資本 \n3) 母公司集團拆分出去的公司(Spin-off)或新創公司(start-up)\n4) 技術授權 Technology licensing\n5) 開放資源 Open source\n6) 供應商 Suppliers\n7) 分散式創造力 Distributed creativity\n8) 其他方式 (請說明) Other approach, please specify',NULL,'{\"cols\":[{\"title\":\"\\u63a1\\u53d6\\u958b\\u653e\\u5275\\u65b0\\u7684\\u7bc4\\u4f8b (\\u8acb\\u8aaa\\u660e)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8acb\\u63d0\\u4f9b\\u4f50\\u8b49\\u6587\\u4ef6\"},{\"type\":\"1\",\"title\":\"\\u589e\\u9032\\u6548\\u76ca (\\u4f8b\\u5982: \\u964d\\u4f4e\\u5468\\u8f49\\u6642\\u9593\\/\\u7e2e\\u77ed\\u4e0a\\u5e02\\u6642\\u9593)\\u3002\\u8acb\\u8aaa\\u660e\\u5f71\\u97ff\\u7a0b\\u5ea6\"},{\"type\":\"1\",\"title\":\"\\u964d\\u4f4e\\u6210\\u672c\\/\\u589e\\u52a0\\u71df\\u6536\\u3002\\u8acb\\u63d0\\u4f9b\\u8aaa\\u660e\\u53ca\\u5c0d\\u7814\\u767c\\u6216\\u6210\\u672c\\/\\u5229\\u6f64\\u4e4b\\u5f71\\u97ff\"},{\"type\":\"1\",\"title\":\"\\u63d0\\u4f9b\\u4e86\\u66f4\\u591a\\u4eba\\u624d\\u8cc7\\u6e90\\u3001\\u6280\\u8853\\u3001\\u5275\\u65b0\\u767c\\u5c55\\u7684\\u7ba1\\u9053\\u3002\\u8acb\\u8aaa\\u660e\\u5176\\u5f71\\u97ff\"},{\"type\":\"1\",\"title\":\"\\u5176\\u4ed6\\u7684\\u5f71\\u97ff\\uff1b\\u8acb\\u63d0\\u4f9b\\u7bc4\\u4f8b\\u8aaa\\u660e\\u8207\\u4f50\\u8b49\\u6587\\u4ef6\"}]}','1',2,1696990340,1696998709,'0'),(23631,184,2083,2,'請提供佐證文件','UploadFile','0','',NULL,'[]','1',1,1696990340,1696998709,'0'),(23632,185,2084,1,'v 請說明本公司相關資訊: \n(1) 本公司法定名稱; (2) 本公司所有權形式(上市公司，僑外資，非上市公司等) (3) 本公司總部位於何處 (4) 本公司營運所在的國家','TextLong','0','GRI 2-1 範例\nOO 股份有限公司 (法定名稱)屬於上市公司(股票代號: OOOO)，資本額OO億元。\n公司總部位於台北市，目前在美國、日本、德國等國家皆設有分公司。',NULL,'[]','1',8,1696990351,1696998721,'0'),(23633,185,2084,2,'v 請說明本報告書報導期間: 例如 2023/1/1-2023/12/31 ','TextItem','0','GRI 2-3 報導期間、頻率及聯絡人(1)',NULL,'[]','1',7,1696990351,1696998721,'0'),(23634,185,2084,3,'v 請說明本次發布之時間: 例如2023年6月份; 並說明永續報導頻率 (上次發行時間與未來預計發行時間)','TextLong','0','GRI 2-3 報導期間、頻率及聯絡人(2)\n',NULL,'[]','1',6,1696990351,1696998721,'0'),(23635,185,2084,4,'V 請說明本報告書參考了以下哪些國內外標準/準則進行編寫? ','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u4e0a\\u5e02\\u6ac3\\u516c\\u53f8\\u7de8\\u88fd\\u8207\\u7533\\u5831\\u6c38\\u7e8c\\u5831\\u544a\\u66f8\\u4f5c\\u696d\\u8fa6\\u6cd5\",\"GRI 2021\",\"SASB\\u884c\\u696d\\u6e96\\u5247\",\"TCFD\",\"\\u806f\\u5408\\u570b\\u76df\\u7d04\",\"\\u5176\\u4ed6(\\u8acb\\u8aaa\\u660e)\"],\"last\":null}','1',5,1696990351,1696998721,'0'),(23636,185,2084,5,'V 本年度是否有資料重編的情況? (例如基準年改變，邊界擴大而重新計算，去年資料發生錯誤等) ','TextLong','0','GRI 2-4 \n請說明本報告書今年度是否有資料重編，可能因為：基準年改變、邊界改變或去年度資料計算錯誤等因素造成，請說明之，並解釋影響。',NULL,'[]','1',4,1696990351,1696998721,'0'),(23637,185,2084,6,'V 請說明今年出版本報告書之特殊意義?','TextLong','0','例如: 擴大邊界(首度納入OO 子公司)；首度納入/採用OO標準等',NULL,'[]','1',3,1696990351,1696998721,'0'),(23638,185,2084,7,'V 請說明本次報告書是否通過第三方機構的查驗或會計師事務所的確信流程? ','TextLong','0','GRI 2-5\n1. 請說明外部保證單位名稱，使用保證類別。\n2. 尋求外部確信單位的作法(高階主管是否參加)。\n3. 確認確認聲明資料、等級、是否有限制？(例如AA1000 Type II 中度保證) \n4. 本公司與外部查驗或確信單位之間的關係？',NULL,'[]','1',2,1696990351,1696998721,'0'),(23639,185,2084,8,'V 本報告書資訊問題的聯絡人','TextLong','0','GRI 2-3 報導期間、頻率及聯絡人 (3) \n如果您對於本報告書的內容有任何指教或建議，歡迎透過以下方式聯絡我們\n負責單位/人：OOOOO\n聯繫電話：OOOOO\nE-mail：OOOO',NULL,'[]','1',1,1696990351,1696998721,'0'),(23640,185,2085,1,'V 報導邊界: 請說明本報告書包含實體 (例如總公司，子公司，分公司，合資企業，關係企業等)','ColumnInput','0','GRI 2-2\n1. 請列出本報告書所包含的所有實體\n2. 本報告書包含之實體，例如公司總部/子公司/分公司/工廠/研發中心等\n3. 請說明本公司之少數不受母公司控制的總部/分公司/子公司之少數股權/所有權',NULL,'{\"rows\":[{\"title\":\"\\u5be6\\u9ad4\\u4e00\"},{\"title\":\"\\u5be6\\u9ad4\\u4e8c\"},{\"title\":\"\\u5be6\\u9ad4\\u4e09\"}],\"cols\":[{\"title\":\"\\u540d\\u7a31(\\u4f8b\\u5982: \\u53f0\\u5317\\u7e3d\\u516c\\u53f8)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u985e\\u578b(\\u4f8b\\u5982: \\u7e3d\\u90e8)\"},{\"type\":\"1\",\"title\":\"\\u6240\\u5728\\u5ee0\\u5740\"}]}','1',2,1696990351,1696998721,'0'),(23641,185,2085,2,'V 請說明本永續報告書與財務報告的邊界是否一致? 如果不同，請說明差異為何? 以及未來計畫何時與財報邊界一致?  ','TextLong','0','GRI 2-2 與財報差異 (註: 國內外趨勢皆傾向 財報與永續報告書邊界一致) ',NULL,'[]','1',1,1696990351,1696998721,'0'),(23642,185,2086,1,'V 經營者的話\n(1) 公司何時開始投入永續發展? 透過甚麼方式? 公司對於永續發展的願景為何? ','TextLong','0','GRI 2-22 \n報導組織最高治理單位或最高階的管理階層與永續發展的關係; 及其投入永續發展的策略之聲明。\n\n永續聲明可包括\n(1) 管理在組織的經濟活動與商業關係中所造成對經濟、環境及人群(包含對其人權)的衝擊的短、中、長期願景與策略；\n(2) 組織的目的、商業策略與商業模式如何預防/達成對經濟、環境與人群的負面/正面衝擊；\n(3) 其對永續發展貢獻的短期與中期策略性排序，包括排序如何與政府間的官方文件一致；\n(4) 影響組織與其對於永續發展貢獻的策略的宏觀趨勢(例如：總體經濟、社會、政治)；\n(5) 於報導期間內，組織對於永續發展貢獻的重要事件、成就或失敗；\n(6) 於報導期間內，與組織的重大主題相關的目標與標的的績效瀏覽；\n(7) 組織在下一年及未來三到五年，與其永續發展貢獻相關的主要挑戰、目標與標的',NULL,'[]','1',4,1696990351,1696998721,'0'),(23643,185,2086,2,'V 經營者的話\n(2) 公司對於2050淨零目標的想法與做法為何? 是否已經有客戶要求我們提出淨零的目標? 公司對於減碳路徑與規劃為何? ','TextLong','0','',NULL,'[]','1',3,1696990351,1696998721,'0'),(23644,185,2086,3,'V 經營者的話\n(3) 2023年公司的永續發展亮點為何，最重要的永續成果為何? ','TextLong','0','',NULL,'[]','1',2,1696990351,1696998721,'0'),(23645,185,2086,4,'V 經營者的話\n(4) 公司未來將如何持續推動永續發展? ','TextLong','0','',NULL,'[]','1',1,1696990351,1696998721,'0'),(23646,186,2087,1,'Please indicate the breakout in R&D investments (% of total R&D spend), duration (months), and success rates (%) for each of the three phases of the healthcare innovation process below','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Pre-clinical Research\"},{\"title\":\"Clinical Research\\/ Pathway to Approval\"},{\"title\":\"Launch\"},{\"title\":\"Total (must equal 100%)\"}],\"cols\":[{\"type\":\"3\",\"title\":\"Share of R&D budget invested (%)\"},{\"type\":\"1\",\"title\":\"Average duration\"},{\"type\":\"3\",\"title\":\"Average success rate (% of products that move to next phase)\"}]}','1',2,1696990363,1696998731,'0'),(23647,186,2087,2,'If the data cannot be aggregated at the company level, indicate which business unit you have chosen to represent in the table above, as well as the revenues generated by that unit (in % of total revenues):','TextLong','0','',NULL,'[]','1',1,1696990363,1696998731,'0'),(23648,186,2088,1,'Please provide us with your R&D spending for the last four fiscal years in the table below: Supporting evidence','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total R&D spending\"},{\"title\":\"Number of R&D positions\"},{\"title\":\"R&D Spending as % of sales\"}],\"cols\":[{\"title\":\"Unit\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"FY 2020   \"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',1,1696990363,1696998731,'0'),(23649,186,2089,1,'Please indicate three approaches you have adopted to profit from or contribute to external knowledge to complement in-house R&D. Please select three different approaches from the provided drop-down menus.','ColumnInput','0','•Example of approach: Please provide an example and attach supporting documents\n•Efficiency gains: Please provide description and impact assessment\n•Cost reduction/ Revenue generation: Please provide a description as well as the quantified impact on R&D costs/benefits\n•Access to human capital, technologies, inventions, etc.: Please provide a description of how this approach.\n•Other impact: Please provide an example and attach supporting documents',NULL,'{\"rows\":[{\"title\":\"Approach 1 \\u2022R&D Collaborations with external business partners \\u2022Corporate Venture Capital \\u2022Spin-offs, start-ups \\u2022Technology licensing \\u2022Open source \\u2022Suppliers \\u2022Other approach, please specify \\u2022Distributed creativity\"},{\"title\":\"Approach 2 \\u2022R&D Collaborations with external business partners \\u2022Corporate Venture Capital \\u2022Spin-offs, start-ups \\u2022Technology licensing \\u2022Open source \\u2022Suppliers \\u2022Other approach, please specify \\u2022Distributed creativity\"},{\"title\":\"Approach 3 \\u2022R&D Collaborations with external business partners \\u2022Corporate Venture Capital \\u2022Spin-offs, start-ups \\u2022Technology licensing \\u2022Open source \\u2022Suppliers \\u2022Other approach, please specify \\u2022Distributed creativity\"}],\"cols\":[{\"title\":\"Example of approach\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Efficiency gains (e.g. reduction of cycle time\\/ time to market, etc.)\"},{\"type\":\"1\",\"title\":\"Cost reduction\\/ Revenue generation\"},{\"type\":\"1\",\"title\":\"Access to human capital, technologies, inventions, etc.\"},{\"type\":\"1\",\"title\":\"Other impact\"}]}','1',2,1696990363,1696998731,'0'),(23650,186,2089,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696990363,1696998731,'0'),(23651,186,2090,1,'Safety of Clinical Trial Participants\nPlease describe company\'s  management process for ensuring quality and patient safety during clinical trials\nHC-BP-210a.1.','TextLong','0','',NULL,'[]','1',3,1696990363,1696998731,'0'),(23652,186,2090,2,'Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) (HC-BP-210a.2.)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\" Clinical trial management\"},{\"title\":\"Pharmacovigilance\"}],\"cols\":[{\"title\":\"Yes (please answer the next question)\",\"type\":\"2\"},{\"type\":\"3\",\"title\":\"Number of incidents resulted in: Voluntary Action Indicated (VAI)\"},{\"type\":\"3\",\"title\":\"Number of incidents resulted in:  Official Action Indicated (OAI)\"},{\"type\":\"1\",\"title\":\"Please provide more details\"}]}','1',2,1696990363,1696998731,'0'),(23653,186,2090,3,'Please provide Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries (HC-BP-210a.3)','TextLong','0','',NULL,'[]','1',1,1696990363,1696998731,'0'),(23654,187,2092,1,'1. 最高決策與治理單位的組織架構 (GRI 2-9, GRI 2-10, GRI 2-11, GRI 2-12, GRI 2-13, GRI 2-14)\n1-1 請說明公司治理架構及組成(GRI 2-9)','TextLong','0','',NULL,'[]','0',21,1696990392,1696998743,'0'),(23655,187,2092,2,'1-2 請說明最高治理單位的提名與遴選(GRI 2-10)\n','TextLong','0','',NULL,'[]','0',20,1696990392,1696998743,'0'),(23656,187,2092,3,'1-3 請說明最高治理單位及其委員會之提名與選選流程，以及最高治理單位成員提名和遴選的準則（包括是否納入以下考量：利害關係人之觀點（含股東）、多元性、獨立性、與組織衝擊相關的能力）','TextLong','0','',NULL,'[]','0',19,1696990392,1696998743,'0'),(23657,187,2092,4,'1-4 最高治理單位的主席，是否亦為高階管理層成員? 如果是，如何避免與減緩利益衝突?','TextLong','0','',NULL,'[]','0',18,1696990392,1696998743,'0'),(23658,187,2092,5,'1-5 最高治理單位於衝擊管理以及永續報導的角色 (GRI2-12, GRI2-13, GRI2-14)\n請說明最高治理單位如何監督公司對於衝擊管理的角色? 以及在永續報導的角色。','TextLong','0','例如: \nOO對於依循GRI 2021年準則，對於各項重大議題進行正向與負向的衝擊評估，並針對負向衝擊進行指標與管理。以環境，社會，人(權)相關的議題管理而言，OO制定了以下重大主題管理指標: \n\n說明指標有哪些?  (例如以重大主題 “法規符合性:而言，管理方針為遵循環保/社會/經濟相關法規，管理指標就是罰款金額；OO2022年報告書揭露的重大主題共有6大項，共計18項管理指標。 \n\nOO管理階層定期向董事會報告指標達成的狀況。並針對重要指標進行預測，確認是否能夠在期限內達成目標。\n\n另外董事會也對於永續揭露的報導內容進行定期的檢視與核准相關專案。',NULL,'[]','0',17,1696990392,1696998743,'0'),(23659,187,2092,6,'2.	董事會多元化與獨立性 (GRI 405-1)\n2-1 董事會組成 （性別、國籍、年齡）','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8077\\u7a31\"},{\"type\":\"1\",\"title\":\"\\u570b\\u7c4d\"},{\"type\":\"2\",\"title\":\"\\u5e74\\u9f61\\uff1a30\\u6b72\\u4ee5\\u4e0b\"},{\"type\":\"2\",\"title\":\"\\u5e74\\u9f61\\uff1a31-50\\u6b72\"},{\"type\":\"2\",\"title\":\"\\u5e74\\u9f61\\uff1a50\\u6b72\\u4ee5\\u4e0a\"},{\"type\":\"1\",\"title\":\"\\u5099\\u8a3b\"}]}','0',16,1696990392,1696998743,'0'),(23660,187,2092,7,'2.	董事會多元化與獨立性 (GRI 405-1)\n2-1 董事會組成 （任期）','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8077\\u7a31\"},{\"type\":\"2\",\"title\":\"\\u8463\\u4e8b\\u4efb\\u671f\\uff1a1-3\\u5e74\"},{\"type\":\"2\",\"title\":\"\\u8463\\u4e8b\\u4efb\\u671f\\uff1a4-6\\u5e74\"},{\"type\":\"2\",\"title\":\"\\u8463\\u4e8b\\u4efb\\u671f\\uff1a7-9\\u5e74\"},{\"type\":\"2\",\"title\":\"\\u662f\\u5426\\u517c\\u4efb\\u9ad8\\u968e\\u4e3b\\u7ba1\\uff1f\"},{\"type\":\"1\",\"title\":\"\\u5982\\u662f\\uff0c\\u8acb\\u63d0\\u4f9b\\u8077\\u7a31\"}]}','0',15,1696990392,1696998743,'0'),(23661,187,2092,8,'2-3 請說明最高治理單位對於多元化與獨立性的管理政策：\n請說明董事會按性別、年齡層、及其他多元化指標劃分，公司治理組織的組成、多元性相關的監督與查核。\n','TextLong','0','範例：本公司積極落實董事會成員多元化與獨立性政策: \n- 所有董事皆有豐富之專業背景及經歷以因應產業營運發展之需求。\n- 因應公司治理要求之董事兼任經理人不宜過高，本公司兼任公司高階主管員工之董事為2名(占比為18%，低於1/3)。\n- 性別組成之多元化，針對女性董事成員目標設定為一席，並於第18屆董事會選任實際達成目標，選任女性董事一名，占比為9%。\n- 董事會成員亦包括3名獨立董事(占比為27%，接近1/3)，確保獨立性。\n',NULL,'[]','0',14,1696990392,1696998743,'0'),(23662,187,2092,9,'2-4 在兼顧董事會成員多元化方面，請問董事組成包含下列哪些考量項目？','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u6027\\u5225\"},{\"title\":\"\\u5e74\\u9f61\"},{\"title\":\"\\u570b\\u7c4d\"},{\"title\":\"\\u5c08\\u696d\\u80cc\\u666f\\/ \\u6280\\u80fd\"},{\"title\":\"\\u5176\\u4ed6\"}],\"cols\":[{\"title\":\"\\u662f\\u5426\\u8003\\u91cf\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"\\u8acb\\u8aaa\\u660e\"}]}','0',13,1696990392,1696998743,'0'),(23663,187,2092,10,'2-5 公司落實董事會多元化與獨立性的情況，請填寫下表','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u696d\\u80cc\\u666f\\/\\u6280\\u80fd\"}]}','0',12,1696990392,1696998743,'0'),(23664,187,2092,11,'3. 董事會績效評估 (GRI 2-18) \n3-1 請說明如何進行績效評估? \n','TextLong','0','例如董事會出席率？\n\n範例：OO依據O年通過之「董事會績效評估辦法」，每年第1季進行整體董事會、個別成員及功能性委員會績效自評並提報董事會，並至少3年由外部機構評估一次。\n',NULL,'[]','0',11,1696990392,1696998743,'0'),(23665,187,2092,12,'4. 董事會進修與群體智識 (GRI 2-17) \n4-1 請說明是否參加進修課程？ 哪些課程和時數？\n','TextLong','0','',NULL,'[]','0',10,1696990392,1696998743,'0'),(23666,187,2092,13,'4-2 請說明公司2023年度進修情形於下表:','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u9032\\u4fee\\u65e5\\u671f\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u4e3b\\u8fa6\\u55ae\\u4f4d\"},{\"type\":\"1\",\"title\":\"\\u8ab2\\u7a0b\\u540d\\u7a31\"},{\"type\":\"3\",\"title\":\"\\u9032\\u4fee\\u6642\\u6578\\uff08\\u5c0f\\u6642\\uff09\"},{\"type\":\"3\",\"title\":\"\\u7576\\u5e74\\u5ea6\\u9032\\u4fee\\u7e3d\\u6642\\u6578\\uff08\\u5c0f\\u6642\\uff09\"}]}','0',9,1696990392,1696998743,'0'),(23667,187,2092,14,'5.	重大主題衝擊評估(今年新增) (GRI 2-12)(GRI 2-16) \n5-1 說明\n- 董事會在「重大主題衝擊評估」擔任監督管理的重要角色和溝通程序\n- 請注意，GRI 2021準則要求先針對重大主題進行正向與負向的衝擊評估。董事會在整體「重大主題衝擊評估」與決策擔任監督管理之責。\n','TextLong','0','例如\n為了管理oo在經濟，環境，社會(人/人權)上的衝擊，董事會授權高階管理層帶領ESG委員會進行多項重大主題的衝擊評估。請分別說明董事會與高階管理層在以下工作的角色為何: \n1.	發展、核准與更新組織的宗旨/價值/願景/策略/政策以及永續相關目標；\n- 由哪個單位提案? 誰決策? 董事會的工作? \n2.	描述最高治理單位在監督「盡職調查」上扮演的角色，以及其他鑑別組織衝擊（對經濟/環境/人群）的程序，包括：最高治理單位是否/如何與利害關係人議合（以展現對這些程序的支持）、如何考量這些程序的結果；\n- 由哪個單位提案? 誰決策? 董事會的工作? \n- 董事會是否/如何與利害關係人議合（以展現對這些程序的支持）、\n- 董事會如何考量這些程序的結果；\n3.	描述最高治理單位在檢視上述程序有效性扮演的角色，以及檢視頻率\n- 董事會多久檢視一次? 如何確保結果? \n',NULL,'[]','0',8,1696990392,1696998743,'0'),(23668,187,2092,15,'*重大主題衝擊評估的流程 (見 永續發展管理) \nStep 1: 蒐集重大主題\nStep 2: 識別正面與負面衝擊 (組織對環境，經濟，社會/人(人權)的影響)\nStep 3: 詢問利害關係人對衝擊的影響程度\nStep 4: 確定重大主題對於營運的影響 (雙重重大性)  \nStep 5: 確定重大主題與排序\n\n5-2在以上流程當中，董事會扮演甚麼角色? ','TextLong','0','',NULL,'[]','0',7,1696990392,1696998743,'0'),(23669,187,2092,16,'*針對重大主題，進行正負向評估(範例如下) – 詳見重大主題評估資料收集表 。','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u91cd\\u5927\\u4e3b\\u984c\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u6b63\\/\\u8ca0\\u5411\\u885d\\u64ca\\u8a55\\u4f30\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\"},{\"type\":\"1\",\"title\":\"\\u7ba1\\u7406\\u65b9\\u91dd\"},{\"type\":\"1\",\"title\":\"\\u7ba1\\u7406\\u6307\\u6a19 (KPI)\"},{\"type\":\"1\",\"title\":\"2021\\u6578\\u503c\"},{\"type\":\"1\",\"title\":\"2022\\u6578\\u503c\"},{\"type\":\"1\",\"title\":\"2023\\u6578\\u503c\"}]}','0',6,1696990392,1696998743,'0'),(23670,187,2092,17,'6. 功能委員會\n6-1 請說明功能委員會的組成和運作情形\n','TextLong','0','參考範例\n❖ 薪酬委員會：OO於董事會下設立「薪酬委員會」，依據「股票上市或於證券商營業處所買賣公司薪資報酬委員會設置及行使職權辦法」(以下簡稱「薪酬委員會職權辦法」)規定，由董事會遴選符合「薪酬委員會職權辦法」第五條及第六條規定之專業、獨立人士以專業客觀之立場，就本公司董事、監察人及經理人之薪酬政策、制度予以規劃、評估並向董事會提出建議案，且本公司最高治理成員(董事及監察人)與高階經理人之績效評估與薪資報酬之政策、制度、標準與結構，均已委由具獨立性及專業性之薪酬委員會定期檢視及評估。依本公司之經營績效及參酌同業標準，來評核最高治理成員與高階經理人的薪酬，供其作為決策參考，以維護利害關係人權益為原則。本公司之薪資報酬委員會委員計3人，分別由許一平、王文聰以及張元龍擔任委員。2021年共召開4次常會，會議中針對董監事酬勞及員工分紅配發、員工調薪及績效獎金案之相關政策、制度、標準與結構、現金增資案進行討論，會後並將議案決議做成議事錄提報董事會。\n❖ 審計委員會：為健全董事會功能及強化管理機制，2017年我們增設審計委員並將委員會之運作及績效評估辦法充分揭露於公開觀測站及公司網站，以備查詢。審計委員會由三位獨立董事組成，任期為三年。審計委員會每季至少召開一次，得視需要隨時召開會議，並請公司相關部門經理人員、內部人員、會計師、法律顧問或其他人員列席，提供相關必要之。委員會主要目的為公司財務報表之允當表達、簽證會計師之選(解)任及獨立性與績效、公司內部控制之有效實施、公司遵循相關法令及規則以及公司存在或潛在風險之管控。此外，對於董事會之議事規範，公司當依照法令召開會議，每季至少召開一次，以審核企業經營績效與討論重要策略議題，會議議題包含經濟(「國際財務報導準則」(IFRS)、投資擴產)、環保(RoHS、GP)及企業社會責任等。',NULL,'[]','0',5,1696990392,1696998743,'0'),(23671,187,2092,18,'7.	政策承諾 (GRI 2-23)(GRI 2-24) \n7-1請說明貴公司是否具有以下政策承諾並公開發布? 請問發布位置/網址?\n','DynamicForm','0','類別範例：\n責任商業行為\n人權政策\n環境政策 \n',NULL,'{\"cols\":[{\"title\":\"\\u985e\\u5225\",\"type\":\"1\"},{\"type\":\"2\",\"title\":\"\\u662f\\u5426\\u5177\\u6709\\uff1f\"},{\"type\":\"1\",\"title\":\"\\u6838\\u51c6\\u627f\\u8afe\\u7684\\u6700\\u9ad8\\u5c64\\u7d1a\"},{\"type\":\"1\",\"title\":\"\\u9069\\u7528\\u6d3b\\u52d5\\u8207\\u7bc4\\u570d\"},{\"type\":\"1\",\"title\":\"\\u5982\\u4f55\\u6e9d\\u901a\"},{\"type\":\"1\",\"title\":\"\\u767c\\u5e03\\u4f4d\\u7f6e\\/\\u7db2\\u5740\"}]}','0',4,1696990392,1696998743,'0'),(23672,187,2092,19,'8. 薪酬政策(GRI2-19, GRI2-20, GRI2-21)\n8-1 說明最高治理單位和高階管理階層的薪酬政策，並說明最高治理單位和高階管理階層的薪酬政策如何與組織的經濟、環境和人群衝擊的目標和績效相關。 (GRI2-19)\n','TextLong','0','',NULL,'[]','0',3,1696990392,1696998743,'0'),(23673,187,2092,20,'8-2 請描述組織設計其薪酬政策與薪酬決定之流程 (GRI2-20)','TextLong','0','',NULL,'[]','0',2,1696990392,1696998743,'0'),(23674,187,2092,21,'8-3 請描述組織年度總薪酬比率 (GRI2-21)','TextLong','0','',NULL,'[]','0',1,1696990392,1696998743,'0'),(23675,187,2093,1,'1.最高決策與治理單位的組織架構 (GRI 2-9) \n','TextLong','0','請提供最高治理單位委員會組織圖\n請描述負責決策和監督管理組織對經濟、環境和人群衝擊的最高治理單位的委員會\n請說明最高治理單位的獨立性、任職期間、承諾性質、組織衝擊的解決能力、性別族群等組成結構、利害關係人代表。',NULL,'[]','1',22,1696990392,1696998743,'0'),(23676,187,2093,2,'2. 董事會的多元化與獨立性\n董事會組成：董事會成員','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8077\\u7a31\"},{\"type\":\"1\",\"title\":\"\\u6027\\u5225\"},{\"type\":\"1\",\"title\":\"\\u570b\\u7c4d\"},{\"type\":\"1\",\"title\":\"\\u5e74\\u9f61\\uff1a31-50\\u6b72\"},{\"type\":\"1\",\"title\":\"\\u5e74\\u9f61\\uff1a51-60\\u6b72\"},{\"type\":\"1\",\"title\":\"\\u5e74\\u9f61\\uff1a61\\u6b72\\u4ee5\\u4e0a\"}]}','1',21,1696990392,1696998743,'0'),(23677,187,2093,3,'3. 董事會的多元化與獨立性\n董事會組成：董事會成員任期','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8077\\u7a31\"},{\"type\":\"1\",\"title\":\"\\u8463\\u4e8b\\u4efb\\u671f \\uff1a1-3\\u5e74\"},{\"type\":\"1\",\"title\":\"\\u8463\\u4e8b\\u4efb\\u671f\\uff1a4-6\\u5e74\"},{\"type\":\"1\",\"title\":\"\\u8463\\u4e8b\\u4efb\\u671f\\uff1a7-9\\u5e74\"},{\"type\":\"1\",\"title\":\"\\u517c\\u4efb\\u9ad8\\u968e\\u7ba1\\u7406\\u66fe\"}]}','1',20,1696990392,1696998743,'0'),(23678,187,2093,4,'4. 請說明最高治理單位對於多元化與獨立性的管理政策','TextLong','0','請說明董事會案性別、年齡、及其他多元化指標劃分、公司治理的組成、多元性相關的監督與查核',NULL,'[]','1',19,1696990392,1696998743,'0'),(23679,187,2093,5,'5. 在兼顧董事會成員多元化方面，請問董事組成有包含哪些考量：','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u6027\\u5225\"},{\"title\":\"\\u5e74\\u9f61\"},{\"title\":\"\\u570b\\u7c4d\"},{\"title\":\"\\u5c08\\u696d\\u80cc\\u666f\\u6280\\u80fd\"},{\"title\":\"\\u5176\\u4ed6\\/\\u8acb\\u8aaa\\u660e\"}],\"cols\":[{\"title\":\"\\u662f\\u5426\\u8003\\u91cf\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8acb\\u8aaa\\u660e\"}]}','1',18,1696990392,1696998743,'0'),(23680,187,2093,6,'6. 公司為落實董事會多元與獨立性，請填寫以下表單','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u696d\\u80cc\\u666f\\/\\u6280\\u80fd\"}]}','1',17,1696990392,1696998743,'0'),(23681,187,2093,7,'7. 請說明最高治理單位的提名與遴選(GRI 2-10)\n','TextLong','0','請提供最高治理單位成員遴選的流程。\n請說明最高治理單位成員遴選的考量(利害關係人觀點/多元性/獨立性/與組織衝擊相關之能力)',NULL,'[]','1',16,1696990392,1696998743,'0'),(23682,187,2093,8,'8. 請說明最高治理單位及其委員會之提名與選選流程，以及最高治理單位成員提名和遴選的準則 (GRI 2-10)','TextLong','0','包括是否納入以下考量：利害關係人之觀點（含股東）、多元性、獨立性、與組織衝擊相關的能力',NULL,'[]','1',15,1696990392,1696998743,'0'),(23683,187,2093,9,'9. 最高治理單位的主席，是否亦為高階管理層成員? (GRI 2-11)','TextLong','0','如果是，如何避免與減緩利益衝突? ',NULL,'[]','1',14,1696990392,1696998743,'0'),(23684,187,2093,10,'10. 最高治理單位於衝擊管理的角色(GRI 2-12)','TextLong','0','請說明最高治理單位於監督組織衝擊管理上的角色\n請說明最高治理單位於監督組織盡職調查的角色與觀點(如何和利害關係人議合/如何考量這些程序的結果)',NULL,'[]','1',13,1696990392,1696998743,'0'),(23685,187,2093,11,'11. 最高治理單位是否委派高階或其他員工負責衝擊事件？。(GRI 2-13)','TextLong','0','請說明衝擊管理單位向最高治理單位回報上述管理衝擊事件的程序與頻率。',NULL,'[]','1',12,1696990392,1696998743,'0'),(23686,187,2093,12,'12. 請描述最高治理單位檢視和核准報導資訊的程序。(GRI 2-14)','TextLong','0','若最高治理單位不具上述檢視和核准職權，請說明原因。',NULL,'[]','1',11,1696990392,1696998743,'0'),(23687,187,2093,13,'13. 請提供最高治理單位避免及減緩利益衝突的流程。(GRI 2-15)','TextLong','0','請提供以下可能利益衝突的說明：於其他董事會任職、與其他利害關係人的交叉持股狀況、控制力股東、利害關係交易及未清餘額。',NULL,'[]','1',10,1696990392,1696998743,'0'),(23688,187,2093,14,'14. 如何向最高治理單位溝通關鍵重大事件(經濟、環境、人群)？(GRI 2-16)','TextLong','0','請說明報導期間向最高治理單位溝通關鍵重大事件的數量與性質。',NULL,'[]','1',9,1696990392,1696998743,'0'),(23689,187,2093,15,'15. 請描述為提升最高治理單位的永續發展的舉措(如群體智識、技能及經驗)。(GRI 2-17)','TextLong','0','',NULL,'[]','1',8,1696990392,1696998743,'0'),(23690,187,2093,16,'16. 請提供最高治理單位監督管理經濟、環境、人群相關衝擊之績效程序。(GRI 2-18)\n','TextLong','0','請描述上述評估程序的獨立性與評估的頻率。\n如何回應上述評估所採取的行動(最高治理單位的組成、組織實務的變化)。',NULL,'[]','1',7,1696990392,1696998743,'0'),(23691,187,2093,17,'17. 請提供最高治理單位和高階管理層的薪資--固定和浮動薪資。(GRI 2-19)','TextLong','0','請提供最高治理單位和高階管理層的薪資--簽約或招聘獎金。\n請提供最高治理單位和高階管理層的薪資--離職金。\n請提供最高治理單位和高階管理層的薪資--索回機制。\n請提供最高治理單位和高階管理層的薪資--退休福利。\n請說明上述薪資和組織永續發展(經濟/社會/人群)目標與績效的關聯性。',NULL,'[]','1',6,1696990392,1696998743,'0'),(23692,187,2093,18,'18. 薪酬決定之流程是否有獨立的最高治理單位成員或委員會監督？(GRI 2-20)','TextLong','0','薪酬決定之流程是否尋求利害關係人(包含股東)的意見？',NULL,'[]','1',5,1696990392,1696998743,'0'),(23693,187,2093,19,'19. 年度總薪酬比率。(GRI2-21)','TextLong','0','請依此公式計算，並說明計算的脈絡資訊以理解數據與如何編彙。','/static/upload/image/5/a7/c7/cef8314f881c3b80cc81ba4ce23e2f2a.png','[]','1',4,1696990392,1696998743,'0'),(23694,187,2093,20,'20. 請提供公司永續發展策略的聲明。(GRI 2-22)','TextLong','0','請說明衝擊/短中長期願景與策略/組織的目的/與政府官方文件一致的策略優化排序/宏觀趨勢/產出--成就或失敗/重大主題的目標與績效/下一階段的挑戰',NULL,'[]','1',3,1696990392,1696998743,'0'),(23695,187,2093,21,'21. 請描述公司的政策承諾--所引用的政府間官方文件。(GRI 2-23)','TextLong','0','公司的政策承諾--是否執行盡職調查？\n公司的政策承諾--是否規定應用預警原則？\n公司的政策承諾--是否尊重人權？\n公司的政策承諾--關於尊重人權，是否承諾涵蓋國際組織認定的人權(如ILO)？\n公司的政策承諾--關於尊重人權，是否承諾特殊族群(如處於風險的弱勢族群)？\n公司的政策承諾是否發布？若已發布請提供連結。\n請提供每個政策承諾核准的層級(是否包括最高層級？)。\n請提供上述政策承諾應用於商業活動與商業關係的程度。\n請描述政策承諾溝通的對象、方法與克服可能障礙的管理。',NULL,'[]','1',2,1696990392,1696998743,'0'),(23696,187,2093,22,'22. 請描述政策承諾的責任分配至不同層級的做法。(GRI 2-24)','TextLong','0','請描述政策承諾整合進組織的策略、營運政策與程序的作法。\n請描述適切地運用商業關係來執行政策承諾的作法。(如供應商管理中置入)\n請描述政策管理相關的培訓內容、對象、頻率、形式、案例、強制與否等。',NULL,'[]','1',1,1696990392,1696998743,'0'),(23697,187,2094,1,'董事會形式：請提供貴公司是屬於一階或是二階董事會\n一階系統：設有董事會的公司','ColumnInput','0','請說明貴公司董事會/監事會中執行董事和非執行董事的人數，並說明在哪裡可以獲得此資訊。此外，請說明貴公司是否為其董事會制定了獨立聲明。關於一級和兩級系統的進一步說明見資料文本\n\n上市公司必須提供公開報告或公司網站的連結。\n非上市公司可能會提供內部檔和/或公共報告或公司網站的連結。',NULL,'{\"rows\":[{\"title\":\"\\u57f7\\u884c\\u8463\\u4e8b\"},{\"title\":\"\\u7368\\u7acb\\u8463\\u4e8b\"},{\"title\":\"\\u975e\\u7368\\u7acb\\u8463\\u4e8b\"},{\"title\":\"\\u8463\\u4e8b\\u6703\\u4eba\\u6578\"}],\"cols\":[{\"title\":\"\\u8463\\u4e8b\\u6703\\u6210\\u54e1\\u4eba\\u6578\",\"type\":\"3\"}]}','1',8,1696990392,1696998743,'0'),(23698,187,2094,2,'\n二階系統：設有監事會的公司','ColumnInput','0','監事會',NULL,'{\"rows\":[{\"title\":\"\\u7368\\u7acb\\u8463\\u4e8b\"},{\"title\":\"\\u975e\\u7368\\u7acb\\u8463\\u4e8b\"},{\"title\":\"\\u54e1\\u5de5\\u4ee3\\u8868 (\\u82e5\\u4e0d\\u9069\\u7528\\u5247\\u4e0d\\u9700\\u586b\\u5beb)\"}],\"cols\":[{\"title\":\"\\u4eba\\u6578\",\"type\":\"3\"}]}','1',7,1696990392,1696998743,'0'),(23699,187,2094,3,'\n二階系統：設有監事會的公司','ColumnInput','0','管理委員會/執行管理層',NULL,'{\"rows\":[{\"title\":\"\\u9ad8\\u968e\\u7ba1\\u7406\\u5c64\"}],\"cols\":[{\"title\":\"\\u4eba\\u6578\",\"type\":\"3\"}]}','1',6,1696990392,1696998743,'0'),(23700,187,2094,4,'\n二階系統：設有監事會的公司','ColumnInput','0','監事會和管理委員會/高階管理層',NULL,'{\"rows\":[{\"title\":\"\\u5169\\u7a2e\\u8463\\u4e8b\\u6703\\u7684\\u7e3d\\u898f\\u6a21\"}],\"cols\":[{\"title\":\"\\u4eba\\u6578\",\"type\":\"3\"}]}','1',5,1696990392,1696998743,'0'),(23701,187,2094,5,'董事會獨立性聲明：\n請說明貴公司是否有董事會的獨立性聲明','Scale','0','',NULL,'{\"rows\":[{\"title\":\"\\u6211\\u5011\\u6709\\u4e00\\u500b\\u7368\\u7acb\\u8072\\u660e\\uff0c\\u8acb\\u5728\\u4e0b\\u65b9\\u8aaa\\u660e\\u8072\\u660e\\u7684\\u5167\\u5bb9\\u4e26\\u63d0\\u4f9b\\u53c3\\u8003\"},{\"title\":\"\\u660e\\u78ba\\u5b9a\\u7fa9\\u8463\\u4e8b\\u6703\\u6210\\u54e1\\u662f\\u7368\\u7acb\\u7684\\uff0c\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\"},{\"title\":\"\\u8463\\u4e8b\\u6703\\u4e2d\\u7368\\u7acb\\u8463\\u4e8b\\u7684\\u8cac\\u4efb\\u76ee\\u6a19\\u3002\\u8acb\\u8aaa\\u660e\\uff1a\\u6211\\u5011\\u6c92\\u6709\\u7b26\\u5408\\u672c\\u554f\\u984c\\u5c0d\\u4e0a\\u5e02\\/\\u975e\\u4e0a\\u5e02\\u516c\\u53f8\\u63ed\\u9732\\u8981\\u6c42\\u7684\\u7368\\u7acb\\u6027\\u8072\\u660e\"}],\"cols\":[{\"title\":\"\\u662f\"},{\"title\":\"\\u5426\"}]}','1',4,1696990392,1696998743,'0'),(23702,187,2094,6,'請具體說明董事會成員獨立性的定義','TextLong','0','',NULL,'[]','1',3,1696990392,1696998743,'0'),(23703,187,2094,7,'上市公司必須提供公開報告或公司網站的連結，請在下方提供網址：','TextItem','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23704,187,2094,8,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23705,187,2095,1,'董監事會是否由非執董和獨董或獨立管理者來領導？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u4e3b\\u5e2d\\u70ba\\u975e\\u57f7\\u8463\\u53ca\\u7368\\u8463\",\"CEO\\u548c\\u8463\\u4e8b\\u9577\\u89d2\\u8272\\u5206\\u958b\\uff0c\\u524dCEO\\/\\u8463\\u4e8b\\u9577(\\u76ee\\u524d\\u64d4\\u4efb\\u975e\\u57f7\\u8463)\\u73fe\\u5728\\u662f\\u4e3b\\u5e2d\",\"CEO\\u548c\\u8463\\u4e8b\\u9577\\u89d2\\u8272\\u5206\\u958b\\uff0c\\u524d\\u4efbCEO\\/\\u8463\\u4e8b\\u9577(\\u73fe\\u4efb\\u8463\\u4e8b\\u9577)\\u4f46\\u53d7\\u547d\\u70ba\\u9996\\u5e2d\\u7368\\u8463\\u3002\\u8acb\\u8a3b\\u660e\\u4e3b\\u5e2d\\u59d3\\u540d\",\"\\u8463\\u4e8b\\u9577\\u548cCEO\\u89d2\\u8272\\u540c\\u4e00\\u4eba\\uff0c\\u4f46\\u53d7\\u547d\\u70ba\\u9996\\u5e2d\\u7368\\u8463\\u3002\\u8acb\\u8a3b\\u660e\\u4e3b\\u5e2d\\u59d3\\u540d\",\"\\u8463\\u4e8b\\u9577\\u548cCEO\\u89d2\\u8272\\u540c\\u4e00\\u4eba\\uff0c\\u4f46\\u53d7\\u547d\\u70ba\\u57f7\\u8463\"],\"last\":null}','1',3,1696990392,1696998743,'0'),(23706,187,2095,2,'董事長和CEO角色是同一人，但受命為首席獨董。請註明主席姓名','TextItem','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23707,187,2095,3,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23708,187,2096,1,'貴公司是否有正式的董事會多元化政策，明確要求在董事會提名過程中考慮性別、種族、民族、原籍裔、國籍或文化背景等多元因素？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\",\"\\u5426\\uff0c\\u6211\\u5011\\u6c92\\u6709\\u7b26\\u5408\\u672c\\u554f\\u984c\\u5c0d\\u4e0a\\u5e02\\u6ac3\\u516c\\u53f8\\u63ed\\u9732\\u8981\\u6c42\\u7684\\u8463\\u4e8b\\u6703\\u591a\\u5143\\u5316\\u653f\\u7b56\"],\"last\":null}','1',2,1696990392,1696998743,'0'),(23709,187,2096,2,'是的，我們的政策具體包括下列：','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u6027\\u5225\",\"\\u7a2e\\u65cf\",\"\\u570b\\u7c4d\"],\"last\":null}','1',1,1696990392,1696998743,'0'),(23710,187,2097,1,'請說明公司董監事會中的女性人數。\n\n','NumberInput','0','若公司為一階董事會結構，請提供女性的執董、非執董和獨董；\n若公司為二階董事會結構，則提供女性的獨董、非執董。(不應包括高階管理層人數和員工)',NULL,'[]','1',2,1696990392,1696998743,'0'),(23711,187,2097,2,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23712,187,2098,1,'公司如何確保董監事會的有效性及股東(長期)利益的一致性？','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u53bb\\u5e74\\u8463\\u4e8b\\u6703\\u51fa\\u5e2d\\u7387\\u767e\\u5206\\u6bd4\"},{\"title\":\"\\u8463\\u4e8b\\u6703\\u6388\\u6b0a\\u6578\\uff1a\\u50c5\\u9069\\u7528\\u65bc\\u975e\\u57f7\\u8463\\u548c\\u7368\\u8463\\uff0c\\u4e0d\\u9069\\u7528\\u65bc\\u57f7\\u8463\\u548c\\u54e1\\u5de5\"},{\"title\":\"\\u8463\\u76e3\\u4e8b\\u6703\\u6210\\u54e1\\u7684\\u7e3e\\u6548\\u8a55\\u4f30\"},{\"title\":\"\\u8463\\u4e8b\\u6703\\u9078\\u8209\\u6d41\\u7a0b\"},{\"title\":\"\\u53bb\\u5e74\\u8463\\u4e8b\\u6703\\u51fa\\u5e2d\\u7387\\u767e\\u5206\\u6bd4\"}],\"cols\":[{\"title\":\"Indicators\\/measures\",\"type\":\"1\"}]}','1',2,1696990392,1696998743,'0'),(23713,187,2098,2,'請提供佐證數據。','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23714,187,2099,1,'董事會成員的平均任期\n','NumberInput','0','請說明公司董監事會成員的平均任期（以年為單位）。如果公司屬一階董事會結構，則此數位包括所有成員（執董、非執董和獨董）。如果公司屬兩級董事會結構，則此數位僅包括獨董和非執董（例如不包括員工代表）。',NULL,'[]','1',2,1696990392,1696998743,'0'),(23715,187,2099,2,'請提供佐證數據','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23716,187,2100,1,'請根據GICS一級行業分類（不包括執行成員和員工代表）說明明公司所在行業具有相關工作經驗的董事會成員人數，並列出董事姓名。\n\n\n','NumberInput','0','具有行業經驗的獨立或非執行成員人數（例如，不包括高管）：',NULL,'[]','1',3,1696990392,1696998743,'0'),(23717,187,2100,2,'請列出上述人數中包括的獨董或非執董：','TextLong','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23718,187,2100,3,'請提供佐證數據','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23719,187,2101,1,'董事會進修與群體智識 (GRI 2-17) \n1. 請說明是否參加進修課程? 哪些課程和時數\n','TextLong','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23720,187,2101,2,'2 請說明公司2023年度董事進修情形於下表單：','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8077\\u7a31\"},{\"type\":\"1\",\"title\":\"\\u9032\\u4fee\\u65e5\\u671f\"},{\"type\":\"1\",\"title\":\"\\u4e3b\\u8fa6\\u55ae\\u4f4d\"},{\"type\":\"1\",\"title\":\"\\u8ab2\\u7a0b\\u540d\\u7a31\"},{\"type\":\"3\",\"title\":\"\\u9032\\u4fee\\u6642\\u6578 (\\u5c0f\\u6642)\"}]}','1',1,1696990392,1696998743,'0'),(23721,187,2102,1,'重大主題衝擊評估(今年新增) (GRI 2-12, GRI 2-16) \na) 董事會在「重大主題衝擊評估」擔任監督管理的重要角色和溝通程序\nb) 請注意，GRI 2021準則要求先針對重大主題進行正向與負向的衝擊評估。董事會在整體「重大主題衝擊評估」與決策擔任監督管理之責。','TextLong','0','例如\n為了管理oo在經濟，環境，社會(人/人權)上的衝擊，董事會授權高階管理層帶領ESG委員會進行多項重大主題的衝擊評估。請分別說明董事會與高階管理層在以下工作的角色為何: \n1. 發展、核准與更新組織的宗旨/價值/願景/策略/政策以及永續相關目標；\n- 由哪個單位提案? 誰決策? 董事會的工作? \n2. 描述最高治理單位在監督「盡職調查」上扮演的角色，以及其他鑑別組織衝擊（對經濟/環境/人群）的程序，包括：最高治理單位是否/如何與利害關係人議合（以展現對這些程序的支持）、如何考量這些程序的結果；\n- 由哪個單位提案? 誰決策? 董事會的工作? \n- 董事會是否/如何與利害關係人議合（以展現對這些程序的支持）、\n- 董事會如何考量這些程序的結果；\n3. 描述最高治理單位在檢視上述程序有效性扮演的角色，以及檢視頻率\n- 董事會多久檢視一次? 如何確保結果? ',NULL,'[]','1',12,1696990392,1696998743,'0'),(23722,187,2102,2,'重大主題衝擊評估的流程 (GRI3-1)','TextLong','0','--> Step 1: 蒐集重大主題\n-->Step 2: 識別正面與負面衝擊 (組織對環境，經濟，社會/人(人權)的影響)\n-->Step 3: 詢問利害關係人對衝擊的影響程度\n-->Step 4: 確定重大主題對於營運的影響 (雙重重大性)  \n-->Step 5: 確定重大主題與排序',NULL,'[]','1',11,1696990392,1696998743,'0'),(23723,187,2102,3,'針對重大主題，進行正負向評估(範例如下) – 詳見重大主題評估資料收集表單','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u91cd\\u5927\\u4e3b\\u984c\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u6b63\\/\\u8ca0\\u5411\\u885d\\u64ca\\u8a55\\u4f30\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\"},{\"type\":\"1\",\"title\":\"\\u7ba1\\u7406\\u65b9\\u91dd\"},{\"type\":\"1\",\"title\":\"\\u7ba1\\u7406\\u6307\\u6a19 (KPI)\"},{\"type\":\"3\",\"title\":\"2022\\u6578\\u503c (NTD)\"},{\"type\":\"3\",\"title\":\"2023\\u6578\\u503c (NTD)\"}]}','1',10,1696990392,1696998743,'0'),(23724,187,2102,4,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',9,1696990392,1696998743,'0'),(23725,187,2102,5,'誠信經營/內線交易防範\n1. 誠信經營與企業倫理  \n1-1 針對重大主題的衝擊評估與管理方針 (GRI3-3)','Scale','0','',NULL,'{\"rows\":[{\"title\":\"a. \\u8acb\\u8aaa\\u660e\\u7d44\\u7e54\\u5c0d\\u65bc\\u7d93\\u6fdf\\u3001\\u74b0\\u5883\\u548c\\u4eba\\u7fa4\\uff08\\u5305\\u542b\\u5176\\u4eba\\u6b0a\\uff09\\u7684\\u5be6\\u969b\\u8207\\u6f5b\\u5728\\u7684\\u3001\\u8ca0\\u9762\\u8207\\u6b63\\u9762\\u7684\\u885d\\u64ca\"},{\"title\":\"b. \\u82e5\\u6d89\\u53ca\\u8ca0\\u9762\\u885d\\u64ca?\\u8aaa\\u660e\\u7d44\\u7e54\\u9020\\u6210\\u8ca0\\u9762\\u5f71\\u97ff\\u7684\\u6d3b\\u52d5(\\u70ba\\u4f55\\u6703\\u767c\\u751f?\\u8a55\\u4f30\\u672a\\u4f86\\u662f\\u5426\\u6703\\u518d\\u767c\\u751f?\\u767c\\u751f\\u6a5f\\u7387?)\"},{\"title\":\"c. \\u63cf\\u8ff0\\u7d44\\u7e54\\u8207\\u91cd\\u5927\\u4e3b\\u984c\\u76f8\\u95dc\\u7684\\u653f\\u7b56\\u6216\\u627f\\u8afe \"},{\"title\":\"d. \\u7ba1\\u7406\\u91cd\\u5927\\u4e3b\\u984c\\u4ee5\\u53ca\\u76f8\\u95dc\\u885d\\u64ca\\u6240\\u63a1\\u53d6\\u4e4b\\u884c\\u52d5(\\u9810\\u9632.\\u6e1b\\u7de9\\u6f5b\\u5728\\u885d\\u64ca\\u53ca\\u7ba1\\u7406\\u5be6\\u969b\\u885d\\u64ca)\"},{\"title\":\"e. \\u8ffd\\u8e64\\u884c\\u52d5\\u6709\\u6548\\u6027\\u7684\\u8aaa\\u660e(\\u6d41\\u7a0b.\\u76ee\\u6a19.\\u6307\\u6a19.\\u5982\\u4f55\\u7d0d\\u5165\\u7d44\\u7e54\\u71df\\u904b\\u653f\\u7b56\\u548c\\u7a0b\\u5e8f)\"},{\"title\":\"f. \\u8207\\u5229\\u5bb3\\u95dc\\u4fc2\\u4eba\\u7684\\u8b70\\u5408\\u5982\\u4f55\\u5f71\\u97ff\\u7d44\\u7e54\\u884c\\u52d5\\u65b9\\u6848; \\u5982\\u4f55\\u8aaa\\u660e\\u884c\\u52d5\\u662f\\u5426\\u6709\\u6548?\"}],\"cols\":[{\"title\":\"\\u7d93\\u6fdf\"},{\"title\":\"\\u74b0\\u5883\"},{\"title\":\"\\u793e\\u6703\"}]}','1',8,1696990392,1696998743,'0'),(23726,187,2102,6,'2.	內線交易與利益衝突防範措施 (GRI2-15)\n2-1 說明最高治理單位如何避免及減緩利益衝突（請描述流程）；並說明是否有向利害關係人揭露利益衝突，至少應包括與以下項目有關的利益衝突：於其他董事會任職、對供應商或其他利害關係人的交叉持股情況、控股股東 (controlling shareholders)、利害關係群體 (related parties) 及其關係、交易和未清餘額 (outstanding balances) ','TextLong','0','',NULL,'[]','1',7,1696990392,1696998743,'0'),(23727,187,2102,7,'3. 補救負面衝擊的程序 (GRI2-25)#若有公司治理相關負面衝擊請提供補救措施與承諾\n3-1 請描述：針對造成或促成的負面衝擊提供（或以合作方式進行）補救措施的承諾；鑑別與處理申訴 (complaints) 的方法（包括已建立或參與的申訴機制）；針對造成/促成的負面衝擊，提供（或合作進行）補救的程序；使用申訴機制的潛在利害關係人如何參與這些機制的設計/檢視/操作和改善；如何追蹤申訴機制和補救程序的有效性，提供有效性的例子（包括利害關係人的意見回饋）','TextLong','0','',NULL,'[]','1',6,1696990392,1696998743,'0'),(23728,187,2102,8,'4.	尋求建議和提出疑慮的機制 (GRI 2-26) \n4-1 描述下列事項的機制：讓個人可尋求關於「責任商業行為政策和實務之實踐」的意見；讓個人可對組織的商業行為 (business conduct) 提出疑慮 (raise concerns)\n','TextLong','0','',NULL,'[]','1',5,1696990392,1696998743,'0'),(23729,187,2102,9,'5. 內部組織及運作\n5-1 請說明內部機制的運作 \n','TextLong','0','',NULL,'[]','1',4,1696990392,1696998743,'0'),(23730,187,2102,10,'6. 反貪腐\n6-1 請說明已進行貪腐風險評估的營運據點 (GRI 205-1)(GRI 205-2) (GRI 205-3)\n','TextLong','0','',NULL,'[]','1',3,1696990392,1696998743,'0'),(23731,187,2102,11,'6. 反貪腐\n6-2 請說明已進行貪腐的政策和程序的溝通及訓練(GRI 205-2) (GRI 205-3)','TextLong','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23732,187,2102,12,'6. 反貪腐\n6-3 請說明已確認的貪腐事件及採取的行動(GRI 205-3)','TextLong','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23733,187,2103,1,'公司CEO和其他執行委員會成員是否持有公司股份？請注意，計算中包含的股票不應被對沖或以其他方式消除持有股票的個人財務風險。\n\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\uff0c\\u516c\\u53f8CEO\\u548c\\u5176\\u4ed6CXO\\u6301\\u6709\\u516c\\u53f8\\u80a1\\u4efd\\u3002\",\"\\u5426\\uff0c\\u516c\\u53f8CEO\\u548c\\u5176\\u4ed6CXO\\u6301\\u6709\\u516c\\u53f8\\u80a1\\u4efd\\u3002\"],\"last\":null}','1',2,1696990392,1696998743,'0'),(23734,187,2103,2,'請填空以下欄位','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"CEO  \\u8acb\\u63d0\\u4f9b\\u4f50\\u8b49\"},{\"title\":\"\\u5176\\u4ed6\\u57f7\\u884c\\u59d4\\u54e1\\u6703\\u6210\\u54e1\\u64c1\\u6709\\u80a1\\u4efd\\u7684\\u5e73\\u5747\\u503c \\u8acb\\u63d0\\u4f9b\\u4f50\\u8b49\"}],\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u57fa\\u672c\\u85aa\\u8cc7\\u7684\\u500d\\u6578\"}]}','1',1,1696990392,1696998743,'0'),(23735,187,2105,1,'公司是否對CEO和執行委員會的其他成員有具體的持股要求？\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\uff0c\\u6709\\u7279\\u5b9a\\u8981\\u6c42\",\"\\u4e0d\\uff0c\\u6c92\\u6709\\u80a1\\u4efd\\u64c1\\u6709\\u6b0a\\u8981\\u6c42\\uff0c\\u6216\\u8005\\u6211\\u5011\\u4e0d\\u6703\\u6309\\u7167\\u9019\\u500b\\u554f\\u984c\\u7684\\u63ed\\u9732\\u8981\\u6c42\\u5c0d\\u6b64\\u9032\\u884c\\u5831\\u544a\\u3002\"],\"last\":null}','1',3,1696990392,1696998743,'0'),(23736,187,2105,2,'如果是，請說明存在哪些級別，並說明持股要求為年薪的倍數。','ChoiceMultiple','0','',NULL,'{\"values\":[\"CEO\\u5fc5\\u9808\\u5efa\\u7acb\\u4e58\\u4ee5\\u5e74\\u57fa\\u672c\\u5de5\\u8cc7\\u7684\\u80a1\\u4efd\\u64c1\\u6709\\u6b0a\",\"\\u9664CEO\\u5916\\uff0c\\u57f7\\u884c\\u59d4\\u54e1\\u6703\\u7684\\u5176\\u4ed6\\u6210\\u54e1\\u5fc5\\u9808\\u5efa\\u7acb\\u4e58\\u4ee5\\u5e74\\u57fa\\u672c\\u5de5\\u8cc7\\u7684\\u80a1\\u4efd\\u64c1\\u6709\\u6b0a\"],\"last\":null}','1',2,1696990392,1696998743,'0'),(23737,187,2105,3,'請提供佐證數據','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23738,187,2106,1,'請說明個別政府機構是否擁有公司總投票權的5%以上，如果是，它們是否存在黃金股。政府擁有5%或更少的投票權無需報告。','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\u7684\\uff0c\\u500b\\u5225\\u653f\\u5e9c\\u6a5f\\u69cb\\u64c1\\u6709\\u8d85\\u904e5%\\u7684\\u6295\\u7968\\u6b0a\\u3002\",\"\\u6c92\\u6709\\uff0c\\u653f\\u5e9c\\u6a5f\\u69cb\\u64c1\\u6709\\u8d85\\u904e\\u7e3d\\u6295\\u7968\\u6b0a\\u76845%\\u3002\\u8acb\\u63d0\\u4f9b\\u516c\\u53f8\\u80a1\\u6b0a\\u7d50\\u69cb\\u7684\\u53ef\\u7528\\u8b49\\u64da\\u3002\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u4e0d\\u6703\\u6309\\u7167\\u6b64\\u554f\\u984c\\u7684\\u62ab\\u9732\\u8981\\u6c42\\u5831\\u544a\\u653f\\u5e9c\\u64c1\\u6709\\u6b0a\\u8cc7\\u8a0a\\u3002\"],\"last\":null}','1',5,1696990392,1696998743,'0'),(23739,187,2106,2,'如果是，請提供政府擁有權的總百分比（擁有5%以上投票權的個別政府機構的百分比之和）','NumberInput','0','',NULL,'[]','1',4,1696990392,1696998743,'0'),(23740,187,2106,3,'如果是，請提供政府擁有權的詳細資訊','TextItem','0','例如計算、成員、組織等，如果有的話',NULL,'[]','1',3,1696990392,1696998743,'0'),(23741,187,2106,4,'政府機構黃金股\n公司是否有政府機構的黃金股？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\uff0c\\u6211\\u5011\\u516c\\u53f8\\u70ba\\u653f\\u5e9c\\u6a5f\\u69cb\\u63d0\\u4f9b\\u9ec3\\u91d1\\u80a1\\u3002\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u4e0d\\u6703\\u6309\\u7167\\u6b64\\u554f\\u984c\\u7684\\u62ab\\u9732\\u8981\\u6c42\\u5831\\u544a\\u653f\\u5e9c\\u64c1\\u6709\\u6b0a\\u8cc7\\u8a0a\\u3002\"],\"last\":null}','1',2,1696990392,1696998743,'0'),(23742,187,2106,5,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23743,187,2107,1,'1. 針對重大主題的衝擊評估與管理方針 (GRI 3-3)','Scale','0','',NULL,'{\"rows\":[{\"title\":\"\\u8acb\\u8aaa\\u660e\\u7d44\\u7e54\\u5c0d\\u65bc\\u7d93\\u6fdf\\u3001\\u74b0\\u5883\\u548c\\u4eba\\u7fa4\\uff08\\u5305\\u542b\\u5176\\u4eba\\u6b0a\\uff09\\u7684\\u5be6\\u969b\\u8207\\u6f5b\\u5728\\u7684\\u3001\\u8ca0\\u9762\\u8207\\u6b63\\u9762\\u7684\\u885d\\u64ca\"},{\"title\":\"\\u82e5\\u6d89\\u53ca\\u8ca0\\u9762\\u885d\\u64ca?\\u8aaa\\u660e\\u7d44\\u7e54\\u9020\\u6210\\u8ca0\\u9762\\u5f71\\u97ff\\u7684\\u6d3b\\u52d5(\\u70ba\\u4f55\\u6703\\u767c\\u751f?\\u8a55\\u4f30\\u672a\\u4f86\\u662f\\u5426\\u6703\\u518d\\u767c\\u751f?\\u767c\\u751f\\u6a5f\\u7387?)\"},{\"title\":\"\\u63cf\\u8ff0\\u7d44\\u7e54\\u8207\\u91cd\\u5927\\u4e3b\\u984c\\u76f8\\u95dc\\u7684\\u653f\\u7b56\\u6216\\u627f\\u8afe \"},{\"title\":\"\\u7ba1\\u7406\\u91cd\\u5927\\u4e3b\\u984c\\u4ee5\\u53ca\\u76f8\\u95dc\\u885d\\u64ca\\u6240\\u63a1\\u53d6\\u4e4b\\u884c\\u52d5(\\u9810\\u9632.\\u6e1b\\u7de9\\u6f5b\\u5728\\u885d\\u64ca\\u53ca\\u7ba1\\u7406\\u5be6\\u969b\\u885d\\u64ca)\"},{\"title\":\"\\u8ffd\\u8e64\\u884c\\u52d5\\u6709\\u6548\\u6027\\u7684\\u8aaa\\u660e(\\u6d41\\u7a0b.\\u76ee\\u6a19.\\u6307\\u6a19.\\u5982\\u4f55\\u7d0d\\u5165\\u7d44\\u7e54\\u71df\\u904b\\u653f\\u7b56\\u548c\\u7a0b\\u5e8f)\"},{\"title\":\"\\u8207\\u5229\\u5bb3\\u95dc\\u4fc2\\u4eba\\u7684\\u8b70\\u5408\\u5982\\u4f55\\u5f71\\u97ff\\u7d44\\u7e54\\u884c\\u52d5\\u65b9\\u6848; \\u5982\\u4f55\\u8aaa\\u660e\\u884c\\u52d5\\u662f\\u5426\\u6709\\u6548?\"}],\"cols\":[{\"title\":\"\\u7d93\\u6fdf\"},{\"title\":\"\\u74b0\\u5883\"},{\"title\":\"\\u793e\\u6703\"}]}','1',4,1696990392,1696998743,'0'),(23744,187,2107,2,'2.請說明公司風險管理的流程 ','TextLong','0','',NULL,'[]','1',3,1696990392,1696998743,'0'),(23745,187,2107,3,'3. 請說明公司風險處理的原則 ','TextLong','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23746,187,2107,4,'4. 請說明公司ESG風險的評估結果  ','TextLong','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23747,187,2108,1,'請說明哪些人、部門和委員會在風險偏好、容忍度、監測、報告方面負責和負責企業風險管理。請說明適用於非執行董事的專業知識和培訓，以及風險管理職能的公司結構。\n\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u5728\\u71df\\u904b\\u9762\\u8ca0\\u6709\\u5c08\\u9580\\u98a8\\u96aa\\u7ba1\\u7406\\u8cac\\u4efb\\u7684\\u6700\\u9ad8\\u7d1a\\u5225\\u4eba\\u54e1\\uff08\\u975eCEO\\uff09\"},{\"title\":\"\\u8ca0\\u8cac\\u76e3\\u63a7\\u548c\\u5be9\\u8a08\\u904b\\u71df\\u5c64\\u9762\\u98a8\\u96aa\\u7ba1\\u7406\\u7e3e\\u6548\\u7684\\u6700\\u9ad8\\u7d1a\\u5225\\u4eba\\u54e1\\uff08\\u975eCEO\\uff09\"}],\"cols\":[{\"title\":\"\\u8acb\\u8aaa\\u660e\\u59d3\\u540d\\u8207\\u8077\\u7a31\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u532f\\u5831\\u5c64\\u7d1a\\uff1a\\u8acb\\u8aaa\\u660e\\u532f\\u5831\\u81f3\\u8ab0\\u6216\\u54ea\\u500b\\u59d4\\u54e1\\u6703\"}]}','1',1,1696990392,1696998743,'0'),(23748,187,2109,1,'公司採取哪些策略來促進整個組織的高效風險文化？請在下面說明相關選項，說明提示的位置並提供支持佐證。\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u5305\\u542b\\u98a8\\u96aa\\u7ba1\\u7406\\u6307\\u6a19\\u7684\\u8ca1\\u52d9\\u6fc0\\u52f5\\u63aa\\u65bd\\uff0c\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\\u6fc0\\u52f5\\u63aa\\u65bd\\u548c\\u6307\\u6a19\\uff0c\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\u3002\",\"\\u5728\\u6574\\u500b\\u7d44\\u7e54\\u5167\\u9032\\u884c\\u6709\\u95dc\\u98a8\\u96aa\\u7ba1\\u7406\\u539f\\u5247\\u7684\\u91cd\\u9ede\\u57f9\\u8a13\\u3002\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\u3002\",\"\\u5c07\\u98a8\\u96aa\\u7ba1\\u7406\\u6a19\\u6e96\\u7d0d\\u5165\\u54e1\\u5de5\\u8a55\\u4f30\\u7684\\u4eba\\u529b\\u8cc7\\u6e90\\u5be9\\u67e5\\u6d41\\u7a0b\\u3002\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\u3002\",\"\\u5141\\u8a31\\u54e1\\u5de5\\u500b\\u4eba\\u4e3b\\u52d5\\u8b58\\u5225\\u548c\\u5831\\u544a\\u6574\\u500b\\u7d44\\u7e54\\u7684\\u6f5b\\u5728\\u98a8\\u96aa\\u7684\\u63aa\\u65bd\\uff0c\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u4f50\\u8b49\\u3002\",\"\\u5c07\\u98a8\\u96aa\\u6a19\\u6e96\\u7d0d\\u5165\\u7522\\u54c1\\u958b\\u767c\\u6216\\u5be9\\u6279\\u6d41\\u7a0b\\u3002\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\u3002\",\"\\u8861\\u91cf\\u6216\\u5275\\u65b0\\u6709\\u6548\\u98a8\\u96aa\\u6587\\u5316\\u7684\\u5176\\u4ed6\\u65b9\\u6cd5\\u3002\\u8acb\\u5177\\u9ad4\\u8aaa\\u660e\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u4f50\\u8b49\\u3002\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u6c92\\u6709\\u4efb\\u4f55\\u7b56\\u7565\\u4f86\\u4fc3\\u9032\\u548c\\u52a0\\u5f37\\u6709\\u6548\\u7684\\u98a8\\u96aa\\u6587\\u5316\"],\"last\":null}','1',3,1696990392,1696998743,'0'),(23749,187,2109,2,'包含風險管理指標的財務激勵措施，請具體說明激勵措施和指標，並提供支持佐證。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u5c0d\\u65bc\\u9ad8\\u7d1a\\u7ba1\\u7406\\u4eba\\u54e1\\uff0c\\u8acb\\u8aaa\\u660e\\u6fc0\\u52f5\\u63aa\\u65bd\\u548c\\u6307\\u6a19\"},{\"title\":\"\\u5c0d\\u65bc\\u76f4\\u7dda\\u7d93\\u7406\\uff0c\\u8acb\\u8aaa\\u660e\\u6fc0\\u52f5\\u63aa\\u65bd\\u548c\\u6307\\u6a19\"}],\"cols\":[{\"title\":\"Incentives\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Metrics\"}]}','1',2,1696990392,1696998743,'0'),(23750,187,2109,3,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23751,187,2110,1,'請說明對政治運動、政治組織、遊說者或遊說組織、行業協會和其他免稅團體的年度捐款和支出總額。','ChoiceOne','0','',NULL,'{\"values\":[\"\\u6211\\u5011\\u80fd\\u9010\\u689d\\u5217\\u51fa\\u9019\\u4e9b\\u91d1\\u984d\",\"\\u6211\\u5011\\u53ea\\u80fd\\u5831\\u544a\\u7e3d\\u652f\\u51fa\\u91d1\\u984d\",\"\\u6211\\u5011\\u6c92\\u6709\\u70ba\\u653f\\u6cbb\\u904b\\u52d5\\u3001\\u653f\\u6cbb\\u7d44\\u7e54\\u3001\\u904a\\u8aaa\\u8005\\u6216\\u904a\\u8aaa\\u7d44\\u7e54\\u3001\\u884c\\u696d\\u5354\\u6703\\u548c\\u5176\\u4ed6\\u514d\\u7a05\\u5718\\u9ad4\\u63d0\\u4f9b\\u4efb\\u4f55\\u6350\\u6b3e\\u548c\\u652f\\u51fa\\u3002\",\"\\u6211\\u5011\\u4e0d\\u6703\\u51fa\\u65bc\\u653f\\u6cbb\\u548c\\u76f8\\u95dc\\u76ee\\u7684\\u4f86\\u8ddf\\u9032\\u5e74\\u5ea6\\u6350\\u6b3e\\u548c\\u5176\\u4ed6\\u652f\\u51fa\\u3002\"],\"last\":null}','1',5,1696990392,1696998743,'0'),(23752,187,2110,2,'我們能夠逐項列出這些金額。\n若尚未奉獻在任何專案上，請輸入 0。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u904a\\u8aaa\\u3001\\u5229\\u76ca\\u4ee3\\u8868\\u6216\\u985e\\u4f3c\\u7684\"},{\"title\":\"\\u5730\\u65b9\\u3001\\u5340\\u57df\\u6216\\u570b\\u5bb6\\u653f\\u6cbb\\u904b\\u52d5\\/\\u7d44\\u7e54\\/\\u5019\\u9078\\u4eba\"},{\"title\":\"\\u884c\\u696d\\u5354\\u6703\\u6216\\u514d\\u7a05\\u5718\\u9ad4\\uff08\\u5982\\u667a\\u5eab\\uff09\"},{\"title\":\"\\u5176\\u4ed6\\uff08\\u5982\\u8207\\u6295\\u7968\\u63aa\\u65bd\\u6216\\u516c\\u6295\\u6709\\u95dc\\u7684\\u652f\\u51fa\\uff09\"},{\"title\":\"\\u6350\\u6b3e\\u7e3d\\u984d\\u548c\\u5176\\u4ed6\\u652f\\u51fa\"},{\"title\":\"\\u8cc7\\u6599\\u8986\\u84cb\\u7387\\uff08\\u5206\\u6bcd\\u767e\\u5206\\u6bd4\\uff0c\\u8868\\u793a\\u5831\\u544a\\u6578\\u64da\\u7684\\u7d44\\u7e54\\u7bc4\\u570d\\uff09\"}],\"cols\":[{\"title\":\"\\u91d1\\u984d\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023 YTD\"}]}','1',4,1696990392,1696998743,'0'),(23753,187,2110,3,'只能報告總支出數位。\n請說明總支出數位中包含的專案。如果專案未包括在內，請選擇“不包括”。如果沒有為特定類別做出任何貢獻，請選擇“無貢獻”。','Scale','0','',NULL,'{\"rows\":[{\"title\":\"\\u904a\\u8aaa\\u3001\\u5229\\u76ca\\u4ee3\\u8868\\u6216\\u985e\\u4f3c\\u7684\"},{\"title\":\"\\u5730\\u65b9\\u3001\\u5340\\u57df\\u6216\\u570b\\u5bb6\\u653f\\u6cbb\\u904b\\u52d5\\/\\u7d44\\u7e54\\/\\u5019\\u9078\\u4eba\"},{\"title\":\"\\u884c\\u696d\\u5354\\u6703\\u6216\\u514d\\u7a05\\u5718\\u9ad4\\uff08\\u5982\\u667a\\u5eab\\uff09\"}],\"cols\":[{\"title\":\"\\u5305\\u542b\"},{\"title\":\"\\u672a\\u5305\\u542b\"},{\"title\":\"\\u6c92\\u6709\\u6350\\u737b\"}]}','1',3,1696990392,1696998743,'0'),(23754,187,2110,4,'請提供上述活動的總金額','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u6350\\u6b3e\\u7e3d\\u984d\\u548c\\u5176\\u4ed6\\u652f\\u51fa\"},{\"title\":\"\\u8cc7\\u6599\\u8986\\u84cb\\u7387\\uff08\\u5206\\u6bcd\\u767e\\u5206\\u6bd4\\uff0c\\u8868\\u793a\\u5831\\u544a\\u6578\\u64da\\u7684\\u7d44\\u7e54\\u7bc4\\u570d\\uff09\"}],\"cols\":[{\"title\":\"\\u91d1\\u984d\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023 YTD\"}]}','1',2,1696990392,1696998743,'0'),(23755,187,2110,5,'請提出佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23756,187,2111,1,'公司是否向政治運動或組織、遊說、貿易協會、免稅實體或其他影響政治運動或公共政策和立法的團體提供任何捐款或支出？在這種情況下，“捐款”是指在財政期間向需要遊說努力的個人候選人、組織、投票措施或“問題領域”或“主題”提供的總金額。','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\uff0c\\u6709\\u6350\\u737b\\u6216\\u662f\\u652f\\u51fa\",\"\\u4e0d\\uff0c\\u6c92\\u6709\\u4efb\\u4f55\\u6350\\u737b\\u6216\\u652f\\u51fa\",\"\\u4e0d\\u6703\\u51fa\\u65bc\\u653f\\u6cbb\\u6216\\u76f8\\u95dc\\u76ee\\u7684\\u8ddf\\u9032\\u6975\\u5927\\u7684\\u6350\\u6b3e\\u6216\\u652f\\u51fa\"],\"last\":null}','1',4,1696990392,1696998743,'0'),(23757,187,2111,2,'是的，我們做出了貢獻。 \n請提供正在參與的議題活動（貨幣：美元）','DynamicForm','0','請在企業定位欄位中填入相對應的數字(1-5) \n1) 支持\n2) 支持但不抱太多期待\n3) 支持而抱有高度期待\n4) 反對\n5) 不捐獻',NULL,'{\"cols\":[{\"title\":\"\\u8b70\\u984c\\/\\u6d3b\\u52d5\\u540d\\u7a31\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"\\u4f01\\u696d\\u5b9a\\u4f4d\"},{\"type\":\"1\",\"title\":\"\\u5b9a\\u4f4d\\/\\u51dd\\u805a\\u7684\\u8aaa\\u660e\"},{\"type\":\"3\",\"title\":\"FY 2020\\u7e3d\\u652f\\u51fa\"},{\"type\":\"3\",\"title\":\"FY 2021\\u7e3d\\u652f\\u51fa\"},{\"type\":\"3\",\"title\":\"FY 2022\\u7e3d\\u652f\\u51fa\"}]}','1',3,1696990392,1696998743,'0'),(23758,187,2111,3,'其他大項目的支出 (美金)','DynamicForm','0','請在組織類型中輸入以下內容之一\n❍	國家政治組織\n❍	地方政治運動、候選人或委員會\n❍	政治行動委員會\n❍	遊說、利益代表或類似\n❍	行業協會\n❍	免稅團體\n❍	無貢獻\n❍	其他：請註明類型\n',NULL,'{\"cols\":[{\"title\":\"\\u5718\\u9ad4\\u540d\\u7a31\\u3001\\u653f\\u6cbb\\u5019\\u9078\\u4eba\\u6216\\u8b70\\u984c\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5718\\u9ad4\\u7a2e\\u985e\"},{\"type\":\"3\",\"title\":\"FY 2020\\u7e3d\\u6350\\u737b\\u91d1\\u984d\"},{\"type\":\"3\",\"title\":\"FY 2021\\u6350\\u737b\\u7e3d\\u91d1\\u984d\"},{\"type\":\"3\",\"title\":\"FY 2022 \\u6350\\u737b\\u7e3d\\u91d1\\u984d\"}]}','1',2,1696990392,1696998743,'0'),(23759,187,2111,4,'請提供作證資料','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23760,187,2112,1,'Which of your company’s public environmental policy covers the following elements of an Environmental Management System?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Commitment and oversight to implementation of environmental management policy and\\/or improving environmental performance.\",\"Roles and responsibilities for implementing environmental management policy\",\"Commitment to set targets and objectives to reduce environmental impacts\",\"Measures to raise internal and external stakeholders\\u2019 awareness of environmental management policy and environmental impacts\",\"Training for employees to understand the impacts of their work activities on the environment\"]}','1',4,1696990392,1696998743,'0'),(23761,187,2112,2,'Commitment and oversight to implementation of environmental management policy and/or improving environmental performance. Please select the highest committing decision-making body:\n','ChoiceOne','0','',NULL,'{\"values\":[\"Board of directors\",\"Executive management\"]}','1',3,1696990392,1696998743,'0'),(23762,187,2112,3,'Roles and responsibilities for implementing environmental management policy (please check all that applies)','ChoiceMultiple','0','',NULL,'{\"values\":[\"Ensuring compliance with relevant environmental laws and regulations\",\"Commitment to continuous improvement of environmental performance\"]}','1',2,1696990392,1696998743,'0'),(23763,187,2112,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23764,187,2113,1,'Which of your company’s public environmental policy covers the following elements of an Environmental Management System?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Commitment and oversight to implementation of environmental management policy and\\/or improving environmental performance.\",\"Roles and responsibilities for implementing environmental management policy\",\"Commitment to set targets and objectives to reduce environmental impacts\",\"Measures to raise internal and external stakeholders\\u2019 awareness of environmental management policy and environmental impacts\",\"Training for employees to understand the impacts of their work activities on the environment\"]}','1',4,1696990392,1696998743,'0'),(23765,187,2113,2,'Commitment and oversight to implementation of environmental management policy and/or improving environmental performance. Please select the highest committing decision-making body:\n','ChoiceOne','0','',NULL,'{\"values\":[\"Board of directors\",\"Executive management\"]}','1',3,1696990392,1696998743,'0'),(23766,187,2113,3,'Roles and responsibilities for implementing environmental management policy (please check all that applies)','ChoiceMultiple','0','',NULL,'{\"values\":[\"Ensuring compliance with relevant environmental laws and regulations\",\"Commitment to continuous improvement of environmental performance\"]}','1',2,1696990392,1696998743,'0'),(23767,187,2113,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23768,187,2114,1,'Which parts of your operations, corporate processes and supply chain are covered by your environmental policy?\nOur public environmental policy covers the following:\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Production operations and business facilities\",\"Products and services\",\"Distribution and logistics\",\"Management of waste\",\"Suppliers, service providers and contractors\",\"Other key business partners (e.g. non-managed operations, joint venture partners, licensees, outsourcing partners, etc.)\",\"Due-diligence, mergers and acquisitions\",\"Other\"]}','1',3,1696990392,1696998743,'0'),(23769,187,2114,2,'Other, please specify:','TextItem','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23770,187,2114,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23771,187,2115,1,'Please complete the following table about total energy consumption. For each row in the table, it is mandatory that the values provided are in the same unit.\n\nBoundary: PEC Japan office (Units: GHG in Metric tons; energy in MWh)\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total direct GHG emission Scope 1 (Unit: metric tons)\"},{\"title\":\"Total non- renewable energy consumption (Unit: MWh)\"},{\"title\":\"Total renewable energy consumption (Unit: MWh)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2022?\"}]}','0',2,1696990392,1696998743,'0'),(23772,187,2115,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','0',1,1696990392,1696998743,'0'),(23773,187,2116,1,'Please provide your company\'s total net fresh water consumption, including data for fresh water extraction and consumption. For each row in the table, it is mandatory that the values are provided in the same unit. \n\nBoundary: PEC Japan office (Units: Million cubic meters)\n','ColumnInput','0','','','{\"rows\":[{\"title\":\"Withdrawal: Total municipal water supplies (or from other water utilities)\"},{\"title\":\"Withdrawal: Fresh surface water (lakes, rivers, etc.)\"},{\"title\":\"Withdrawal: Fresh groundwater\"},{\"title\":\"Discharge: Water returned to the source of extraction at similar or higher quality as raw water extracted (only applies to B and C)\"},{\"title\":\"TOTAL NET FRESH WATER CONSUMPTION (A+B+C-D)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2022?\"}]}','0',2,1696990392,1696998743,'0'),(23774,187,2116,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','0',1,1696990392,1696998743,'0'),(23775,187,2117,1,'Please provide your company\'s total net fresh water consumption, including data for fresh water extraction and consumption. For each row in the table, it is mandatory that the values are provided in the same unit. \n\nBoundary: PEC Japan office (Units: Million cubic meters)\n','ColumnInput','0','','','{\"rows\":[{\"title\":\"Withdrawal: Total municipal water supplies (or from other water utilities)\"},{\"title\":\"Withdrawal: Fresh surface water (lakes, rivers, etc.)\"},{\"title\":\"Withdrawal: Fresh groundwater\"},{\"title\":\"Discharge: Water returned to the source of extraction at similar or higher quality as raw water extracted (only applies to B and C)\"},{\"title\":\"TOTAL NET FRESH WATER CONSUMPTION (A+B+C-D)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2022?\"}]}','0',2,1696990392,1696998743,'0'),(23776,187,2117,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','0',1,1696990392,1696998743,'0'),(23777,187,2118,1,'Please provide your company\'s total net fresh water consumption, including data for fresh water extraction and consumption. For each row in the table, it is mandatory that the values are provided in the same unit. \n\nBoundary: PEC Japan office (Units: Million cubic meters)\n','ColumnInput','0','','','{\"rows\":[{\"title\":\"Withdrawal: Total municipal water supplies (or from other water utilities)\"},{\"title\":\"Withdrawal: Fresh surface water (lakes, rivers, etc.)\"},{\"title\":\"Withdrawal: Fresh groundwater\"},{\"title\":\"Discharge: Water returned to the source of extraction at similar or higher quality as raw water extracted (only applies to B and C)\"},{\"title\":\"TOTAL NET FRESH WATER CONSUMPTION (A+B+C-D)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2022?\"}]}','0',2,1696990392,1696998743,'0'),(23778,187,2118,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','0',1,1696990392,1696998743,'0'),(23779,187,2119,1,'Please provide your company\'s total net fresh water consumption, including data for fresh water extraction and consumption. For each row in the table, it is mandatory that the values are provided in the same unit. \n\nBoundary: PEC Japan office (Units: Million cubic meters)\n','ColumnInput','0','','','{\"rows\":[{\"title\":\"Withdrawal: Total municipal water supplies (or from other water utilities)\"},{\"title\":\"Withdrawal: Fresh surface water (lakes, rivers, etc.)\"},{\"title\":\"Withdrawal: Fresh groundwater\"},{\"title\":\"Discharge: Water returned to the source of extraction at similar or higher quality as raw water extracted (only applies to B and C)\"},{\"title\":\"TOTAL NET FRESH WATER CONSUMPTION (A+B+C-D)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2022?\"}]}','1',2,1696990392,1696998743,'0'),(23780,187,2119,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23781,187,2120,1,'Does your company have a group-wide strategy that provides guidance to your corporate citizenship/ philanthropic activities? Please indicate how this strategy aligns with your overall corporate strategy and the 17 UN Sustainable Development Goals.','DynamicForm','0','Please specify and provide supporting documents:\nPriorities & KPIs\n- Please indicate the three main voluntary or charitable priorities as outlined in your group-wide corporate citizenship/philanthropy strategy specified above and whether the priority is publicly available. \n- For each priority, please indicate which UN Sustainable Development Goal the priority is aligned with. Furthermore, please provide a short description of how the priority is aligned with your business drivers. In addition, please indicate which KPIs your company uses to measure the benefits of the three main priorities. \n- The KPIs need to be measurable and you should provide quantitative results wherever possible. Please clearly describe the benefit KPIs as well as the activity in the provided text boxes.\nBelow is an example from the HQ','/static/upload/image/d/d7/7b/8dce2ca9eb86e90f9228e1e64f2889da.6','{\"cols\":[{\"title\":\"Priorities\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Description of alignment between priority and your business drivers.\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',7,1696990392,1696998743,'0'),(23782,187,2120,2,'Please provide ONE examples from the JP team which focus on (A) R&D innovation','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"R&D innovation programs \"}],\"cols\":[{\"title\":\"Description of alignment between priority and your business drivers.\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',6,1696990392,1696998743,'0'),(23783,187,2120,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',5,1696990392,1696998743,'0'),(23784,187,2120,4,'Please provide ONE examples from the JP team which focus on (B) Quality drugs','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Quality drugs\"}],\"cols\":[{\"title\":\"Description of alignment between priority and your business drivers.\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',4,1696990392,1696998743,'0'),(23785,187,2120,5,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',3,1696990392,1696998743,'0'),(23786,187,2120,6,'Please provide ONE examples from the JP team which focus on (C) Access to Medicine ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Access to Medicine \"}],\"cols\":[{\"title\":\"Description of alignment between priority and your business drivers.\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',2,1696990392,1696998743,'0'),(23787,187,2120,7,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23788,187,2121,1,'For the last fiscal year (2022), please indicate on a consolidated group-wide basis what percentage of your corporate citizenship and/or philanthropic contributions falls within each category. Please refer to the information button for definitions and explanations of the categories.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Charitable Donations\"},{\"title\":\"Community Investments\"},{\"title\":\"Commercial Initiatives\"},{\"title\":\"Other \"},{\"title\":\"Total \"}],\"cols\":[{\"title\":\"Type or Name of activities \",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Please describe your contribution (e.g. intangible or tangible)\"}]}','1',2,1696990392,1696998743,'0'),(23789,187,2121,2,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23790,187,2123,1,'風險管理與因應相關問題','Scale','0','',NULL,'{\"rows\":[{\"title\":\"\\u8acb\\u554f\\u516c\\u53f8\\u662f\\u5426\\u6709\\u8a2d\\u7acb\\u98a8\\u96aa\\u7ba1\\u7406\\u8207\\u56e0\\u61c9\\u7684\\u59d4\\u54e1\\u6703\\u53ca\\u6c7a\\u7b56\\u7ba1\\u7406\\u5c64\\u7d1a?\"},{\"title\":\"\\u96b8\\u5c6c\\u65bc\\u8463\\u4e8b\\u6703\\u9084\\u662f\\u71df\\u904b\\u7ba1\\u7406\\u5c64\\u7d1a? \"}],\"cols\":[{\"title\":\"\\u662f\"},{\"title\":\"\\u5426\"}]}','1',9,1696990392,1696998743,'0'),(23791,187,2123,2,'請提供風險管理與因應委員會及決策管理層級的說明','TextLong','0','',NULL,'[]','1',8,1696990392,1696998743,'0'),(23792,187,2123,3,'請問公司多久進行一次風險辨識與風險管理? ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u98a8\\u96aa\\u8fa8\\u8b58\"},{\"title\":\"\\u98a8\\u96aa\\u7ba1\\u7406\"}],\"cols\":[{\"title\":\"\\u57f7\\u884c\\u9031\\u671f\",\"type\":\"1\"}]}','1',7,1696990392,1696998743,'0'),(23793,187,2123,4,'請問與公司本業有關最重大的前3項風險為何？（至多勾選3項）並說明公司針對上述3大風險的管理與因應。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u50b3\\u67d3\\u75c5\\u6216\\u5176\\u4ed6\\u5065\\u5eb7\\u5371\\u6a5f\"},{\"title\":\"\\u5730\\u7de3\\u653f\\u6cbb\\u98a8\\u96aa\"},{\"title\":\"\\u4f9b\\u61c9\\u93c8\\u4e2d\\u65b7\"},{\"title\":\"\\u7db2\\u8def\\u5a01\\u8105\\uff08\\u8cc7\\u5b89\\u98a8\\u96aa\\uff09\"},{\"title\":\"\\u6c23\\u5019\\u8b8a\\u9077\"},{\"title\":\"\\u80fd\\u6e90\\u53ca\\u8cc7\\u6e90\\u77ed\\u7f3a\"},{\"title\":\"\\u85e5\\u7269\\u56de\\u6536\"},{\"title\":\"\\u4eba\\u624d\\u53ca\\u52de\\u52d5\\u529b\\u77ed\\u7f3a\"},{\"title\":\"\\u5176\\u4ed6\\uff0c\\u8acb\\u8aaa\\u660e                                               \"}],\"cols\":[{\"title\":\"\\u52fe\\u9078\\u6392\\u5e8f\\u524d\\u4e09\\u9805\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\\u516c\\u53f8\\u91dd\\u5c0d\\u4e0a\\u8ff03\\u5927\\u98a8\\u96aa\\u7684\\u7ba1\\u7406\\u8207\\u56e0\\u61c9\"}]}','1',6,1696990392,1696998743,'0'),(23794,187,2123,5,'董事會組成席次','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u8463\\u4e8b\\u6703\\u7e3d\\u5e2d\\u6b21\"},{\"title\":\"\\u7368\\u7acb\\u8463\\u4e8b\\u5e2d\\u6b21\"},{\"title\":\"\\u5973\\u6027\\u8463\\u4e8b\\u5e2d\\u6b21\"},{\"title\":\"\\u5177\\u6709\\u914d\\u5076\\u6216\\u4e8c\\u7b49\\u89aa\\u4ee5\\u5167\\u89aa\\u5c6c\\u95dc\\u4fc2\\u4e4b\\u8463\\u4e8b\\u5e2d\\u6b21\"},{\"title\":\"\\u517c\\u4efb\\u516c\\u53f8\\u7d93\\u7406\\u4eba\\u4e4b\\u8463\\u4e8b\\u5e2d\\u6b21\"}],\"cols\":[{\"type\":\"1\",\"title\":\"\\u7e3d\\u5e2d\\u6578\"}]}','1',5,1696990392,1696998743,'0'),(23795,187,2123,6,'請說明董事會績效評估作法? 如何強化董事會績效? ','TextLong','0','',NULL,'[]','1',4,1696990392,1696998743,'0'),(23796,187,2123,7,'請問藥華董事會在2023年度是否有效發揮董事職能？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u6709\",\"\\u6c92\\u6709\"]}','1',3,1696990392,1696998743,'0'),(23797,187,2123,8,'藥華2023全年召開董事會次數','NumberInput','0','',NULL,'[]','1',2,1696990392,1696998743,'0'),(23798,187,2123,9,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696990392,1696998743,'0'),(23799,188,2124,1,'公司基本資料','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u6210\\u7acb\\u6642\\u9593\"},{\"title\":\"\\u8cc7\\u672c\\u984d (\\u65b0\\u53f0\\u5e63: \\u5143)\"},{\"title\":\"\\u80a1\\u7968\\u4ee3\\u865f (TWSE\\u53f0\\u7063\\u8b49\\u5238\\u4ea4\\u6613\\u6240)\"},{\"title\":\"\\u884c\\u696d\\u985e\\u5225 \"},{\"title\":\"\\u4e3b\\u8981\\u7522\\u54c1(\\u7c21\\u7b54)\"}],\"cols\":[{\"title\":\"\\u6b04\\u4f4d1\",\"type\":\"1\"}]}','1',4,1696990408,1696998757,'0'),(23800,188,2124,2,'公司使命，目標與願景','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u516c\\u53f8\\u4f7f\\u547d\"},{\"title\":\"\\u516c\\u53f8\\u76ee\\u6a19\\u8207\\u9858\\u666f\"}],\"cols\":[{\"title\":\"\\u6b04\\u4f4d1\",\"type\":\"1\"}]}','1',3,1696990408,1696998757,'0'),(23801,188,2124,3,'請說明公司的使命，目標與願景是否與聯合國17項永續發展目標(SDGs)相呼應? 為什麼?  ','TextLong','0','',NULL,'[]','1',2,1696990408,1696998757,'0'),(23802,188,2124,4,'請勾選公司主要呼應哪些聯合國17項永續發展目標(SDGs)  ','ChoiceMultiple','0','',NULL,'{\"values\":[\"1 \\u6d88\\u9664\\u8ca7\\u56f0 No Poverty\\uff1a\\u6d88\\u9664\\u4e00\\u5207\\u5f62\\u5f0f\\u7684\\u8ca7\\u56f0\\uff0c\\u78ba\\u4fdd\\u4eba\\u4eba\\u4eab\\u6709\\u5c0a\\u56b4\\u548c\\u5e73\\u7b49\\u7684\\u6b0a\\u5229\\u3002\",\"2 \\u6d88\\u9664\\u98e2\\u9913 Zero Hunger\\uff1a\\u6d88\\u9664\\u98e2\\u9913\\uff0c\\u5be6\\u73fe\\u7ce7\\u98df\\u5b89\\u5168\\uff0c\\u4fc3\\u9032\\u5065\\u5eb7\\u98f2\\u98df\\u3002\",\"3 \\u5065\\u5eb7\\u8207\\u798f\\u7949 Good Health and Well-being\\uff1a\\u78ba\\u4fdd\\u6240\\u6709\\u4eba\\u7684\\u5065\\u5eb7\\u751f\\u6d3b\\u65b9\\u5f0f\\uff0c\\u63d0\\u4f9b\\u5168\\u9762\\u91ab\\u7642\\u4fdd\\u5065\\u3002\",\"4 \\u512a\\u8cea\\u6559\\u80b2 Quality Education\\uff1a\\u63d0\\u4f9b\\u516c\\u5e73\\u4e14\\u8cea\\u91cf\\u9ad8\\u7684\\u6559\\u80b2\\uff0c\\u4fc3\\u9032\\u7d42\\u8eab\\u5b78\\u7fd2\\u6a5f\\u6703\\u3002\",\"5 \\u6027\\u5225\\u5e73\\u7b49 Gender Equality\\uff1a\\u5be6\\u73fe\\u6027\\u5225\\u5e73\\u7b49\\uff0c\\u6d88\\u9664\\u6027\\u5225\\u6b67\\u8996\\uff0c\\u63a8\\u52d5\\u5a66\\u5973\\u548c\\u5973\\u7ae5\\u7684\\u6b0a\\u76ca\\u3002\",\"6 \\u6e05\\u6f54\\u6c34\\u8207\\u885b\\u751f Clean Water and Sanitation\\uff1a\\u4fdd\\u969c\\u53ef\\u7372\\u5f97\\u7684\\u6e05\\u6f54\\u6c34\\u548c\\u885b\\u751f\\u8a2d\\u65bd\\uff0c\\u63d0\\u9ad8\\u885b\\u751f\\u6c34\\u5e73\\u3002\",\"7 \\u53ef\\u8ca0\\u64d4\\u7684\\u6f54\\u6de8\\u80fd\\u6e90 Affordable and Clean Energy\\uff1a\\u78ba\\u4fdd\\u53ef\\u6301\\u7e8c\\u80fd\\u6e90\\u4f9b\\u61c9\\uff0c\\u4fc3\\u9032\\u53ef\\u518d\\u751f\\u80fd\\u6e90\\u4f7f\\u7528\\u3002\",\"8 \\u5c31\\u696d\\u8207\\u7d93\\u6fdf\\u6210\\u9577 Decent Work and Economic Growth\\uff1a\\u4fc3\\u9032\\u6c38\\u7e8c\\u7d93\\u6fdf\\u589e\\u9577\\u548c\\u793e\\u6703\\u5305\\u5bb9\\u3002\",\"9 \\u5de5\\u696d\\u3001\\u5275\\u65b0\\u8207\\u57fa\\u790e\\u8a2d\\u65bd Industry, Innovation, and Infrastructure\\uff1a\\u5efa\\u8a2d\\u5f37\\u5927\\u3001\\u6c38\\u7e8c\\u548c\\u5177\\u5099\\u97cc\\u6027\\u7684\\u57fa\\u790e\\u8a2d\\u65bd\\u3002\",\"10 \\u6e1b\\u5c11\\u4e0d\\u5e73\\u7b49 Reduced Inequality\\uff1a\\u6e1b\\u5c11\\u570b\\u5167\\u5916\\u4e0d\\u5e73\\u7b49\\uff0c\\u63d0\\u9ad8\\u793e\\u6703\\u5305\\u5bb9\\u6027\\u3002\",\"11 \\u6c38\\u7e8c\\u57ce\\u5e02\\u8207\\u793e\\u5340 Sustainable Cities and Communities\\uff1a\\u5efa\\u8a2d\\u5b89\\u5168\\u3001\\u97cc\\u6027\\u3001\\u6c38\\u7e8c\\u7684\\u57ce\\u5e02\\u793e\\u5340\\u3002\",\"12 \\u8ca0\\u8cac\\u4efb\\u7684\\u6d88\\u8cbb\\u8207\\u751f\\u7522 Responsible Consumption and Production\\uff1a\\u4fc3\\u9032\\u6c38\\u7e8c\\u7684\\u6d88\\u8cbb\\u548c\\u751f\\u7522\\u65b9\\u5f0f\\u3002\",\"13 \\u6c23\\u5019\\u884c\\u52d5 Climate Action\\uff1a\\u63a1\\u53d6\\u7dca\\u6025\\u884c\\u52d5\\u61c9\\u5c0d\\u6c23\\u5019\\u8b8a\\u5316\\u548c\\u5176\\u5f71\\u97ff\\u3002\",\"14 \\u6d77\\u6d0b\\u751f\\u614b Life Below Water\\uff1a\\u4fdd\\u8b77\\u6d77\\u6d0b\\u751f\\u614b\\u7cfb\\u7d71\\uff0c\\u6e1b\\u5c11\\u6d77\\u6d0b\\u6c61\\u67d3\\u3002\",\"15 \\u9678\\u5730\\u751f\\u614b Life on Land\\uff1a\\u4fdd\\u8b77\\u9678\\u5730\\u751f\\u614b\\u7cfb\\u7d71\\uff0c\\u61c9\\u5c0d\\u571f\\u5730\\u9000\\u5316\\u3002\",\"16 \\u548c\\u5e73\\u3001\\u6b63\\u7fa9\\u8207\\u5f37\\u5927\\u6a5f\\u69cb Peace, Justice, and Strong Institutions\\uff1a\\u5efa\\u8a2d\\u548c\\u5e73\\u3001\\u516c\\u6b63\\u3001\\u5f37\\u5927\\u7684\\u793e\\u6703\\u5236\\u5ea6\\u3002\",\"17 \\u5168\\u7403\\u5925\\u4f34\\u95dc\\u4fc2 Partnerships for the Goals\\uff1a\\u5f37\\u5316\\u5168\\u7403\\u5925\\u4f34\\u95dc\\u4fc2\\uff0c\\u5171\\u540c\\u5be6\\u73fe\\u6c38\\u7e8c\\u767c\\u5c55\\u76ee\\u6a19\\u3002\"],\"last\":null}','1',1,1696990408,1696998757,'0'),(23803,188,2125,1,'請說明公司重要大事紀 ','ColumnInput','0','以下為範例，可以自由增添',NULL,'{\"rows\":[{\"title\":\"\\u6210\\u7acb\\u6642\\u9593(\\u5e74\\/\\u6708)\"},{\"title\":\"\\u53d6\\u5f97\\u91cd\\u8981\\u6a19\\u7ae0(\\u5e74\\/\\u6708)\"},{\"title\":\"\\u4e0a\\u5e02\\u6642\\u9593(\\u5e74\\/\\u6708)\"},{\"title\":\"\\u9996\\u6b21\\u51fa\\u7248\\u6c38\\u7e8c\\u5831\\u544a\\u66f8(\\u5e74\\/\\u6708)\"}],\"cols\":[{\"title\":\"\\u6b04\\u4f4d1\",\"type\":\"1\"}]}','1',1,1696990408,1696998757,'0'),(23804,188,2126,1,'公司主要產品與營業額 (收入)','ColumnInput','0','GRI 201-1 組織所產生及分配的直接經濟價值 (收入)\ni. 產生的直接經濟價值：收入；',NULL,'{\"rows\":[{\"title\":\"\\u7522\\u54c1\\u4e00\"},{\"title\":\"\\u7522\\u54c1\\u4e8c\"},{\"title\":\"\\u7522\\u54c1\\u4e09\"},{\"title\":\"\\u7522\\u54c1\\u56db\"},{\"title\":\"\\u7522\\u54c1\\u4e94\"},{\"title\":\"\\u52a0\\u7e3d\"}],\"cols\":[{\"title\":\"2019 \\u71df\\u696d\\u6536\\u5165(\\u5343\\u5143)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2020 \\u71df\\u696d\\u6536\\u5165(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2021 \\u71df\\u696d\\u6536\\u5165(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2022 \\u71df\\u696d\\u6536\\u5165(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2023 \\u71df\\u696d\\u6536\\u5165(\\u5343\\u5143)\"}]}','1',6,1696990408,1696998757,'0'),(23805,188,2126,2,'公司主要產品與營業額  (成本)','ColumnInput','0','GRI 201-1 組織所產生及分配的直接經濟價值 \nii. 分配的經濟價值：營運成本、員工薪資和福利、支付出資人的款項、按國家別支付政府的款項，及社區投資；',NULL,'{\"rows\":[{\"title\":\"\\u7522\\u54c1\\u4e00\"},{\"title\":\"\\u7522\\u54c1\\u4e8c\"},{\"title\":\"\\u7522\\u54c1\\u4e09\"},{\"title\":\"\\u7522\\u54c1\\u56db\"},{\"title\":\"\\u7522\\u54c1\\u4e94\"},{\"title\":\"\\u52a0\\u7e3d\"}],\"cols\":[{\"title\":\"2019 \\u71df\\u696d\\u6210\\u672c(\\u5343\\u5143)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2020 \\u71df\\u696d\\u6210\\u672c(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2021 \\u71df\\u696d\\u6210\\u672c(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2022 \\u71df\\u696d\\u6210\\u672c(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2023 \\u71df\\u696d\\u6210\\u672c(\\u5343\\u5143)\"}]}','1',5,1696990408,1696998757,'0'),(23806,188,2126,3,'公司主要產品與營業額  (營業利益)','ColumnInput','0','GRI 201-1 組織所產生及分配的直接經濟價值 \niii. 留存的經濟價值：「產生的直接經濟價值」減去「分配的經濟價值」',NULL,'{\"rows\":[{\"title\":\"\\u7522\\u54c1\\u4e00\"},{\"title\":\"\\u7522\\u54c1\\u4e8c\"},{\"title\":\"\\u7522\\u54c1\\u4e09\"},{\"title\":\"\\u7522\\u54c1\\u56db\"},{\"title\":\"\\u7522\\u54c1\\u4e94\"},{\"title\":\"\\u52a0\\u7e3d\"}],\"cols\":[{\"title\":\"2019 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2020 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2021 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2022 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2023 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"}]}','1',4,1696990408,1696998757,'0'),(23807,188,2126,4,'公司主要產品與銷售地區','ColumnInput','0','說明年度變化之原因',NULL,'{\"rows\":[{\"title\":\"\\u5167\\u92b7 (\\u53f0\\u7063\\u5e02\\u5834)\"},{\"title\":\"\\u5916\\u92b7 (\\u4e9e\\u6d32)\"},{\"title\":\"\\u5916\\u92b7 (\\u7f8e\\u6d32)\"},{\"title\":\"\\u5916\\u92b7 (\\u6b50\\u6d32)\"},{\"title\":\"\\u5916\\u92b7 (\\u975e\\u6d32)\"},{\"title\":\"\\u5916\\u92b7 (\\u5176\\u4ed6)\"},{\"title\":\"\\u52a0\\u7e3d\"}],\"cols\":[{\"type\":\"3\",\"title\":\"2019 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2020 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2021 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2022 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"},{\"type\":\"3\",\"title\":\"2023 \\u71df\\u696d\\u5229\\u76ca(\\u5343\\u5143)\"}]}','1',3,1696990408,1696998757,'0'),(23808,188,2126,5,'說明公司經濟績效(2019-2023)年度變化之原因','ColumnInput','0','請以PESTEL說明: 是否因為 (1)政治環境 (2)經濟市場 (3)社會人口結構 (4)新興技術 (5)環境與氣候變遷 (6)政策法規 等造成公司經濟績效的變化',NULL,'{\"rows\":[{\"title\":\"\\u653f\\u6cbb\\u74b0\\u5883\"},{\"title\":\"\\u7d93\\u6fdf\\u5e02\\u5834\"},{\"title\":\"\\u793e\\u6703\\u4eba\\u53e3\\u7d50\\u69cb\"},{\"title\":\"\\u65b0\\u8208\\u6280\\u8853\"},{\"title\":\"\\u74b0\\u5883\\u8207\\u6c23\\u5019\\u8b8a\\u9077\"},{\"title\":\"\\u653f\\u7b56\\u6cd5\\u898f\"},{\"title\":\"\\u5176\\u4ed6(\\u8aaa\\u660e\\u65bc\\u4e0b\\u984c)\"}],\"cols\":[{\"title\":\"\\u662f\\u5426\\u767c\\u751f\\u8b8a\\u5316\",\"type\":\"1\"}]}','1',2,1696990408,1696998757,'0'),(23809,188,2126,6,'(承上題)，請說明公司經濟績效(2019-2023)年度變化之其他原因或補充說明','TextLong','0','',NULL,'[]','1',1,1696990408,1696998757,'0'),(23810,189,2127,1,'1. 請說明貴公司是否有接受政府的財務補助，如有的話，補助金額是多少？(GRI 201-4)','TextLong','0','',NULL,'[]','1',4,1696990419,1696998773,'0'),(23811,189,2127,2,'2. 請說明貴公司的稅務方針，並描述稅務治理與管控架構 (GRI 207-1, GRI 207-2)','TextLong','0','提供2022報告作為參考：\n本公司稅務管理單位由總公司會計部協同各子公司會計部門統籌規劃並辦理申報，過程中若有任何重要決策，依\n照情況得諮詢或委任專業稅務顧問，嚴格按照台灣和各運營所在地當地司法管轄區的商業法和稅務規範，依規定\n資訊透明揭露，以強化集團之稅務法令遵循及承諾達成企業社會責任，並承諾遵循以下稅務管理方針，以降低稅\n務風險，優化稅後經營成果，維護股東權益。','/static/upload/image/5/d9/91/6e16a1428df466ab93499836603b334b.png','[]','1',3,1696990419,1696998773,'0'),(23812,189,2127,3,'3. 請說明貴公司的稅務議題如何與利害關係人溝通 (GRI 207-3)','TextLong','0','',NULL,'[]','1',2,1696990419,1696998773,'0'),(23813,189,2127,4,'4.	請填寫以下表格關於稅務管轄區的揭露 (GRI 207-4)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u5c45\\u4f4f\\u8005\\u5be6\\u9ad4\\u540d\\u7a31\"},{\"title\":\"\\u7d44\\u7e54\\u4e3b\\u8981\\u6d3b\\u52d5\"},{\"title\":\"\\u54e1\\u5de5\\u4eba\\u6578\\u3001\\u53ca\\u8a08\\u7b97\\u4eba\\u6578\\u7684\\u57fa\\u790e\"},{\"title\":\"\\u4f86\\u81ea\\u7b2c\\u4e09\\u65b9\\u92b7\\u552e\\u4e4b\\u6536\\u5165\"},{\"title\":\"\\u8207\\u5176\\u4ed6\\u7a05\\u52d9\\u7ba1\\u8f44\\u5340\\u7684\\u96c6\\u5718\\u5167\\u90e8\\u4ea4\\u6613\\u6536\\u5165\"},{\"title\":\"\\u7a05\\u524d\\u6536\\u76ca\\uff0f\\u640d\\u5931\"},{\"title\":\"\\u73fe\\u91d1\\u53ca\\u7d04\\u7576\\u73fe\\u91d1\\u4ee5\\u5916\\u7684\\u6709\\u5f62\\u8cc7\\u7522\"},{\"title\":\"\\u4ee5\\u73fe\\u91d1\\u652f\\u4ed8\\u7684\\u4f01\\u696d\\u6240\\u5f97\\u7a05\"},{\"title\":\"\\u61c9\\u8a08\\u4f01\\u696d\\u6240\\u5f97\\u7a05\\u7684\\u6536\\u76ca\\uff0f\\u640d\\u5931\"},{\"title\":\"\\u5982\\u679c\\u7a05\\u524d\\u640d\\u76ca\\u63a1\\u7528\\u6cd5\\u5b9a\\u7a05\\u7387\\uff0c\\u8aaa\\u660e\\u9020\\u6210\\u61c9\\u8a08\\u4f01\\u696d\\u6240\\u5f97\\u7a05\\u6536\\u76ca\\uff0f\\u640d\\u5931\\u8207\\u61c9\\u4ed8\\u7a05\\u6b3e\\u5dee\\u7570\\u7684\\u539f\\u56e0\"}],\"cols\":[{\"title\":\"\\u7a05\\u52d9\\u7ba1\\u8f44\\u5340\\u7684\\u63ed\\u9732\",\"type\":\"1\"}]}','1',1,1696990419,1696998773,'0'),(23814,189,2128,1,'請選擇貴公司的稅收政策、戰略或原則中涵蓋的內容： \n','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u627f\\u8afe\\u9075\\u5b88\\u516c\\u53f8\\u71df\\u904b\\u570b\\u5bb6\\u7684\\u7a05\\u6cd5\\u548c\\u6cd5\\u898f\\u7684\\u7cbe\\u795e\\u548c\\u6587\\u5b57\",\"\\u627f\\u8afe\\u4e0d\\u5c07\\u5275\\u9020\\u51fa\\u7684\\u50f9\\u503c\\u8f49\\u79fb\\u5230\\u4f4e\\u7a05\\u6536\\u53f8\\u6cd5\\u7ba1\\u8f44\\u5340\",\"\\u627f\\u8afe\\u4e0d\\u4f7f\\u7528\\u6c92\\u6709\\u5546\\u696d\\u5be6\\u8cea\\u7684\\u7a05\\u6536\\u7d50\\u69cb\",\"\\u627f\\u8afe\\u6309\\u7167\\u7368\\u7acb\\u4ea4\\u6613\\u539f\\u5247\\u9032\\u884c\\u50f9\\u683c\\u8f49\\u79fb\",\"\\u627f\\u8afe\\u4e0d\\u4f7f\\u7528\\u79d8\\u5bc6\\u53f8\\u6cd5\\u7ba1\\u8f44\\u5340\\u6216\\u6240\\u8b02\\u7684\\u201c\\u907f\\u7a05\\u5929\\u5802\\u201d\\u9032\\u884c\\u907f\\u7a05\",\"\\u7531\\u8463\\u4e8b\\u6703\\u6279\\u51c6\\u7684\\u7a05\\u6536\\u653f\\u7b56\\u6d41\\u7a0b\",\"\\u5176\\u4ed6\"],\"last\":null}','1',3,1696990419,1696998773,'0'),(23815,189,2128,2,'若選擇其他，請說明','TextItem','0','',NULL,'[]','1',2,1696990419,1696998773,'0'),(23816,189,2128,3,'請提供佐證資料\n','UploadFile','0','',NULL,'[]','1',1,1696990419,1696998773,'0'),(23817,189,2129,1,'請提供以下稅收相關指標(按稅收管轄區區分)，並填寫以下答案：','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u5be6\\u9ad4\\u540d\\u7a31\",\"\\u4e3b\\u8981\\u6d3b\\u52d5\",\"\\u54e1\\u5de5\\u4eba\\u6578\",\"2020\\u5e74~2023\\u5e74(\\u622a\\u81f3\\u76ee\\u524d)\\u7684\\u6536\\u5165\",\"2020\\u5e74~2023\\u5e74(\\u622a\\u81f3\\u76ee\\u524d)\\u7684\\u7a05\\u524d\\u5229\\u6f64(\\u8667\\u640d)\",\"2020\\u5e74~2023\\u5e74(\\u622a\\u81f3\\u76ee\\u524d)\\u7684\\u61c9\\u8a08\\u6240\\u5f97\\u7a05\",\"2020\\u5e74~2023\\u5e74(\\u622a\\u81f3\\u76ee\\u524d)\\u5df2\\u652f\\u4ed8\\u7684\\u6240\\u5f97\\u7a05\"],\"last\":null}','1',2,1696990419,1696998773,'0'),(23818,189,2129,2,'請提供佐證資料\n','UploadFile','0','',NULL,'[]','1',1,1696990419,1696998773,'0'),(23819,189,2130,1,'請填寫以下表格，以記錄過去兩年內的報告稅率（損益表）和現金稅率（現金流量表）相關數據。\n此外，請選擇（如果需要）解釋報告的稅率和/或現金稅率可能低於預期的原因。\n貨幣：美元','ColumnInput','0','單一管轄區稅收法規（國外銷售最高稅率為10%，國內公司所得稅率低於行業平均水平）',NULL,'{\"rows\":[{\"title\":\"\\u7a05\\u524d\\u6de8\\u5229\"},{\"title\":\"\\u7d2f\\u7a4d\\u53ef\\u63a5\\u53d7\\u7684\\u8abf\\u6574*\\uff08\\u8acb\\u53c3\\u95b1\\u4e0a\\u8ff0\\u5167\\u5bb9\\uff09\"},{\"title\":\"\\u6709\\u6548\\u7a05\\u7387\\uff08\\u4ee5%\\u8868\\u793a\\uff09 \"},{\"title\":\"\\u5be6\\u969b\\u652f\\u4ed8\\u7684\\u73fe\\u91d1\\u7a05\\u91d1\"},{\"title\":\"\\u73fe\\u91d1\\u7a05\\u7387\\uff08\\u4ee5%\\u8868\\u793a\\uff09\"}],\"cols\":[{\"title\":\"2020\\u5e74\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\\u5e74\"},{\"type\":\"3\",\"title\":\"2022\\u5e74\"},{\"type\":\"3\",\"title\":\"2023\\u5e74 (2024\\u5f8c\\u53ef\\u7528) \"},{\"type\":\"3\",\"title\":\"\\u8a08\\u7b97\\u7684\\u5e73\\u5747\\u7387\"}]}','1',3,1696990419,1696998773,'0'),(23820,189,2130,2,'理由/證據解釋','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u96c6\\u5718\\u6574\\u9ad4\\u7684\\u6de8\\u71df\\u904b\\u8667\\u640d\"},{\"title\":\"\\u55ae\\u4e00\\u7ba1\\u8f44\\u5340\\u7a05\\u6cd5\\uff08\\u570b\\u5916\\u92b7\\u552e\\u6700\\u9ad8\\u7a05\\u7387\\u70ba10%\\uff0c\\u570b\\u5167\\u516c\\u53f8\\u6240\\u5f97\\u7a05\\u7387\\u4f4e\\u65bc\\u884c\\u696d\\u5e73\\u5747\\u6c34\\u5e73\\uff09\"},{\"title\":\"\\u975e\\u7d93\\u5e38\\u6027\\uff08\\u4e00\\u6b21\\u6027\\uff09\\u7d93\\u71df\\u8667\\u640d\"},{\"title\":\" \\u4f86\\u81ea\\u524d\\u671f\\u548c\\/\\u6216\\u88ab\\u6536\\u8cfc\\u516c\\u53f8\\u7684\\u6de8\\u71df\\u904b\\u8667\\u640d\"},{\"title\":\"\\u6642\\u9593 - \\u905e\\u5ef6\\u6240\\u5f97\\u7a05\\u8cc7\\u7522\\/\\u8ca0\\u50b5\\u6de8\\u984d\\u548c\\u5831\\u544a\\u5169\\u5e74\\u671f\\u4ee5\\u5916\\u7684\\u4e3b\\u8981\\u554f\\u984c\\uff08\\u5305\\u62ec\\u7531\\u65bc\\u91cd\\u5927\\u7a05\\u6536\\u653f\\u7b56\\u8b8a\\u5316\\u800c\\u5c0d\\u5148\\u524d\\u5831\\u544a\\u671f\\u9593\\u7684\\u6703\\u8a08\\u8abf\\u6574\\uff09\\t\"}],\"cols\":[{\"title\":\"2020\\u5e74\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\\u5e74\"},{\"type\":\"3\",\"title\":\"2022\\u5e74\"},{\"type\":\"3\",\"title\":\"2023\\u5e74 (2024\\u5f8c\\u53ef\\u7528) \"},{\"type\":\"1\",\"title\":\"\\u89e3\\u91cb\"}]}','1',2,1696990419,1696998773,'0'),(23821,189,2130,3,'請提供佐證資料\n','UploadFile','0','',NULL,'[]','1',1,1696990419,1696998773,'0'),(23822,190,2131,1,'請問[市場准入]是否為公司的重大主題? 相關的管理政策與行動，以及指標與目標為何?','ColumnInput','0','市場准入(Market Access) 相關活動可參考Access to Medicines Index (ATMI) 2022所列之活動。相關涉及範圍從製造、研發、患者安全教育、醫事人員培訓或針對療程所提供的財務補助計畫都算。',NULL,'{\"rows\":[{\"title\":\"\\u5167\\u90e8\\u7ba1\\u7406\\u653f\\u7b56\"},{\"title\":\"\\u5916\\u90e8\\u7ba1\\u7406\\u653f\\u7b56\"},{\"title\":\"\\u7ba1\\u7406\\u627f\\u8afe\"},{\"title\":\"\\u6b0a\\u8cac\\u55ae\\u4f4d\"},{\"title\":\"\\u6295\\u5165\\u8cc7\\u6e90\"},{\"title\":\"\\u77ed\\u671f\\u76ee\\u6a19(2024)\"},{\"title\":\"\\u4e2d\\u671f\\u76ee\\u6a19(2025-2027\"},{\"title\":\"\\u9577\\u671f\\u76ee\\u6a19(2027~\\u9577\\u671f\"}],\"cols\":[{\"title\":\"\\u53f0\\u7063\\/\\u7e3d\\u90e8\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u7f8e\\u570b\"},{\"type\":\"1\",\"title\":\"\\u65e5\\u672c\"}]}','1',3,1696990431,1696998791,'0'),(23823,190,2131,2,'請依照相關部門說明公司在2023年所進行的市場准入活動(其目的都是為了推廣藥物更普及使用)','ColumnInput','0','CSA 問卷題',NULL,'{\"rows\":[{\"title\":\"\\u88fd\\u9020\\u7aef\\u80fd\\u529b\\u5efa\\u69cb\"},{\"title\":\"\\u7814\\u767c\\u7aef\\u80fd\\u529b\\u5efa\\u69cb\"},{\"title\":\"\\u4f9b\\u61c9\\u93c8\\u7aef\\u80fd\\u529b\\u5efa\\u69cb\"},{\"title\":\"\\u85e5\\u7269\\u76e3\\u7ba1\\u80fd\\u529b\\u5efa\\u69cb\"},{\"title\":\"\\u75c5\\u60a3\\u6559\\u80b2\\u80fd\\u529b\\u5efa\\u69cb\"},{\"title\":\"\\u91ab\\u4e8b\\u4eba\\u54e1\\u80fd\\u529b\\u5efa\\u69cb\"},{\"title\":\"\\u7642\\u7a0b\\u8ca1\\u52d9\\u88dc\\u52a9\\u76f8\\u95dc\"},{\"title\":\"\\u8cc7\\u6599\\u6536\\u96c6\\u8207\\u7522\\u54c1\\u54c1\\u8cea\\u76f8\\u95dc\"},{\"title\":\"\\u5176\\u4ed6(\\u8acb\\u8aaa\\u660e)\"}],\"cols\":[{\"title\":\"\\u5c08\\u6848\\u76ee\\u7684 (\\u60f3\\u89e3\\u6c7a\\u751a\\u9ebc\\u554f\\u984c)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u6848\\u5c0d\\u8c61\\u8207\\u7bc4\\u570d\"},{\"type\":\"1\",\"title\":\"\\u5275\\u9020\\u7684\\u6548\\u76ca\\/\\u50f9\\u503c\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u6848\\u6642\\u7a0b (\\u77ed\\u671f\\u6216\\u9577\\u671f? \\u6301\\u7e8c\\u591a\\u4e45)\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u6848\\u57f7\\u884c\\u983b\\u7387(\\u591a\\u4e45\\u4e00\\u6b21)\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u6848\\u6210\\u679c\\u6539\\u5584\\/\\u5efa\\u69cb\\u4e86\\u54ea\\u7a2e\\u80fd\\u529b\"}]}','1',2,1696990431,1696998791,'0'),(23824,190,2131,3,'請提供佐證資料\n','UploadFile','0','',NULL,'[]','1',1,1696990431,1696998791,'0'),(23825,190,2132,1,'請提供病患總數，以及能夠以低成本獲得貴組織產品或服務的病患數量。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u80fd\\u5920\\u4ee5\\u4f4e\\u6210\\u672c\\u7372\\u5f97\\u8cb4\\u6a5f\\u69cb\\u7528\\u65bc\\u8655\\u7406\\u75be\\u75c5\\/\\u72c0\\u6cc1\\u7684\\u7522\\u54c1\\u6216\\u670d\\u52d9\\u7684\\u60a3\\u8005\\u6578\\u91cf\"}],\"cols\":[{\"title\":\"FY 2020   \",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',2,1696990431,1696998791,'0'),(23826,190,2132,2,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990431,1696998791,'0'),(23827,190,2133,1,'請指出與上一年相比，貴公司的美國產品組合中的平均定價和平均淨價的百分比變化（根據報告貨幣的銷售額加權計算）。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u5e73\\u5747\\u5b9a\\u50f9\"},{\"title\":\"\\u5e73\\u5747\\u6de8\\u50f9\"}],\"cols\":[{\"title\":\"FY 2020   \",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',4,1696990431,1696998791,'0'),(23828,190,2133,2,'如果無法在公司級別匯總數據，請說明選擇在上表中代表的營業單位/產品部門，以及該部門產生的收入（以總收入的百分比為單位）','TextLong','0','',NULL,'[]','1',3,1696990431,1696998791,'0'),(23829,190,2133,3,'如果不適用。請在下面的評論框中提供解釋。','TextLong','0','',NULL,'[]','1',2,1696990431,1696998791,'0'),(23830,190,2133,4,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',1,1696990431,1696998791,'0'),(23831,190,2134,1,'公司是否通過健康經濟評估（例如成本效益、成本效用、成本效益分析）來評估產品對醫療保健成本的影響，並在可能的情況下將其與標準治療方案和其他競爭性創新進行比較？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\u7684\\uff0c\\u516c\\u53f8\\u901a\\u904e\\u5065\\u5eb7\\u7d93\\u6fdf\\u8a55\\u4f30\\uff08\\u4f8b\\u5982\\u6210\\u672c\\u6548\\u76ca\\u3001\\u6210\\u672c\\u6548\\u7528\\u3001\\u6210\\u672c\\u6548\\u76ca\\u5206\\u6790\\uff09\\u4f86\\u8a55\\u4f30\\u7522\\u54c1\\u5c0d\\u91ab\\u7642\\u4fdd\\u5065\\u6210\\u672c\\u7684\\u5f71\\u97ff\\uff0c\\u4e26\\u5728\\u53ef\\u80fd\\u7684\\u60c5\\u6cc1\\u4e0b\\u5c07\\u5176\\u8207\\u6a19\\u6e96\\u6cbb\\u7642\\u65b9\\u6848\\u548c\\u5176\\u4ed6\\u7af6\\u722d\\u6027\\u5275\\u65b0\\u9032\\u884c\\u6bd4\\u8f03\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u4e0d\\u6703\\u901a\\u904e\\u5065\\u5eb7\\u7d93\\u6fdf\\u8a55\\u4f30\\u4f86\\u8a55\\u4f30\\u6211\\u5011\\u7684\\u7522\\u54c1\\u5c0d\\u91ab\\u7642\\u4fdd\\u5065\\u6210\\u672c\\u7684\\u5f71\\u97ff\\u3002\",\"\\u4e0d\\u9069\\u7528\\u3002\\u8acb\\u5728\\u4e0b\\u9762\\u7684\\u8a55\\u8ad6\\u6846\\u4e2d\\u63d0\\u4f9b\\u89e3\\u91cb\\u3002\"]}','1',8,1696990431,1696998791,'0'),(23832,190,2134,2,'如果是，請回答下列問題','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u8acb\\u8aaa\\u660e\\u8a55\\u4f30\\u7522\\u54c1\\u7684\\u767e\\u5206\\u6bd4\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"\\u8acb\\u8aaa\\u660e\\u60a8\\u53ef\\u4ee5\\u5728\\u4e0a\\u4e00\\u8ca1\\u653f\\u5e74\\u5ea6\\u7522\\u751f\\u7684\\u6536\\u5165\\u4e2d\\u63d0\\u4f9b\\u6b64\\u985e\\u8b49\\u64da\\u7684\\u767e\\u5206\\u6bd4\"},{\"type\":\"3\",\"title\":\"\\u8acb\\u8aaa\\u660e\\u8207\\u6a19\\u6e96\\u91ab\\u5b78\\u7642\\u6cd5\\u76f8\\u6bd4\\uff0c\\u9019\\u4e9b\\u8a55\\u4f30\\u5728\\u4e0a\\u4e00\\u8ca1\\u653f\\u5e74\\u5ea6\\u7522\\u751f\\u7684\\u96c6\\u5718\\u7e3d\\u6536\\u5165\\u4e2d\\u5177\\u6709\\u986f\\u8457\\u6210\\u672c\\u6548\\u76ca\\u7684\\u767e\\u5206\\u6bd4\"},{\"type\":\"1\",\"title\":\"\\u8acb\\u8aaa\\u660e\\u8207\\u5176\\u4ed6\\u7af6\\u722d\\u6027\\u5275\\u65b0\\u76f8\\u6bd4\\uff0c\\u9019\\u4e9b\\u8a55\\u4f30\\u5728\\u4e0a\\u4e00\\u8ca1\\u653f\\u5e74\\u5ea6\\u7522\\u751f\\u7684\\u96c6\\u5718\\u7e3d\\u6536\\u5165\\u4e2d\\u6240\\u4f54\\u7684\\u767e\\u5206\\u6bd4\"}]}','1',7,1696990431,1696998791,'0'),(23833,190,2134,3,'如果是，請提供作證資料','UploadFile','0','',NULL,'[]','1',6,1696990431,1696998791,'0'),(23834,190,2134,4,'如果不是，請解釋狀況。','TextLong','0','',NULL,'[]','1',5,1696990431,1696998791,'0'),(23835,190,2135,1,'在過去五年中，有多少創新產品獲得了上市許可一直得到知名衛生技術評估機構（HTA，如 NICE、IQWIG、PBAC 等）？','ChoiceOne','0','只有在任何其他知名機構沒有做出負面決定的情況下，才應將產品包括在內。因此，如果兩個或多個機構對產品進行評論，並且其中任何一個機構提供負面評論，則該產品不被視為始終如一的認可。\n\n注：衛生技術評估機構，如英國的NICE、德國的IQWIG、加拿大的CDR和澳大利亞的PBAC，評估新藥的相對有效性和/或成本效益（取決於立法），並就藥物和干預措施的益處、使用和/或報銷提出建議。',NULL,'{\"values\":[\"\\u7d93\\u904e\\u5be9\\u67e5\\u7684HTA\\u4e00\\u81f4\\u8a8d\\u53ef\\u7684\\u7522\\u54c1\\u767e\\u5206\\u6bd4\\uff08\\u5360\\u5be9\\u67e5\\u7684\\u5275\\u65b0\\u7522\\u54c1\\u7e3d\\u6578\\u7684\\u767e\\u5206\\u6bd4\\uff09\",\"\\u6211\\u5011\\u7684\\u7522\\u54c1\\u5747\\u672a\\u7372\\u5f97\\u76f8\\u95dcHTA\\u7684\\u8a8d\\u53ef\",\"\\u4e0d\\u9069\\u7528\\u3002\\u8acb\\u5728\\u4e0b\\u9762\\u7684\\u8a55\\u8ad6\\u6846\\u4e2d\\u63d0\\u4f9b\\u89e3\\u91cb\\u3002\",\"\\u4e0d\\u77e5\\u9053\"]}','1',4,1696990431,1696998791,'0'),(23836,190,2135,2,'請提供證據，說明“經過審查的HTA一致認可的產品百分比（占審查的創新產品總數的百分比）”。','TextItem','0','',NULL,'[]','1',3,1696990431,1696998791,'0'),(23837,190,2135,3,'如果不是，請說明此一狀況','TextLong','0','',NULL,'[]','1',2,1696990431,1696998791,'0'),(23838,190,2136,1,'公司是否系統地衡量您對改善患者整個護理周期的貢獻？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\",\"\\u4e0d\\u662f\\uff0c\\u6211\\u5011\\u4e0d\\u6703\\u7cfb\\u7d71\\u5730\\u8861\\u91cf\\u6211\\u5011\\u5c0d\\u6539\\u5584\\u60a3\\u8005\\u6574\\u500b\\u8b77\\u7406\\u5468\\u671f\\u7684\\u8ca2\\u737b\",\"\\u4e0d\\u662f\\uff0c\\u8acb\\u65bc\\u4e0b\\u65b9\\u63d0\\u51fa\\u8aaa\\u660e\",\"\\u4e0d\\u77e5\\u9053\"]}','1',6,1696990431,1696998791,'0'),(23839,190,2136,2,'主要專案\n如果是，請簡要說明關鍵計劃、用於衡量其影響的最相關的關鍵績效指標以及相應的影響數位。請為每個關鍵計劃提供支持證據。','ColumnInput','0','貨幣：美元 (USD)',NULL,'{\"rows\":[{\"title\":\"\\u9810\\u9632\\u63aa\\u65bd\"},{\"title\":\"\\u8a3a\\u65b7 \"},{\"title\":\"\\u6cbb\\u7642\\uff08\\u4f9d\\u5f9e\\u6027\\u548c\\u5eb7\\u5fa9\\uff09 \"},{\"title\":\"\\u7aef\\u5230\\u7aef(\\u5b8c\\u6574?)\\u5faa\\u74b0\\u89e3\\u6c7a\\u65b9\\u6848\\/\\u5176\\u4ed6\\u8a08\\u5283\"}],\"cols\":[{\"title\":\"\\u8acb\\u5728\\u4e0b\\u9762\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\u548c\\u76f8\\u95dc\\u8aaa\\u660e\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u7528\\u65bc\\u8861\\u91cf\\u5f71\\u97ff\\u7684 KPI\\uff08\\u4f8b\\u5982\\uff0c\\u9054\\u5230\\u7684\\u60a3\\u8005\\u6578\\u91cf #\\uff09\"},{\"type\":\"1\",\"title\":\"2023\\u5e74\\u7684\\u5f71\\u97ff\"},{\"type\":\"1\",\"title\":\"2024\\u5e74\\u7684\\u9810\\u4f30\"}]}','1',5,1696990431,1696998791,'0'),(23840,190,2136,3,'全球範圍內實施的計劃數量（占計劃總數的百分比）？','TextLong','0','請提供佐證說明',NULL,'[]','1',4,1696990431,1696998791,'0'),(23841,190,2136,4,'公司在多少疾病領域/適應症中為改善患者全週期護理做出了貢獻（與貴公司相關的疾病領域的百分比）\n','TextLong','0','請提供佐證資料',NULL,'[]','1',3,1696990431,1696998791,'0'),(23842,190,2136,5,'請提供佐證資料','UploadFile','0','',NULL,'[]','1',2,1696990431,1696998791,'0'),(23843,190,2137,1,'公司是否向所有利益相關者提供患者結果數據？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\",\"\\u6211\\u5011\\u6c92\\u6709\\u9019\\u6a23\\u7684\\u6d41\\u7a0b\",\"\\u4e0d\\u9069\\u7528\\u3002\\u8acb\\u5728\\u4e0b\\u9762\\u7684\\u8a55\\u8ad6\\u6846\\u4e2d\\u63d0\\u4f9b\\u89e3\\u91cb\",\"\\u4e0d\\u77e5\\u9053\"]}','1',7,1696990431,1696998791,'0'),(23844,190,2137,2,'如果是，請說明提供哪類資料，並提供支持證據。','TextLong','0','• 臨床試驗和上市後觀察研究的結果\n• 付款方/監管機構/健康技術評估機構\n• 醫療專業人員/患者倡導組織/患者\n• 與安全性和有效性相關的患者層次的臨床研究數據\n• 成本效益分析和藥物經濟學/健康經濟學數據',NULL,'[]','1',6,1696990431,1696998791,'0'),(23845,190,2137,3,'如果是，請說明向誰提供這一資訊，並提供支持證據。','TextLong','0','•臨床試驗和上市后觀察性研究的結果\n•付款人/監管機構/HTA\n•醫療保健專業人員/患者倡導團體/患者\n•與安全性和有效性相關的患者級臨床研究數據\n•付款人/監管機構/HTA\n•醫療保健專業人員/患者倡導團體/患者\n•成本效益分析和藥物經濟學/健康經濟數據\n•付款人/監管機構/HTA\n•醫療保健專業人員/患者倡導團體/患者',NULL,'[]','1',5,1696990431,1696998791,'0'),(23846,190,2137,4,'如果是，請說明公司在上一財政年度是否因與隱瞞臨床數據有關的備案和訴訟而產生費用或罰款，並提供支持證據：\n\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u5982\\u679c\\u662f\\uff0c\\u8acb\\u8aaa\\u660e\\u91d1\\u984d\",\"\\u4e0d\\uff0c\\u53bb\\u5e74\\u6c92\\u6709\\u56e0\\u8207\\u96b1\\u779e\\u81e8\\u5e8a\\u6578\\u64da\\u6709\\u95dc\\u7684\\u7533\\u8acb\\u548c\\u8a34\\u8a1f\\u800c\\u7522\\u751f\\u8cbb\\u7528\\u6216\\u7f70\\u6b3e\"]}','1',4,1696990431,1696998791,'0'),(23847,190,2137,5,'若為是，\n請寫出具體金額與幣別\n','TextLong','0','',NULL,'[]','1',3,1696990431,1696998791,'0'),(23848,190,2137,6,'請提供佐證資料\n','UploadFile','0','',NULL,'[]','1',2,1696990431,1696998791,'0'),(23849,190,2138,1,'請提供以下證實侵犯病人隱私之投訴 (若未有任何投訴，則簡單陳述此事實。)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u4f86\\u81ea\\u5916\\u90e8\\u5404\\u65b9\\u4e26\\u7d93\\u7531\\u516c\\u53f8\\u5df2\\u8b49\\u5be6\\u7684\\u6295\\u8a34\\u6578--\\u4fb5\\u72af\\u75c5\\u60a3\\u96b1\\u79c1\\u6216\\u907a\\u5931\\u75c5\\u60a3\\u8cc7\\u6599\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u4f86\\u81ea\\u76e3\\u7ba1\\u6a5f\\u95dc\\u7684\\u6295\\u8a34\\u6578--\\u4fb5\\u72af\\u75c5\\u60a3\\u96b1\\u79c1\\u6216\\u907a\\u5931\\u75c5\\u60a3\\u8cc7\\u6599\"},{\"type\":\"1\",\"title\":\"\\u7d93\\u8b49\\u5be6\\u4e4b\\u8cc7\\u8a0a\\u6d29\\u9732\\u3001\\u5931\\u7aca\\u6216\\u907a\\u5931\\u5ba2\\u6236\\u8cc7\\u6599\\u4e8b\\u4ef6\\u7684\\u7e3d\\u6578\"}]}','0',1,1696990431,1696998791,'0'),(23850,191,2139,1,'請問[產品品質與安全管理]是否為公司的重大主題? 相關的管理政策與行動，以及指標與目標為何? ','ColumnInput','0','GRI 3-3 重大主題管理\nSASB HC-BP-250a.1 / a.2 / a.3 / a.4 / a.5',NULL,'{\"rows\":[{\"title\":\"\\u5167\\u90e8\\u7ba1\\u7406\\u653f\\u7b56\"},{\"title\":\"\\u5916\\u90e8\\u7ba1\\u7406\\u653f\\u7b56\"},{\"title\":\"\\u7ba1\\u7406\\u627f\\u8afe\"},{\"title\":\"\\u6b0a\\u8cac\\u55ae\\u4f4d\"},{\"title\":\"\\u6295\\u5165\\u8cc7\\u6e90\"},{\"title\":\"\\u77ed\\u671f\\u76ee\\u6a19(2024)\"},{\"title\":\"\\u4e2d\\u671f\\u76ee\\u6a19(2025-2027)\"},{\"title\":\"\\u9577\\u671f\\u76ee\\u6a19(2027~\\u9577\\u671f\\u76ee\\u6a19)\"}],\"cols\":[{\"title\":\"\\u6b04\\u4f4d1\",\"type\":\"1\"}]}','1',5,1696990440,1696998802,'0'),(23851,191,2139,2,'各廠區取得藥品優良製造規範(GMP)認證的情況如何?','ColumnInput','0','請自行添加各廠獲得品質保證的情況',NULL,'{\"rows\":[{\"title\":\"GMP\"},{\"title\":\"\\u5176\\u4ed6\\u54c1\\u8cea\\u4fdd\\u8b49(\\u8acb\\u8aaa\\u660e)\"}],\"cols\":[{\"title\":\"\\u53f0\\u7063(\\u53f0\\u4e2d\\u5ee0)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u7f8e\\u570b\"},{\"type\":\"1\",\"title\":\"\\u65e5\\u672c\"},{\"type\":\"1\",\"title\":\"\\u97d3\\u570b\"}]}','1',4,1696990440,1696998802,'0'),(23852,191,2139,3,'請問公司在各階段如何確保產品品質與安全管理','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u7814\\u767c\\u968e\\u6bb5\"},{\"title\":\"\\u81e8\\u5e8a\\u8a66\\u9a57\\u968e\\u6bb5\"},{\"title\":\"\\u4e0a\\u5e02\\u5f8c\"},{\"title\":\"\\u5176\\u4ed6\"}],\"cols\":[{\"title\":\"\\u7ba1\\u7406\\u7cfb\\u7d71(e.g. ISO)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5167\\u63a7\\u6b0a\\u8cac\\u55ae\\u4f4d\"},{\"type\":\"1\",\"title\":\"\\u5167\\u63a7\\u6d41\\u7a0b\"},{\"type\":\"1\",\"title\":\"\\u5916\\u90e8\\u6aa2\\u9a57\\u6d41\\u7a0b\"}]}','1',3,1696990440,1696998802,'0'),(23853,191,2139,4,'(承上)，請問公司目前如何進行患者安全監測? ','TextLong','0','',NULL,'[]','1',2,1696990440,1696998802,'0'),(23854,191,2139,5,'(承上)，請問公司目前如何進行患者安全監測? ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u91dd\\u5c0d\\u5df2\\u4e0a\\u5e02\\u570b\\u5bb6\\u7684\\u505a\\u6cd5\"},{\"title\":\"\\u91dd\\u5c0d\\u672a\\u4e0a\\u5e02\\u570b\\u5bb6\\u7684\\u505a\\u6cd5\"},{\"title\":\"\\u5176\\u4ed6\"}],\"cols\":[{\"title\":\"\\u53f0\\u7063\\u5e02\\u5834\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u7f8e\\u570b\\u5e02\\u5834\"},{\"type\":\"1\",\"title\":\"\\u65e5\\u672c\\u5e02\\u5834\"},{\"type\":\"1\",\"title\":\"\\u5176\\u4ed6\\u5e02\\u5834\"}]}','1',1,1696990440,1696998802,'0'),(23855,191,2140,1,'請問公司是否具有一套評估機制來評估產品和服務類別對於使用者的健康與安全的影響? 請說明如何評估? ','TextLong','0','GRI 416-1 評估產品和服務類別對健康和安全的衝擊',NULL,'[]','1',5,1696990440,1696998802,'0'),(23856,191,2140,2,'(承上題)，請問為改善健康和安全的衝擊而進行評估的主要產品和服務類別之百分比為何? ','NumberSlider','0','GRI 416-1 評估產品和服務類別對健康和安全的衝擊',NULL,'{\"min\":0,\"max\":100}','1',4,1696990440,1696998802,'0'),(23857,191,2140,3,'請問2023年公司是否發生 \"違反產品與健康安全法規和自願規約的事件\" ? ','ColumnInput','0','GRI 416-2 違反有關產品與服務的健康和安全法規之事件\nSASB HC-BP-250a.1 / a.2 / a.3 / a.4 / a.5',NULL,'{\"rows\":[{\"title\":\"\\u5c0e\\u81f4\\u7f70\\u6b3e\\u7684\\u9055\\u898f\\u4e8b\\u4ef6\"},{\"title\":\"\\u5c0e\\u81f4\\u8b66\\u544a\\u7684\\u9055\\u898f\\u4e8b\\u4ef6\"},{\"title\":\"\\u9055\\u53cd\\u81ea\\u9858\\u6027\\u898f\\u7d04\\u7684\\u4e8b\\u4ef6\"},{\"title\":\"\\u7121\\u9055\\u53cd\\u4e8b\\u4ef6\"}],\"cols\":[{\"title\":\"\\u662f\\u5426\\u767c\\u751f\\u904e \",\"type\":\"1\"}]}','1',3,1696990440,1696998802,'0'),(23858,191,2141,1,'公司在產品標示上提供哪些要素的說明？','ChoiceMultiple','0','GRI 417-1 產品和服務資訊與標示的要求\nSASB HC-BP-250a.1 / a.2 / a.3 / a.4 / a.5',NULL,'{\"values\":[\"\\u7522\\u54c1\\u6210\\u5206\\u4f86\\u6e90\\u7684\\u4f9b\\u61c9\\u8005\",\"\\u7522\\u54c1\\u5167\\u5bb9\\u7269\\u6210\\u5206\\uff0c\\u7279\\u5225\\u662f\\u53ef\\u80fd\\u7522\\u751f\\u8ca0\\u9762\\u74b0\\u5883\\u6216\\u793e\\u6703\\u885d\\u64ca\\u7684\\u7269\\u8cea\",\"\\u7522\\u54c1\\u6216\\u670d\\u52d9\\u7684\\u4f7f\\u7528\\u5b89\\u5168\\u9808\\u77e5\",\"\\u7522\\u54c1\\u7684\\u6e05\\u9664\\u53ca\\u5176\\u5c0d\\u74b0\\u5883\\/\\u793e\\u6703\\u885d\\u64ca\",\"\\u5176\\u4ed6\"],\"last\":null}','1',4,1696990440,1696998802,'0'),(23859,191,2141,2,'呈上題，若勾選其他，請說明','TextLong','0','',NULL,'[]','1',3,1696990440,1696998802,'0'),(23860,191,2141,3,'請說明符合產品行銷與標示相關法規評估之產品數目的百分比。','TextItem','0','417-2 未遵循產品與服務之資訊與標示相關法規的事件',NULL,'[]','1',2,1696990440,1696998802,'0'),(23861,191,2141,4,'請問2023年公司是否發生 \"違反產品與服務之資訊與標示規定或自願性規約的事件\" ? 如果有，共有幾件? ','ColumnInput','0','GRI 417-2 未遵循產品與服務之資訊與標示相關法規的事件',NULL,'{\"rows\":[{\"title\":\"\\u5c0e\\u81f4\\u7f70\\u6b3e\\u7684\\u9055\\u898f\\u4e8b\\u4ef6\"},{\"title\":\"\\u5c0e\\u81f4\\u8b66\\u544a\\u7684\\u9055\\u898f\\u4e8b\\u4ef6\"},{\"title\":\"\\u9055\\u53cd\\u81ea\\u9858\\u6027\\u898f\\u7d04\\u7684\\u4e8b\\u4ef6\"},{\"title\":\"\\u7121\\u9055\\u898f\\u4e8b\\u4ef6\"}],\"cols\":[{\"title\":\"2023\\u5e74\\u4ef6\\u6578\",\"type\":\"3\"}]}','1',1,1696990440,1696998802,'0'),(23862,191,2142,1,'貴公司在過去4個財政年度（2020-2023）是否曾經召回任何產品？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\uff1b\\u66fe\\u7d93\\u6709\\u904e\\u4e00\\u985e(Type I)\\u53ec\\u56de \",\"\\u662f\\uff1b\\u66fe\\u7d93\\u6709\\u904e\\u4e8c\\u985e(Type II)\\u53ec\\u56de \",\"\\u662f\\uff1b\\u66fe\\u7d93\\u6709\\u904e\\u4e09\\u985e(Type III)\\u53ec\\u56de \",\"\\u6c92\\u6709\\u4efb\\u4f55\\u7522\\u54c1\\u53ec\\u56de\"],\"last\":null}','1',7,1696990440,1696998802,'0'),(23863,191,2142,2,'如果是，請註明各類召回的次數和價值(以百萬美元為單位)。 ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"I\\u985e\\u53ec\\u56de\\u6b21\\u6578\"},{\"title\":\"I\\u985e\\u53ec\\u56de\\u7522\\u54c1\\u7684\\u7e3d\\u91d1\\u984d\"},{\"title\":\"II\\u985e\\u53ec\\u56de\\u6b21\\u6578\"},{\"title\":\"\\u53ec\\u56de\\u7522\\u54c1\\u7684\\u7e3d\\u91d1\\u984d\"}],\"cols\":[{\"title\":\"FY 2019\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY  2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',6,1696990440,1696998802,'0'),(23864,191,2142,3,'若公司並未發生產品召回，也請公開揭露在此報導期間並未發生產品召回事件。','TextLong','0','',NULL,'[]','1',5,1696990440,1696998802,'0'),(23865,191,2144,1,'請指出與上一年相比，貴公司的美國產品組合中的平均定價和平均淨價的百分比變化（根據報告貨幣的銷售額加權計算）。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u5e73\\u5747\\u5b9a\\u50f9\"},{\"title\":\"\\u5e73\\u5747\\u6de8\\u50f9\"}],\"cols\":[{\"title\":\"FY 2020   \",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','0',4,1696990440,1696998802,'0'),(23866,191,2144,2,'如果無法在公司級別匯總數據，請說明選擇在上表中代表的營業單位/產品部門，以及該部門產生的收入（以總收入的百分比為單位）','TextLong','0','',NULL,'[]','0',3,1696990440,1696998802,'0'),(23867,191,2144,3,'如果不適用。請在下面的評論框中提供解釋。','TextLong','0','',NULL,'[]','0',2,1696990440,1696998802,'0'),(23868,191,2144,4,'請提供佐證資料','UploadFile','0','',NULL,'[]','0',1,1696990440,1696998802,'0'),(23869,191,2145,1,'公司是否通過健康經濟評估（例如成本效益、成本效用、成本效益分析）來評估產品對醫療保健成本的影響，並在可能的情況下將其與標準治療方案和其他競爭性創新進行比較？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\u7684\\uff0c\\u516c\\u53f8\\u901a\\u904e\\u5065\\u5eb7\\u7d93\\u6fdf\\u8a55\\u4f30\\uff08\\u4f8b\\u5982\\u6210\\u672c\\u6548\\u76ca\\u3001\\u6210\\u672c\\u6548\\u7528\\u3001\\u6210\\u672c\\u6548\\u76ca\\u5206\\u6790\\uff09\\u4f86\\u8a55\\u4f30\\u7522\\u54c1\\u5c0d\\u91ab\\u7642\\u4fdd\\u5065\\u6210\\u672c\\u7684\\u5f71\\u97ff\\uff0c\\u4e26\\u5728\\u53ef\\u80fd\\u7684\\u60c5\\u6cc1\\u4e0b\\u5c07\\u5176\\u8207\\u6a19\\u6e96\\u6cbb\\u7642\\u65b9\\u6848\\u548c\\u5176\\u4ed6\\u7af6\\u722d\\u6027\\u5275\\u65b0\\u9032\\u884c\\u6bd4\\u8f03\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u4e0d\\u6703\\u901a\\u904e\\u5065\\u5eb7\\u7d93\\u6fdf\\u8a55\\u4f30\\u4f86\\u8a55\\u4f30\\u6211\\u5011\\u7684\\u7522\\u54c1\\u5c0d\\u91ab\\u7642\\u4fdd\\u5065\\u6210\\u672c\\u7684\\u5f71\\u97ff\\u3002\",\"\\u4e0d\\u9069\\u7528\\u3002\\u8acb\\u5728\\u4e0b\\u9762\\u7684\\u8a55\\u8ad6\\u6846\\u4e2d\\u63d0\\u4f9b\\u89e3\\u91cb\\u3002\"]}','0',8,1696990440,1696998802,'0'),(23870,191,2145,2,'如果是，請回答下列問題','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u8acb\\u8aaa\\u660e\\u8a55\\u4f30\\u7522\\u54c1\\u7684\\u767e\\u5206\\u6bd4\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"\\u8acb\\u8aaa\\u660e\\u60a8\\u53ef\\u4ee5\\u5728\\u4e0a\\u4e00\\u8ca1\\u653f\\u5e74\\u5ea6\\u7522\\u751f\\u7684\\u6536\\u5165\\u4e2d\\u63d0\\u4f9b\\u6b64\\u985e\\u8b49\\u64da\\u7684\\u767e\\u5206\\u6bd4\"},{\"type\":\"3\",\"title\":\"\\u8acb\\u8aaa\\u660e\\u8207\\u6a19\\u6e96\\u91ab\\u5b78\\u7642\\u6cd5\\u76f8\\u6bd4\\uff0c\\u9019\\u4e9b\\u8a55\\u4f30\\u5728\\u4e0a\\u4e00\\u8ca1\\u653f\\u5e74\\u5ea6\\u7522\\u751f\\u7684\\u96c6\\u5718\\u7e3d\\u6536\\u5165\\u4e2d\\u5177\\u6709\\u986f\\u8457\\u6210\\u672c\\u6548\\u76ca\\u7684\\u767e\\u5206\\u6bd4\"},{\"type\":\"1\",\"title\":\"\\u8acb\\u8aaa\\u660e\\u8207\\u5176\\u4ed6\\u7af6\\u722d\\u6027\\u5275\\u65b0\\u76f8\\u6bd4\\uff0c\\u9019\\u4e9b\\u8a55\\u4f30\\u5728\\u4e0a\\u4e00\\u8ca1\\u653f\\u5e74\\u5ea6\\u7522\\u751f\\u7684\\u96c6\\u5718\\u7e3d\\u6536\\u5165\\u4e2d\\u6240\\u4f54\\u7684\\u767e\\u5206\\u6bd4\"}]}','0',7,1696990440,1696998802,'0'),(23871,191,2145,3,'如果是，請提供作證資料','UploadFile','0','',NULL,'[]','0',6,1696990440,1696998802,'0'),(23872,191,2145,4,'如果不是，請解釋狀況。','TextLong','0','',NULL,'[]','0',5,1696990440,1696998802,'0'),(23873,191,2146,1,'在過去五年中，有多少創新產品獲得了上市許可一直得到知名衛生技術評估機構（HTA，如 NICE、IQWIG、PBAC 等）？','ChoiceOne','0','只有在任何其他知名機構沒有做出負面決定的情況下，才應將產品包括在內。因此，如果兩個或多個機構對產品進行評論，並且其中任何一個機構提供負面評論，則該產品不被視為始終如一的認可。\n\n注：衛生技術評估機構，如英國的NICE、德國的IQWIG、加拿大的CDR和澳大利亞的PBAC，評估新藥的相對有效性和/或成本效益（取決於立法），並就藥物和干預措施的益處、使用和/或報銷提出建議。',NULL,'{\"values\":[\"\\u7d93\\u904e\\u5be9\\u67e5\\u7684HTA\\u4e00\\u81f4\\u8a8d\\u53ef\\u7684\\u7522\\u54c1\\u767e\\u5206\\u6bd4\\uff08\\u5360\\u5be9\\u67e5\\u7684\\u5275\\u65b0\\u7522\\u54c1\\u7e3d\\u6578\\u7684\\u767e\\u5206\\u6bd4\\uff09\",\"\\u6211\\u5011\\u7684\\u7522\\u54c1\\u5747\\u672a\\u7372\\u5f97\\u76f8\\u95dcHTA\\u7684\\u8a8d\\u53ef\",\"\\u4e0d\\u9069\\u7528\\u3002\\u8acb\\u5728\\u4e0b\\u9762\\u7684\\u8a55\\u8ad6\\u6846\\u4e2d\\u63d0\\u4f9b\\u89e3\\u91cb\\u3002\",\"\\u4e0d\\u77e5\\u9053\"]}','0',4,1696990440,1696998802,'0'),(23874,191,2146,2,'請提供證據，說明“經過審查的HTA一致認可的產品百分比（占審查的創新產品總數的百分比）”。','TextItem','0','',NULL,'[]','0',3,1696990440,1696998802,'0'),(23875,191,2146,3,'如果不是，請說明此一狀況','TextLong','0','',NULL,'[]','0',2,1696990440,1696998802,'0'),(23876,191,2147,1,'公司是否系統地衡量您對改善患者整個護理周期的貢獻？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\",\"\\u4e0d\\u662f\\uff0c\\u6211\\u5011\\u4e0d\\u6703\\u7cfb\\u7d71\\u5730\\u8861\\u91cf\\u6211\\u5011\\u5c0d\\u6539\\u5584\\u60a3\\u8005\\u6574\\u500b\\u8b77\\u7406\\u5468\\u671f\\u7684\\u8ca2\\u737b\",\"\\u4e0d\\u662f\\uff0c\\u8acb\\u65bc\\u4e0b\\u65b9\\u63d0\\u51fa\\u8aaa\\u660e\",\"\\u4e0d\\u77e5\\u9053\"]}','0',6,1696990440,1696998802,'0'),(23877,191,2147,2,'主要專案\n如果是，請簡要說明關鍵計劃、用於衡量其影響的最相關的關鍵績效指標以及相應的影響數位。請為每個關鍵計劃提供支持證據。','ColumnInput','0','貨幣：美元 (USD)',NULL,'{\"rows\":[{\"title\":\"\\u9810\\u9632\\u63aa\\u65bd\"},{\"title\":\"\\u8a3a\\u65b7 \"},{\"title\":\"\\u6cbb\\u7642\\uff08\\u4f9d\\u5f9e\\u6027\\u548c\\u5eb7\\u5fa9\\uff09 \"},{\"title\":\"\\u7aef\\u5230\\u7aef(\\u5b8c\\u6574?)\\u5faa\\u74b0\\u89e3\\u6c7a\\u65b9\\u6848\\/\\u5176\\u4ed6\\u8a08\\u5283\"}],\"cols\":[{\"title\":\"\\u8acb\\u5728\\u4e0b\\u9762\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\u548c\\u76f8\\u95dc\\u8aaa\\u660e\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u7528\\u65bc\\u8861\\u91cf\\u5f71\\u97ff\\u7684 KPI\\uff08\\u4f8b\\u5982\\uff0c\\u9054\\u5230\\u7684\\u60a3\\u8005\\u6578\\u91cf #\\uff09\"},{\"type\":\"1\",\"title\":\"2023\\u5e74\\u7684\\u5f71\\u97ff\"},{\"type\":\"1\",\"title\":\"2024\\u5e74\\u7684\\u9810\\u4f30\"}]}','0',5,1696990440,1696998802,'0'),(23878,191,2147,3,'全球範圍內實施的計劃數量（占計劃總數的百分比）？','TextLong','0','請提供佐證說明',NULL,'[]','0',4,1696990440,1696998802,'0'),(23879,191,2147,4,'公司在多少疾病領域/適應症中為改善患者全週期護理做出了貢獻（與貴公司相關的疾病領域的百分比）\n','TextLong','0','請提供佐證資料',NULL,'[]','0',3,1696990440,1696998802,'0'),(23880,191,2147,5,'請提供佐證資料','UploadFile','0','',NULL,'[]','0',2,1696990440,1696998802,'0'),(23881,191,2148,1,'公司是否向所有利益相關者提供患者結果數據？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\",\"\\u6211\\u5011\\u6c92\\u6709\\u9019\\u6a23\\u7684\\u6d41\\u7a0b\",\"\\u4e0d\\u9069\\u7528\\u3002\\u8acb\\u5728\\u4e0b\\u9762\\u7684\\u8a55\\u8ad6\\u6846\\u4e2d\\u63d0\\u4f9b\\u89e3\\u91cb\",\"\\u4e0d\\u77e5\\u9053\"]}','0',7,1696990440,1696998802,'0'),(23882,191,2148,2,'如果是，請說明提供哪類資料，並提供支持證據。','TextLong','0','• 臨床試驗和上市後觀察研究的結果\n• 付款方/監管機構/健康技術評估機構\n• 醫療專業人員/患者倡導組織/患者\n• 與安全性和有效性相關的患者層次的臨床研究數據\n• 成本效益分析和藥物經濟學/健康經濟學數據',NULL,'[]','0',6,1696990440,1696998802,'0'),(23883,191,2148,3,'如果是，請說明向誰提供這一資訊，並提供支持證據。','TextLong','0','•臨床試驗和上市后觀察性研究的結果\n•付款人/監管機構/HTA\n•醫療保健專業人員/患者倡導團體/患者\n•與安全性和有效性相關的患者級臨床研究數據\n•付款人/監管機構/HTA\n•醫療保健專業人員/患者倡導團體/患者\n•成本效益分析和藥物經濟學/健康經濟數據\n•付款人/監管機構/HTA\n•醫療保健專業人員/患者倡導團體/患者',NULL,'[]','0',5,1696990440,1696998802,'0'),(23884,191,2148,4,'如果是，請說明公司在上一財政年度是否因與隱瞞臨床數據有關的備案和訴訟而產生費用或罰款，並提供支持證據：\n\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u5982\\u679c\\u662f\\uff0c\\u8acb\\u8aaa\\u660e\\u91d1\\u984d\",\"\\u4e0d\\uff0c\\u53bb\\u5e74\\u6c92\\u6709\\u56e0\\u8207\\u96b1\\u779e\\u81e8\\u5e8a\\u6578\\u64da\\u6709\\u95dc\\u7684\\u7533\\u8acb\\u548c\\u8a34\\u8a1f\\u800c\\u7522\\u751f\\u8cbb\\u7528\\u6216\\u7f70\\u6b3e\"]}','0',4,1696990440,1696998802,'0'),(23885,191,2148,5,'若為是，\n請寫出具體金額與幣別\n','TextLong','0','',NULL,'[]','0',3,1696990440,1696998802,'0'),(23886,191,2148,6,'請提供佐證資料\n','UploadFile','0','',NULL,'[]','0',2,1696990440,1696998802,'0'),(23887,191,2149,1,'請提供以下證實侵犯病人隱私之投訴 (若未有任何投訴，則簡單陳述此事實。)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u4f86\\u81ea\\u5916\\u90e8\\u5404\\u65b9\\u4e26\\u7d93\\u7531\\u516c\\u53f8\\u5df2\\u8b49\\u5be6\\u7684\\u6295\\u8a34\\u6578--\\u4fb5\\u72af\\u75c5\\u60a3\\u96b1\\u79c1\\u6216\\u907a\\u5931\\u75c5\\u60a3\\u8cc7\\u6599\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u4f86\\u81ea\\u76e3\\u7ba1\\u6a5f\\u95dc\\u7684\\u6295\\u8a34\\u6578--\\u4fb5\\u72af\\u75c5\\u60a3\\u96b1\\u79c1\\u6216\\u907a\\u5931\\u75c5\\u60a3\\u8cc7\\u6599\"},{\"type\":\"1\",\"title\":\"\\u7d93\\u8b49\\u5be6\\u4e4b\\u8cc7\\u8a0a\\u6d29\\u9732\\u3001\\u5931\\u7aca\\u6216\\u907a\\u5931\\u5ba2\\u6236\\u8cc7\\u6599\\u4e8b\\u4ef6\\u7684\\u7e3d\\u6578\"}]}','0',1,1696990440,1696998802,'0'),(23889,131,1433,4,'請說明本公司相關資訊: \n(1) 本公司法定名稱; (2) 本公司所有權形式(上市公司，僑外資，非上市公司等) (3) 本公司總部位於何處 (4) 本公司營運所在的國家\n','TextLong','0','GRI 2-1 範例\nOO 股份有限公司 (法定名稱)屬於上市公司(股票代號: OOOO)，資本額OO億元。\n公司總部位於台北市，目前在美國、日本、德國等國家皆設有分公司。',NULL,'[]','1',21,1696996178,1697410079,'0'),(23890,167,1889,2,'Please list of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) (SASB HC-BP-240a.2)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Product Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"PQP Category\"},{\"type\":\"1\",\"title\":\"Details\"}]}','1',1,1696996434,1696998577,'0'),(23891,131,1432,2,'請說明本報告書報導期間: 例如 2023/1/1-2023/12/31 ','TextLong','0','GRI 2-3 報導期間、頻率及聯絡人(1)',NULL,'[]','1',17,1696996634,1697410079,'0'),(23892,131,1432,3,'請說明本次發布之時間: 例如2023年6月份; 並說明永續報導頻率 (上次發行時間與未來預計發行時間)','TextLong','0','GRI 2-3 報導期間、頻率及聯絡人(2)\n',NULL,'[]','1',16,1696996634,1697410079,'0'),(23893,167,1891,1,'Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic products to market for a defined time period. (SASB HC-BP-240b.1.)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of ANDA litigation\"},{\"type\":\"1\",\"title\":\"ANDA litigation-details\"},{\"type\":\"1\",\"title\":\"ANDA litigation-mitigation\"},{\"type\":\"1\",\"title\":\"Resolved \\/ Target resolved Date\"}]}','1',4,1696996658,1696998577,'0'),(23894,131,1432,7,'請說明本報告書參考了以下哪些國內外標準/準則進行編寫? ','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u4e0a\\u5e02\\u6ac3\\u516c\\u53f8\\u7de8\\u88fd\\u8207\\u7533\\u5831\\u6c38\\u7e8c\\u5831\\u544a\\u66f8\\u4f5c\\u696d\\u8fa6\\u6cd5\",\"GRI 2021\",\"SASB\\u884c\\u696d\\u6e96\\u5247\",\"TCFD\",\"\\u806f\\u5408\\u570b\\u76df\\u7d04\",\"\\u5176\\u4ed6(\\u8acb\\u8aaa\\u660e)\"]}','1',12,1696996793,1697410079,'0'),(23895,131,1432,8,'本年度是否有資料重編的情況? (例如基準年改變，邊界擴大而重新計算，去年資料發生錯誤等) ','TextLong','0','GRI 2-4 \n請說明本報告書今年度是否有資料重編，可能因為：基準年改變、邊界改變或去年度資料計算錯誤等因素造成，請說明之，並解釋影響。',NULL,'[]','1',11,1696996793,1697410079,'0'),(23896,131,1432,4,'本報告書資訊問題的聯絡人','TextLong','0','GRI 2-3 報導期間、頻率及聯絡人 (3) \n如果您對於本報告書的內容有任何指教或建議，歡迎透過以下方式聯絡我們\n負責單位/人：OOOOO\n聯繫電話：OOOOO\nE-mail：OOOO',NULL,'[]','1',15,1696997027,1697410079,'0'),(23897,131,1432,9,'請說明今年出版本報告書之特殊意義?','TextLong','0','例如: 擴大邊界(首度納入OO 子公司)；首度納入/採用OO標準等',NULL,'[]','1',10,1696997027,1697410079,'0'),(23898,131,1432,10,'請說明本次報告書是否通過第三方機構的查驗或會計師事務所的確信流程? ','TextLong','0','GRI 2-5\n1. 請說明外部保證單位名稱，使用保證類別。\n2. 尋求外部確信單位的作法(高階主管是否參加)。\n3. 確認確認聲明資料、等級、是否有限制？(例如AA1000 Type II 中度保證) \n4. 本公司與外部查驗或確信單位之間的關係？',NULL,'[]','1',9,1696997027,1697410079,'0'),(23899,167,1891,2,'Changes in Pricing (SASBHC-BP-240b.2.)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"2022 Average List Price (USD)\"},{\"type\":\"3\",\"title\":\"2023 Average List Price (USD)\"},{\"type\":\"3\",\"title\":\"Changes in Average List Price 2023 vs 2022 (USD)\"},{\"type\":\"3\",\"title\":\"Percentage Change in Average List Price 2023 vs 2022 (%)\"},{\"type\":\"3\",\"title\":\"2022 Net Price (USD)\"},{\"type\":\"3\",\"title\":\"2023 Average Net Price (USD)\"},{\"type\":\"3\",\"title\":\"Changes in Net List Price 2023 vs 2022 (USD)\"},{\"type\":\"3\",\"title\":\"Percentage Net in Average List Price 2023 vs 2022 (%)\"},{\"type\":\"1\",\"title\":\"Details on changes (including reasons for increase or decrease)\"}]}','1',3,1696997214,1696998577,'0'),(23900,167,1891,3,'Based on the findings on changes in Pricing, please provide more details on the product with largest increase compared to previous year (SASB HC-BP-240b.3.)','TextLong','0','',NULL,'[]','1',2,1696997214,1696998577,'0'),(23901,167,1891,4,'Please upload supporting documents.','UploadFile','0','',NULL,'[]','1',1,1696997237,1696998577,'0'),(23903,131,1432,1,'報導邊界: 請說明本報告書包含實體 (例如總公司，子公司，分公司，合資企業，關係企業等)','ColumnInput','0','GRI 2-2\n1. 請列出本報告書所包含的所有實體\n2. 本報告書包含之實體，例如公司總部/子公司/分公司/工廠/研發中心等\n3. 請說明本公司之少數不受母公司控制的總部/分公司/子公司之少數股權/所有權',NULL,'{\"rows\":[{\"title\":\"\\u7e3d\\u516c\\u53f8\"},{\"title\":\"\\u5de5\\u5ee0A\"},{\"title\":\"\\u5de5\\u5ee0B\"},{\"title\":\"\\u5b50\\u516c\\u53f8\"}],\"cols\":[{\"title\":\"\\u540d\\u7a31(\\u4f8b\\u5982: \\u53f0\\u5317\\u7e3d\\u516c\\u53f8)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5730\\u5740\"},{\"type\":\"1\",\"title\":\"\\u5168\\u8077\\u54e1\\u5de5\\u7e3d\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u7537\\u6027\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u5973\\u6027\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u517c\\u8077\\u54e1\\u5de5\\u7e3d\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u7537\\u6027\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u5973\\u6027\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u975e\\u54e1\\u5de5\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u7537\\u6027\\u4eba\\u6578\"},{\"type\":\"1\",\"title\":\"\\u5973\\u6027\\u4eba\\u6578\"}]}','1',18,1696997831,1697410079,'0'),(23904,167,2150,1,'1.Governance on Access to Medicine (ATM) (SASB HC-BP-000.A)\n1-1 Please highlight any major achievements in the area of ATM','TextLong','0','',NULL,'[]','1',3,1696997984,1696998577,'0'),(23905,167,2150,2,'1-2 Provide 2023 data for ATM related actitvities (SASB HC-BP-000.A)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of patients treated during clinical trials phase\"},{\"type\":\"3\",\"title\":\"Number of patients treated during compassionate use phase\"},{\"type\":\"3\",\"title\":\"Number of patients treated during sales after market approval phase\"},{\"type\":\"3\",\"title\":\"Total number of patients treated in 2023\"}]}','1',2,1696997984,1696998577,'0'),(23907,167,2150,3,'2. New Drug Development and Innovation (SASB HC-BP-000.B)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Details\"},{\"type\":\"1\",\"title\":\"Phase\"},{\"type\":\"1\",\"title\":\"Link to coipany\'s website\"}]}','1',1,1696998300,1696998577,'0'),(23908,131,2151,1,'經營者的話\n(1) 公司何時開始投入永續發展? 透過甚麼方式? 公司對於永續發展的願景為何? ','TextLong','0','GRI 2-22 \n報導組織最高治理單位或最高階的管理階層與永續發展的關係; 及其投入永續發展的策略之聲明。\n\n永續聲明可包括\n(1) 管理在組織的經濟活動與商業關係中所造成對經濟、環境及人群(包含對其人權)的衝擊的短、中、長期願景與策略；\n(2) 組織的目的、商業策略與商業模式如何預防/達成對經濟、環境與人群的負面/正面衝擊；\n(3) 其對永續發展貢獻的短期與中期策略性排序，包括排序如何與政府間的官方文件一致；\n(4) 影響組織與其對於永續發展貢獻的策略的宏觀趨勢(例如：總體經濟、社會、政治)；\n(5) 於報導期間內，組織對於永續發展貢獻的重要事件、成就或失敗；\n(6) 於報導期間內，與組織的重大主題相關的目標與標的的績效瀏覽；\n(7) 組織在下一年及未來三到五年，與其永續發展貢獻相關的主要挑戰、目標與標的',NULL,'[]','1',4,1696998582,1697410079,'0'),(23909,131,2151,2,'經營者的話\n(2) 公司對於2050淨零目標的想法與做法為何? 是否已經有客戶要求我們提出淨零的目標? 公司對於減碳路徑與規劃為何? ','TextLong','0','',NULL,'[]','1',3,1696998582,1697410079,'0'),(23910,131,2151,3,'經營者的話\n(3) 2023年公司的永續發展亮點為何，最重要的永續成果為何? ','TextLong','0','',NULL,'[]','1',2,1696998582,1697410079,'0'),(23911,131,2151,4,'經營者的話\n(4) 公司未來將如何持續推動永續發展? ','TextLong','0','',NULL,'[]','1',1,1696998582,1697410079,'0'),(23912,192,2152,1,'Does your company have predefined financial returns and/or relative financial metrics relevant for Chief Executive Officer’s variable compensation? Please indicate where this information is available:\n\nListed companies are required to provide links to public reports or corporate websites.\n\nNon-Listed companies may provide internal documents and/or links public reports or corporate websites.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company has pre-defined financial returns and\\/or relative financial metrics relevant for Chief Executive Officer\\u2019s variable compensation? Please provide supporting evidence.\",\"No, we do not have pre-defined corporate indicators for our CEO\'s variable compensation or we do not report on them following the disclosure requirements of this question.\"],\"last\":null}','1',5,1696998929,1696999442,'0'),(23913,192,2152,2,'Yes, our company has pre-defined financial returns and/or relative financial metrics relevant for Chief Executive Officer’s variable compensation? Please provide supporting evidence.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Financial Returns (e.g. return on assets, return on equity, return on invested capital, etc.). Please list all metrics used for this category:\",\"Relative Financial Metrics (e.g. comparison to peers using metrics such as total shareholder return, Tobin\\u2019s Q, growth, etc.). Please list all metrics used for this category:\"]}','1',4,1696998929,1696999442,'0'),(23914,192,2152,3,'If you have answered \"Yes\",  please provide 1) Link to Financial Returns (e.g. return on assets, return on equity, return on invested capital, etc.). Please list all metrics used for this category:\n','TextItem','0','',NULL,'[]','1',3,1696998929,1696999442,'0'),(23915,192,2152,4,'If you have answered \"Yes\",  please provide 2) Relative Financial Metrics (e.g. comparison to peers using metrics such as total shareholder return, Tobin’s Q, growth, etc.). Please list all metrics used for this category:','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(23916,192,2152,5,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23917,192,2153,1,'Does your company have the following compensation structures in place to align with long-term performance? \n\nListed companies are required to provide links to public reports or corporate websites.\n\nNon-Listed companies may provide internal documents and/or links public reports or corporate websites.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company has guidelines on deferred bonus, time vesting, and performance period for the CEO\\u2019s variable compensation.\",\"No, we do not have a performance-based variable compensation system or we do not report on this following the disclosure requirements of this question.\"],\"last\":null}','1',4,1696998929,1696999442,'0'),(23918,192,2153,2,'If you have answered \"Yes\",  please indicate where this information is available:','TextLong','0','',NULL,'[]','1',3,1696998929,1696999442,'0'),(23919,192,2153,3,'Yes, our company has guidelines on deferred bonus, time vesting, and performance period for the CEO’s variable compensation.\n1) Deferral of Bonus for Short-term CEO Compensation\n2) Performance Period for Variable CEO Compensation\n3) Time Vesting for Variable CEO Compensation','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Is a portion of the CEO\\u2019s short-term incentive deferred in the form of shares or stock options?\"},{\"title\":\"Please indicate the percentage of the short-term bonus deferred in the form of shares or stock options: (%)\"},{\"title\":\"What is the longest performance period applied to evaluate variable compensation (based on predefinedtargets, either relative or absolute), covered in your executive compensation plan? \"},{\"title\":\"Is there a clawback policy in place? (Please note that compensation that only is time vested is not considered as performance based compensation in this part of the question.)\"},{\"title\":\"Please indicate the longest performance period covered by your executive compensation plan: \"},{\"title\":\"Please give details on clawback provision\"}],\"cols\":[{\"title\":\"Please provide answer\",\"type\":\"1\"}]}','1',2,1696998929,1696999442,'0'),(23920,192,2153,4,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23921,192,2154,1,'Please provide the annual compensation for the Chief Executive Officer and the median of the annual compensation of all other employees as well as the ratio between the two. If you are unable to provide the median, please provide figures for total mean compensation and the ratio using the mean. The currency provided should remain consistent for all figures.','ColumnInput','0','The currency used in the table: TWD - New Taiwan Dollar',NULL,'{\"rows\":[{\"title\":\"Please indicate the total annual compensation of the Chief Executive Officer (or any equivalent position):\"},{\"title\":\"Please indicate either median or mean annual compensation of all employees, except the Chief Executive Officer (or any equivalent position):\"},{\"title\":\"The ratio between the total annual compensation of the Chief Executive Officer and the mean or median employee compensation:\"},{\"title\":\"The ratio between the total annual compensation of the Chief Executive Officer and the mean or median employee compensation:\"}],\"cols\":[{\"title\":\"Median Employee Compensation\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Mean Employee Compensation\"}]}','1',6,1696998929,1696999442,'0'),(23922,192,2154,2,'Public Reporting','ChoiceOne','0','',NULL,'{\"values\":[\"For Listed companies: The information is publicly available. Please provide link to public reports or corporate website.\",\"For Non-Listed companies: The information is available in internal documents, public reports or corporate website.\"]}','1',5,1696998929,1696999442,'0'),(23923,192,2154,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(23924,192,2155,1,'Our policy and measures include the following:\n(Select all that applies)','ChoiceMultiple','0','',NULL,'{\"values\":[\"Explicit statement prohibiting Sexual harassment\",\"Explicit statement prohibiting Non-sexual harassment\",\"Zero tolerance policy for discrimination\",\"Trainings for all employees on discrimination and harassment in the workplace\",\"Defined escalation process for reporting incidents\",\"Corrective or disciplinary action taken in case of discriminatory behavior or harassment\",\"We disclose the number of incidents of discrimination and harassment reviewed in the last fiscal year:\"],\"last\":null}','1',3,1696998929,1696999442,'0'),(23925,192,2155,2,'Number of incidents of discrimination and harassment reviewed in the last fiscal year:','NumberSlider','0','',NULL,'{\"min\":0,\"max\":100}','1',2,1696998929,1696999442,'0'),(23926,192,2155,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23927,192,2156,1,'Please provide the number of employees by gender by the following diversity indicators.\n\n[Managerial position breakdown] -FY 2020','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Non-managers\"},{\"title\":\"Managers\"},{\"title\":\"\\u2022 Junior manager\"},{\"title\":\"\\u2022 Middle manager\"},{\"title\":\"\\u2022 Top manager\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please provide your definition of manager-levels)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',24,1696998929,1696999442,'0'),(23928,192,2156,2,'Please provide the number of employees by gender by the following diversity indicators.\n\n[Managerial position breakdown] -FY 2021','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Non-managers\"},{\"title\":\"Managers\"},{\"title\":\"\\u2022 Junior manager\"},{\"title\":\"\\u2022 Middle manager\"},{\"title\":\"\\u2022 Top manager\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please provide your definition of manager-levels)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',23,1696998929,1696999442,'0'),(23929,192,2156,3,'Please provide the number of employees by gender by the following diversity indicators.\n\n[Managerial position breakdown] -FY 2022','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Non-managers\"},{\"title\":\"Managers\"},{\"title\":\"\\u2022 Junior manager\"},{\"title\":\"\\u2022 Middle manager\"},{\"title\":\"\\u2022 Top manager\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please provide your definition of manager-levels)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',22,1696998929,1696999442,'0'),(23930,192,2156,4,'Please provide the number of employees by gender by the following diversity indicators.\n\n[Managerial position breakdown] -2023 YTD','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Non-managers\"},{\"title\":\"Managers\"},{\"title\":\"\\u2022 Junior manager\"},{\"title\":\"\\u2022 Middle manager\"},{\"title\":\"\\u2022 Top manager\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please provide your definition of manager-levels)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',21,1696998929,1696999442,'0'),(23931,192,2156,5,'Follow-up questions: \nHave you set a public target for women representation?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"]}','1',20,1696998929,1696999442,'0'),(23932,192,2156,6,'If Yes, What is the public target? (%)','NumberInput','0','',NULL,'[]','1',19,1696998929,1696999442,'0'),(23933,192,2156,7,'If Yes, Share of women representation in junior management:  (%) ','NumberInput','0','',NULL,'[]','1',18,1696998929,1696999442,'0'),(23934,192,2156,8,'If Yes, Share of women representation in middle management: (%)','NumberInput','0','',NULL,'[]','1',17,1696998929,1696999442,'0'),(23935,192,2156,9,'If Yes, Share of women representation in top management: (%)','NumberInput','0','',NULL,'[]','1',16,1696998929,1696999442,'0'),(23936,192,2156,10,'Please provide supporting evidence: (e.g. website) ','TextItem','0','',NULL,'[]','1',15,1696998929,1696999442,'0'),(23937,192,2156,11,'If No, do you have plan in place to do so in the future?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"],\"last\":null}','1',14,1696998929,1696999442,'0'),(23938,192,2156,12,'If you have plan in place to do so in the future, which year?','NumberInput','0','',NULL,'[]','1',13,1696998929,1696999442,'0'),(23939,192,2156,13,'[Management positions in revenue-generating functions] FY 2020','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Managers in Revenue-generating functions (e.g. sales)\"},{\"title\":\"Manager in other functions (e.g.support functions such as HR, IT, Legal, etc.)\"},{\"title\":\"Total number of managers\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',12,1696998929,1696999442,'0'),(23940,192,2156,14,'[Management positions in revenue-generating functions] FY 2021','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Managers in Revenue-generating functions (e.g. sales)\"},{\"title\":\"Manager in other functions (e.g.support functions such as HR, IT, Legal, etc.)\"},{\"title\":\"Total number of managers\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',11,1696998929,1696999442,'0'),(23941,192,2156,15,'[Management positions in revenue-generating functions] FY 2022','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Managers in Revenue-generating functions (e.g. sales)\"},{\"title\":\"Manager in other functions (e.g.support functions such as HR, IT, Legal, etc.)\"},{\"title\":\"Total number of managers\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',10,1696998929,1696999442,'0'),(23942,192,2156,16,'[Management positions in revenue-generating functions] 2023 YTD','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Managers in Revenue-generating functions (e.g. sales)\"},{\"title\":\"Manager in other functions (e.g.support functions such as HR, IT, Legal, etc.)\"},{\"title\":\"Total number of managers\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',9,1696998929,1696999442,'0'),(23943,192,2156,17,'[STEM positions] FY 2020 ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"STEM-related positions\"},{\"title\":\"Non-STEM-related positions\"},{\"title\":\"Total number of employees\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',8,1696998929,1696999442,'0'),(23944,192,2156,18,'[STEM positions] FY 2021','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"STEM-related positions\"},{\"title\":\"Non-STEM-related positions\"},{\"title\":\"Total number of employees\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',7,1696998929,1696999442,'0'),(23945,192,2156,19,'[STEM positions] FY 2022','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"STEM-related positions\"},{\"title\":\"Non-STEM-related positions\"},{\"title\":\"Total number of employees\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',6,1696998929,1696999442,'0'),(23946,192,2156,20,'[STEM positions] 2023 YTD\nNote:*STEM refers to Science, Technology, Engineering and Mathematics. To be classified as a STEM employee, the employee should have a STEM-related qualification and make use of these skills in their operational position. Positions include, but are not limited to, the following: Computer programmer, web developer, statistician, logistician, engineer, physicist, scientist, etc.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"STEM-related positions\"},{\"title\":\"Non-STEM-related positions\"},{\"title\":\"Total number of employees\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Definition (please describe which functions\\/job and titles below to this definition)\"},{\"type\":\"3\",\"title\":\"Number of Male\"},{\"type\":\"3\",\"title\":\"Number of Female\"},{\"type\":\"3\",\"title\":\"Total\"}]}','1',5,1696998929,1696999442,'0'),(23947,192,2156,21,'Does your company monitor the following indicators regarding workforce gender diversity?Yes, we monitor the following indicators:\nPlease select the coverage of the data reported on as a % of FTEs:','ChoiceOne','0','',NULL,'{\"values\":[\">75% of FTEs\",\"50-75% of FTEs\",\"25-50% of FTEs\",\"<25% of FTEs\"]}','1',4,1696998929,1696999442,'0'),(23948,192,2156,22,'Diversity Indicator','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Share of women in total workforce (as % of total workforce)\"},{\"title\":\"Share of women in all management positions, including junior, middle and top management (as % of total management positions)\"},{\"title\":\"Share of women in junior management positions, i.e. first level of management (as % of total junior management positions)\"},{\"title\":\"Share of women in top management positions, i.e. maximum two levels away from the CEO or comparable positions (as % of total top management positions)\"},{\"title\":\"Share of women in management positions in revenue-generating functions (e.g. sales) as % of all such managers (i.e. excluding support functions such as HR, IT, Legal, etc.)\"},{\"title\":\"Share of women in STEM-related positions (as % of total STEM positions)\"}],\"cols\":[{\"title\":\"Percentage (0 - 100 %)\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Public Target\"}]}','1',3,1696998929,1696999442,'0'),(23949,192,2156,23,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(23950,192,2156,24,'Please provide supporting document (e.g. organizational chart): ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23951,192,2157,1,'Please provide a breakdown of the workforce according to racial and ethnic self-identifications, or nationality.\n\nBreakdown FY 2020','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total number\"}],\"cols\":[{\"title\":\"Number of non-managers\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of Junior managers\"},{\"type\":\"3\",\"title\":\"Number of Middle managers\"},{\"type\":\"3\",\"title\":\"Number of Top managers\"},{\"type\":\"3\",\"title\":\"Total number of employees\"}]}','1',11,1696998929,1696999442,'0'),(23952,192,2157,2,'Please provide a breakdown of the workforce according to racial and ethnic self-identifications, or nationality.\n\nBreakdown FY 2021','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total number\"}],\"cols\":[{\"title\":\"Number of non-managers\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of Junior managers\"},{\"type\":\"3\",\"title\":\"Number of Middle managers\"},{\"type\":\"3\",\"title\":\"Number of Top managers\"},{\"type\":\"3\",\"title\":\"Total number of employees\"}]}','1',10,1696998929,1696999442,'0'),(23953,192,2157,3,'Please provide a breakdown of the workforce according to racial and ethnic self-identifications, or nationality.\n\nBreakdown FY 2022','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total number\"}],\"cols\":[{\"title\":\"Number of non-managers\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of Junior managers\"},{\"type\":\"3\",\"title\":\"Number of Middle managers\"},{\"type\":\"3\",\"title\":\"Number of Top managers\"},{\"type\":\"3\",\"title\":\"Total number of employees\"}]}','1',9,1696998929,1696999442,'0'),(23954,192,2157,4,'Please provide a breakdown of the workforce according to racial and ethnic self-identifications, or nationality.\n\nBreakdown 2023 YTD','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total number\"}],\"cols\":[{\"title\":\"Number of non-managers\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of Junior managers\"},{\"type\":\"3\",\"title\":\"Number of Middle managers\"},{\"type\":\"3\",\"title\":\"Number of Top managers\"},{\"type\":\"3\",\"title\":\"Total number of employees\"}]}','1',8,1696998929,1696999442,'0'),(23955,192,2157,5,'For others, please specify:','TextItem','0','',NULL,'[]','1',7,1696998929,1696999442,'0'),(23956,192,2157,6,'At least 20% of our workforce is based in the US and we monitor the breakdown of our workforce according to ethnic and racial indicators.\nPlease select the coverage of the data reported on as a % of FTEs:','ChoiceOne','0','',NULL,'{\"values\":[\">75% of FTEs\",\"50-75% of FTEs\",\"25-50% of FTEs\",\"<25% of FTEs\"]}','1',6,1696998929,1696999442,'0'),(23957,192,2157,7,'Breakdown(2023 YTD)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Other, please specify:\"}],\"cols\":[{\"title\":\"Share in total workforce (as % of total workforce)\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Share in all management positions, including junior, middle and senior management (as % of total management workforce)\"}]}','1',5,1696998929,1696999442,'0'),(23958,192,2157,8,'For others, please specify: ','TextItem','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(23959,192,2157,9,'Breakdown based on, please specify:','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Category name:(\\u274f Not relevant)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Share in total workforce (as % of total workforce)\"},{\"type\":\"1\",\"title\":\"Share in all management positions, including junior, middle and senior management (as % of total management workforce)\"}]}','1',3,1696998929,1696999442,'0'),(23960,192,2157,10,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(23961,192,2157,11,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23962,192,2158,1,'Please provide the following diversity indicators if suitable. \nWe do not expect companies to report on all three indicators. We expect at least one of these indicators (disability, LGBTQI+ identification, or another relevant category) to be reported publicly.\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"People with disability\"},{\"title\":\"LGBTQI+\"},{\"title\":\"Other indicator\"}],\"cols\":[{\"title\":\"Number of employees in  FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of employees in  FY 2021\"},{\"type\":\"3\",\"title\":\"Number of employees in  FY 2022\"},{\"type\":\"3\",\"title\":\"Number of employees in  2023 YTD\"}]}','1',3,1696998929,1696999442,'0'),(23963,192,2158,2,'Please specify other indicator:','TextItem','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(23964,192,2158,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23965,192,2159,1,'Does your company conduct gender pay gap analysis or equal pay analysis?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes (Gender pay gap analysis)\",\"Yes (Equal pay analysis)\",\"No, we do not conduct either of these assessments.\"]}','1',7,1696998929,1696999442,'0'),(23966,192,2159,2,'Gender pay gap analysis','ChoiceMultiple','0','',NULL,'{\"values\":[\"We monitor and disclose the results of our gender pay gap analysis by our own\",\"If the gender pay gap analysis information (or the ratios) is publicly reported, please provide the relevant URL below.\",\"Our gender pay gap analysis is third-party verified. Please provide supporting evidence\"]}','1',6,1696998929,1696999442,'0'),(23967,192,2159,3,'URL for publicly reported gender pay gap analysis information (or the ratios):','TextItem','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(23968,192,2159,4,'URL for equal pay assessment by third-party: ','TextItem','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(23969,192,2159,5,'Please fill in the following information (this is only for PEC internal use)\n\nRef: \nDefinition of “Executive level” They hold senior positions and impact company-wide decisions. Executives usually report directly to the CEO and the CEO is included in the definition of executive level.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Executive level (base salary only)\"},{\"title\":\"Executive level (base salary + other cash incentives)\"},{\"title\":\"Management level (base salary + other cash incentives)\"},{\"title\":\"Non-management level (base salary only)\"}],\"cols\":[{\"title\":\"Average women salary Currency: USD\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Average men salary  Currency: USD\"}]}','1',3,1696998929,1696999442,'0'),(23970,192,2159,6,'Indicator\nRef: \nGender pay gap: The gender pay gap is the difference in average gross hourly earnings between women and men – it therefore assesses the difference in pay at the aggregated level\nEqual pay: Equal pay compares the salary of men and women who have the same or equivalent positions to assess whether they are paid the same for equal work.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Mean gender pay gap\"},{\"title\":\"Median gender pay gap\"},{\"title\":\"Mean bonus gap\"},{\"title\":\"Median bonus gap\"}],\"cols\":[{\"title\":\"Difference between men and women employees (%)\",\"type\":\"3\"}]}','1',2,1696998929,1696999442,'0'),(23971,192,2159,7,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23972,192,2160,1,'Number of employees represented by an independent trade union or covered by collective bargaining agreements:\nPlease note: employees who are eligible but are not actually covered by collective bargaining agreements should be excluded from the count.','NumberInput','0','',NULL,'[]','1',6,1696998929,1696999442,'0'),(23973,192,2160,2,'Which type of unions?','TextLong','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(23974,192,2160,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(23975,192,2160,4,'What percent of your total number of employees are represented by an independent trade union or covered by collective bargaining agreements? Please indicate where this is available in your public reporting.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, please answer the next question on the form\",\"We do not track freedom of association metrics.\",\"Not applicable. Please provide explanations in the comment box below.\"]}','1',3,1696998929,1696999442,'0'),(23976,192,2160,5,'If yes, please answer this question','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"% of employees represented by an independent trade union or covered by collective bargaining agreements:\"},{\"title\":\"Link to public reporting\"}],\"cols\":[{\"title\":\"\\u6b04\\u4f4d1\",\"type\":\"1\"}]}','1',2,1696998929,1696999442,'0'),(23977,192,2160,6,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(23978,192,2161,1,'Commitment\nL1. Does the company have a policy commitment in relation to the following labour rights principles? For the user, the \"Working conditions (wages, working hours)\" option would be visible only if selected in HR1.\n','Scale','0','- GRI Disclosure 3-3-c (2021) for topics GRI 407 (2016), GRI 409 (2016), GRI 408 (2016), GRI 406 (2016), GRI 403 (2018)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\"Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"No, and we have no plans to develop a policy\"},{\"title\":\"No, but we plan to within the next two years\"},{\"title\":\"Yes, included within a broader policy or as a stand-alone policy (Please answer L1.1)\"},{\"title\":\"Not applicable (Please provide additional information)\"}]}','1',29,1696998929,1696999442,'0'),(23979,192,2161,2,'Not applicable (Please provide additional information)','TextLong','0','',NULL,'[]','1',28,1696998929,1696999442,'0'),(23980,192,2161,3,'Please input the year the relevant labour rights policy was last reviewed\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\"Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"Year (YYYY)\",\"type\":\"3\"}]}','1',27,1696998929,1696999442,'0'),(23981,192,2161,4,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',26,1696998929,1696999442,'0'),(23982,192,2161,5,'If respondent answers ‘Yes’  in L1, the below question will be displayed for each relevant topic. \nL1.1. For each labour rights policy, is it:\n','ColumnInput','0','- ILO C155 - Occupational Safety and Health Convention 1981 (No. 155); GRI Disclosures 2-23-c, 2-23-d, 2-23-e (2021)\n- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\" Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"Aligned with international labour standards\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Publicly available\"},{\"type\":\"2\",\"title\":\"Approved at most senior level of the company\"},{\"type\":\"2\",\"title\":\"Applied to the company\\u2019s own operations\"},{\"type\":\"2\",\"title\":\"Applied to the company\'s own operations and the value chain (e.g., suppliers, consumers, communities, other business relationships)\"},{\"type\":\"2\",\"title\":\"Developed in consultation with workers and their representatives\"},{\"type\":\"2\",\"title\":\"Developed involving labour rights expertise from inside and outside the company\"},{\"type\":\"2\",\"title\":\"Other (Please provide additional information)\"}]}','1',25,1696998929,1696999442,'0'),(23983,192,2161,6,'Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',24,1696998929,1696999442,'0'),(23984,192,2161,7,'L1.2. Does the existing company’s policy on freedom of association and collective bargaining:\nLinked to: ILO, Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87); GRI Disclosure 2-30 (2021)\n','ChoiceMultiple','0','- ILO, Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87); GRI Disclosure 2-30 (2021)\n- ( Select all that apply)\n',NULL,'{\"values\":[\"Reference the respect for the right of all workers to form and join a trade union of their choice without fear  of intimidation or reprisal and protect workers against  acts of antiunion discrimination\",\"Prohibit any acts of interference in trade unions\",\"Facilitate collective bargaining with the trade  union representatives\",\"Provide trade union representatives with the information required for meaningful bargaining in the context of bona fide negotiations\",\"Reference the respect for the right of workers to submit grievances without suffering\",\"We do have a policy on freedom of association or collective bargaining but it does not include any of these details\",\"We do not have a policy on freedom of association or collective bargaining\"]}','1',23,1696998929,1696999442,'0'),(23985,192,2161,8,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',22,1696998929,1696999442,'0'),(23986,192,2161,9,'Prevention\nL2. In the course of the reporting period, has the company engaged with affected stakeholders or their legitimate representatives in relation to the following labour rights topics? For the user, the \"Working conditions (wages, working hours)\" option would be visible only if selected in HR1.\n','ColumnInput','0','- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\" Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"No engagement on this topic\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"To better understand the risks\\/ impacts in question\"},{\"type\":\"2\",\"title\":\"To discuss potential ways to prevent or mitigate the risks\\/ impacts in question\"},{\"type\":\"2\",\"title\":\"To agree on a way to prevent\\/ mitigate the risks\\/ impacts in question\"},{\"type\":\"2\",\"title\":\"To assess progress in preventing\\/ mitigating the risks \\/impacts in question\"},{\"type\":\"2\",\"title\":\"To collaborate in the prevention\\/ mitigation of the risks\\/ impacts in question\"},{\"type\":\"2\",\"title\":\"Other (Please provide additional information)\"}]}','1',21,1696998929,1696999442,'0'),(23987,192,2161,10,'Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',20,1696998929,1696999442,'0'),(23988,192,2161,11,'L3. What type of action has the company taken in the reporting period with the aim of preventing/mitigating the risks/impacts associated with this labour rights topic? For the user, the \"Working conditions (wages, working hours)\" option would be visible only if selected in HR1.\n','ColumnInput','0','- GRI Disclosure 3-3-d (2021) for topics GRI 407 (2016), GRI 409 (2016), GRI 408 (2016), GRI 406 (2016), GRI 403 (2018)\n- (Matrix – Select all that apply for each line)',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\" Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"Provided internal training\\/ capacity building for the direct workforce\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Built capacity among relevant business relationships (e.g., suppliers, consumers, communities)\"},{\"type\":\"2\",\"title\":\"Conducted an audit process and\\/or corrective action plan\"},{\"type\":\"2\",\"title\":\"Collective Action with peers or other stakeholders, in particular workers\' organizations, to address the issue\"},{\"type\":\"2\",\"title\":\"Collaborated with governmental or regulatory bodies\"},{\"type\":\"2\",\"title\":\"Other (Please provide additional information)\"},{\"type\":\"2\",\"title\":\"No action within reporting period\"}]}','1',19,1696998929,1696999442,'0'),(23989,192,2161,12,'Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',18,1696998929,1696999442,'0'),(23990,192,2161,13,'L4. Who receives training for the following labour rights topics? For the user, the \"Working conditions (wages, working hours)\" option would be visible only if selected in HR1.\n','ColumnInput','0','- GRI Disclosure 3-3-d (2021) for topics GRI 407 (2016), GRI 409 (2016), GRI 408 (2016), GRI 406 (2016), GRI 403 (2018)\n- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\" Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"No training provided\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Select employees\"},{\"type\":\"2\",\"title\":\"All employees\"},{\"type\":\"2\",\"title\":\"Contractors\"},{\"type\":\"2\",\"title\":\"Direct suppliers of the organization\"},{\"type\":\"2\",\"title\":\"Indirect suppliers of the organization\"},{\"type\":\"2\",\"title\":\"Other \\u2013 such as partners, clients, etc.\"}]}','1',17,1696998929,1696999442,'0'),(23991,192,2161,14,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',16,1696998929,1696999442,'0'),(23992,192,2161,15,'L5. How does the company assess progress in preventing/mitigating the risks/impacts associated with the following labour rights topics? For the user, the \"Working conditions (wages, working hours)\" option would be visible only if selected in HR1.\n','ColumnInput','0','- GRI Disclosure 3-3-e (2021) for topics GRI 407 (2016), GRI 409 (2016), GRI 408 (2016), GRI 406 (2016), GRI 403 (2018)\n- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\" Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"No monitoring of progress\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Review topics on ad hoc basis\"},{\"type\":\"2\",\"title\":\"Set annual targets\\/ goals, track progress over time (internal programmes only)\"},{\"type\":\"2\",\"title\":\"Set annual targets\\/ goals, track progress over time (internal and external programmes)\"},{\"type\":\"2\",\"title\":\"Other (Please provide additional information)\"}]}','1',15,1696998929,1696999442,'0'),(23993,192,2161,16,'Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',14,1696998929,1696999442,'0'),(23994,192,2161,17,'Performance\nL6. Do(es) the existing collective bargaining agreement(s) provide(s) more favourable rights than those provided in legislation, where appropriate?\n','ChoiceMultiple','0','- (Select all that apply)',NULL,'{\"values\":[\"Yes, by providing more favourable conditions related to wages\",\"Yes, by providing more favourable conditions related to working hours\",\"Yes, by providing more favourable conditions related to health coverage and\\/or sick leave\",\"Yes, by providing additional rights not otherwise provided (Please provide additional information) \",\"There is (are) no existing collective bargaining agreement(s)\",\"No\"]}','1',13,1696998929,1696999442,'0'),(23995,192,2161,18,'Please provide additional information):','TextLong','0','',NULL,'[]','1',12,1696998929,1696999442,'0'),(23996,192,2161,19,'L7. In the course of the reporting period, what was the percentage of women in managerial positions? (%)\n','ColumnInput','0','- ISAR C.1.1. ',NULL,'{\"rows\":[{\"title\":\"Managerial position\"}],\"cols\":[{\"title\":\"Percent women (%) \",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"}]}','1',11,1696998929,1696999442,'0'),(23997,192,2161,20,'Please provide additional information):','TextLong','0','',NULL,'[]','1',10,1696998929,1696999442,'0'),(23998,192,2161,21,'L8. What was the average ratio of the basic salary and remuneration of women to men (comparing jobs of equal value) during the reporting period?\n','ColumnInput','0','- GRI Disclosure 405-2 (2016) ',NULL,'{\"rows\":[{\"title\":\"Women\"},{\"title\":\"Men\"}],\"cols\":[{\"title\":\"Salary ratio (%) \",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"Choose to not disclose\"}]}','1',9,1696998929,1696999442,'0'),(23999,192,2161,22,'Please provide additional information):','TextLong','0','',NULL,'[]','1',8,1696998929,1696999442,'0'),(24000,192,2161,23,'L9. In the course of the reporting period, how frequently were workers injured (injuries per hour worked)?','ColumnInput','0','ISAR C.3.2; GRI Disclosure 403-9 (2018)',NULL,'{\"rows\":[{\"title\":\"Frequency of injury\"}],\"cols\":[{\"title\":\"Frequency of injury (%)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"Choose to not disclose\"}]}','1',7,1696998929,1696999442,'0'),(24001,192,2161,24,'Please provide additional information):','TextLong','0','',NULL,'[]','1',6,1696998929,1696999442,'0'),(24002,192,2161,25,'L10. In the course of the reporting period, what was the company’s incident rate (injuries per worker)? \n','ColumnInput','0','- ISAR C.3.2; GRI Disclosure 403-9 (2018)\n',NULL,'{\"rows\":[{\"title\":\"Incident rate\"}],\"cols\":[{\"title\":\"Incident rate (%)\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Unknown\"},{\"type\":\"1\",\"title\":\"Choose to not disclose\"}]}','1',5,1696998929,1696999442,'0'),(24003,192,2161,26,'Please provide additional information):','TextLong','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(24004,192,2161,27,'Response and Reporting\nL11. In the course of the reporting period, has the company been involved in providing or enabling remedy if it has caused or contributed to the adverse impact associated with the following labour rights topics? For the user, the \"Working conditions (wages, working hours)\" option would be visible only if selected in HR1.\n','Scale','0','- GRI Disclosure 3-3-d-ii (2021) for topics GRI 407 (2016), GRI 409 (2016), GRI 408 (2016), GRI 406 (2016), GRI 403 (2018)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of association and the effective recognition of the right to collective bargaining\"},{\"title\":\"Forced labour\"},{\"title\":\"Non-discrimination in respect of employment and occupation\"},{\"title\":\"Safe and healthy working environment\"},{\"title\":\"Working conditions (wages, working hours)\"}],\"cols\":[{\"title\":\"No remedy provided\\/enabled\"},{\"title\":\"Yes, remedy provided\\/enabled\"},{\"title\":\"No adverse impact identified or caused\"},{\"title\":\"Choose to not disclose (Please provide more information)\"}]}','1',3,1696998929,1696999442,'0'),(24005,192,2161,28,'Please provide additional information):','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24006,192,2161,29,'L12. Briefly describe additional relevant practical actions the company has taken during the reporting period and/or plans to take to implement the labour rights principles, including any challenges faced and actions taken towards prevention and/or remediation.\n','TextLong','0','GRI Disclosures 3-3-c and 3-3-d (2021) for topics GRI 407 (2016), GRI 409 (2016), GRI 408 (2016), GRI 406 (2016), GRI 403 (2018)',NULL,'[]','1',1,1696998929,1696999442,'0'),(24007,192,2162,1,'Materiality/Saliency\nHR1. Which of the following has the company identified as material human rights topics connected with its operations and/or value chain, whether based on their salience (e.g., the most severe potential negative impacts on people) or another basis? \n','ChoiceMultiple','0','- GRI Disclosure 3-2 (2021)\n- (Select all that apply)\n',NULL,'{\"values\":[\"Freedom of association and the effective recognition of the right to collective bargaining\",\"Child labour \",\"Non-discrimination in respect of employment and occupation \",\"Safe and healthy working environment\",\"Working conditions (wages, working hours) [Prompts additional line \'Working conditions (wages, working hours)\' in Questions L1, L2, L3, L4, L5, L12]\",\"Access to water and sanitation [Prompts additional line \\u2018Access to water and sanitation\\u2019 in Questions HR2\\u2013HR7]\",\"Digital security \\/ privacy [Prompts additional line \'Digital security \\/ privacy\' in Questions HR2\\u2013HR7]\",\"Gender equality and women\'s rights [Prompts additional line \\u2018Gender equality and women\'s rights\\u2019 in Questions HR2\\u2013HR7]\",\"Rights of indigenous peoples [Prompts additional line \\u2018Rights of indigenous peoples\' in Questions HR2\\u2013HR7]\",\"Rights of refugees and migrants [Prompts additional line \'Rights of refugees and migrants\\u2019 in Questions HR2\\u2013HR7]\",\"Other (Please specify)\",\"No human rights topics have been identified as material\"]}','1',19,1696998929,1696999442,'0'),(24008,192,2162,2,'Other (Please specify)','TextLong','0','',NULL,'[]','1',18,1696998929,1696999442,'0'),(24009,192,2162,3,'Commitment\nHR2. Does the company have a policy commitment in relation to the following human rights topics? Matrix will be populated only for the human rights topics selected in HR1.\n','Scale','0','- GRI Disclosures 2-23-a-iv, 2-23-b, 3-3-c (2021)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"No, and we have no plans to develop a policy\",\"type\":\"1\"},{\"type\":\"2\",\"title\":\"No, but we plan to within the next two years\"},{\"type\":\"3\",\"title\":\"Yes,\\u00a0included within a broader policy or as a stand-alone policy [Please answer HR2.1]\"}]}','1',17,1696998929,1696999442,'0'),(24010,192,2162,4,'Please provide additional explanation: ____________________________________________________________________________\n','TextLong','0','',NULL,'[]','1',16,1696998929,1696999442,'0'),(24011,192,2162,5,'Please input the year the relevant human rights policy was last reviewed\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"Year (YYYY)\",\"type\":\"3\"}]}','1',15,1696998929,1696999442,'0'),(24012,192,2162,6,'Please provide additional explanation:____________________________________________________________________________\n','TextLong','0','',NULL,'[]','1',14,1696998929,1696999442,'0'),(24013,192,2162,7,'If respondent answers ‘Yes’ in HR2, the below question will be displayed for each relevant topic.\nHR2.1. For each human rights policy, is it:\n','Scale','0','- GRI Disclosures 2-23-c, 2-23-d, 2-23-e (2021)\n- (Matrix – Select all that apply for each line)',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"Aligned with international human rights standards\",\"type\":\"1\"},{\"type\":\"2\",\"title\":\"Publicly available\"},{\"type\":\"3\",\"title\":\"Approved at most senior level of the company\"},{\"type\":\"4\",\"title\":\"Applied to the company\\u2019s own operations\"},{\"type\":\"5\",\"title\":\"Applied to the company\'s own operations and suppliers\"},{\"type\":\"6\",\"title\":\"Applied to the company\'s own operations and the value chain (e.g., suppliers, consumers, communities, other business relationships)\"},{\"type\":\"7\",\"title\":\"Developed involving human rights expertise from inside outside the company\"},{\"type\":\"8\",\"title\":\"Other (Please provide additional explanation) \"}]}','1',13,1696998929,1696999442,'0'),(24014,192,2162,8,'Other (Please provide additional explanation) ','TextLong','0','',NULL,'[]','1',12,1696998929,1696999442,'0'),(24015,192,2162,9,'Prevention\nHR3. In the course of the reporting period, has the company engaged with affected stakeholders or their legitimate representatives in relation to the following human rights topics? Matrix will be populated only for the human rights topics selected in HR1. \n','Scale','0','- GRI Disclosures 3-1-b, 3-3-f (2021)\n- Select one answer option per line',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"No engagement on this topic\",\"type\":\"1\"},{\"type\":\"2\",\"title\":\"To better understand the risks\\/ impacts in question\"},{\"type\":\"3\",\"title\":\"To discuss potential ways to prevent or mitigate the risks\\/ impacts in question\"},{\"type\":\"4\",\"title\":\"To agree on a way to prevent\\/ mitigate the risks\\/ impacts in question\"},{\"type\":\"5\",\"title\":\"To assess progress in preventing \\/mitigating the risks\\/impacts in question\"},{\"type\":\"6\",\"title\":\"To collaborate in the prevention\\/ mitigation of the risks\\/ impacts in question\"}]}','1',11,1696998929,1696999442,'0'),(24016,192,2162,10,'Please provide additional explanation:\n','TextLong','0','',NULL,'[]','1',10,1696998929,1696999442,'0'),(24017,192,2162,11,'HR4. What type of action has the company taken in the reporting period with the aim of preventing/mitigating the risks/impacts associated with this human rights topic? Matrix will be populated only for the human rights topics selected in HR1.\n','ColumnInput','0','- GRI Disclosure 3-3-d (2021)\n- (Matrix – Select all that apply for each line)',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"Provided internal training\\/ capacity building for the direct workforce\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Built capacity among relevant business relationships (e.g., partners, suppliers, clients, etc.)\"},{\"type\":\"2\",\"title\":\"Conducted an audit process and\\/or corrective action plan\"},{\"type\":\"2\",\"title\":\"Collective Action with peers or other stakeholders to address the issue\"},{\"type\":\"2\",\"title\":\"Collaborated with governmental or regulatory bodies\"},{\"type\":\"2\",\"title\":\"Other (Please provide additional information)\"},{\"type\":\"2\",\"title\":\"No action within reporting period\"}]}','1',9,1696998929,1696999442,'0'),(24018,192,2162,12,'Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',8,1696998929,1696999442,'0'),(24019,192,2162,13,'HR5. Who receives training for the following human rights topics? Matrix will be populated only for the human rights topics selected in HR1.\n','ColumnInput','0','- GRI Disclosure 3-3-d (2021)\n- (Matrix – Select all that apply for each line)',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"No training provided\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Select employees\"},{\"type\":\"2\",\"title\":\"All employees\"},{\"type\":\"2\",\"title\":\"Contractors\"},{\"type\":\"2\",\"title\":\"Direct suppliers of the organization\"},{\"type\":\"2\",\"title\":\"Indirect suppliers of the organization\"},{\"type\":\"2\",\"title\":\"Other (Please provide additional information)\"}]}','1',7,1696998929,1696999442,'0'),(24020,192,2162,14,'Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',6,1696998929,1696999442,'0'),(24021,192,2162,15,'HR6. How does the company assess progress in preventing/mitigating the risks/impacts associated with the following human rights topics? Matrix will be populated only for the human rights topics selected in HR1.\n','Scale','0','- GRI Disclosure 3-3-e (2021)\n- Select one answer option per line',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"No monitoring of progress\",\"type\":\"1\"},{\"type\":\"2\",\"title\":\"Review topics on ad hoc basis\"},{\"type\":\"3\",\"title\":\"Set annual targets\\/ goals, track progress over time (internal programmes only)\"},{\"type\":\"4\",\"title\":\"Set annual targets\\/ goals, track progress over time (internal and external programmes)\"},{\"type\":\"5\",\"title\":\"Other (Please provide additional explanation) \"}]}','1',5,1696998929,1696999442,'0'),(24022,192,2162,16,'Other (Please provide additional explanation) ','TextLong','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(24023,192,2162,17,'Response and Reporting\nHR7. During the reporting period, has the company been involved in providing or enabling remedy where it has caused or contributed to adverse impact associated with the following human rights topic(s)? Matrix will be populated only for the human rights topics selected in HR1.\n','Scale','0','- GRI Disclosure 3-3-d-ii (2021) \n- Select one answer option per line',NULL,'{\"rows\":[{\"title\":\"Freedom of expression\"},{\"title\":\"Access to water and sanitation\"},{\"title\":\"Digital security \\/ privacy\"},{\"title\":\"Gender equality and women\'s rights\"},{\"title\":\"Rights of indigenous peoples\"},{\"title\":\"Rights of refugees and migrants\"}],\"cols\":[{\"title\":\"No remedy provided\\/enabled\",\"type\":\"1\"},{\"type\":\"2\",\"title\":\"Yes, remedy provided\\/enabled\"},{\"type\":\"3\",\"title\":\"No adverse impact identifid or caused\"},{\"type\":\"4\",\"title\":\"Choose to not disclose\"}]}','1',3,1696998929,1696999442,'0'),(24024,192,2162,18,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24025,192,2162,19,'HR8. Briefly describe additional relevant practical actions the company has taken during the reporting period and/or plans to take to implement the human rights principles, including any challenges faced and actions taken towards prevention and/or remediation.','TextLong','0','- GRI Disclosures 3-3-c and 3-3-d (2021)',NULL,'[]','1',1,1696998929,1696999442,'0'),(24026,192,2163,1,'Do you have a publicly available, company-specific policy in place for your commitment to respect human rights? Please indicate where this information is available in your public reporting or corporate website.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes. A statement of commitment to respect human rights in accordance with internationally accepted standards\",\"Yes. A statement of commitment to prevent\\/respect.\",\"The policy also covers: Requirements for our own operations (employees, direct activities, products or services)\",\"The policy also covers: Requirements for our suppliers\",\"he policy also covers:  Requirements for our partners\",\"No, we do not have a human rights policy. \"]}','1',8,1696998929,1696999442,'0'),(24027,192,2163,2,'Does the statement of commitment to prevent/respect the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"human trafficking\",\"forced labor\",\"freedom of association\",\"the right to collective bargaining\",\"equal remuneration\",\"other rights\"]}','1',7,1696998929,1696999442,'0'),(24028,192,2163,3,'Please specify: Other Rights','TextItem','0','',NULL,'[]','1',6,1696998929,1696999442,'0'),(24029,192,2163,4,'If you do not have a human rights policy,please indicate your comments on this topic:','TextLong','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(24030,192,2163,5,'This question requires publicly available information.\nDo you have a publicly available, company-specific policy in place for your commitment to respect human rights? The policy must be company-wide, covering all company operations.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes. We have a publicly available policy for our commitments to human rights.\",\"No, we do not have a human rights policy.\",\"Not applicable. Please provide explanations in the comment box below.\"]}','1',4,1696998929,1696999442,'0'),(24031,192,2163,6,'The policy covers/contains the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"A statement of commitment to respect human rights in accordance with internationally accepted standards\",\"human trafficking\",\"forced labor\",\"child labor\",\"freedom of association\",\"the right to collective bargaining\",\"equal remuneration\",\"discrimination\",\"other rights\",\"Requirements for our own operations (employees, direct activities, products or services)\",\"Requirements for our suppliers\",\"Requirements for our partners\"]}','1',3,1696998929,1696999442,'0'),(24032,192,2163,7,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24033,192,2163,8,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24034,192,2164,1,'Has your company developed a due diligence process to proactively identify and assess potential impacts and risks relating to respecting human rights?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"We are developing a process, but we have not yet conducted any assessments.\",\"No, we do not have a process.\"],\"last\":null}','1',8,1696998929,1696999442,'0'),(24035,192,2164,2,'Does the process covers the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Risk identification in our own operations\",\"Risk identification in our value chain or other activities related to our business\",\"Risk identification in new business relations (mergers, acquisitions, joint ventures...)\",\"We do a systematic periodic review of the risk mapping of potential issues\"]}','1',7,1696998929,1696999442,'0'),(24036,192,2164,3,'Please indicate the issues and vulnerable groups covered or identified in your due diligence risk identification process. Please attach public supporting evidence for all of the aspects covered. Actual or potential human rights issues covered/identified:\nCheck all that apply and provide relevant evidence for each issue covered. We expect at least four issues to be covered.\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Forced labor\",\"Human trafficking\",\"Child labor\",\"Freedom of association\",\"Right to collective bargaining\",\"Equal remuneration\",\"Discrimination\",\"Others\"]}','1',6,1696998929,1696999442,'0'),(24037,192,2164,4,'Others, please specify','TextItem','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(24038,192,2164,5,'Groups at risk of human rights issues covered/identified:\nCheck all that apply and provide evidence for each group covered. We expect at least four groups to be covered.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Own employees\",\"Women\",\"Children\",\"Indigenous people\",\"Migrant workers\",\"Third-party employees\",\"Local communities\",\"Others\"]}','1',4,1696998929,1696999442,'0'),(24039,192,2164,6,'Others, please specify','TextItem','0','',NULL,'[]','1',3,1696998929,1696999442,'0'),(24040,192,2164,7,'If you are developing a process, please provide information indicating the status and expected completion date assessments to be done., ','DateInput','0','',NULL,'{\"type\":\"1\"}','1',2,1696998929,1696999442,'0'),(24041,192,2164,8,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24042,192,2165,1,'Has your company conducted an assessment of potential human rights issues across your business activities in the past three years?\n\nIf Yes, Please specify which types of assessment?','TextLong','0','',NULL,'[]','1',8,1696998929,1696999442,'0'),(24043,192,2165,2,'If Yes, Number of total assessment conducted in the last 3 years','NumberInput','0','',NULL,'[]','1',7,1696998929,1696999442,'0'),(24044,192,2165,3,'If Yes, have there been any risks identified (e.g. risks on potential human right violation)','TextLong','0','',NULL,'[]','1',6,1696998929,1696999442,'0'),(24045,192,2165,4,'If Yes, when/If there were any risks occurred, were there any mitigation actions taken?','TextLong','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(24046,192,2165,5,'If No, it is important that human risk assessments been conducted. Would you have any plan in place to do so? How and when? ','TextLong','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(24047,192,2165,6,'Has your company conducted an assessment of potential human rights issues across your business activities\nin the past three years?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes. We have proactively conducted an assessment of potential human rights issues in the last 3 years. Please complete the table below related to the portion of activities assessed, the portion of activities where risks have been identified, and the portion of activities with mitigation actions taken. If any of the business categories are not material to your company, select \\\"Not relevant\\\" and provide an explanation.\",\"No, we have not conducted a human rights assessment in the last three years.\",\"Not applicable. Please provide an explanation in the comment box below.\",\"Not known\"]}','1',3,1696998929,1696999442,'0'),(24048,192,2165,7,'Category','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"FTEs\"},{\"title\":\"Revenues\"},{\"title\":\"Clients\"},{\"title\":\"Investment Portfolio\"},{\"title\":\"Sites\"},{\"title\":\"Products\"},{\"title\":\"Contractors and Tier I Suppliers (as a % of contractors or Tier I Suppliers)\"},{\"title\":\"Joint Ventures (including stakes above 10%) (as a % of joint ventures)\"},{\"title\":\"Not applicable. We do not have any joint ventures at stakes above 10%.\"}],\"cols\":[{\"title\":\"Own Operations (including Joint Ventures where the company has management control) Please select the basis for reporting (denominator): as a % of\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"A. % of total assessed in last three years\"},{\"type\":\"1\",\"title\":\"B. % of total assessed (column A) where risks have been identified\"},{\"type\":\"1\",\"title\":\"C. % of risk (column B) with mitigation actions taken\"}]}','1',2,1696998929,1696999442,'0'),(24049,192,2165,8,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24050,192,2166,1,'Does your company have human rights mitigation and remediation actions in place?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"],\"last\":null}','1',9,1696998929,1696999442,'0'),(24051,192,2166,2,'If Yes, which types','ChoiceMultiple','0','',NULL,'{\"values\":[\"Processes implemented to mitigate human rights risks\",\"The number of sites with mitigation plans\",\"The type of remediation actions taken\",\"Other\"]}','1',8,1696998929,1696999442,'0'),(24052,192,2166,3,'Other, please specify','TextItem','0','',NULL,'[]','1',7,1696998929,1696999442,'0'),(24053,192,2166,4,'If No, Which types are potentially easier to be implemented in your office?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Processes implemented to mitigate human rights risks\",\"The number of sites with mitigation plans\",\"The type of remediation actions taken\",\"Other\"]}','1',6,1696998929,1696999442,'0'),(24054,192,2166,5,'Other, please specify','TextItem','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(24055,192,2166,6,'Does your company publicly disclose on the following measures?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, our company publicly reports on human rights mitigation and remediation actions. The following are publicly available:\",\"No, we do not publicly report about mitigation and remediation actions\",\"Not applicable. Please provide an explanation in the comment box below.\"]}','1',4,1696998929,1696999442,'0'),(24056,192,2166,7,'The following are publicly available:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Processes implemented to mitigate human rights risks\",\"The number of sites with mitigation plans\",\"The type of remediation actions taken\"]}','1',3,1696998929,1696999442,'0'),(24057,192,2166,8,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24058,192,2166,9,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24059,192,2167,1,'Please fill out the following table for the related training & development data for the last 3 fiscal year (2020~2022) and YTD (end of Oct, 2023). \n\nIndicators by gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total training spending and hours spent on total employees\"},{\"title\":\"Total training spending and hours spent on male employees \"},{\"title\":\"Total training spending and hours spent on female employees\"}],\"cols\":[{\"title\":\"FY 2020 (USD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2021 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2022 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"2023 YTD (USD)\"},{\"type\":\"3\",\"title\":\"2023 YTD (Hours)\"}]}','1',14,1696998929,1696999442,'0'),(24060,192,2167,2,'\nIndicators by Age group','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total training spending and hours spent on total employees \"},{\"title\":\"Total training spending and hours spent on employees with <30 years of age\"},{\"title\":\"Total training spending and hours spent on employees with 31-50 years of age\"},{\"title\":\"Total training spending and hours spent on employees with >51 years of age\"}],\"cols\":[{\"title\":\"FY 2020 (USD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2021 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2022 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"2023 YTD (USD)\"},{\"type\":\"3\",\"title\":\"2023 YTD (Hours)\"}]}','1',13,1696998929,1696999442,'0'),(24061,192,2167,3,'Indicators by Management level','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total training spending and hours spent on junior managers\"},{\"title\":\"Total training spending and hours spent on middle managers\"},{\"title\":\"Total training spending and hours spent on top managers  \"},{\"title\":\"Total training spending and hours spent on non-managers\"}],\"cols\":[{\"title\":\"FY 2020 (USD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2021 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2022 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"2023 YTD (USD)\"},{\"type\":\"3\",\"title\":\"2023 YTD (Hours)\"}]}','1',12,1696998929,1696999442,'0'),(24062,192,2167,4,'Indicators by Ethnicity','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino \"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"}],\"cols\":[{\"title\":\"FY 2020 (USD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 20202 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2021 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2022 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"2023 YTD (USD)\"},{\"type\":\"3\",\"title\":\"2023 YTD (Hours)\"}]}','1',11,1696998929,1696999442,'0'),(24063,192,2167,5,'Please specify other ethnicity','TextItem','0','',NULL,'[]','1',10,1696998929,1696999442,'0'),(24064,192,2167,6,'Indicators by Type of Training ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total training spending and hours spent on internal training \"},{\"title\":\"Total training spending and hours spent on external training \"}],\"cols\":[{\"title\":\"FY 2020 (USD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2021 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2022 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"2023 YTD (USD)\"},{\"type\":\"3\",\"title\":\"2023 YTD (Hours)\"}]}','1',9,1696998929,1696999442,'0'),(24065,192,2167,7,'Please specify Internal training content and coverage','TextLong','0','',NULL,'[]','1',8,1696998929,1696999442,'0'),(24066,192,2167,8,'Please specify External training content and coverage','TextLong','0','',NULL,'[]','1',7,1696998929,1696999442,'0'),(24067,192,2167,9,'Indicators by type of training','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total training spending and hours spent on technical purposes\"},{\"title\":\"Total training spending and hours spent on general\\/managerial purposes\"}],\"cols\":[{\"title\":\"FY 2020 (USD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2021 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2021 (Hours)\"},{\"type\":\"3\",\"title\":\"FY 2022 (USD)\"},{\"type\":\"3\",\"title\":\"FY 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"2023 YTD (USD)\"},{\"type\":\"3\",\"title\":\"2023 YTD (Hours)\"}]}','1',6,1696998929,1696999442,'0'),(24068,192,2167,10,'Please specify Technical training content and coverage','TextLong','0','',NULL,'[]','1',5,1696998929,1696999442,'0'),(24069,192,2167,11,'Please specify Managerial training content and coverage','TextLong','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(24070,192,2167,12,'Please fill out the following table for the related training & development data for the last fiscal year and attach supporting evidence of where this information is reported.\n\nPlease indicate the percentage of global FTEs the data in the table below represents','ChoiceOne','0','',NULL,'{\"values\":[\">75% of all FTEs globally\",\"50-75% of all FTEs globally\",\"25-50% of all FTEs globally\",\"< 25% of all FTEs globally\",\"We do not track these metrics related to employee training and development.\",\"Not applicable.\",\"Not known\"]}','1',3,1696998929,1696999442,'0'),(24071,192,2167,13,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a question is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24072,192,2167,14,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24073,192,2168,1,'Please provide two examples of employee development programs in your company that have been developed to upgrade and improve employee skills. Please fill out the fields of the table and provide supporting evidence.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Time of implementation\"},{\"title\":\"Name & Description of the program\"},{\"title\":\"Description of program objective\\/ business benefits\"},{\"title\":\"Quantitative impact of business benefits (monetary or non monetary)\"},{\"title\":\"% of FTEs participating in the program\"},{\"title\":\"Supporting Evidence (Internal publication)\"},{\"title\":\"Supporting Evidence (Public Information)\"}],\"cols\":[{\"title\":\"Program 1\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Program 2\"}]}','1',4,1696998929,1696999442,'0'),(24074,192,2168,2,'Please provide the program names & details for Program 1','TextLong','0','',NULL,'[]','1',3,1696998929,1696999442,'0'),(24075,192,2168,3,'Please provide the program names & details for Program 2','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24076,192,2168,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24077,192,2169,1,'Please indicate the following information on a standard Human Capital Return on Investment metric, serving as a global measure of the return on your Human Capital programs.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"a) Total Revenue (USD)\"},{\"title\":\"b) Total Operating Expenses (USD)\"},{\"title\":\"c) Total employee related expenses (salaries + benefits)\"},{\"title\":\"Resulting HC ROI (a- (b-c)) \\/ c\"},{\"title\":\"Total Employees, as specified in the \\\"Denominator\\\" question.\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',2,1696998929,1696999442,'0'),(24078,192,2169,2,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24079,192,2170,1,'Please indicate the total number of new employee hire rates and the percentage of open positions filled by internal candidates. Please also report the average hiring cost/FTE for the last fiscal year.\n\nPlease note: The average hiring cost/FTE should specifically relate to the number of employees hired last year, not average cost for all employees.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total number of new employee hires\"},{\"title\":\"Percentage of open positions filled byU(internal hires)\"},{\"title\":\"Average hiring cost\\/FTE Currency: USD\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',9,1696998929,1696999442,'0'),(24080,192,2170,2,'Breakdown by Age Group (Number of employees)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',8,1696998929,1696999442,'0'),(24081,192,2170,3,'Breakdown by Gender (Number of employees)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',7,1696998929,1696999442,'0'),(24082,192,2170,4,'Breakdown by Management Level (Number of employees)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',6,1696998929,1696999442,'0'),(24083,192,2170,5,'Breakdown by Race, ethnicity, nationality, country of origin or cultural background (Number of employees) 複製','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Other\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',5,1696998929,1696999442,'0'),(24084,192,2170,6,'Other, please specify:','TextItem','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(24085,192,2170,7,'DATA BREAKDOWN\nWe break down the new employee hires and/or internal hires data based on the following categories. Please provide supporting evidence:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Age group\",\"Gender\",\"Management level (e.g. junior\\/low level, middle, senior\\/top level management)\",\"Race, ethnicity, nationality, country of origin or cultural background\"]}','1',3,1696998929,1696999442,'0'),(24086,192,2170,8,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24087,192,2170,9,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a question is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24088,192,2171,1,'Does your company use any People Analytics (PA) for any of the analysis work mention in Question 2?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"],\"last\":null}','1',3,1696998929,1696999442,'0'),(24089,192,2171,2,'If Yes, does your company use any People Analytics (PA) in any of the following analysis? (please select all that applies)','ChoiceMultiple','0','',NULL,'{\"values\":[\"Measuring employee performance\",\"Strategic workforce planning\",\"Identifying current workforce skills gaps\",\"Recruiting & hiring (e.g. evaluating recruiting channels, screening of candidates, assessing talent supply\\/demand)\",\"Identifying flight risks to improve retention\",\"Competitive intelligence\",\"Organizational network analysis\"]}','1',2,1696998929,1696999442,'0'),(24090,192,2171,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24091,192,2172,1,'Does your company currently use People Analytics (PA)/or other tools for your Strategic Workforce Planning (SWP)?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes. We use PA\\/other tools.\",\"No, we do not use People Analytics for our Strategic Workforce Planning.\"]}','1',4,1696998929,1696999442,'0'),(24092,192,2172,2,'If Yes, please describe the process in the table below and provide supporting evidence:','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Opportunity: Why does your company use PA\\/other tools for SWP?\"},{\"title\":\"Action\\/process\\/tool used: How PA\\/other tools have been used?\"},{\"title\":\"Outcome: What is the business impact\\/result of the initiative?\"}],\"cols\":[{\"title\":\"Answers\",\"type\":\"1\"}]}','1',3,1696998929,1696999442,'0'),(24093,192,2172,3,'If No, will you consider to do so in the future? Why or why not? ','TextLong','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24094,192,2172,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24095,192,2173,1,'Please indicate the type and employee coverage of the individual performance appraisals used for individual performance-related compensation.\n\nType of performance appraisal','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management by objectives: systematic use of agreed measurable targets by line superior\"},{\"title\":\"Multidimensional performance appraisal (e.g. 360 degree feedback)\"},{\"title\":\"Formal comparative ranking of employees within one employee category\"}],\"cols\":[{\"title\":\"Number of all employees\",\"type\":\"3\"}]}','1',5,1696998929,1696999442,'0'),(24096,192,2173,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',4,1696998929,1696999442,'0'),(24097,192,2173,3,'Does your company conduct individual and/or team-based performance management appraisals and publicly share this information?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our type(s) of individual and\\/or team-based performance management appraisals are publicly available and include the following: (Click all that apply)\",\"No, we do not have any of these types of performance appraisals in place\",\"Not applicable. Please provide explanations in the comment box below\"]}','1',3,1696998929,1696999442,'0'),(24098,192,2173,4,'If yes, please answer this question','ChoiceMultiple','0','',NULL,'{\"values\":[\"Management by objectives\",\"Multidimensional performance appraisal (e.g. 360 degree feedback)\",\"Team-based performance appraisal\",\"Agile conversations\"]}','1',2,1696998929,1696999442,'0'),(24099,192,2173,5,'Performance Appraisal Frequency:\nPlease indicate the frequency at which performance appraisals take place, for at least one type of performance appraisal','ChoiceMultiple','0','',NULL,'{\"values\":[\"Ongoing\",\"Quarterly\\/Twice a year\",\"At least yearly\",\"Not reported\"]}','1',1,1696998929,1696999442,'0'),(24100,192,2174,1,'Does your company provide long-term incentives for employees below the senior management level? \nLong-term incentives for the executive management and/or senior management are not accepted in this question.\nPlease note: senior management includes employees that are at most two management levels from the CEO (or equivalent).\n(1) Employee stock option plan','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"2 years\"},{\"title\":\"3 years\"},{\"title\":\"Longer than 3 years\"},{\"title\":\"Others, please specify\"}],\"cols\":[{\"title\":\"Type of employees below the senior management level the program applies to\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of employees below the senior management level the program applies to\"},{\"type\":\"1\",\"title\":\"Do the long-term incentives include targets associated with sustainability performance? How? \"}]}','1',5,1696998929,1696999442,'0'),(24101,192,2174,2,'(2) employee restricted stock plan','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"2 years\"},{\"title\":\"3 years\"},{\"title\":\"Longer than 3 years\"},{\"title\":\"Others, please specify\"}],\"cols\":[{\"title\":\"Type of employees below the senior management level the program applies to\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of employees below the senior management level the program applies to\"},{\"type\":\"1\",\"title\":\"Do the long-term incentives include targets associated with sustainability performance? How? \"}]}','1',4,1696998929,1696999442,'0'),(24102,192,2174,3,'(3) cash incremental employee stock options','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"2 years\"},{\"title\":\"3 years\"},{\"title\":\"Longer than 3 years\"},{\"title\":\"Others, please specify\"}],\"cols\":[{\"title\":\"Type of employees below the senior management level the program applies to\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of employees below the senior management level the program applies to\"},{\"type\":\"1\",\"title\":\"Do the long-term incentives include targets associated with sustainability performance? How? \"}]}','1',3,1696998929,1696999442,'0'),(24103,192,2174,4,'(4) Others, please specific','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"2 years\"},{\"title\":\"3 years\"},{\"title\":\"Longer than 3 years\"},{\"title\":\"Others, please specify\"}],\"cols\":[{\"title\":\"Type of employees below the senior management level the program applies to\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of employees below the senior management level the program applies to\"},{\"type\":\"1\",\"title\":\"Do the long-term incentives include targets associated with sustainability performance? How? \"}]}','1',2,1696998929,1696999442,'0'),(24104,192,2174,5,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24105,192,2175,1,'Does your company provide special training and/or measures to foster employees\' health and well-being in the following areas?\nPlease select if you have the following programs and policies in place:\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Workplace stress management\",\"Sport & health initiatives\",\"Flexible working hours\",\"Working-from-home arrangements\",\"Part-time working options\",\"Childcare facilities or contributions\",\"Breast-feeding\\/lactation facilities or benefits\",\"Paid parental leave for the primary caregiver in excess of the minimum legal requirement. \",\"Paid parental leave for the non-primary caregiver in excess of the minimum legal requirement. \",\"Paid family or care leave beyond parental leave (care for a child, spouse, partner, dependent, parent, sibling, or other designated relation with a physical or mental health condition)\"],\"last\":null}','1',6,1696998929,1696999442,'0'),(24106,192,2175,2,'For Paid parental leave for the primary caregiver in excess of the minimum legal requirement. Please indicate the number of paid weeks. If the minimum legal requirement is 30 weeks or more, please also tick this option and select the corresponding bracket.','ChoiceOne','0','',NULL,'{\"values\":[\"Less than 12 weeks\",\"12 to 17 weeks\",\"18 to 29 weeks\",\"30 weeks or more\"]}','1',5,1696998929,1696999442,'0'),(24107,192,2175,3,'For Paid parental leave for the non-primary caregiver in excess of the minimum legal requirement. Please indicate the number of paid weeks. If the minimum legal requirement is 4 weeks or more, please also tick this option and select the corresponding bracket.','ChoiceOne','0','',NULL,'{\"values\":[\"Less than 12 weeks\",\"2 weeks\",\"3 weeks\",\"4 weeks or more\"]}','1',4,1696998929,1696999442,'0'),(24108,192,2175,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',3,1696998929,1696999442,'0'),(24109,192,2175,5,'Paid parental leave for the primary caregiver (please enter total number of paid leave in weeks offered to　the majority of your employees):','TextItem','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24110,192,2175,6,'Paid parental leave for the non-primary caregiver (please enter total number of paid leave in weeks　offered to the majority of your employees):','TextItem','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24111,192,2176,1,'Please indicate your company\'s total and voluntary turnover rates for the last 3 years as a percentage of total number of employees in the table below.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total employee turnover rate\"},{\"title\":\"Voluntary employee turnover rate\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',8,1696998929,1696999442,'0'),(24112,192,2176,2,'Please provide breakdown by Age group\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total \"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',7,1696998929,1696999442,'0'),(24113,192,2176,3,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',6,1696998929,1696999442,'0'),(24114,192,2176,4,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior\\/top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',5,1696998929,1696999442,'0'),(24115,192,2176,5,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Other\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',4,1696998929,1696999442,'0'),(24116,192,2176,6,'Other, please specify','TextItem','0','',NULL,'[]','1',3,1696998929,1696999442,'0'),(24117,192,2176,7,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24118,192,2176,8,'DATA BREAKDOWN\nWe break down the data of the total employee turnover rate based on the following categories. Please provide supporting evidence:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Age group\",\"Gender\",\"Management level (e.g. junior\\/low level, middle, senior\\/top level management)\",\"Race, ethnicity, nationality, country of origin or cultural background\"]}','1',1,1696998929,1696999442,'0'),(24119,192,2177,1,'Methodology\nPlease provide a definition of the company\'s approach to measuring employee engagement or satisfaction: Please provide the scale or options used in the survey (e.g. 5 point scale; \"actively engaged\", \"disengaged\", \"strongly agree\", \"agree\", \"don\'t know\", \"disagree\", \"strongly agree\")\n','TextLong','0','',NULL,'[]','1',6,1696998929,1696999442,'0'),(24120,192,2177,2,'If your company only conducts an Employee Engagement or Satisfaction survey every two years, please duplicate the value of the previous year in the table and provide the target for the most recent year a survey was conducted.\nNote: Actively engaged: for example, on 1-5 point scale, points 4-5 are considered actively engaged, 3 equals somewhat engaged, 1-2 are not engaged. For satisfaction levels, 4-5 points are considered satisfied\n\nEmployee engagement','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"% of actively engaged Employees\"},{\"title\":\"Number of employees engaged in the survey\"},{\"title\":\"Number of total employees\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\" FY 2022\"},{\"type\":\"3\",\"title\":\" FY 2023\"}]}','1',5,1696998929,1696999442,'0'),(24121,192,2177,3,'Please provide breakdown by Age group\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\" FY 2022\"},{\"type\":\"3\",\"title\":\" FY 2023\"}]}','1',4,1696998929,1696999442,'0'),(24122,192,2177,4,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Other\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\" FY 2022\"},{\"type\":\"3\",\"title\":\" FY 2023\"}]}','1',3,1696998929,1696999442,'0'),(24123,192,2177,5,'Other, please specify:','TextItem','0','',NULL,'[]','1',2,1696998929,1696999442,'0'),(24124,192,2177,6,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24125,192,2178,1,'Does your company have an OHS policy/ commitment? ','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"]}','1',4,1696998929,1696999442,'0'),(24126,192,2178,2,'Yes, we have a commitment on Occupational Health and Safety and it includes the following elements:','ChoiceMultiple','0','',NULL,'{\"values\":[\"It is applicable to the company\\u2019s entire operations\\/ employees as well as contractors or individuals under the company\\u2019s supervision.\",\"Compliance with relevant OHS international standards and regulations, voluntary programs and\\/or collective agreements on OHS.\",\"Consultation with and participation of workers, and, where they exist, workers\\u2019 representatives.\",\"A commitment to continually improve the performance of the OHS management system.\",\"Setting up prioritization and action plans.\",\"Establishment of quantitative targets for improving OHS performance metrics.\",\"Endorsement of the implementation of the OHS policy.\"]}','1',3,1696998929,1696999442,'0'),(24127,192,2178,3,'Endorsement of the implementation of the OHS policy. Please select the highest endorsing decision- making body:','ChoiceOne','0','',NULL,'{\"values\":[\"Board of directors\",\"Executive management\"]}','1',2,1696998929,1696999442,'0'),(24128,192,2178,4,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24129,192,2179,1,'Does your company have an OHS management system?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"]}','1',3,1696998929,1696999442,'0'),(24130,192,2179,2,'Yes, we have an OHS management system that covers the following elements:\n(Select all that applies)','ChoiceMultiple','0','',NULL,'{\"values\":[\"OHS risk and hazard assessments to identify what could cause harm in the workplace.\",\"Prioritization and integration of action plans with quantified targets to address those risks.\",\"Integration of actions to prepare for and respond to emergency situations.\",\"Evaluation of progress in reducing\\/preventing health issues\\/risks against targets.\",\"Internal inspections.\",\"Independent external verification of health, safety and well-being: please provide the names and standards used (such as ISO 45001)\",\"Procedures to investigate work-related injuries, ill health, diseases and incidents.\",\"OHS training provided to employees and\\/or other relevant parties to raise awareness and reduce operational health & safety incidents.\",\"OHS criteria introduced in procurement and contractual requirements.\"],\"last\":null}','1',2,1696998929,1696999442,'0'),(24131,192,2179,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998929,1696999442,'0'),(24132,192,2180,1,'Please complete the following table with the number of work-related fatalities for employees and contractors.\nNote: Definitions Work-related fatalities: The death of a worker arising from an occupational disease or injury sustained or contracted while performing work that is controlled by the\norganization or that is being performed in workplaces that the organization controls\nFatalities (Employees)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Employees\"},{\"title\":\"Contractors \"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',14,1696998929,1696999442,'0'),(24133,192,2180,2,'Please provide breakdown by Age group\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',13,1696998929,1696999443,'0'),(24134,192,2180,3,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"YTD2023\"}]}','1',12,1696998929,1696999443,'0'),(24135,192,2180,4,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior \\/ top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',11,1696998929,1696999443,'0'),(24136,192,2180,5,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',10,1696998929,1696999443,'0'),(24137,192,2180,6,'Other, please specify:','TextItem','0','',NULL,'[]','1',9,1696998929,1696999443,'0'),(24138,192,2180,7,'Fatalities (Contractors)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Employees (total number)\"},{\"title\":\"Employees (%)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',8,1696998929,1696999443,'0'),(24139,192,2180,8,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 202\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',7,1696998929,1696999443,'0'),(24140,192,2180,9,'Please provide breakdown by Age group','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',6,1696998929,1696999443,'0'),(24141,192,2180,10,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management) ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior \\/ top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2021\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',5,1696998929,1696999443,'0'),(24142,192,2180,11,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2021\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023\"}]}','1',4,1696998929,1696999443,'0'),(24143,192,2180,12,'Other, please specify: ','TextItem','0','',NULL,'[]','1',3,1696998929,1696999443,'0'),(24144,192,2180,13,'THIRD-PARTY VERIFICATION','ChoiceOne','0','',NULL,'{\"values\":[\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\"]}','1',2,1696998929,1696999443,'0'),(24145,192,2180,14,'DATA CONSISTENCY\nWe report publicly on this information, but the data in the table above differs from our publicly reported figures. Please provide an explanation in the comment box for this difference:','TextLong','0','',NULL,'[]','1',1,1696998929,1696999443,'0'),(24146,192,2181,1,' LTIFR=(Number of lost-time injuries ) / (Total hours worked in accounting period)x 1\'000\'000 Lost- Time Injury Rate (LTIR)\nLTIR=(Number of lost-time injuries ) / (Total hours worked in accounting period)x 200\'000 DART (Days Away/Restricted or Transfer Rate)\nLost-Time Injury Frequency Rate (LTIFR) (Employees)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Employees LTIFR (n\\/million hours worked)\"},{\"title\":\"Employees LTIR (n\\/million hours worked)\"},{\"title\":\"Total number of Employees\"},{\"title\":\"Data coverage (as % of employees)\"},{\"title\":\"Data coverage (as % of operations)\"},{\"title\":\"Data coverage (as % of revenues)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',17,1696998929,1696999443,'0'),(24147,192,2181,2,'Please provide breakdown by Age group\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',16,1696998929,1696999443,'0'),(24148,192,2181,3,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 202\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',15,1696998929,1696999443,'0'),(24149,192,2181,4,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior \\/ top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',14,1696998929,1696999443,'0'),(24150,192,2181,5,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',13,1696998929,1696999443,'0'),(24151,192,2181,6,'Other, please specify:','TextItem','0','',NULL,'[]','1',12,1696998929,1696999443,'0'),(24152,192,2181,7,'Alternative Metric\nPlease provide your company\'s Lost Workday Rate (LWR) or Days Away/Restricted or Transfer Rate (DART) for employees (per 200,000 hours worked). \n\nLost-Time Injury Frequency Rate (LTIFR) (Contractors)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Employees Lost Workday Rate (n\\/200,000 hours worked)\"},{\"title\":\"Employees Days Away Restricted Transfer Rate (n\\/200,000 hours worked)\"},{\"title\":\"Total number of employees\"},{\"title\":\"Data coverage (as % of employees)\"},{\"title\":\"Data coverage (as % of operations)\"},{\"title\":\"Data coverage (as % of revenues)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',11,1696998929,1696999443,'0'),(24153,192,2181,8,'Please provide breakdown by Age group','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',10,1696998929,1696999443,'0'),(24154,192,2181,9,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',9,1696998929,1696999443,'0'),(24155,192,2181,10,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management) ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior \\/ top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',8,1696998929,1696999443,'0'),(24156,192,2181,11,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',7,1696998929,1696999443,'0'),(24157,192,2181,12,'Other, please specify: ','TextItem','0','',NULL,'[]','1',6,1696998929,1696999443,'0'),(24158,192,2181,13,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',5,1696998929,1696999443,'0'),(24159,192,2181,14,'THIRD-PARTY VERIFICATION','ChoiceOne','0','',NULL,'{\"values\":[\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\"]}','1',4,1696998929,1696999443,'0'),(24160,192,2181,15,'DATA CONSISTENCY','ChoiceOne','0','',NULL,'{\"values\":[\"We only track DART or LWR on a consolidated basis. Please provide the combined figures in the table above and mark \\\"Not applicable\\\" in the next question (Lost-Time Injuries Frequency Rate (LTIFR) - Contractors).\"]}','1',3,1696998929,1696999443,'0'),(24161,192,2181,16,'We report publicly on this information, but the data in the table above differs from our publicly reported figures. Please provide an explanation in the comment box for this difference:','TextLong','0','',NULL,'[]','1',2,1696998929,1696999443,'0'),(24162,192,2181,17,'We have a temporary coverage reduction or target challenge due to corporate actions. Please briefly explain if a merger, acquisition, divestment, etc. has temporarily caused a reduction in your ability to report optimal coverage or caused your target to appear abnormal:','TextLong','0','',NULL,'[]','1',1,1696998929,1696999443,'0'),(24163,192,2182,1,' LTIFR=(Number of lost-time injuries ) / (Total hours worked in accounting period)x 1\'000\'000 Lost- Time Injury Rate (LTIR)\nLTIR=(Number of lost-time injuries ) / (Total hours worked in accounting period)x 200\'000 DART (Days Away/Restricted or Transfer Rate)\nLost-Time Injury Frequency Rate (LTIFR) (Contractors)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Contractors LTIFR (n\\/million hours worked)\"},{\"title\":\"Contractors LTIR (n\\/million hours worked)\"},{\"title\":\"Total number of contractors\"},{\"title\":\"Data coverage (as % of contractors)\"},{\"title\":\"Data coverage (as % of operations)\"},{\"title\":\"Data coverage (as % of revenues))\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',17,1696998929,1696999443,'0'),(24164,192,2182,2,'Please provide breakdown by Age group\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',16,1696998929,1696999443,'0'),(24165,192,2182,3,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',15,1696998929,1696999443,'0'),(24166,192,2182,4,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior \\/ top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',14,1696998929,1696999443,'0'),(24167,192,2182,5,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',13,1696998929,1696999443,'0'),(24168,192,2182,6,'Other, please specify:','TextItem','0','',NULL,'[]','1',12,1696998929,1696999443,'0'),(24169,192,2182,7,'Alternative Metric\nPlease provide your company\'s Lost Workday Rate (LWR) or Days Away/Restricted or Transfer Rate (DART) for employees (per 200,000 hours worked). \n\nLost-Time Injury Frequency Rate (LTIFR) (Contractors)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Contractors Lost Workday Rate (n\\/200,000 hours worked)\"},{\"title\":\"Contractors Days Away Restricted Transfer Rate (n\\/200,000 hours worked)\"},{\"title\":\"Total number of contractors\"},{\"title\":\"Data coverage (as % of employees)\"},{\"title\":\"Data coverage (as % of operations)\"},{\"title\":\"Data coverage (as % of revenues))\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',11,1696998929,1696999443,'0'),(24170,192,2182,8,'Please provide breakdown by Age group','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"<30 years of age\"},{\"title\":\"31-50 years of age\"},{\"title\":\">51 years of age\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',10,1696998929,1696999443,'0'),(24171,192,2182,9,'Please provide breakdown by Gender','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',9,1696998929,1696999443,'0'),(24172,192,2182,10,'Please provide breakdown by Management level (e.g. junior/low level, middle, senior/top level management) ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Junior manager\"},{\"title\":\"Middle manager\"},{\"title\":\"Senior \\/ top manager\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',8,1696998929,1696999443,'0'),(24173,192,2182,11,'Please provide breakdown by Race, ethnicity, nationality, country of origin or cultural background','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Asian\"},{\"title\":\"Black or African American\"},{\"title\":\"Hispanic or Latino\"},{\"title\":\"White\"},{\"title\":\"Indigenous or Native\"},{\"title\":\"Others\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',7,1696998929,1696999443,'0'),(24174,192,2182,12,'Other, please specify: ','TextItem','0','',NULL,'[]','1',6,1696998929,1696999443,'0'),(24175,192,2182,13,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',5,1696998929,1696999443,'0'),(24176,192,2182,14,'PUBLIC REPORTING','ChoiceOne','0','',NULL,'{\"values\":[\"Our data is publicly available. Please provide supporting evidence or web link.\"]}','1',4,1696998929,1696999443,'0'),(24177,192,2182,15,'THIRD-PARTY VERIFICATION','ChoiceOne','0','',NULL,'{\"values\":[\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\"]}','1',3,1696998929,1696999443,'0'),(24178,192,2182,16,'DATA CONSISTENCY\nWe report publicly on this information, but the data in the table above differs from our publicly reported figures. Please provide an explanation in the comment box for this difference:','TextLong','0','',NULL,'[]','1',2,1696998929,1696999443,'0'),(24179,192,2182,17,'We have a temporary coverage reduction or target challenge due to corporate actions. Please briefly explain if a merger, acquisition, divestment, etc. has temporarily caused a reduction in your ability to report optimal coverage or caused your target to appear abnormal:','TextLong','0','',NULL,'[]','1',1,1696998929,1696999443,'0'),(24180,192,2183,1,'Human Rights Policy (GRI 406, GRI 407, GRI 408, GRI 409)\nPlease answer the following questions.','Scale','0','',NULL,'{\"rows\":[{\"title\":\"Does the compant has Commitments related to respecting human rights (non-discrimination, freedom of association, no child labor, no forced labor, etc.) in place?\"},{\"title\":\"Does the company conduct a human rights risk assessment?\"},{\"title\":\"Does the company have human rights assurance management indicators?\"},{\"title\":\"Are the targets based on monitoring indicators been achieved?\"}],\"cols\":[{\"title\":\"Yes\"},{\"title\":\"No, but we are in the process of implementing\"},{\"title\":\"No, we have no plans of impletmenting\"}]}','1',9,1696998929,1696999443,'0'),(24181,192,2183,2,'If the answer is \"yes,\" please provide specific management measures for the implementation of the policy.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"No Discrimination\"},{\"title\":\"Workers\\u2019 rights to exercise freedom of association\"},{\"title\":\"No Forced Labor\"},{\"title\":\"No Child Labor\"}],\"cols\":[{\"title\":\"Management Measure for Policy\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Management Indicators\"}]}','1',8,1696998929,1696999443,'0'),(24182,192,2183,3,'Human Rights Training\nKindly provide details regarding the total training hours and the percentage of employees who have received training on human rights policies or procedures relevant to your company\'s operational activities.','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Location\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of employees trained (2020)\"},{\"type\":\"3\",\"title\":\"Number of employees trained (2021)\"},{\"type\":\"3\",\"title\":\"Number of employees trained (2022)\"},{\"type\":\"3\",\"title\":\"Number of employees trained (2023)\"},{\"type\":\"3\",\"title\":\"Percentage of employees trained (2020)\"},{\"type\":\"3\",\"title\":\"Percentage of employees trained (2021)\"},{\"type\":\"3\",\"title\":\"Percentage of employees trained (2022)\"},{\"type\":\"3\",\"title\":\"Percentage of employees trained (2023)\"}]}','1',7,1696998929,1696999443,'0'),(24183,192,2183,4,'Prevention of Discrimination and Harassment (GRI 406-1)\nPlease provide a description of the company\'s grievance mechanism and policy. In the year 2023, were there any complaints or reports received by the company related to human rights incidents, encompassing issues such as but not limited to sexual harassment, child labor, forced labor, bullying, and discrimination?','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Sexual harassment\"},{\"title\":\"Child labor\"},{\"title\":\"Forced labor\"},{\"title\":\"Bullying\"},{\"title\":\"Discrimination\"},{\"title\":\"Others\"}],\"cols\":[{\"title\":\"Does the company has a grievance mechanism in place?\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"Please provide information on the grievance channels available\"},{\"type\":\"2\",\"title\":\"Are there any grievance incidents in 2023?\"},{\"type\":\"3\",\"title\":\"If yes, please provide number of grievance cases in 2023\"},{\"type\":\"1\",\"title\":\"Please provide information on grievance incidents\"},{\"type\":\"1\",\"title\":\"Please describe the handling process and outcomes\"}]}','1',6,1696998929,1696999443,'0'),(24184,192,2183,5,'Discrimination Incidents and Company Improvement Actions (GRI 406)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Please provide information on:\"}],\"cols\":[{\"title\":\"Total incident relating to discrimination in 2023\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Investigations process launched by the Company (Please describe the status and actions taken)\"},{\"type\":\"1\",\"title\":\"Implemented Improvement Plans (Please describe the status and actions taken)\"},{\"type\":\"1\",\"title\":\" Completed and Internally Audited Improvement Plans (Please describe the status and actions taken)\"},{\"type\":\"1\",\"title\":\"Incidents Requiring No Action\"}]}','1',5,1696998929,1696999443,'0'),(24185,192,2183,6,'Operations Sites Potentially Facing Freedom of Association and Collective Bargaining (GRI 407-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Freedom of Association\"},{\"title\":\"Collective Bargaining\"}],\"cols\":[{\"title\":\"Comapany\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Locations (country or region)\"},{\"type\":\"1\",\"title\":\" Actions Taken by the Company to Ensure Employee Freedom of Association and Collective Bargaining Rights\"}]}','1',4,1696998929,1696999443,'0'),(24186,192,2183,7,'Significant Risks of Child Labor in Operating Locations (GRI 408-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Use of Child Labor\"},{\"title\":\"Employing Minors in Hazardous Work\"}],\"cols\":[{\"title\":\"Comapany\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Locations (country or region)\"},{\"type\":\"1\",\"title\":\" Actions Taken by the Company to Ensure Employee Freedom of Association and Collective Bargaining Rights\"}]}','1',3,1696998929,1696999443,'0'),(24187,192,2183,8,'Significant Risks of Forced or Compulsory Labor (GRI 409-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Forced Labor\"},{\"title\":\"Compulsory Labor\"}],\"cols\":[{\"title\":\"Comapany\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Locations (country or region)\"},{\"type\":\"1\",\"title\":\" Actions Taken by the Company to Ensure Employee Freedom of Association and Collective Bargaining Rights\"}]}','1',2,1696998929,1696999443,'0'),(24188,192,2183,9,'Security Personnel Training on Human Rights Policies or Procedures (GRI 410-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u7b2c\\u4e00\\u984c\"}],\"cols\":[{\"title\":\"Percentage of Security Personnel Trained on Human Rights Policies (%)\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Please describe the Application in Security Operations\"},{\"type\":\"2\",\"title\":\"Have external training providers received professional training on human rights policies?\"}]}','1',1,1696998929,1696999443,'0'),(24189,192,2184,1,'1. Diversity-Friendly Workplace\n1-1 Percentage of Diversity Among Management and Employees (GRI 405-1)\nPEC HQ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of Employees\"},{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Age: 30 years old and below\"},{\"title\":\"Age: 30-50 years old\"},{\"title\":\"Age: 51 years old and above\"},{\"title\":\"Permanent\"},{\"title\":\"Part-timers\"},{\"title\":\"Doctorate Degree\"},{\"title\":\"Master\'s Degree\"},{\"title\":\"Bachelor\'s Degree\"},{\"title\":\"Other\"},{\"title\":\"Experience: Less than 1 year\"},{\"title\":\"Experience: 1-3 years\"},{\"title\":\"Experience: 3-5 years\"},{\"title\":\"Experience: 10-20 years\"},{\"title\":\"Experience: 20 years and above\"}],\"cols\":[{\"title\":\"Male (number)\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Male (%)\"},{\"type\":\"3\",\"title\":\"Female (number)\"},{\"type\":\"3\",\"title\":\"Female (%)\"},{\"type\":\"3\",\"title\":\"Total (number)\"},{\"type\":\"3\",\"title\":\"Total (%)\"},{\"type\":\"3\",\"title\":\"Average age of employees\"},{\"type\":\"3\",\"title\":\"Average years of experience\"}]}','1',21,1696998929,1696999443,'0'),(24190,192,2184,2,'1. Diversity-Friendly Workplace\n1-2 Percentage of Diversity Among Management and Employees (GRI 405-1)\nPANCO','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of Employees\"},{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Age: 30 years old and below\"},{\"title\":\"Age: 30-50 years old\"},{\"title\":\"Age: 51 years old and above\"},{\"title\":\"Permanent\"},{\"title\":\"Part-timers\"},{\"title\":\"Doctorate Degree\"},{\"title\":\"Master\'s Degree\"},{\"title\":\"Bachelor\'s Degree\"},{\"title\":\"Other\"},{\"title\":\"Experience: Less than 1 year\"},{\"title\":\"Experience: 1-3 years\"},{\"title\":\"Experience: 3-5 years\"},{\"title\":\"Experience: 10-20 years\"},{\"title\":\"Experience: 20 years and above\"}],\"cols\":[{\"title\":\"Male (number)\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Male (%)\"},{\"type\":\"3\",\"title\":\"Female (number)\"},{\"type\":\"3\",\"title\":\"Female (%)\"},{\"type\":\"3\",\"title\":\"Total (number)\"},{\"type\":\"3\",\"title\":\"Total (%)\"},{\"type\":\"3\",\"title\":\"Average age of employees\"},{\"type\":\"3\",\"title\":\"Average years of experience\"}]}','1',20,1696998929,1696999443,'0'),(24191,192,2184,3,'1-3. The Compensation and Remuneration Ratio of Male Employees Compared to Female Employees in 2023.\nPEC HQ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employee (non managerial)\"}],\"cols\":[{\"title\":\"Average Salary-Male (NTD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Average Salary-Female (NTD)\"},{\"type\":\"3\",\"title\":\"Average Basic Salary Ratio by Job Position (NTD)\"},{\"type\":\"1\",\"title\":\"Compensation Ratio\"},{\"type\":\"1\",\"title\":\" Salary Ratio\"}]}','1',19,1696998929,1696999443,'0'),(24192,192,2184,4,'1-3. The Compensation and Remuneration Ratio of Male Employees Compared to Female Employees in 2023.\nPANCO','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employee (non managerial)\"}],\"cols\":[{\"title\":\"Average Salary-Male (NTD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Average Salary-Female (NTD)\"},{\"type\":\"3\",\"title\":\"Average Basic Salary Ratio by Job Position (NTD)\"},{\"type\":\"1\",\"title\":\"Compensation Ratio\"},{\"type\":\"1\",\"title\":\" Salary Ratio\"}]}','1',18,1696998929,1696999443,'0'),(24193,192,2184,5,'1-4. Salary Information for Non-Managerial Full-Time Employees Over the Past 4 Years.\nPEC HQ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of Employees\"},{\"title\":\"Total Salary (NTD)\"},{\"title\":\"Average Salary\"},{\"title\":\"Median Salary\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',17,1696998929,1696999443,'0'),(24194,192,2184,6,'1-4. Salary Information for Non-Managerial Full-Time Employees Over the Past 4 Years.\nPANCO','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of Employees\"},{\"title\":\"Total Salary (NTD)\"},{\"title\":\"Average Salary\"},{\"title\":\"Median Salary\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',16,1696998929,1696999443,'0'),(24195,192,2184,7,'2. New Hires and Departures of Employees in the Past 4 Years (GRI 401-1)\n2-1a In 2020','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Age: 30 years old and below\"},{\"title\":\"Age: 30-50 years old\"},{\"title\":\"Age: 51 years old and above\"},{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Locals\"},{\"title\":\"Foreigners\"},{\"title\":\"PEC HQ\"},{\"title\":\"PANCO\"}],\"cols\":[{\"title\":\"New Hires (Number of Employees)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"New Hires Rate (%)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure Rate (%)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure Rate (%)\"}]}','1',15,1696998929,1696999443,'0'),(24196,192,2184,8,'2. New Hires and Departures of Employees in the Past 4 Years (GRI 401-1)\n2-1b In 2021','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Age: 30 years old and below\"},{\"title\":\"Age: 30-50 years old\"},{\"title\":\"Age: 51 years old and above\"},{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Locals\"},{\"title\":\"Foreigners\"},{\"title\":\"PEC HQ\"},{\"title\":\"PANCO\"}],\"cols\":[{\"title\":\"New Hires (Number of Employees)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"New Hires Rate (%)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure Rate (%)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure Rate (%)\"}]}','1',14,1696998929,1696999443,'0'),(24197,192,2184,9,'2. New Hires and Departures of Employees in the Past 4 Years (GRI 401-1)\n2-1c In 2022','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Age: 30 years old and below\"},{\"title\":\"Age: 30-50 years old\"},{\"title\":\"Age: 51 years old and above\"},{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Locals\"},{\"title\":\"Foreigners\"},{\"title\":\"PEC HQ\"},{\"title\":\"PANCO\"}],\"cols\":[{\"title\":\"New Hires (Number of Employees)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"New Hires Rate (%)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure Rate (%)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure Rate (%)\"}]}','1',13,1696998929,1696999443,'0'),(24198,192,2184,10,'2. New Hires and Departures of Employees in the Past 4 Years (GRI 401-1)\n2-1d In 2023','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Age: 30 years old and below\"},{\"title\":\"Age: 30-50 years old\"},{\"title\":\"Age: 51 years old and above\"},{\"title\":\"Male\"},{\"title\":\"Female\"},{\"title\":\"Locals\"},{\"title\":\"Foreigners\"},{\"title\":\"PEC HQ\"},{\"title\":\"PANCO\"}],\"cols\":[{\"title\":\"New Hires (Number of Employees)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"New Hires Rate (%)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Voluntary Departure Rate (%)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure (Number of Employees)\"},{\"type\":\"3\",\"title\":\"Non-Voluntary Departure Rate (%)\"}]}','1',12,1696998929,1696999443,'0'),(24199,192,2184,11,'2-2 Absenteeism Rate\nPlease provide the absenteeism rate of company employees for the past four years.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total Absenteeism Days (PEC HQ)\"},{\"title\":\"Absenteeism Rate (AR) (PEC HQ)\"},{\"title\":\"Total Absenteeism Days (PANCO)\"},{\"title\":\"Absenteeism Rate (AR) (PANCO)\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',11,1696998929,1696999443,'0'),(24200,192,2184,12,'3. Employee Compensation Policy (GRI 2-19) (GRI 2-20) (GRI 202-1) (GRI 405-2)\n3-1 Please describe your company\'s approach to managing its compensation policy.','TextLong','0','(Including compensation policies for the highest governance unit and senior management, and how these compensation policies are linked to the company\'s goals and performance related to the management of economic, environmental, and societal impacts.)',NULL,'[]','1',10,1696998929,1696999443,'0'),(24201,192,2184,13,'3-2 Please describe the process by which your company determines compensation (GRI 2-20).','TextLong','0','',NULL,'[]','1',9,1696998929,1696999443,'0'),(24202,192,2184,14,'4. Notice Period for Operational Changes (GRI 402-1)\nPlease explain the shortest notice period regarding operational changes.','TextLong','0','\nExample:\n❖ Minimum Notice Period for Operational Changes\nWe highly value the factors leading to employee departures, and therefore, each case is discussed in exit interviews conducted by supervisors or personnel. We gather reasons and make necessary improvements to provide a more comprehensive workplace environment and system, enhancing employee stability.\n[Company Name] adheres to statutory notification procedures. The company specifies the minimum notice periods for terminating labor contracts as follows:\n\nFor employees who have worked continuously for more than three months but less than one year, a ten-day notice is provided.\nFor employees who have worked continuously for more than one year but less than three years, a twenty-day notice is given.\nFor employees who have worked continuously for more than three years, a thirty-day notice is issued.\nIn the event of job changes, discussions with employees take place several weeks prior to the change by their immediate supervisors, and the change is officially announced upon mutual agreement when the job transition is confirmed.',NULL,'[]','1',8,1696998929,1696999443,'0'),(24203,192,2184,15,'5. Employee Benefits and Well-being\n5-1. Employee Benefits Policy (GRI 201-3, GRI 401-2, GRI 401-3, GRI 411)','TextLong','0','\nExample:\n❖ Benefits System: [Company Name] places a strong emphasis on talent retention and ensures equal job opportunities for employees. We have a fair performance appraisal system that is superior to industry standards, offering competitive salary and bonus structures. We take our corporate responsibility seriously and provide comprehensive insurance and retirement schemes as required by law. In addition to promoting a safe working environment for our employees\' physical health, we also focus on their mental well-being. We organize domestic and international employee travel and leisure activities to promote physical and mental health and relieve stress. All subsidiary companies of [Company Name] comply with or exceed local government regulations and labor laws, ensuring that our employees, both domestically and internationally, are well-protected. The company holds regular meetings of the Employee Welfare Committee, where employees can voice their needs and propose improvements to the company\'s management, collectively maintaining and creating a positive working environment. Through the Employee Welfare Committee, various activities are organized, including cultural and recreational events, quarterly gatherings, travel events, maternity subsidies, holiday gift vouchers, and emergency relief funds. We also offer a stock subscription program for employees when the company issues new shares. In 2021, [Company Name] offered 600,000 shares of treasury stock for subscription by group employees to retain talent, motivate employees, and enhance their commitment and productivity. In addition to providing a robust personnel system, we insist on offering diverse and comprehensive benefits and facilities for employees, allowing them to relax and rejuvenate beyond their work responsibilities. These activities promote interactions among colleagues and create a happy and harmonious working environment. Employees at [Company Name] are protected under government labor laws and agreements between labor and management. They enjoy the following benefits:\n● Domestic and international employee travel for physical and mental relaxation\n● Comprehensive insurance coverage (labor insurance, health insurance, group insurance, cancer insurance, travel safety insurance, and commercial insurance)\n● Monthly contribution of 6% to the new labor pension system; full contribution to the old labor pension system\n● Full subsidy for educational and training courses\n● Free regular health check-ups and free health check-up subsidies for supervisors\n● Employee bonuses and stock options\n● Emergency relief funds, hospitalization condolence money, and funeral subsidies\n● Marriage gift money\n● Childbirth gift money: NT$30,000 for the first child, NT$60,000 for the second child, and NT$100,000 for the third child\n● Holiday gift vouchers and birthday vouchers\n● Quarterly departmental dinners\n● Club activities, including weekly aerobics yoga\n● Comfortable and modern employee dormitories\nIn addition to the mandatory labor and health insurance systems, [Company Name] offers group insurance (life insurance, accident insurance, medical insurance) at a lower premium rate for employees and extends coverage to their dependents. This comprehensive insurance system allows employees to work without worries. In 2021, due to the global Covid-19 pandemic, [Company Name] suspended the year-end party and employee travel activities to prioritize epidemic control and employee health. Instead, we provided gift vouchers to employees, allowing them to plan their own relaxation activities while reducing gatherings.\n\n❖ Retirement System: [Company Name] provides retirement benefits based on statutory retirement systems in various regions. We contribute retirement pensions for all employees, with a 100% participation rate. For employees in Taiwan, based on the Labor Standards Act and Labor Pension Act, those who were hired before June 30, 2005 (inclusive) are entitled to the old retirement pension system. However, employees can choose to switch to the new retirement pension system voluntarily. The old retirement pension is calculated at 2% of monthly salary for each year of service, with the full amount deposited into the Taiwan Bank\'s old retirement pension reserve account. The new retirement pension is determined based on the labor pension grade of employees eligible for the new retirement pension system, with 6% of their salary deposited monthly into their individual retirement pension accounts. In addition to the mandatory employer contribution of 6%, employees can choose to contribute an additional 0% to 6% to their retirement pension accounts based on their preference, with the amount deposited into their individual retirement pension accounts. At the end of 2021, there was one employee who chose the old retirement pension system, and 166 employees who chose the new retirement pension system.\n❖ Leave without Pay: [Company Name] also provides various types of leaves in accordance with labor laws. If employees require extended leave due to reasons such as child-rearing or serious illness, they may apply for leave without pay. After the leave period expires, they can apply to return to work. During the reporting period, three employees applied for leave without pay. In addition, [Company Name] provides maternity leave, paternity leave, and parental leave in accordance with the Gender Equity in Employment Act and the Implementation Measures for Maternity Leave without Pay. [Company Name] also follows regulations to provide employees with maternity leave without pay, paternity leave, and parental leave, and has established relevant regulations for employee parental leave without pay and reemployment. In 2021, [Company Name] had two male and one female employee who applied for parental leave without pay, and none of them returned to work after their maternity leave expired, as two of them considered personal family factors.',NULL,'[]','1',7,1696998929,1696999443,'0'),(24204,192,2184,16,'5-2. Maternity Leave Policy (GRI 401-3)\n5-2-1 Please describe your company\'s maternity leave policy.','TextLong','0','',NULL,'[]','1',6,1696998929,1696999443,'0'),(24205,192,2184,17,'5-2. Maternity Leave Policy (GRI 401-3)\n5-2-2 Does the company offer the following related benefits?','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u7b2c\\u4e00\\u984c\"}],\"cols\":[{\"title\":\"Exceeds legal requirements.\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Met legal requirements.\"},{\"type\":\"1\",\"title\":\"None\"}]}','1',5,1696998929,1696999443,'0'),(24206,192,2184,18,'5-2. Maternity Leave Policy (GRI 401-3)\n5-2-2 Does the company offer the following related benefits?','Scale','0','',NULL,'{\"rows\":[{\"title\":\"Maternity leave without pay\"},{\"title\":\"Family care leave\"},{\"title\":\"Maternity leave\"},{\"title\":\"Paternity leave\"},{\"title\":\"Other (such as employee trips, full-pay sick leave not counted as sick leave, or other special types of leave)\"}],\"cols\":[{\"title\":\"Exceeds legal requirements\"},{\"title\":\"Met legal requirements\"},{\"title\":\"None\"}]}','1',4,1696998929,1696999443,'0'),(24207,192,2184,19,'5-2-3 Return to Work and Retention Statistics After Maternity Leave in 2023\nPEC HQ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of eligible employees for maternity without pay leave in 2023\"},{\"title\":\"Actual number of employees who applied for maternity leave without pay in 2023\"},{\"title\":\"Total number of employees who should have returned to work in 2023 (A).\"},{\"title\":\"Total number of employees who actually returned to work in 2023 (B).\"},{\"title\":\"Return-to-work rate in 2023, expressed as a percentage (B\\/A x 100%)\"},{\"title\":\"Total number of employees who returned to work in 2022 (C)\"},{\"title\":\"Number of employees who remained employed 12 months after returning to work in 2022 (D)\"},{\"title\":\"Retention rate in 2023, expressed as a percentage (D\\/C x 100%)\"}],\"cols\":[{\"title\":\"Male\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Female\"},{\"type\":\"1\",\"title\":\"Addtional Information (if any)\"}]}','1',3,1696998929,1696999443,'0'),(24208,192,2184,20,'5-2-3 Return to Work and Retention Statistics After Maternity Leave in 2023\nPANCO','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of eligible employees for maternity without pay leave in 2023\"},{\"title\":\"Actual number of employees who applied for maternity leave without pay in 2023\"},{\"title\":\"Total number of employees who should have returned to work in 2023 (A).\"},{\"title\":\"Total number of employees who actually returned to work in 2023 (B).\"},{\"title\":\"Return-to-work rate in 2023, expressed as a percentage (B\\/A x 100%)\"},{\"title\":\"Total number of employees who returned to work in 2022 (C)\"},{\"title\":\"Number of employees who remained employed 12 months after returning to work in 2022 (D)\"},{\"title\":\"Retention rate in 2023, expressed as a percentage (D\\/C x 100%)\"}],\"cols\":[{\"title\":\"Male\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Female\"},{\"type\":\"1\",\"title\":\"Addtional Information (if any)\"}]}','1',2,1696998929,1696999443,'0'),(24209,192,2184,21,'5-3. Employee Transition Assistance Program (GRI 404-2)\n5-3-1 Does the company provide an employee transition assistance program?','TextLong','0','\nExample:\nIn 2021, the company continued to provide an \"Employee Assistance Program (EAP)\" through the Chinese Mental Health Association, offering counseling helplines and individual consultations for employees. Employees could also utilize the Employee Assistance Program for counseling related to retirement or career transition issues. In 2021, a total of 26 employees engaged in EAP counseling sessions via telephone (none of which were related to retirement counseling).\n\nFor retiring employees, the company employed four transition consultants by the end of 2021. These consultants participated in projects and counseling to assist with the transition of retiring managers, helping them adapt to retirement life and ensuring the effective transfer of their valuable workplace experience.',NULL,'[]','1',1,1696998929,1696999443,'0'),(24210,192,2185,1,'1. Training Opportunities and Career Development (GRI 404-1)\n1-1 Please describe your company\'s employee training practices and outcomes (number of trainees and total expenses, etc.).','TextLong','0','Example:\n❖ Talent Development: OO regards employees as the most important asset of the company. Therefore, talent development is one of the key priorities. We address the development needs of various departments based on the industry\'s environment and future trends. We combine internal resources and external training opportunities to design diverse training programs that enhance the overall competitiveness of both employees and the company. Our approach is guided by organizational goals, departmental development, and individual skill growth requirements. We align our training plans with the industry\'s environment and future trends, offering a range of training programs, including new employee orientation, ongoing skill development, specialized skill training, technical training, leadership development, and general education, to enhance the overall competitiveness of our team.',NULL,'[]','1',7,1696998929,1696999443,'0'),(24211,192,2185,2,'1-2 Please complete the 2023 Employee Training Hours information for the company.\nPEC HQ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"Total Training Hours (Male) in 2022 (Hours)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Total Training Hours (Female) in 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Male) in 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Female) in 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"Total Training Cost in 2022 (NTD)\"},{\"type\":\"3\",\"title\":\"Total Training Hours (Male) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Total Training Hours (Female) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Male) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Female) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Total Training Cost in 2023 (NTD)\"}]}','1',6,1696998929,1696999443,'0'),(24212,192,2185,3,'1-2 Please complete the 2023 Employee Training Hours information for the company.\nPANCO','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Management Executives (Vice President and above)\"},{\"title\":\"Senior Managers (Director)\"},{\"title\":\"Middle Managers  (Manager)\"},{\"title\":\"Supervisors (Team leader)\"},{\"title\":\"General Employees\"},{\"title\":\"Total\"}],\"cols\":[{\"title\":\"Total Training Hours (Male) in 2022 (Hours)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Total Training Hours (Female) in 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Male) in 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Female) in 2022 (Hours)\"},{\"type\":\"3\",\"title\":\"Total Training Cost in 2022 (NTD)\"},{\"type\":\"3\",\"title\":\"Total Training Hours (Male) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Total Training Hours (Female) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Male) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Average Training Hours (Female) in 2023 (Hours)\"},{\"type\":\"3\",\"title\":\"Total Training Cost in 2023 (NTD)\"}]}','1',5,1696998929,1696999443,'0'),(24213,192,2185,4,'1-3 Employee Training Satisfaction Survey','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Has the company conducted an Employee Training Satisfaction Survey?\"}],\"cols\":[{\"title\":\"Yes\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"No\"},{\"type\":\"1\",\"title\":\"(If Yes) Please provide Survey Results\"},{\"type\":\"1\",\"title\":\"(If Yes) Please provide Improvement Plans\"}]}','1',4,1696998929,1696999443,'0'),(24214,192,2185,5,'2. Pre-employment Training\n2-1 Please describe the company\'s training program for new employees.','TextLong','0','\nExample:\n\nPre-Employment Training: To establish and maintain effective communication with our employees, new hires undergo pre-employment training on their first day. The training program covers various aspects, including the company\'s mission, history, organizational structure, HR policies and procedures, human rights policy awareness, employee rights, prevention of harassment, labor laws, code of ethics, compliance with company rules and regulations, occupational safety and health, and environmental awareness. This comprehensive 12-hour training helps new employees understand the company\'s values, fosters a sense of belonging, and facilitates a smooth transition into their roles within the organization. Additionally, during this training, employees sign their employment contracts, clarifying the rights and responsibilities of both parties. In the current year, a total of 87 new employees completed this pre-employment training program. We also implement job-specific training based on job descriptions for each new hire, ensuring they acquire the necessary knowledge and skills to excel in their roles.',NULL,'[]','1',3,1696998929,1696999443,'0'),(24215,192,2185,6,'3. Performance Appraisal (GRI 404-3)\n3-1 Please describe the company\'s regular performance appraisal system and career development review.','TextLong','0','Example:\n❖ Fair Performance Appraisal System: Our performance management and development system aim to enhance individual and overall organizational performance. We implement a fair and equitable performance evaluation process, involving all employees in regular performance assessments. Throughout the year, employees undergo goal management, with a review of their job performance every six months. At the end of each year, we review their past goals and job execution results, project future work tasks, identify employees with development potential, and base decisions on job promotions, salary adjustments, bonus distributions, and employee development and training needs. We emphasize consistency and fairness in salary operations and management, using educational background, expertise, and professional experience as salary criteria for each employee. Regarding cash bonuses, employee bonuses, total amounts, and distribution methods, we propose them to the board of directors based on the company\'s operational results to ensure that distribution standards are closely linked to the company\'s financial and operational performance. Subsequently, we consider individual employees\' job responsibilities, contributions, and performance assessment results to determine individual bonus amounts. Employee salaries and performance bonuses are never differentiated by gender, age, religion, race, color, marital or disability status, nationality, political affiliation, zodiac sign, blood type, or any other differences. Our \"Goal Management and Performance Appraisal\" process achieves the goal of \"identifying and developing talents\" through three cycles: \"initial goal setting,\" \"mid-term goal review,\" and \"end-of-year performance assessment.\" All employees in the company can undergo performance appraisal, except for those with less than 3 months of employment. In 2021, 154 employees participated in the performance appraisal (33 females and 121 males), and the gender ratio of evaluated employees was 100%, demonstrating that the company provides equal opportunities for career development without gender discrimination. The company conducts performance appraisals twice a year, with employees setting their individual KPIs in the first half of the year. They then have performance discussions with their supervisors to review progress on their first-half goals and establish second-half goals. In the second half of the year, employees complete their annual performance assessments, followed by performance discussions with supervisors to review their performance and set goals for the next year.',NULL,'[]','1',2,1696998929,1696999443,'0'),(24216,192,2185,7,'4. Security Education and Training (GRI 410-1)\n4-1 Please describe the training of security personnel in the company on human rights policies or procedures.','TextLong','0','\nExample:\n\nSecurity Personnel Education and Training: The company\'s security personnel are contracted through Guoxing Security and are required to undergo duty training before being assigned. Additionally, they receive 2 hours of security personnel education and training each month. The training covers topics such as traffic management, case sharing and prevention of incidents within the patrol area, company regulations and labor laws, and human rights-related regulations. This training aims to prevent security personnel from violating basic human rights while on duty and emphasizes the importance of adhering to relevant social behavioral norms.',NULL,'[]','1',1,1696998929,1696999443,'0'),(24217,193,2186,1,'Tax Strategy and Governance (GRI 207-1, GRI 207-2, GRI 207-3, GRI 207-4)\nPlease explain company\'s tax policy and describe the tax governance and control framework. (GRI 207-1, GRI 207-2)','TextLong','0','Example from previous year:\nOur company\'s tax management unit is coordinated and managed by the accounting departments of PharmaEssentia\nHeadquarters and subsidiaries. If there are any important decisions, professional tax consultants may be consulted or appointed\naccording to the situation. We strictly comply with the commercial laws and tax regulations of Taiwan and the local\njurisdictions where we operate, and is transparent in disclosing information in accordance with regulations to strengthen\nthe group\'s compliance with tax laws and commitment to fulfill its corporate social responsibility. We are committed to the\nfollowing tax management policy to reduce tax risks, optimize post-tax operating results, and protect shareholder interests.',NULL,'[]','1',4,1696998942,1696999458,'0'),(24218,193,2186,2,'Please explain how your company communicates its tax issues with stakeholders. (GRI 207-3)\nPlease refer to example from previous year.','TextLong','0','','/static/upload/image/5/7a/03/b0568d84dc04ffd68ca83c71f6e33f63.png','[]','1',3,1696998942,1696999458,'0'),(24219,193,2186,3,'Please fill out the following table regarding tax jurisdiction disclosures (GRI 207-4).','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Names of the resident entities\"},{\"title\":\"Primary activities of the organization\"},{\"title\":\"Number of employees, and the basis of calculation of this number\"},{\"title\":\"Revenues from third-party sales\"},{\"title\":\"Revenues from intra-group transactions with other tax jurisdictions\"},{\"title\":\"Profit\\/loss before tax\"},{\"title\":\"Tangible assets other than cash and cash equivalents\"},{\"title\":\"Corporate income tax paid on a cash basis\"},{\"title\":\"Corporate income tax accrued on profit\\/loss\"},{\"title\":\"Reasons for the difference between corporate income tax accrued on profit\\/loss and the tax due if the statutory tax rate is applied to profit\\/loss before tax\"},{\"title\":\"The time period covered in this reprot\"}],\"cols\":[{\"title\":\"Please provide information\",\"type\":\"1\"}]}','1',2,1696998942,1696999458,'0'),(24220,193,2186,4,'Please provide supporting documents.','UploadFile','0','',NULL,'[]','1',1,1696998942,1696999458,'0'),(24221,193,2187,1,'Please select which of the following does your company’s tax policy, strategy or principles cover: \nOur tax policy covers the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"A commitment to compliance with the spirit as well as the letter of the tax laws and regulations in the countries in which the company operates\",\"A commitment not to transfer value created to low tax jurisdictions\",\"A commitment not to use tax structures without commercial substance\",\"A commitment to undertake transfer pricing using the arm\\u2019s length principle\",\"A commitment not to use secrecy jurisdictions or so-called \\\"tax havens\\u201d for tax avoidance\",\"An approval process of the tax policy by the board of directors\",\"Others\"],\"last\":null}','1',6,1696998942,1696999458,'0'),(24222,193,2187,2,'Other, please specify','TextItem','0','',NULL,'[]','1',5,1696998942,1696999458,'0'),(24223,193,2187,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',4,1696998942,1696999458,'0'),(24224,193,2187,4,'Does your company have a publicly available and group-wide tax policy, strategy or principles in place which\nindicate your approach towards taxation?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we have a publicly available, group-wide tax policy covering the following elements. Please provide the relevant web link\",\"No, we do not have a publicly available group-wide tax policy. \",\"Not applicable. Please provide explanations in the comment box below.\"],\"last\":null}','1',3,1696998942,1696999458,'0'),(24225,193,2187,5,'If yes,  Please provide the relevant web link:','TextLong','0','✓  A commitment to compliance with the spirit as well as the letter of the tax laws and regulations in the\ncountries in which the company operates\n✓ A commitment not to transfer value created to low tax jurisdictions\n✓ A commitment not to use tax structures without commercial substance\n✓ A commitment to undertake transfer pricing using the arm’s length principle\n✓ A commitment not to use secrecy jurisdictions or so-called \"tax havens” for tax avoidance\n✓ An approval process of the tax policy by the board of directors',NULL,'[]','1',2,1696998942,1696999458,'0'),(24226,193,2187,6,'If not applicable. Please provide explanations in the comment box below.','TextLong','0','',NULL,'[]','1',1,1696998942,1696999458,'0'),(24227,193,2188,1,'Please indicate the following tax related metrics on a tax jurisdiction basis: \nPlease fill in the following answers: \n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Names of entity\",\"Primary activities\",\"Number of employees\",\"Revenue in 2020, 2021, 2022, 2023 YTD\",\"Profit (Loss) before tax in 2020, 2021, 2023, 2022 YTD\",\"Income tax accrued in 2020, 2021, 2022, 2023 YTD\",\"Income tax paid in 2020, 2021, 2022, 2023 YTD\"]}','1',5,1696998942,1696999458,'0'),(24228,193,2188,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',4,1696998942,1696999458,'0'),(24229,193,2188,3,'Does your company publicly report on key business, financial and tax information for each tax jurisdiction where the entities included in your organization’s audited consolidated financial statements are resident for tax purposes? ','ChoiceMultiple','0','Please indicate where this information is available in your public reporting',NULL,'{\"values\":[\"Yes, we publicly report on the following for each tax jurisdiction in which we operate\",\"No, we do not report on tax related metrics on a tax jurisdiction basis. \",\"Not applicable. Please provide explanations in the comment box below.\"],\"last\":null}','1',3,1696998942,1696999458,'0'),(24230,193,2188,4,'If yes, please select which of the following you have provided and indicate where this information is available in your public reporting.','DynamicForm','0','Please indicate where this information is available in your public reporting',NULL,'{\"cols\":[{\"title\":\"Names of all the resident entities \",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Primary activities\"},{\"type\":\"1\",\"title\":\"Number of employees\"},{\"type\":\"1\",\"title\":\"Revenue \"},{\"type\":\"1\",\"title\":\" Profit (Loss) before tax\"},{\"type\":\"1\",\"title\":\"Income tax accrued (current year)\"},{\"type\":\"1\",\"title\":\"Income tax paid\"}]}','1',2,1696998942,1696999458,'0'),(24231,193,2188,5,'If not applicable. Please provide explanations in the comment box below.','TextLong','0','',NULL,'[]','1',1,1696998942,1696999458,'0'),(24232,193,2189,1,'Please complete the following table related to your reported tax rate (income statement) and cash tax rate (cash flow statement) for the last two years.\nAdditionally, please select (if necessary) why the reported tax rate and/or the cash tax rate might be lower than expected.\nCurrency: TWD - New Taiwan Dollar\nListed companies are required to provide links to public reports or corporate websites.\nNon-Listed companies may provide internal documents and/or links to public reports or corporatewebsites.','ColumnInput','0','Single jurisdiction tax code (maximum 10% sales abroad and domestic corporate income tax rate below the posted industry group average)\n\n2023新增以下\nIf the calculated average tax rate and/or cash tax rate is lower than the industry group averages shared via the information text, please specify the reason why, indicate the tax amount per item and provide explanations in the table below. \nPlease also indicate where this information is available in your reporting or corporate website',NULL,'{\"rows\":[{\"title\":\"Earnings before Tax\"},{\"title\":\"Reported Taxes\"},{\"title\":\"Cumulative acceptable adjustments* (see above)\"},{\"title\":\"Effective Tax Rate (in %)\"},{\"title\":\"Cash Taxes Paid\"},{\"title\":\"Cash Tax Rate (in %)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"FY 2023 (available after 2024) \"},{\"type\":\"3\",\"title\":\"Calculated Average Rate\"}]}','1',5,1696998942,1696999458,'0'),(24233,193,2189,2,'Please specify the reason why and  indicate where this information is available in your reporting or corporate website\n','TextLong','0','',NULL,'[]','1',4,1696998942,1696999458,'0'),(24234,193,2189,3,'If the aspect reduced your tax burden (tax benefit), please indicate the impact as a negative number,\nhowever if the aspect increased your tax burden (tax expense), please indicate the impact as a positive\nnumber. \nOn the basis of the numbers inputted, you will see an autocalculation of the rate above: please\ndouble-check that figure to ensure you have reported these aspects with the correct sign.','ColumnInput','0','Listed companies are required to provide links to public reports or corporate websites.\nNon-Listed companies may provide internal documents and/or links public reports or corporate websites',NULL,'{\"rows\":[{\"title\":\"Group-wide net operating losses \"},{\"title\":\"Single jurisdiction tax code (maximum 10% sales abroad and domestic corporate income tax rate below the posted industry group average)\"},{\"title\":\"Non-recurring (one time) operating losses in own operations\"},{\"title\":\"Net operating losses from prior periods and\\/or acquired companies\"},{\"title\":\"Timing - net deferred tax assets\\/liabilities and major issues outside of the two year period reported (including accounting adjustments for prior reporting periods due to major tax policy changes)\"}],\"cols\":[{\"title\":\"Tax Impact FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Tax Impact FY 2021\"},{\"type\":\"3\",\"title\":\"Tax Impact FY 2022\"},{\"type\":\"3\",\"title\":\"Tax Impact FY 2023 (available after 2024) \"},{\"type\":\"1\",\"title\":\"Explanation\"}]}','1',3,1696998942,1696999458,'0'),(24235,193,2189,4,'If it\'s not applicable. Please provide explanations in the comment box below','TextLong','0','',NULL,'[]','1',2,1696998942,1696999458,'0'),(24236,193,2189,5,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998942,1696999458,'0'),(24237,193,2190,1,'Climate-Related Information for Listed Companies\nPlease describe the Risks and Opportunities related to Climate Change and Relevant Mitigation Measures Taken by the Company','TextLong','0','Example from previous year:\nClimate change is a challenge faced by the entire world today. We are actively planning\nvarious climate actions, hoping that the implementation of internal operational strategies\ncan help us be in line with world standards, move towards SDG13-Climate Action, and\nwork with others to exert PharmaEssentia’s influence and strive to mitigate climate change.\nIn 2022, under the TCFD framework, we prioritized climate-related physical and transitional\nrisk and opportunity identification as well as the GHG Inventories of our plants. In the\nfuture, we will continue to conduct scenario and quantitative financial impact analysis on\nmajor risk and opportunity projects, provide stakeholders with relevant and reliable financial\nmeasurement information, and work with others to help maintain the sustainable development\nof the environment.',NULL,'[]','1',7,1696998942,1696999458,'0'),(24238,193,2190,2,'Climate-Related Information for Listed Companies\n(Select one answer option per line)\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Please elaborate on the guidance and governance of climate-related risks and opportunities by the Board of Directors and the executive management.\"},{\"title\":\"Please describe the financial repercussions of extreme climate change and respective transistional tisk mitigations measures.\"},{\"title\":\"Please outline how the climate risk identification, assessment, and management processes are integrated into the overall risk management framework.\"},{\"title\":\"Using scenario analysis to assess resilience to climate change risks, please describe the scenarios used, parameters, assumptions, analysis factors, and key financial impacts.\"},{\"title\":\"If there is a climate-related risk mitigation and transformation plan, please outline its contents, including the indicators and goals used to identify and manage physical and transitional risks.\"},{\"title\":\"If internal carbon pricing is utilized for planning purposes, please specify the pricing methodology and its foundations.\"},{\"title\":\"If climate-related goals are established, please provide details on covered activities, greenhouse gas emission scopes, planning timelines, annual progress, and if carbon offsets or Renewable Energy Certificates (RECs) are utilized, specify their source and quantity.\"}],\"cols\":[{\"title\":\"Already Planned\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Planning in Progress\"},{\"type\":\"2\",\"title\":\"Not Yet Planned\"},{\"type\":\"1\",\"title\":\"Pleasse provide more information on the answer you have provided.\"}]}','1',6,1696998942,1696999458,'0'),(24239,193,2190,3,'Please provide information your company\'s greenhouse gas (GHG) inventory and verification status.\nThe company has conducted GHG inventories assessments according to the following standards:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Greenhouse Gas (GHG) Protocol \",\"ISO 14064-1 issued by the International Organization for Standardization (ISO).\"]}','1',5,1696998942,1696999458,'0'),(24240,193,2190,4,'Please provide information on the company\'s  authorized capital. (USD)','NumberInput','0','',NULL,'[]','1',4,1696998942,1696999458,'0'),(24241,193,2190,5,'Please explain the scope of disclosures required by the Sustainability Development Roadmap for listed companies.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Parent Company\'s Individual GHG Inventory\"},{\"title\":\"Subsidiary Companies\' GHG Inventory in Consolidated Financial Reports\"},{\"title\":\"Assurance for Parent Company\'s GHG Emissions\"},{\"title\":\"Assurance for Subsidiary Companies in Consolidated Financial Reports\"}],\"cols\":[{\"title\":\"Is this in the disclosure?\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"Please provide more information\"}]}','1',3,1696998942,1696999458,'0'),(24242,193,2190,6,'Please provide more information on the company\'s total GHG emissions and intensity for the year 2023.\n(Unit: metric tons)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Scope 1\"},{\"title\":\"Scope 2\"},{\"title\":\"Scope 3\"}],\"cols\":[{\"title\":\"Total Emissions (metric tons CO2e)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Intensity (metric tons CO2e per million dollars)\"},{\"type\":\"1\",\"title\":\"Assurance Provider (entity)\"},{\"type\":\"1\",\"title\":\"Description of Assurance Status\"}]}','1',2,1696998942,1696999458,'0'),(24243,193,2190,7,'Please provide supporting documents.','UploadFile','0','',NULL,'[]','1',1,1696998942,1696999458,'0'),(24244,194,2191,1,'Assessment of the health and safety\nimpacts of product and service categories\nPercentage of significant product and service categories for which health and safety\nimpacts are assessed for improvement.','NumberInput','0','',NULL,'[]','1',3,1696998953,1696999477,'0'),(24245,194,2191,2,'Incidents of non-compliance concerning the health and safety impacts of products and services\n\nTotal number of incidents of non-compliance with regulations and/or voluntary codes\nconcerning the health and safety impacts of products and services within the reporting\nperiod, by','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"incidents of non-compliance with regulations resulting in a fine or penalty;\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"incidents of non-compliance with regulations resulting in a warning; \"},{\"type\":\"3\",\"title\":\"incidents of non-compliance with regulations resulting in a warning; \"}]}','1',2,1696998953,1696999477,'0'),(24246,194,2191,3,'If the organization has not identified any non-compliance with regulations and/or\nvoluntary codes, a brief statement of this fact is sufficient.\nb.','TextLong','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24247,194,2192,1,'Requirements for product and service\ninformation and labeling','ChoiceMultiple','0','',NULL,'{\"values\":[\"The sourcing of components of the product or service\",\"Content, particularly with regard to substances that might produce an environmental or social impact\",\"Safe use of the product or service\",\"Disposal of the product and environmental or social impacts\"],\"last\":null}','1',6,1696998953,1696999477,'0'),(24248,194,2192,2,'If the above anwser is \"other\", please explain the reasons. ','TextLong','0','',NULL,'[]','1',5,1696998953,1696999477,'0'),(24249,194,2192,3,'Please indicate the percentage of important product or service categories for which regulatory assessments have been conducted.\n\n','NumberInput','0','',NULL,'[]','1',4,1696998953,1696999477,'0'),(24250,194,2192,4,'Incidents of non-compliance\nconcerning product and service information and labeling','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"incidents of non-compliance with regulations resulting in a fine or penalty\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"incidents of non-compliance with regulations resulting in a warning; ii. i\"},{\"type\":\"1\",\"title\":\"incidents of non-compliance with voluntary codes.\"}]}','1',3,1696998953,1696999477,'0'),(24251,194,2192,5,'Incidents of non-compliance\nconcerning marketing communications\nTotal number of incidents of non-compliance with regulations and/or voluntary codes\nconcerning marketing communications, including advertising, promotion, and\nsponsorship, by','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"incidents of non-compliance with regulations resulting in a fine or penalty\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"incidents of non-compliance with regulations resulting in a warning\"},{\"type\":\"3\",\"title\":\"incidents of non-compliance with voluntary codes\"}]}','1',2,1696998953,1696999477,'0'),(24252,194,2192,6,'If the organization has not identified any non-compliance with regulations and/or\nvoluntary codes, a brief statement of this fact is sufficient.\n','TextLong','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24253,194,2193,1,'1.Governance on Access to Medicine (ATM) (SASB HC-BP-000.A)\n1-1 Please highlight any major achievements in the area of ATM','TextLong','0','',NULL,'[]','1',3,1696998953,1696999477,'0'),(24254,194,2193,2,'1-2 Provide 2023 data for ATM related actitvities (SASB HC-BP-000.A)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of patients treated during clinical trials phase\"},{\"type\":\"3\",\"title\":\"Number of patients treated during compassionate use phase\"},{\"type\":\"3\",\"title\":\"Number of patients treated during sales after market approval phase\"},{\"type\":\"3\",\"title\":\"Total number of patients treated in 2023\"}]}','1',2,1696998953,1696999477,'0'),(24255,194,2193,3,'2. New Drug Development and Innovation (SASB HC-BP-000.B)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Details\"},{\"type\":\"1\",\"title\":\"Phase\"},{\"type\":\"1\",\"title\":\"Link to coipany\'s website\"}]}','1',1,1696998953,1696999477,'0'),(24256,194,2194,1,'List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database (SASB HC-BP-250a.1)\nDoes the company market or produce any products in the United States which are on the FDA’s MedWatch Safety Alerts for Human Medical Products database?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, the company\'s drugs are on the in the FDA\\u2019s MedWatch Safety Alerts for Human Medical Products databased.\",\"Not Applicable, company does not market any products in the United States and has no drugs in the FDA\\u2019s database. \"],\"last\":null}','1',3,1696998953,1696999477,'0'),(24257,194,2194,2,'If you answered Yes to the above, please provide more information below.','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24258,194,2194,3,'Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System. (SASB HC-BP-250a.2)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Name of Product\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of fatalities\"},{\"type\":\"1\",\"title\":\"Please provide information\"},{\"type\":\"1\",\"title\":\"Please provide information on the process and outcomes of the incidents\"}]}','1',1,1696998953,1696999477,'0'),(24259,194,2195,1,'Did your company recall any products during the last 4 financial years (i.e. 2020-2023)?','ChoiceOne','0','',NULL,'{\"values\":[\" Yes, we have had recalls in the past four years.\",\"No, we did not recall any products in the last four years. (Please indicate whether this information is publicly available. )\",\"We do not disclose information on our product recalls. Please provide explanations in the comment box.\",\"Not applicable. Please provide explanations in the comment box.\",\"Not known\"],\"last\":null}','1',6,1696998953,1696999477,'0'),(24260,194,2195,2,'If Yes, please indicate the number and value of Class I (or equivalent) recalls. \nPlease provide the monetary figures in USD millions, as reported in the \"Denominator\" question.','ColumnInput','0','Please indicate whether the information is available in the public domain.',NULL,'{\"rows\":[{\"title\":\"Number of Class I recalls (or equivalent)\"},{\"title\":\"Total value of recalled products. Please report this in USD millions.\"}],\"cols\":[{\"title\":\"FY 2019\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"}]}','1',5,1696998953,1696999477,'0'),(24261,194,2195,3,'If Yes, please indicate the number and value of Class II (or equivalent) recalls. \nPlease provide the monetary figures in USD millions, as reported in the \"Denominator\" question.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of Class II recalls (or equivalent)\"},{\"title\":\"Total value of recalled products. Please report this in USD millions.\"}],\"cols\":[{\"title\":\"FY 2019\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"}]}','1',4,1696998953,1696999477,'0'),(24262,194,2195,4,'If no, please indicate whether this information is publicly available. ','TextLong','0','',NULL,'[]','1',3,1696998953,1696999477,'0'),(24263,194,2195,5,'If not applicable. Please provide explanations in the comment box.','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24264,194,2195,6,'Please provide supporting document: \n\n','UploadFile','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24265,194,2196,1,'Please provide information on the programs, partnerships or activities to improve local capacities in 2020 and 2023 with the goal of improving market access. \nPlease consider all sorts of tangible and intangible input such as monetary investment, sponsorship; hours spent on the events by the employees, etc \nResults also include tangible and intangible benefits such as sales revenues, brand value, etc.  ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Capacity building in manufacturing\"},{\"title\":\"Capacity building in supply chain management and health system strengthening\"},{\"title\":\"Capacity building in R&D\"},{\"title\":\"Capacity building in medical or patient education\"},{\"title\":\"Capacity building in provider education\"},{\"title\":\"Capacity building in Pharmacovigilance\"},{\"title\":\"Capacity building in financing program\"},{\"title\":\"Capacity building in support for local data generation and quality\"},{\"title\":\"Other\"}],\"cols\":[{\"title\":\" The issues addressed by the activity\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"The scope\"},{\"type\":\"1\",\"title\":\"The impact\\/benefits for the market involved\"},{\"type\":\"1\",\"title\":\"The duration\\/frequency of the activity.\"}]}','1',4,1696998953,1696999477,'0'),(24266,194,2196,2,'Please list and briefly describe the most important activities in which your company was involved during the last fiscal year. Please include information that makes clear:','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"1) The issues addressed by the activity;\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"2) The scope;\"},{\"type\":\"1\",\"title\":\"3) The impact\\/benefits for the market involved;\"},{\"type\":\"1\",\"title\":\"4) The duration\\/frequency of the activity\"}]}','1',3,1696998953,1696999477,'0'),(24267,194,2196,3,'Note that each activity type may only be used twice (e.g., if three R&D activities are reported, only the first two will be accepted).','DynamicForm','0','Type of Activity：\n❍ Manufacturing\n❍ R&D\n❍ Supply Chain Management\n❍ Pharmacovigilance\n❍ Patient Education\n❍ Provider Education\n❍ Financing\n❍ Data Collection or Quality\n❍ Other, please specify:\nIf \"Other\", please explain:_ _ _ _ _ _ _ _ _ _ _ _ _ _\n\nDuration of Initiative：\n❏ Long-term\n❏ Short-term',NULL,'{\"cols\":[{\"title\":\"Type of Activity\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Description of Local Capacity Improvement Initiatives\"},{\"type\":\"1\",\"title\":\"Duration of Initiative\"}]}','1',2,1696998953,1696999477,'0'),(24268,194,2196,4,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24269,194,2197,1,'Please provide the total number of patients, and number of patients with low-cost access to your organization\'s products or services','ChoiceOne','0','',NULL,'{\"values\":[\"We track our total number of patients and number of patients with low-cost access to healthcare products or services\",\"We do not track the number of patients with access to our products or services to address diseases\\/ conditions\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"]}','1',4,1696998953,1696999477,'0'),(24270,194,2197,2,'If yes, you track our total number of patients and number of patients with low-cost access to healthcare products\nor services:','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Number of patients with low-cost access to the organization\'s products or services to address diseases\\/ conditions\"},{\"title\":\"Total number of patients for the organization\'s products or services to address diseases\\/ conditions\"}],\"cols\":[{\"title\":\"FY 2019\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"}]}','1',3,1696998953,1696999477,'0'),(24271,194,2197,3,'If not applicable. Please provide explanations in the comment box below.','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24272,194,2197,4,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24273,194,2198,1,'Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index. (SASB HC-BP-240a.1)','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24274,194,2198,2,'Please list of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP) (SASB HC-BP-240a.2)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Product Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"PQP Category\"},{\"type\":\"1\",\"title\":\"Details\"}]}','1',1,1696998953,1696999477,'0'),(24275,194,2199,1,'Please indicate the percentage change (weighted by sales in reporting currency) in average list price and average net price across your U.S. product portfolio compared to the previous year.','ColumnInput','0','If your company’s sales in the Unites States account for less than 10% of your total sales, please mark the question \"Not applicable\" and leave a comment in the comment box',NULL,'{\"rows\":[{\"title\":\"Average List Price\"},{\"title\":\"Average Net Price\"}],\"cols\":[{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"}]}','1',4,1696998953,1696999477,'0'),(24276,194,2199,2,'If the data cannot be aggregated at the company level, indicate which business unit/product segment you have chosen to represent in the table above, as well as the revenues generated by that unit (in % of total revenues','TextLong','0','',NULL,'[]','1',3,1696998953,1696999477,'0'),(24277,194,2199,3,'If it\'s not applicable. Please provide explanations in the comment box below.','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24278,194,2199,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24279,194,2200,1,'Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic products to market for a defined time period. (SASB HC-BP-240b.1.)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"Number of ANDA litigation\"},{\"type\":\"1\",\"title\":\"ANDA litigation-details\"},{\"type\":\"1\",\"title\":\"ANDA litigation-mitigation\"},{\"type\":\"1\",\"title\":\"Resolved \\/ Target resolved Date\"}]}','1',4,1696998953,1696999477,'0'),(24280,194,2200,2,'Changes in Pricing (SASBHC-BP-240b.2.)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Drug Name\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"2022 Average List Price (USD)\"},{\"type\":\"3\",\"title\":\"2023 Average List Price (USD)\"},{\"type\":\"3\",\"title\":\"Changes in Average List Price 2023 vs 2022 (USD)\"},{\"type\":\"3\",\"title\":\"Percentage Change in Average List Price 2023 vs 2022 (%)\"},{\"type\":\"3\",\"title\":\"2022 Net Price (USD)\"},{\"type\":\"3\",\"title\":\"2023 Average Net Price (USD)\"},{\"type\":\"3\",\"title\":\"Changes in Net List Price 2023 vs 2022 (USD)\"},{\"type\":\"3\",\"title\":\"Percentage Net in Average List Price 2023 vs 2022 (%)\"},{\"type\":\"1\",\"title\":\"Details on changes (including reasons for increase or decrease)\"}]}','1',3,1696998953,1696999477,'0'),(24281,194,2200,3,'Based on the findings on changes in Pricing, please provide more details on the product with largest increase compared to previous year (SASB HC-BP-240b.3.)','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24282,194,2200,4,'Please upload supporting documents.','UploadFile','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24283,194,2201,1,'Does your company assess the impact of your products on healthcare costs by means of health economic evaluation (e.g. cost-effectiveness, cost-utility, cost-benefit analysis) and, when possible, compare them to standard therapeutic options and other competitive innovations?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company assesses the impact of your products on healthcare costs by means of health economic evaluation (e.g. cost-effectiveness, cost-utility, cost-benefit analysis) and, when possible, compare them to standard therapeutic options and other competitive innovations\",\"No, we do not assess the impact of our products on healthcare costs by means of health economic evaluation.\",\"Not applicable. Please provide explanations in the comment box below.\"]}','1',4,1696998953,1696999477,'0'),(24284,194,2201,2,'If yes, please complete the following questions:','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Please specify the percentage of products assessed\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Please indicate the percentage of your revenues generated during the last fiscal year for which you can provide such evidence\"},{\"type\":\"1\",\"title\":\"Please indicate the percentage of your total group revenues generated during the last fiscal year that these evaluations have a significant cost-benefit compared to standard medical therapies\"},{\"type\":\"1\",\"title\":\"Please indicate the percentage of your total group revenues generated during the last fiscal year that these evaluations have a significant cost-benefit compared to other competitive innovations\"}]}','1',3,1696998953,1696999477,'0'),(24285,194,2201,3,'If yes, please provide supporting evidence','UploadFile','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24286,194,2201,4,'If not applicable. Please provide explanations in the comment box below.','TextLong','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24287,194,2202,1,'How many innovative products that have gained marketing authorization during the last five years have\nconsistently been endorsed by well-known Health Technology Assessment Agencies (HTAs, such as NICE,\nIQWIG, PBAC, etc.)?','ChoiceOne','0','By consistently, we mean that a product should only be included if there are no negative decisions by any other well-known agency. Thus, if two or more agencies review a product, and any one of the agencies provides a negative review, the product is not considered to be consistently endorsed.\n\nNote: Health Technology Assessment bodies such as the NICE in the UK, the IQWIG in Germany, the CDR in Canada and PBAC in Australia assess relative effectiveness and/or cost benefit of new medicines (depending on legislation), and provide recommendations on the benefit, use and/or reimbursement of medicines and interventions.',NULL,'{\"values\":[\"% of products have been consistently endorsed by the HTAs that have performed reviews (in % of total innovative products reviewed)\",\"None of our products have been endorsed by relevant HTAs\",\"Not applicable. Please provide explanations in the comment box below.\",\" Not known\"]}','1',3,1696998953,1696999477,'0'),(24288,194,2202,2,'Please provide evidence regarding the \"% of products have been consistently endorsed by the HTAs that have performed reviews (in % of total innovative products reviewed).\"','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24289,194,2202,3,'If not applicable. Please provide explanations in the comment box below.','TextLong','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24290,194,2203,1,'Does your company systematically measure your contributions toward improving the patient\'s full cycle of care? ','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No, we do not systematically measure our contribution toward improving the patient\'s full cycle of care\",\"Not applicable. Please provide explanations in the comment box below\",\"Not known\"]}','1',6,1696998953,1696999477,'0'),(24291,194,2203,2,'Key Programs\nIf yes, please provide a short description of the key programs, the most relevant KPI used to measure their impact, and corresponding impact figures. Please provide supporting evidence for each key program.','ColumnInput','0','Currency: TWD - New Taiwan Dolla',NULL,'{\"rows\":[{\"title\":\"Prevention\"},{\"title\":\"Diagnosis\"},{\"title\":\"Treatment (adherence\\/ compliance and rehabilitation)\"},{\"title\":\"End to End Cycle Solutions \\/ Other Program\"}],\"cols\":[{\"title\":\"Please provide supporting evidence and relevant description below:\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"KPI used to measure impact (e.g. # of patients reached)\"},{\"type\":\"1\",\"title\":\"Impact FY 2023\"},{\"type\":\"1\",\"title\":\"Forecast Impact FY 2023\"}]}','1',5,1696998953,1696999477,'0'),(24292,194,2203,3,'How many programs are implemented on a global scale (in percentage of the total number of programs)? \n','TextLong','0','Please provide supporting evidence.',NULL,'[]','1',4,1696998953,1696999477,'0'),(24293,194,2203,4,'In how many disease areas/indications does your company contribute to the improvement of the patient full cycle of care (in % of disease areas relevant to your company)','NumberInput','0','Please provide supporting evidence.',NULL,'[]','1',3,1696998953,1696999477,'0'),(24294,194,2203,5,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24295,194,2204,1,'Does your company make patient outcome data available to all stakeholders?\n','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"We do not have such a process in place.\",\"Not applicable. Please provide explanations in the comment box below\",\"Not known\"]}','1',6,1696998953,1696999477,'0'),(24296,194,2204,2,'If yes, please indicate what type of information is made available and provide supporting evidence.','TextLong','0','•Outcomes from clinical trials and post-launch observational studies\n•Payors/Regulators/HTAs \n•Healthcare professionals/Patient Advocacy Groups/Patients \n•Patient-level clinical research data with relevance to safety and effectiveness \n•Cost effectiveness analysis and pharmacoeconomic/health economic data',NULL,'[]','1',5,1696998953,1696999477,'0'),(24297,194,2204,3,'If yes, please indicate to whom this information is made available and provide supporting evidence.','TextLong','0','•Outcomes from clinical trials and post-launch observational studies\n•Payors/Regulators/HTAs\n•Healthcare professionals/Patient Advocacy Groups/Patients\n•Patient-level clinical research data with relevance to safety and effectiveness\n•Payors/Regulators/HTAs\n•Healthcare professionals/Patient Advocacy Groups/Patients\n•Cost effectiveness analysis and pharmacoeconomic/health economic data\n•Payors/Regulators/HTAs\n•Healthcare professionals/Patient Advocacy Groups/Patients',NULL,'[]','1',4,1696998953,1696999477,'0'),(24298,194,2204,4,'If yes, please indicate if your company incurred expenses or fines on filings, lawsuits related to withholding clinical data in the last financial year and provide supporting evidence:','ChoiceOne','0','',NULL,'{\"values\":[\"Yes,please specify the amount\",\"No, we did not incur expenses or fines on filings, lawsuits related to withholding clinical data in the last year\"],\"last\":null}','1',3,1696998953,1696999477,'0'),(24299,194,2204,5,'If yes\nplease specify amount: _______\nCurrency: _________\n','TextLong','0','',NULL,'[]','1',2,1696998953,1696999477,'0'),(24300,194,2204,6,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998953,1696999477,'0'),(24301,194,2205,1,'Substantiated complaints concerning breaches of customer privacy and losses of customer data','DynamicForm','0','If the organization has not identified any substantiated complaints, a brief statement ofthis fact is sufficient.',NULL,'{\"cols\":[{\"title\":\"complaints received concerning breaches of customer privacy from outside parties and substantiated by the organization\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"complaints  received concerning breaches of customer privacy from regulatory bodies. \"}]}','1',1,1696998953,1696999477,'0'),(24302,195,2206,1,'Corporate Governance Framework (GRI 2-9, GRI 2-10, GRI2-11, GRI2-12, GRI2-13, GRI2-14)\n1.	Governance Structure and Highest Governance Body (GRI 2-9) \n1-1 Please let us know what your Corporate Governance Structure and Composition look like','TextLong','0','',NULL,'[]','1',10,1696998963,1696999508,'0'),(24303,195,2206,2,'Diversity and Independence of the Board of Directors\n\nBoard Composition: Board Members','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Designation\"},{\"type\":\"1\",\"title\":\"Gender\"},{\"type\":\"1\",\"title\":\"Nationality\"},{\"type\":\"1\",\"title\":\"Age: 31-50\"},{\"type\":\"1\",\"title\":\"Age: 51-60\"},{\"type\":\"1\",\"title\":\"Age: 61-70\"},{\"type\":\"1\",\"title\":\"Age: 71 & above\"},{\"type\":\"2\",\"title\":\"Management Experience\"},{\"type\":\"2\",\"title\":\"Pharama\\/Biotech Experience\"},{\"type\":\"3\",\"title\":\"IT\\/Cyber Security Experience\"}]}','1',9,1696998963,1696999508,'0'),(24304,195,2206,3,'Board Composition: Directors Tenure\"','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Designation \"},{\"type\":\"1\",\"title\":\"Tenture: 1-3 years\"},{\"type\":\"1\",\"title\":\"Tenture: 4-6 years\"},{\"type\":\"1\",\"title\":\"Tenture: 7-9 years\"},{\"type\":\"2\",\"title\":\"Member of senior executive team\"}]}','1',8,1696998963,1696999508,'0'),(24305,195,2206,4,'Please give us explain your Highest Governance Unit\'s Policies on Diversity and Independence','TextLong','0','Please explain the composition of the board of directors by gender, age group, and other diversity indicators, as well as the direction and auditing related to diversity in the corporate governance structure.',NULL,'[]','1',7,1696998963,1696999508,'0'),(24306,195,2206,5,'When considering the diversity of board members, what considerations are included in board composition?','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Gender\"},{\"title\":\"Age\"},{\"title\":\"Nationality\"},{\"title\":\"professional background\\/skills\"},{\"title\":\"Others\"}],\"cols\":[{\"title\":\"\\u662f\\u5426\\u8003\\u91cf\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"\\u8acb\\u8aaa\\u660e\"}]}','1',6,1696998963,1696999508,'0'),(24307,195,2206,6,'Please complete the following form regarding  company\'s implementation of board diversity and independence:','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Name\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u5c08\\u696d\\u80cc\\u666f\\/\\u6280\\u80fd\"}]}','1',5,1696998963,1696999508,'0'),(24308,195,2206,7,'1-2 Please explain the nomination and selection of the top governance body (GRI 2-10).','TextLong','0','',NULL,'[]','1',4,1696998963,1696999508,'0'),(24309,195,2206,8,'1-3 Explanation of Nomination and Selection Processes for the Top Governance Body and Its Committees, as well as Criteria for Nominating and Selecting Members of the Top Governance Body (Including Considerations of Stakeholder Perspectives, Diversity, Independence, and Skills Relevant to Organizational Impact)','TextLong','0','',NULL,'[]','1',3,1696998963,1696999508,'0'),(24310,195,2206,9,'1-4 Is the Chairman of the top governance body also a member of senior management? If so, how is conflict of interest avoided and mitigated?','TextLong','0','',NULL,'[]','1',2,1696998963,1696999508,'0'),(24311,195,2206,10,'1-5 The role of the top governance body in impact management and sustainability reporting (GRI 2-12) (GRI 2-13) (GRI 2-14).','TextLong','0','Please explain how the top governance body supervises the company\'s role in impact management and its role in sustainability reporting.',NULL,'[]','1',1,1696998963,1696999508,'0'),(24312,195,2207,1,'Board of Directors\' Performance Evaluation (GRI 2-18)\nPlease explain how the performance evaluation is conducted\n','TextLong','0','',NULL,'[]','1',3,1696998963,1696999508,'0'),(24313,195,2207,2,'Functional Committee\nPlease explain the composition and functioning of functional committees.','TextLong','0','',NULL,'[]','1',2,1696998963,1696999508,'0'),(24314,195,2207,3,'Please provide supporting documents:','UploadFile','0','',NULL,'[]','1',1,1696998963,1696999508,'0'),(24315,195,2208,1,'Policies and Responsibilities\nG1. Does the board/highest governance body or most senior executive of the company:','ChoiceMultiple','0','- GRI Disclosures 2-12, 2-14, 2-22 (2021)\n- (Select all that apply)',NULL,'{\"values\":[\"Issue an annual statement about the relevance of sustainable development to the company\",\"Issue an annual statement that addresses impacts on both people and the environment\",\"Issue an annual statement highlighting a zero tolerance for corruption\",\"Sign off on organizational sustainability targets\",\"Supervise Environmental, Social, and Governance reporting\",\"Regularly review potential risks related to the business model\",\"None of the above\"]}','1',30,1696998963,1696999508,'0'),(24316,195,2208,2,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',29,1696998963,1696999508,'0'),(24317,195,2208,3,'G2. Does the company have a publicly stated commitment regarding the following sustainability topics?','Scale','0','- GRI Disclosure 2-23 (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights\\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No, this is not a current priority\"},{\"title\":\"No, but we plan to have a commitment within the next two years\"},{\"title\":\"Yes, and the commitment is focused on our own operations\"},{\"title\":\"Yes, and the commitment includes our own operations and suppliers\"},{\"title\":\"Yes, and the commitment includes our own operations and the value chain (e.g., suppliers, consumers, communities, other business relationships)\"}]}','1',28,1696998963,1696999508,'0'),(24318,195,2208,4,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',27,1696998963,1696999508,'0'),(24319,195,2208,5,'G3. Does the company have a code of conduct in place regarding each of the following sustainability topics?','Scale','0','- NASDAQ G6.1; GRI Disclosure 2-23 (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights\\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No, this is not a current priority\"},{\"title\":\"No, but we plan to within the next two years\"},{\"title\":\"Yes, focused on employee conduct\"},{\"title\":\"Yes, and the commitment includes our own operations and suppliers\"},{\"title\":\"Yes, focused on own operations and the value chain (e.g., suppliers, consumers, communities, other business relationships)\"}]}','1',26,1696998963,1696999508,'0'),(24320,195,2208,6,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',25,1696998963,1696999508,'0'),(24321,195,2208,7,'G4. Has the company appointed an individual or group responsible for each of the following sustainability topics?','Scale','0','- GRI Disclosure 2-13 (2021) \n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights\\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No one is specifically responsible for this topic\"},{\"title\":\"Yes, with limited influence on outcomes (e.g., limited access to internal information, limited decision-making authority)\"},{\"title\":\"Yes, with moderate influence on outcomes (e.g., has access to relevant information, reports to senior manager)\"},{\"title\":\"Yes, with direct influence of some outcomes (e.g., has access to relevant information, includes one or more senior manager with decision making rights)\"},{\"title\":\"Yes, with direct influence at the highest levels of the organization (e.g., has access to relevant information, includes most senior members of organization)\"}]}','1',24,1696998963,1696999508,'0'),(24322,195,2208,8,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',23,1696998963,1696999508,'0'),(24323,195,2208,9,'G5. Does the company have a formal structure(s) (such as a cross-functional committee) to address each of the following sustainability topics?','Scale','0','- GRI Disclosures 2-9, 2-13 (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights\\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No formal structure\"},{\"title\":\"Yes, and with limited influence on outcomes (e.g., limited access to internal information necessary to understand risks, poor representation from relevant departments or functions)\"},{\"title\":\"Yes, with moderate influence on outcomes (e.g., it includes representatives of some functions, departments, or business units most relevant for addressing the risks concerned, has access to relevant information, reports to senior manager)\"},{\"title\":\"Yes, with direct influence on some outcomes (e.g., it includes representatives of functions, departments, or business units most relevant for addressing the risks concerned, has access to relevant information, it involves one or more members of senior management)\"},{\"title\":\"Yes, and with direct influence at the highest level of the organization (e.g., full access to relevant information, it involves members at highest level of organization)\"}]}','1',22,1696998963,1696999508,'0'),(24324,195,2208,10,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',21,1696998963,1696999508,'0'),(24325,195,2208,11,'G6.1. During the assessment of risk, has your company reviewed those suppliers and/or other business relationships where the risk related to human rights, \nlabour, environment and/or anti-corruption may be particularly severe? ','Scale','0','',NULL,'{\"rows\":[{\"title\":\"Human rights risks\"},{\"title\":\"Labour rights risks\"},{\"title\":\"Environmental risks\"},{\"title\":\"Corruption risks\"}],\"cols\":[{\"title\":\"Yes\"},{\"title\":\"No\"}]}','1',20,1696998963,1696999508,'0'),(24326,195,2208,12,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',19,1696998963,1696999508,'0'),(24327,195,2208,13,'G7. Does the company have a due diligence process through which it identifies, prevents, mitigates, and accounts for actual and potential negative impacts on sustainability topics?','Scale','0','- GRI Disclosures 2-12, 2-23-a-ii, 3-1, 3-3-d (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights\\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No, this is not a current priority\"},{\"title\":\"No, but we are planning to develop one within the next two years\"},{\"title\":\"Yes, related to our own operations\"},{\"title\":\"Yes, related to our own operations and suppliers [Prompts G7.1]\"},{\"title\":\"Yes, related to our own operations and  the value chain (including suppliers,  consumers, communities, other  business relationships) [Prompts G7.1]\"}]}','1',18,1696998963,1696999508,'0'),(24328,195,2208,14,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',17,1696998963,1696999508,'0'),(24329,195,2208,15,'G7.1. During the due diligence process, has your company reviewed those suppliers and/or other business relationships where the risk of adverse impacts on human \nrights, labour, environment and/or anti-corruption may be particularly severe?','Scale','0','- GRI Disclosures 2-23-e, 3-1 (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human rights risks\"},{\"title\":\"Labour rights risks\"},{\"title\":\"Environmental risks\"},{\"title\":\"Corruption risks\"}],\"cols\":[{\"title\":\"Yes\"},{\"title\":\"No\"}]}','1',16,1696998963,1696999508,'0'),(24330,195,2208,16,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',15,1696998963,1696999508,'0'),(24331,195,2208,17,'Concerns and Grievance Mechanisms\nG8. Are there any processes through which members of the company’s workforce can raise concerns about the company’s conduct related to human rights, labour rights, environment, or anti-corruption?','ChoiceOne','0','',NULL,'{\"values\":[\"No, this is not a current priority\",\"No, but we plan to within two years\",\"Yes, we have an informal process (e.g., through supervisors, others) [Prompts G8.1]\",\"Yes, we have a formal process [Prompts G8.1]\"]}','1',14,1696998963,1696999508,'0'),(24332,195,2208,18,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',13,1696998963,1696999508,'0'),(24333,195,2208,19,'If respondent answers either of the ‘yes’ options in G8, the below question will be displayed.\nG8.1. Please provide additional detail regarding the process(es) the company has through which members of the company’s workforce can raise concerns about the company’s conduct.','Scale','0','- GRI Disclosure 2-26 (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Is the process communicated to all employees\\/workers in local languages?\"},{\"title\":\"Is the process available to non-employees (e.g., suppliers, consumers, communities, and other business relationships)?\\u00a0\"},{\"title\":\"Is the process confidential (e.g., whistleblowing process)?\"},{\"title\":\"Can concerns be raised about suppliers or other business relationships (e.g., clients, partners, etc.)\"}],\"cols\":[{\"title\":\"Yes\"},{\"title\":\"No\"}]}','1',12,1696998963,1696999508,'0'),(24334,195,2208,20,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',11,1696998963,1696999508,'0'),(24335,195,2208,21,'Lessons\nG9. How does the company capture lessons regarding each of the following sustainability topics?','Scale','0','- GRI Disclosure 3-3-e (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights \\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No lessons are regularly captured\"},{\"title\":\"Conducts root cause analyses\\/investigation of incidents\"},{\"title\":\"Conducts root cause analyses\\/investigation and changes organizational policies, processes, and practices accordingly\"},{\"title\":\"Systematically conducts root cause analyses\\/investigation and leverages learnings to influence both internal and external affairs\"}]}','1',10,1696998963,1696999508,'0'),(24336,195,2208,22,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',9,1696998963,1696999508,'0'),(24337,195,2208,23,'Executive Pay\nG10. Is executive pay linked to performance on one or more of the following sustainability topics?','Scale','0','- CDP W6.4 2022, CDP F4.3a 2022, CDP C1.3a (2022); Nasdaq G3 2335; GRI Disclosure 2-19 (2021)\n- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Human Rights\"},{\"title\":\"Labour Rights \\/ Decent Work\"},{\"title\":\"Environment\"},{\"title\":\"Anti-Corruption\"}],\"cols\":[{\"title\":\"No, and we have no intention to change for this is not  a current priority\"},{\"title\":\"No, but we plan to within two years\"},{\"title\":\"Yes\"}]}','1',8,1696998963,1696999508,'0'),(24338,195,2208,24,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',7,1696998963,1696999508,'0'),(24339,195,2208,25,'Board Composition\nG11. Percentage of individuals within the company’s board/highest governance body by:','ColumnInput','0','- ISAR D.1.2., ISAR D.1.3.; GRI Disclosures 2-9 (2021), 405-1 (2016)\n- (Matrix – Percentage & Commentary for each line)\n- Note: Please input answer as whole number (e.g., 95% = 95)',NULL,'{\"rows\":[{\"title\":\"Total number of board members (#)\"},{\"title\":\"Male (%)\"},{\"title\":\"Female (%)\"},{\"title\":\"Non-binary (%)\"},{\"title\":\"Under 30 years old (%)\"},{\"title\":\"30-50 years old (%)\"},{\"title\":\"From minority or vulnerable groups (%) \"},{\"title\":\"Executive (%)\"},{\"title\":\"Independent (%) \"}],\"cols\":[{\"title\":\"Answer(s)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Not applicable\"}]}','1',6,1696998963,1696999508,'0'),(24340,195,2208,26,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',5,1696998963,1696999508,'0'),(24341,195,2208,27,'G12. Do you produce sustainability reporting according to:','ChoiceMultiple','0','- Nasdaq G9.1\n- (Select all that apply)',NULL,'{\"values\":[\"National\\/local regulation on sustainability\",\"Security exchange regulations\",\"Non-Financial Reporting Directive of the European Union (NRFD)\",\"Global Reporting Initiative (GRI)\",\"Sustainability Accounting Standards Board (SASB, now consolidated into the IFRS Foundation)\",\"International Integrated Reporting Council (IIRC, now consolidated into the IFRS Foundation)\",\"Climate Disclosure Standards Board (CDSB, now consolidated into the IFRS Foundation)\",\"Task Force on Climate-related Financial Disclosures (TCFD)\",\"Other voluntary frameworks (please specify in text box) [Makes text box mandatory]\",\"No sustainability reporting according to any frameworks nor regulations outside of this Communication on Progress\"]}','1',4,1696998963,1696999508,'0'),(24342,195,2208,28,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',3,1696998963,1696999508,'0'),(24343,195,2208,29,'Data Assurance\nG13. Is the information disclosed in this questionnaire assured by a third-party?','ChoiceMultiple','0','- CDP C10.1 2022; GRI Disclosure 2-5 (2021)\n- (Select all that apply)',NULL,'{\"values\":[\"Limited assurance for minority of metrics (e.g., GHG emissions only) \",\"Limited assurance for majority of metrics \",\"Reasonable assurance from minority of metrics \",\" Reasonable assurance for majority of metrics\",\"Other (Please provide additional explanation) [Makes text box mandatory]\",\"No assurance for any metrics\"]}','1',2,1696998963,1696999508,'0'),(24344,195,2208,30,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',1,1696998963,1696999508,'0'),(24345,195,2209,1,'Does your company publicly report on its board type?','ChoiceOne','0','Does your company publicly report on its board type? Please indicate the number of executive and nonexecutive directors on the board of directors/supervisory board of your company and specify where this information is available. Additional clarification on one-tier and two-tier systems is available in the information text.\nListed companies are required to provide links to public reports or corporate websites\nNon-Listed companies may provide internal documents and/or links to public reports or corporate websites.',NULL,'{\"values\":[\"Yes, we publicly report on our board type.\",\"No, we do not report on our board type.\",\"Other non-executive directors\",\"Not known\"]}','1',8,1696998963,1696999508,'0'),(24346,195,2209,2,'\nYes, we publicly report on our board type.\nONE-TIER SYSTEM (companies with a board of directors)\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Executive directors \"},{\"title\":\"Independent directors\"},{\"title\":\"Other non-executive directors\"},{\"title\":\"Total board size\"}],\"cols\":[{\"title\":\"Number of members\",\"type\":\"3\"}]}','1',7,1696998963,1696999508,'0'),(24347,195,2209,3,' TWO-TIER SYSTEM (companies with a supervisory board)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"SUPERVISORY BOARD(Independent directors)\"},{\"title\":\"SUPERVISORY BOARD(Other non-executive directors)\"},{\"title\":\"SUPERVISORY BOARD(Employee representatives (if not applicable, please leave the field empty))\"},{\"title\":\"MANAGEMENT BOARD\\/ EXECUTIVE MANAGEMENT(Senior executives)\"},{\"title\":\"Total size of both boards\"}],\"cols\":[{\"title\":\"Number of members\",\"type\":\"3\"}]}','1',6,1696998963,1696999508,'0'),(24348,195,2210,1,'Is the board of directors/supervisory board headed by a non-executive and independent chairperson and/or an independent lead director? ','ChoiceOne','0','',NULL,'{\"values\":[\"Chairperson is non-executive and independent\",\"Role of CEO and chairperson is split and former CEO\\/chairperson (presently in a non-executive position) is now chairperson\",\"Role of CEO and chairperson is split and chairperson is non-executive but not independent\",\"Role of CEO and chairperson is split and former CEO\\/chairperson is now chairperson, but independent lead director is appointed. Please indicate the name of the lead director:\",\"Role of chairperson and CEO is joint, but independent lead director is appointed. Please indicate the name of the lead director:\",\"Role of chairperson and CEO is joint or chairperson is an executive director\",\"We do not report this information\",\"Not known\"],\"last\":null}','1',4,1696998963,1696999508,'0'),(24349,195,2210,2,'Role of CEO and chairperson is split and former CEO/chairperson is now chairperson, but independent lead director is appointed. Please indicate the name of the lead director:','TextItem','0','',NULL,'[]','1',3,1696998963,1696999508,'0'),(24350,195,2210,3,'Role of chairperson and CEO is joint, but independent lead director is appointed. Please indicate the name of the lead director:','TextItem','0','',NULL,'[]','1',2,1696998963,1696999508,'0'),(24351,195,2211,1,'Does your company have a formal board diversity policy that clearly requires diversity factors such as gender, race, ethnicity, country of origin, nationality, or cultural background in the board nomination process? ','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No, we do not have a board diversity policy that meets the disclosure requirements of this question for listed\\/non-listed companies\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"],\"last\":null}','1',2,1696998964,1696999508,'0'),(24352,195,2211,2,'Yes, our policy specifically includes the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Gender\",\"Race or Ethnicity\",\"Nationality, country of origin or cultural background\"]}','1',1,1696998964,1696999508,'0'),(24353,195,2212,1,'Please indicate the number of women on your company\'s board of directors/supervisory board. If your company has a one-tier board structure, this figure includes: female executive directors, non-executive directors and independent directors. If your company has a two-tier board structure, this figure ONLY includes female independent directors and non-executive directors (this means that senior executives and employee representatives should not be included).\n\nNumber of female directors:   ','NumberInput','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24354,195,2212,2,'Listed companies are required to provide links to public reports or corporate websites.\nNon-Listed companies may provide internal documents and/or links to public reports or corporate websites.','ChoiceOne','0','',NULL,'{\"values\":[\"We do not report this information\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"],\"last\":null}','1',1,1696998964,1696999508,'0'),(24355,195,2213,1,'How does your company ensure the effectiveness of your board of directors/supervisory board and the\nalignment with the (long-term) interests of shareholders?\nListed companies are required to provide links to public reports or corporate websites.\nNon-Listed companies may provide internal documents and/or links public reports or corporate websites.\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Board Meeting Attendance\",\"Board Mandates\",\"Board Performance Review\",\"Board Election Process\",\"We do not report this information\",\" Not applicable. Please provide explanations in the comment box below.\",\"Not known\"]}','1',9,1696998964,1696999508,'0'),(24356,195,2213,2,'Board Meeting Attendance\n\n','ColumnInput','0','Number of meetings attended in percentage last\nbusiness/fiscal year.',NULL,'{\"rows\":[{\"title\":\"Average board meeting attendance\"},{\"title\":\"Minimum of attendance for all members required, at least (in %)\"}],\"cols\":[{\"title\":\"Indicators\\/measure\",\"type\":\"1\"}]}','1',8,1696998964,1696999508,'0'),(24357,195,2213,3,'Board Mandates\nNumber of non-executive/ independent directors with 4 or less other mandates','TextItem','0','',NULL,'[]','1',7,1696998964,1696999508,'0'),(24358,195,2213,4,'Board Mandates\nPlease provide the names of these directors','TextItem','0','',NULL,'[]','1',6,1696998964,1696999508,'0'),(24359,195,2213,5,'Board Mandates\nNumber of other mandates for non-executive/\nindependent directors restricted to','TextItem','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24360,195,2213,6,'Board Performance Review\nPerformance assessment of board of directors/\nsupervisory board members.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Regular self-assessment of board performance. Please specify or provide documents\",\"Regular independent assessment of board performance. Please specify or provide supporting documents\"]}','1',4,1696998964,1696999508,'0'),(24361,195,2213,7,'Regular self-assessment of board performance.\nPlease specify or provide documents','TextItem','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24362,195,2213,8,'Regular independent assessment of board\nperformance. Please specify or provide\nsupporting documents','TextItem','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24363,195,2213,9,'Board Election Process','ChoiceOne','0','',NULL,'{\"values\":[\"Board members are elected and re-elected on an annual basis\",\"Board members are elected individually (as opposed to elected by slate)\"]}','1',1,1696998964,1696999508,'0'),(24364,195,2214,1,'Please indicate the average tenure of board members on your company’s board of directors/supervisory board in years. If your company has a one-tier board structure, this figure includes all members (executive directors, non-executive directors and independent directors). If your company has a two-tier board structure, this figure ONLY includes independent directors and non-executive directors (e.g. exclude employee representatives).\n\nAverage tenure of board members in years:\n','NumberInput','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24365,195,2214,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24366,195,2215,1,'Please indicate the number of board members with relevant work experience in your company\'s sector according to GICS Level 1 sector classification (excluding executive members and employee representatives) and list the directors\' names.\n\nNumber of independent or non-executive members with industry experience (e.g., excludes executives):','NumberInput','0','',NULL,'[]','1',4,1696998964,1696999508,'0'),(24367,195,2215,2,'Please indicate the number of board members with relevant work experience in your company\'s sector\naccording to GICS Level 1 sector classification (excluding executive members and employee representatives) and list the directors\' names.\nListed companies are required to provide links to public reports or corporate websites.\nNon-Listed companies may provide internal documents and/or links to public reports or corporate websites.','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Number of independent or non-executive members with industry experience (e.g., excludes executives):\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Please list the independent or non-executive directors included in the above count\"}]}','1',3,1696998964,1696999508,'0'),(24368,195,2215,3,'Please list the independent or non-executive directors included in the above count:','TextLong','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24369,195,2215,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24370,195,2216,1,'4.	董事會進修與群體智識 (GRI 2-17) \n4-1 請說明是否參加進修課程? 哪些課程和時數\n','TextLong','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24371,195,2216,2,'4.2 請說明公司2023年度董事進修情形於下表單：','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u59d3\\u540d\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u8077\\u7a31\"},{\"type\":\"1\",\"title\":\"\\u9032\\u4fee\\u65e5\\u671f\"},{\"type\":\"1\",\"title\":\"\\u4e3b\\u8fa6\\u55ae\\u4f4d\"},{\"type\":\"1\",\"title\":\"\\u8ab2\\u7a0b\\u540d\\u7a31\"},{\"type\":\"3\",\"title\":\"\\u9032\\u4fee\\u6642\\u6578 (\\u5c0f\\u6642)\"}]}','1',1,1696998964,1696999508,'0'),(24372,195,2217,1,'重大主題衝擊評估(今年新增) (GRI 2-12, GRI 2-16) \n1 說明\n\na) 董事會在「重大主題衝擊評估」擔任監督管理的重要角色和溝通程序\nb) 請注意，GRI 2021準則要求先針對重大主題進行正向與負向的衝擊評估。董事會在整體「重大主題衝擊評估」與決策擔任監督管理之責。','TextLong','0','例如\n為了管理oo在經濟，環境，社會(人/人權)上的衝擊，董事會授權高階管理層帶領ESG委員會進行多項重大主題的衝擊評估。請分別說明董事會與高階管理層在以下工作的角色為何: \n1. 發展、核准與更新組織的宗旨/價值/願景/策略/政策以及永續相關目標；\n- 由哪個單位提案? 誰決策? 董事會的工作? \n2. 描述最高治理單位在監督「盡職調查」上扮演的角色，以及其他鑑別組織衝擊（對經濟/環境/人群）的程序，包括：最高治理單位是否/如何與利害關係人議合（以展現對這些程序的支持）、如何考量這些程序的結果；\n- 由哪個單位提案? 誰決策? 董事會的工作? \n- 董事會是否/如何與利害關係人議合（以展現對這些程序的支持）、\n- 董事會如何考量這些程序的結果；\n3. 描述最高治理單位在檢視上述程序有效性扮演的角色，以及檢視頻率\n- 董事會多久檢視一次? 如何確保結果? ',NULL,'[]','1',12,1696998964,1696999508,'0'),(24373,195,2217,2,'*重大主題衝擊評估的流程','TextLong','0','--> Step 1: 蒐集重大主題\n-->Step 2: 識別正面與負面衝擊 (組織對環境，經濟，社會/人(人權)的影響)\n-->Step 3: 詢問利害關係人對衝擊的影響程度\n-->Step 4: 確定重大主題對於營運的影響 (雙重重大性)  \n-->Step 5: 確定重大主題與排序',NULL,'[]','1',11,1696998964,1696999508,'0'),(24374,195,2217,3,'* *針對重大主題，進行正負向評估(範例如下) – 詳見重大主題評估資料收集表單','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"\\u91cd\\u5927\\u4e3b\\u984c\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"\\u6b63\\/\\u8ca0\\u5411\\u885d\\u64ca\\u8a55\\u4f30\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\"},{\"type\":\"1\",\"title\":\"\\u7ba1\\u7406\\u65b9\\u91dd\"},{\"type\":\"1\",\"title\":\"\\u7ba1\\u7406\\u6307\\u6a19 (KPI)\"},{\"type\":\"3\",\"title\":\"2022\\u6578\\u503c (NTD)\"},{\"type\":\"3\",\"title\":\"2023\\u6578\\u503c (NTD)\"}]}','1',10,1696998964,1696999508,'0'),(24375,195,2217,4,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',9,1696998964,1696999508,'0'),(24376,195,2217,5,'誠信經營/內線交易防範\n1. 誠信經營與企業倫理  \n\n1-1 針對重大主題的衝擊評估與管理方針 (GRI3-3)','Scale','0','',NULL,'{\"rows\":[{\"title\":\"a. \\u8acb\\u8aaa\\u660e\\u7d44\\u7e54\\u5c0d\\u65bc\\u7d93\\u6fdf\\u3001\\u74b0\\u5883\\u548c\\u4eba\\u7fa4\\uff08\\u5305\\u542b\\u5176\\u4eba\\u6b0a\\uff09\\u7684\\u5be6\\u969b\\u8207\\u6f5b\\u5728\\u7684\\u3001\\u8ca0\\u9762\\u8207\\u6b63\\u9762\\u7684\\u885d\\u64ca\"},{\"title\":\"b. \\u82e5\\u6d89\\u53ca\\u8ca0\\u9762\\u885d\\u64ca?\\u8aaa\\u660e\\u7d44\\u7e54\\u9020\\u6210\\u8ca0\\u9762\\u5f71\\u97ff\\u7684\\u6d3b\\u52d5(\\u70ba\\u4f55\\u6703\\u767c\\u751f?\\u8a55\\u4f30\\u672a\\u4f86\\u662f\\u5426\\u6703\\u518d\\u767c\\u751f?\\u767c\\u751f\\u6a5f\\u7387?)\"},{\"title\":\"c. \\u63cf\\u8ff0\\u7d44\\u7e54\\u8207\\u91cd\\u5927\\u4e3b\\u984c\\u76f8\\u95dc\\u7684\\u653f\\u7b56\\u6216\\u627f\\u8afe \"},{\"title\":\"d. \\u7ba1\\u7406\\u91cd\\u5927\\u4e3b\\u984c\\u4ee5\\u53ca\\u76f8\\u95dc\\u885d\\u64ca\\u6240\\u63a1\\u53d6\\u4e4b\\u884c\\u52d5(\\u9810\\u9632.\\u6e1b\\u7de9\\u6f5b\\u5728\\u885d\\u64ca\\u53ca\\u7ba1\\u7406\\u5be6\\u969b\\u885d\\u64ca)\"},{\"title\":\"e. \\u8ffd\\u8e64\\u884c\\u52d5\\u6709\\u6548\\u6027\\u7684\\u8aaa\\u660e(\\u6d41\\u7a0b.\\u76ee\\u6a19.\\u6307\\u6a19.\\u5982\\u4f55\\u7d0d\\u5165\\u7d44\\u7e54\\u71df\\u904b\\u653f\\u7b56\\u548c\\u7a0b\\u5e8f)\"},{\"title\":\"f. \\u8207\\u5229\\u5bb3\\u95dc\\u4fc2\\u4eba\\u7684\\u8b70\\u5408\\u5982\\u4f55\\u5f71\\u97ff\\u7d44\\u7e54\\u884c\\u52d5\\u65b9\\u6848; \\u5982\\u4f55\\u8aaa\\u660e\\u884c\\u52d5\\u662f\\u5426\\u6709\\u6548?\"}],\"cols\":[{\"title\":\"\\u7d93\\u6fdf\"},{\"title\":\"\\u74b0\\u5883\"},{\"title\":\"\\u793e\\u6703\"}]}','1',8,1696998964,1696999508,'0'),(24377,195,2217,6,'2.	內線交易與利益衝突防範措施 (GRI2-15)\n\n2-1 說明最高治理單位如何避免及減緩利益衝突（請描述流程）；並說明是否有向利害關係人揭露利益衝突，至少應包括與以下項目有關的利益衝突：於其他董事會任職、對供應商或其他利害關係人的交叉持股情況、控股股東 (controlling shareholders)、利害關係群體 (related parties) 及其關係、交易和未清餘額 (outstanding balances) ','TextLong','0','',NULL,'[]','1',7,1696998964,1696999508,'0'),(24378,195,2217,7,'3. 補救負面衝擊的程序 (GRI2-25)#若有公司治理相關負面衝擊請提供補救措施與承諾\n3-1 請描述：針對造成或促成的負面衝擊提供（或以合作方式進行）補救措施的承諾；鑑別與處理申訴 (complaints) 的方法（包括已建立或參與的申訴機制）；針對造成/促成的負面衝擊，提供（或合作進行）補救的程序；使用申訴機制的潛在利害關係人如何參與這些機制的設計/檢視/操作和改善；如何追蹤申訴機制和補救程序的有效性，提供有效性的例子（包括利害關係人的意見回饋）','TextLong','0','',NULL,'[]','1',6,1696998964,1696999508,'0'),(24379,195,2217,8,'4.	尋求建議和提出疑慮的機制 (GRI 2-26) \n4-1 描述下列事項的機制：讓個人可尋求關於「責任商業行為政策和實務之實踐」的意見；讓個人可對組織的商業行為 (business conduct) 提出疑慮 (raise concerns)\n','TextLong','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24380,195,2217,9,'5. 內部組織及運作\n5-1 請說明內部機制的運作 \n','TextLong','0','',NULL,'[]','1',4,1696998964,1696999508,'0'),(24381,195,2217,10,'6. 反貪腐\n6-1 請說明已進行貪腐風險評估的營運據點 (GRI 205-1)(GRI 205-2) (GRI 205-3)\n','TextLong','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24382,195,2217,11,'6. 反貪腐\n6-2 請說明已進行貪腐的政策和程序的溝通及訓練(GRI 205-2) (GRI 205-3)','TextLong','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24383,195,2217,12,'6. 反貪腐\n6-3 請說明已確認的貪腐事件及採取的行動(GRI 205-3)','TextLong','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24384,195,2218,1,'政策承諾 (GRI 2-23)(GRI 2-24) \n1. 請說明藥華是否具有以下政策承諾並公開發布? 請問發布位置/網址?  \n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u8cac\\u4efb\\u5546\\u696d\\u884c\\u70ba\"},{\"title\":\"\\u4eba\\u6b0a\\u653f\\u7b56\"},{\"title\":\"\\u74b0\\u5883\\u653f\\u7b56\"},{\"title\":\"\\u5176\\u4ed6\\uff08\\u8acb\\u8aaa\\u660e\\uff09\"}],\"cols\":[{\"title\":\"\\u662f\\u5426\\u6709?\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"\\u6838\\u51c6\\u627f\\u8afe\\u7684\\u6700\\u9ad8\\u5c64\\u7d1a\"},{\"type\":\"1\",\"title\":\"\\u9069\\u7528\\u6d3b\\u52d5\\u8207\\u7bc4\\u570d\"},{\"type\":\"1\",\"title\":\"\\u5982\\u4f55\\u6e9d\\u901a\"},{\"type\":\"1\",\"title\":\"\\u767c\\u5e03\\u4f4d\\u7f6e\\/\\u7db2\\u5740\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\"}]}','1',6,1696998964,1696999508,'0'),(24385,195,2218,2,'2. 請說明如何將以上政策納入組織的活動與商業關係中 (GRI 2-24)','TextLong','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24386,195,2218,3,'薪酬政策\n1. 說明最高治理單位和高階管理階層的薪酬政策，並說明最高治理單位和高階管理階層的薪酬政策如何與組織的經濟、環境和人群衝擊的目標和績效相關。 (GRI2-19)\n','TextLong','0','',NULL,'[]','1',4,1696998964,1696999508,'0'),(24387,195,2218,4,'薪酬政策\n2. 請描述組織設計其薪酬政策與薪酬決定之流程(GRI2-20)','TextLong','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24388,195,2218,5,'薪酬政策\n3. 請描述組織年度總薪酬比率(GRI2-21)','TextLong','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24389,195,2218,6,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24390,195,2219,1,'Do your company\'s CEO and other executive committee members hold company shares? Please note that the shares included in the calculation should not be hedged or the personal financial risk of holding the shares otherwise removed.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, company CEO and other executive officers hold company shares\",\"No, company CEO and other executive officers do not hold company share\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"],\"last\":null}','1',5,1696998964,1696999508,'0'),(24391,195,2219,2,'Yes, company CEO and other executive officers hold company shares','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Chief Executive Officer Please provide supporting evidence: \\u2713 For Listed companies: The information is publicly available. Please provide link to public reports or corporate website. For Non-Listed companies: The information is available in internal documents, public reports or corporate website.\"},{\"title\":\"Average across other executive committee members owning shares Please provide supporting evidence: \\u2713 For Listed companies: The information is publicly available. Please provide link to public reports or corporate website. For Non-Listed companies: The information is available in internal documents, public reports or corporate website.\"}],\"cols\":[{\"title\":\"Name(s) \",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Multiple of base salary\"}]}','1',4,1696998964,1696999508,'0'),(24392,195,2220,1,'Does your company have specific stock ownership requirements for the CEO and other members of your\nexecutive committee? Please indicate where this information is available:\n','ChoiceOne','0','Listed companies are required to provide links to public reports or corporate websites.\nNon-Listed companies may provide internal documents and/or links to public reports or corporate websites.',NULL,'{\"values\":[\"Yes, there are specific requirements in place. Please indicate at which levels this exist and indicate the share ownership requirements as a multiple of the annual base salary.\",\"No, there are no share ownership requirements or we do not report on this following the disclosure requirements of this question\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"],\"last\":null}','1',3,1696998964,1696999508,'0'),(24393,195,2220,2,'If yes, please fill in','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"The CEO has to build up a share ownership of _ _ _ _ _ _ _ _ _ _ times the annual base salary\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Other members of the executive committee besides the CEO have to build up a share ownership of _ _ _ _ _ _ _ _  times the annual base salary\"}]}','1',2,1696998964,1696999508,'0'),(24394,195,2220,3,'If no','ChoiceOne','0','',NULL,'{\"values\":[\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"]}','1',1,1696998964,1696999508,'0'),(24395,195,2221,1,'Please indicate whether individual governmental institutions own more than 5% of the total voting rights of your company and if yes, whether golden shares exist for them. Government ownership of 5% or less of the voting rights need not be reported. Please also indicate where this information is available. ','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, individual governmental institutions have more than 5% of the voting rights. Please provide the total percentage of government ownership (sum of % of individual governmental institutions owning more than 5% of voting rights)\",\"No governmental institutions own more than 5% of the total voting rights. Please provide available evidence of the company share ownership structure.\",\"No, we do not report on government ownership information following the disclosure requirements of this question.\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not Known\"],\"last\":null}','1',4,1696998964,1696999508,'0'),(24396,195,2221,2,'If Yes, please provide the total percentage of government ownership (sum of % of individual governmental institutions owning more than 5% of voting rights):','NumberInput','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24397,195,2221,3,'If Yes, please provide details for the government ownership (e.g. calculation, members, organizations etc. if available): ','TextItem','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24398,195,2221,4,'Golden Shares for Governmental Institutions\nDoes your company have golden shares for governmental institutions?\n','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company has golden shares for governmental institutions.\",\"No, our company doesn\\u2019t have any golden shares for governmental institutions.\"],\"last\":null}','1',1,1696998964,1696999508,'0'),(24399,195,2222,1,'Please indicate which people, departments and committees are responsible and accountable for enterprise risk management in terms of risk appetite & tolerance as well as risk monitoring & reporting. Please also indicate the expertise and training applicable to non-executive directors as well as the corporate structure of risk management functions. Please indicate where this information is available in your public reporting.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, Our company have people, departments and committees are responsible and accountable for enterprise risk management in terms of risk appetite & tolerance as well as risk monitoring & reporting and are available in the public reporting\",\" No, there are no such responsibilities in place\",\" Not applicable. Please provide an explanation in the comment box below.\"],\"last\":null}','1',8,1696998964,1696999508,'0'),(24400,195,2222,2,'If yes, Number of non-executive members of board of directors/supervisory board with expertise in (enterprise)\nrisk management. Please specify number of non-executive directors and provide supporting evidence.','TextItem','0','Last year answer: 5',NULL,'[]','1',7,1696998964,1696999508,'0'),(24401,195,2222,3,'If yes, Regular risk management education for non-executive directors ensured. Please specify and provide supporting evidence.','TextItem','0','Last year answer:In 2022, all board members (11 people) have completed sustainability training hours in compliance with\nregulatory requirements: Supervision of enterprise risk management and crisis management for board of\ndirectors (3 people/hour)\n',NULL,'[]','1',6,1696998964,1696999508,'0'),(24402,195,2222,4,'The risk management function is structurally independent of the business lines. Please specify and\nprovide supporting evidence.\n','TextItem','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24403,195,2222,5,'Highest ranking person with dedicated risk management responsibility on an operational level (not CEO)\n','ChoiceOne','0','Please indicate name and position',NULL,'{\"values\":[\"Chief Risk Officer or Risk Committee\",\"Other person or committee\",\"No information available\"]}','1',4,1696998964,1696999508,'0'),(24404,195,2222,6,'Highest ranking person with dedicated risk management responsibility on an operational level (not CEO)\n','ChoiceOne','0',' Reporting line: please indicate who the person or committee reports to',NULL,'{\"values\":[\"Executive Management\",\"Board of Directors\",\"Other reporting line\",\"No information available\"]}','1',3,1696998964,1696999508,'0'),(24405,195,2222,7,'Highest ranking person with responsibility for monitoring and auditing risk management performance on an operational level (not CEO)','ChoiceOne','0','Please indicate name and position',NULL,'{\"values\":[\"Internal Audit or Compliance\",\"Other person or committee\",\"No information available\"]}','1',2,1696998964,1696999508,'0'),(24406,195,2222,8,'Highest ranking person with responsibility for monitoring and auditing risk management performance on an operational level (not CEO) ','ChoiceOne','0',' Reporting line: please indicate who the person or committee reports to',NULL,'{\"values\":[\"Board of Directors\",\" Other reporting line\",\"No information available\"]}','1',1,1696998964,1696999508,'0'),(24407,195,2223,1,'What strategies does your company pursue in order to promote and enhance an effective risk culture\nthroughout the organization? Please indicate the relevant options below, specify where prompted and provide supporting evidence.','ChoiceOne','0','',NULL,'{\"values\":[\"Financial incentives which incorporate risk management metrics, please specify the incentives and metrics and provide supporting evidence.\",\"No, we do not have any strategies to promote and enhance an effective risk culture\",\"Not applicable. Please provide explanations in the comment box below\",\"Not known\"]}','1',12,1696998964,1696999508,'0'),(24408,195,2223,2,'Financial incentives which incorporate risk management metrics, please specify the incentives and\nmetrics and provide supporting evidence. For senior executives, please specify the incentives and metrics','TextItem','0','',NULL,'[]','1',11,1696998964,1696999508,'0'),(24409,195,2223,3,'Financial incentives which incorporate risk management metrics, please specify the incentives and\nmetrics and provide supporting evidence.For line managers, please specify the incentives and metrics','TextItem','0','',NULL,'[]','1',10,1696998964,1696999508,'0'),(24410,195,2223,4,'Focused training throughout the organization on risk management principles. Please specify and provide\nsupporting evidence.\n','TextItem','0','Last year answer: Comprehensive Risk Management The company holds multiple educational training workshops and uses\nthe COSO ERM Enterprise Risk Management Framework to carefully examine the company\'s structure\nand manage the effective allocation of resources. At the same time, existing management mechanisms\nare fed back into the management policies of highly significant sustainable issues, demonstrating the\ncompany\'s commitment to sustainable development',NULL,'[]','1',9,1696998964,1696999508,'0'),(24411,195,2223,5,'Inclusion of risk management criteria in the HR review process for employee evaluations. Please specify\nand provide supporting evidence.\n','TextItem','0','Last year answer: Establishing a culture of legal compliance, resilience and entrepreneurship, and strengthening the\neducation and training of new employees.\n',NULL,'[]','1',8,1696998964,1696999508,'0'),(24412,195,2223,6,'Measures allowing individual employees to proactively identify and report potential risks throughout the\norganization, please specify and provide supporting evidence.','TextItem','0','Last year answer: Diverse channels of communication including the employee mailbox, labor-management meetings, and\nEmployee Welfare Committee meetings have been set up internally to welcome employee feedback.\n',NULL,'[]','1',7,1696998964,1696999508,'0'),(24413,195,2223,7,'Measures allowing continuous improvement in risk management practices through the involvement of\nemployees in structured feedback process. Please specify and provide supporting evidence.\n','TextItem','0','Last year answer: We have Effective Pharmacovigilance and Recall Mechanism. For more information please refer to our\n2021 Sustainability Report.',NULL,'[]','1',6,1696998964,1696999508,'0'),(24414,195,2223,8,'Incorporating risk criteria in the product development or approval process. Please specify and provide\nsupporting evidence.','TextItem','0','Last year answer: Our company has clearly formulated the operation procedures and related risk criteria in the internal\ncontrol R & D cycle. We have GMP/GDP quality training and follow with international standards in\nmanufacturing process.\n',NULL,'[]','1',5,1696998964,1696999508,'0'),(24415,195,2223,9,'Other means of measuring or innovating for an effective risk culture. Please specify and provide\nsupporting evidence.\n','TextItem','0','',NULL,'[]','1',4,1696998964,1696999508,'0'),(24416,195,2224,1,'1. 針對重大主題的衝擊評估與管理方針 (GRI3-3)','Scale','0','',NULL,'{\"rows\":[{\"title\":\"\\u8acb\\u8aaa\\u660e\\u7d44\\u7e54\\u5c0d\\u65bc\\u7d93\\u6fdf\\u3001\\u74b0\\u5883\\u548c\\u4eba\\u7fa4\\uff08\\u5305\\u542b\\u5176\\u4eba\\u6b0a\\uff09\\u7684\\u5be6\\u969b\\u8207\\u6f5b\\u5728\\u7684\\u3001\\u8ca0\\u9762\\u8207\\u6b63\\u9762\\u7684\\u885d\\u64ca\"},{\"title\":\"\\u82e5\\u6d89\\u53ca\\u8ca0\\u9762\\u885d\\u64ca?\\u8aaa\\u660e\\u7d44\\u7e54\\u9020\\u6210\\u8ca0\\u9762\\u5f71\\u97ff\\u7684\\u6d3b\\u52d5(\\u70ba\\u4f55\\u6703\\u767c\\u751f?\\u8a55\\u4f30\\u672a\\u4f86\\u662f\\u5426\\u6703\\u518d\\u767c\\u751f?\\u767c\\u751f\\u6a5f\\u7387?)\"},{\"title\":\"\\u63cf\\u8ff0\\u7d44\\u7e54\\u8207\\u91cd\\u5927\\u4e3b\\u984c\\u76f8\\u95dc\\u7684\\u653f\\u7b56\\u6216\\u627f\\u8afe \"},{\"title\":\"\\u7ba1\\u7406\\u91cd\\u5927\\u4e3b\\u984c\\u4ee5\\u53ca\\u76f8\\u95dc\\u885d\\u64ca\\u6240\\u63a1\\u53d6\\u4e4b\\u884c\\u52d5(\\u9810\\u9632.\\u6e1b\\u7de9\\u6f5b\\u5728\\u885d\\u64ca\\u53ca\\u7ba1\\u7406\\u5be6\\u969b\\u885d\\u64ca)\"},{\"title\":\"\\u8ffd\\u8e64\\u884c\\u52d5\\u6709\\u6548\\u6027\\u7684\\u8aaa\\u660e(\\u6d41\\u7a0b.\\u76ee\\u6a19.\\u6307\\u6a19.\\u5982\\u4f55\\u7d0d\\u5165\\u7d44\\u7e54\\u71df\\u904b\\u653f\\u7b56\\u548c\\u7a0b\\u5e8f)\"},{\"title\":\"\\u8207\\u5229\\u5bb3\\u95dc\\u4fc2\\u4eba\\u7684\\u8b70\\u5408\\u5982\\u4f55\\u5f71\\u97ff\\u7d44\\u7e54\\u884c\\u52d5\\u65b9\\u6848; \\u5982\\u4f55\\u8aaa\\u660e\\u884c\\u52d5\\u662f\\u5426\\u6709\\u6548?\"}],\"cols\":[{\"title\":\"\\u7d93\\u6fdf\"},{\"title\":\"\\u74b0\\u5883\"},{\"title\":\"\\u793e\\u6703\"}]}','1',4,1696998964,1696999508,'0'),(24417,195,2224,2,'2.請說明公司風險管理的流程 ','TextLong','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24418,195,2224,3,'3. 請說明公司風險處理的原則 ','TextLong','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24419,195,2224,4,'4. 請說明公司ESG風險的評估結果  ','TextLong','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24420,195,2225,1,'Please indicate your annual total monetary contributions to and spending for political campaigns, political organizations, lobbyists or lobbying organizations, trade associations and other tax-exempt groups, as defined in the Info Text.','ChoiceOne','0','',NULL,'{\"values\":[\"We are able to itemize the figures. \",\"We can only report the total spending figures.\",\"We did not make any contributions to and spending for political campaigns, political organizations, lobbyists or lobbying organizations, trade associations and other tax-exempt groups, as defined in the information button.\",\"We do not track our annual monetary contributions and other spending for political and related purposes.\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"],\"last\":null}','1',5,1696998964,1696999508,'0'),(24421,195,2225,2,'We are able to itemize the figures. If you have not made any contributions for one or more items, please\nenter 0 and indicate if this information is available in your public reporting.\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Lobbying, interest representation or similar\"},{\"title\":\"Local, regional or national political campaigns \\/ organizations \\/ candidates\"},{\"title\":\"Trade associations or tax-exempt groups (e.g. think tanks)\"},{\"title\":\"Other (e.g. spending related to ballot measures or referendums)\"},{\"title\":\"Total contributions and other spending\"},{\"title\":\"Data coverage (as % of denominator, indicating the organizational scope of the reported data)\"}],\"cols\":[{\"title\":\"Currency\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"FY 2019\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"}]}','1',4,1696998964,1696999508,'0'),(24422,195,2225,3,'We can only report the total spending figures. Please indicate the items included in your total spending\nfigures. If an item is not included, please select \"not included\". If you have not made any contributions for a specific category, please select \"No contribution.\" Please also indicate if these figures are provided in your\npublic reporting.\n','Scale','0','',NULL,'{\"rows\":[{\"title\":\"Lobbying, interest representation or similar\"},{\"title\":\"Local, regional or national political campaigns \\/ candidates\"},{\"title\":\"Trade associations or tax-exempt groups (e.g. think tanks)\"},{\"title\":\"Other (e.g. spending related to ballot measures or referendums)\"}],\"cols\":[{\"title\":\"Included\"},{\"title\":\"Not included\"},{\"title\":\"No contribution\"},{\"type\":\"4\",\"title\":\" Not known\"}]}','1',3,1696998964,1696999508,'0'),(24423,195,2225,4,'Please indicate the total spending for items included above.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total contributions and other spending\"},{\"title\":\"Data coverage (as % of denominator, indicating the organizational scope of the reported data)\"}],\"cols\":[{\"title\":\"Currency\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"FY 2019\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"}]}','1',2,1696998964,1696999508,'0'),(24424,195,2225,5,'We did not make any contributions to and spending for political campaigns, political organizations,\nlobbyists or lobbying organizations, trade associations and other tax-exempt groups, as defined in the\ninformation button.','ChoiceOne','0','',NULL,'{\"values\":[\"This information must be available in public domain\"]}','1',1,1696998964,1696999508,'0'),(24425,195,2226,1,'Did your company make any contributions to or expenditures to political campaigns or organizations, lobbying, trade associations, tax-exempt entities, or other groups whose role is to influence political campaigns or public policy and legislation? In this context, a “contribution” is the aggregate amount given during the fiscal period to an individual candidate, organization, ballot measure, or “issue area” or “topic” requiring lobbying efforts. ','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we made contributions or had expenditures\",\"No, we did not make any contributions or have any expenditures.\",\"We do not track our largest contributions or expenditures for political and related purposes.\",\" Not applicable. Please provide explanations in the comment box below.\",\"Not know\"],\"last\":null}','1',3,1696998964,1696999508,'0'),(24426,195,2226,2,'Yes, we made contributions. \nPlease provide information on the Issue or Topic you are contributing towards:\n','DynamicForm','0','Please enter one of the following for Corporate Position \n1) Support\n2) Support with minor exceptions\n3)Support with major exceptions\n4)Oppose\n5)No contribution',NULL,'{\"cols\":[{\"title\":\" Issue \\/ Topic\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Corporate Position\"},{\"type\":\"1\",\"title\":\"Description of Position \\/ Engagement\"},{\"type\":\"3\",\"title\":\"Total spend in FY 2023\"}]}','1',2,1696998964,1696999508,'0'),(24427,195,2226,3,'Yes, we made contributions. \nOther Large Expenditures\n\n','DynamicForm','0','Please enter one of the following for Type of Organization\n❍ National political organization\n❍ State or local political\ncampaign, candidates or\ncommittees\n❍ Political Action Committee\n(PAC)\n❍ Lobbying, interest\nrepresentation or similar\n❍ Trade association\n❍ Tax-exempt group\n❍ No contribution\n❍ Not known\n❍ Other: please specify type\n',NULL,'{\"cols\":[{\"title\":\"Name of organization, candidate or topic\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Type of Organization\"},{\"type\":\"3\",\"title\":\"Total amount paid in FY 2020\"},{\"type\":\"3\",\"title\":\"Total amount paid in FY 2021\"},{\"type\":\"3\",\"title\":\"Total amount paid in FY 2022\"},{\"type\":\"1\",\"title\":\"Total amount paid in FY 2023\"}]}','1',1,1696998964,1696999508,'0'),(24428,195,2227,1,'To ensure a successful implementation of a reliable and robust Environmental Management System (EMS),key organisational elements as well as high level commitments need to be defined in a public policy. Does your company have a public environmental policy which covers the following elements of an Environmental Management System?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we have a public environmental policy, and it defines the following elements.\",\"We do not have a public environmental policy or none of the elements are covered.\",\"Not applicable. Please provide explanations in the comment box below\"]}','1',7,1696998964,1696999508,'0'),(24429,195,2227,2,'Yes, we have a public environmental policy, and it defines the following elements.','ChoiceOne','0','',NULL,'{\"values\":[\"Commitment and oversight to implementation of environmental management policy and\\/or improving environmental performance. Please select the highest committing decision-making body\",\"Roles and responsibilities for implementing environmental management policy\",\"Ensuring compliance with relevant environmental laws and regulations\",\"Commitment to continuous improvement of environmental performance\",\"Commitment to set targets and objectives to reduce environmental impacts\",\"Measures to raise internal and external stakeholders\\u2019 awareness of environmental management policy and environmental impacts\",\"Training for employees to understand the impacts of their work activities on the environment\"]}','1',6,1696998964,1696999508,'0'),(24430,195,2227,3,'Commitment and oversight to implementation of environmental management policy and/or improving\nenvironmental performance. Please select the highest committing decision-making body','ChoiceOne','0','',NULL,'{\"values\":[\"Board of directors\",\"Executive management\"]}','1',5,1696998964,1696999508,'0'),(24431,195,2228,1,'Which parts of your operations, corporate processes and supply chain are covered by your environmental\npolicy? All chosen options should be clearly defined in the publicly available policy (i.e. formal policies and not different sections of a report or case study).','ChoiceOne','0','',NULL,'{\"values\":[\"Our public environmental policy covers the following\",\"We do not have an environmental policy publicly available\",\"Not applicable. Please provide explanations in the comment box below\"]}','1',6,1696998964,1696999508,'0'),(24432,195,2228,2,'Our public environmental policy covers the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Production operations and business facilities\",\"Products and services\",\"Distribution and logistics\",\"Management of waste\",\"Suppliers, service providers and contractors\",\"Other key business partners (e.g. non-managed operations, joint venture partners, licensees, outsourcing partners, etc.)\",\"Due-diligence, mergers and acquisitions\",\"Other, please specify:\"]}','1',5,1696998964,1696999508,'0'),(24433,195,2228,3,'Other, please specify:','TextItem','0','',NULL,'[]','1',4,1696998964,1696999508,'0'),(24434,195,2229,1,'Please complete the following table about total energy consumption. For each row in the table, it is mandatory that the values provided are in the same unit. Please see the Information Button for definitions of the cost options. Also, please ensure that you have correctly filled in the Company Information section at the beginning of the questionnaire, and that the coverage in the table below is related to the denominator relevant for your company as indicated in that section.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No, we do not track energy consumption.\",\"Not applicable. Please provide explanations in the comment box below.\",\"Not known\"],\"last\":null}','1',7,1696998964,1696999508,'0'),(24435,195,2229,2,'Please complete the following table about total energy consumption. For each row in the table, it is mandatory that the values provided are in the same unit.\n\nBoundary: PEC Japan office (Units: GHG in Metric tons; energy in MWh)\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total non\\u0002renewable energy consumption (Unit: MWh )\"},{\"title\":\"Total non- renewable energy consumption (Unit: MWh)\"},{\"title\":\"ata coverage (as % of denominator) (Unit: percentage of: Revenues in reporting currency)\"}],\"cols\":[{\"title\":\"FY 2019\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"1\",\"title\":\"FY 2023\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2023?\"}]}','1',6,1696998964,1696999508,'0'),(24436,195,2229,3,'PUBLIC REPORTING','TextItem','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24437,195,2229,4,'THIRD-PARTY VERIFICATION','ChoiceOne','0','',NULL,'{\"values\":[\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\"]}','1',4,1696998964,1696999508,'0'),(24438,195,2229,5,'DATA CONSISTENCY','ChoiceOne','0','',NULL,'{\"values\":[\"We report publicly on this information, but the data in the table above differs from our publicly reported figures.\",\"\\u274f We have a temporary coverage reduction or target challenge due to corporate actions. Please briefly explain if a merger, acquisition, divestment, etc. has temporarily caused a reduction in your ability to report optimal coverage or caused your target to appear abnormal\",\"We are not able to report this information in absolute terms, the information provided in the table above is normalized data. For the purpose of this question, please always provide absolute figures if available.\"]}','1',3,1696998964,1696999508,'0'),(24439,195,2229,6,'We report publicly on this information, but the data in the table above differs from our publicly reported\nfigures. Please provide an explanation in the comment box for this difference:','TextItem','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24440,195,2229,7,'We have a temporary coverage reduction or target challenge due to corporate actions. Please briefly\nexplain if a merger, acquisition, divestment, etc. has temporarily caused a reduction in your ability to\nreport optimal coverage or caused your target to appear abnormal\n','TextItem','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24441,195,2230,1,'Please provide your company\'s total net fresh water consumption, including data for fresh water extraction and consumption. For each row in the table, it is mandatory that the values are provided in the same unit. \n\nBoundary: PEC Japan office (Units: Million cubic meters)\n','ColumnInput','0','','','{\"rows\":[{\"title\":\"Withdrawal: Total municipal water supplies (or from other water utilities)\"},{\"title\":\"Withdrawal: Fresh surface water (lakes, rivers, etc.)\"},{\"title\":\"Withdrawal: Fresh groundwater\"},{\"title\":\"Discharge: Water returned to the source of extraction at similar or higher quality as raw water extracted (only applies to B and C)\"},{\"title\":\"TOTAL NET FRESH WATER CONSUMPTION (A+B+C-D)\"}],\"cols\":[{\"title\":\"Unit\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"FY 2019\"},{\"type\":\"1\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"Please indicate what was your target for the FY 2023\"}]}','1',6,1696998964,1696999508,'0'),(24442,195,2230,2,'PUBLIC REPORTING','ChoiceOne','0','',NULL,'{\"values\":[\"PUBLIC REPORTING\"]}','1',5,1696998964,1696999508,'0'),(24443,195,2230,3,'THIRD PARTY VERIFICATION','ChoiceOne','0','',NULL,'{\"values\":[\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\"]}','1',4,1696998964,1696999508,'0'),(24444,195,2230,4,'DATA CONSISTENCY','ChoiceOne','0','',NULL,'{\"values\":[\"We report publicly on this information, but the data in the table above differs from our publicly reported figures. Please provide an explanation in the comment box for this difference:\",\"We have a temporary coverage reduction or target challenge due to corporate actions. Please briefly explain if a merger, acquisition, divestment, etc. has temporarily caused a reduction in your ability to report optimal coverage or caused your target to appear abnormal\",\"We are not able to report this information in absolute terms, the information provided in the table above is normalized data. For the purpose of this question, please always provide absolute figures if available.\"],\"last\":null}','1',3,1696998964,1696999508,'0'),(24445,195,2230,5,'Please provide an explanation in the comment box for this difference:','TextItem','0','',NULL,'[]','1',2,1696998964,1696999508,'0'),(24446,195,2230,6,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24447,195,2231,1,'Sustainable Environmental Management (GRI 3-3) (RT-CH-530a.1)','TextLong','0','',NULL,'[]','1',12,1696998964,1696999508,'0'),(24448,195,2231,2,'Impact Assessment and Management Policies for Significant Topics (GRI 3-3) (RT-CH-530a.1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"a. Please explain the organization\'s actual and potential, both negative and positive, impacts on the economy, the environment, and populations (including their human rights).\"},{\"title\":\" b. If there are negative impacts involved, please explain the organization\'s activities that cause these negative effects (why do they occur? Assess the likelihood of recurrence in the future).\"},{\"title\":\" c. Describe the organization\'s policies or commitments related to significant topics.\"},{\"title\":\" d. Explain the actions taken by the organization to manage significant topics and related impacts (preventing, mitigating potential impacts, and managing actual impacts).\"},{\"title\":\"e. Provide an explanation of how the effectiveness of these actions is tracked (process, objectives, indicators, and how they are integrated into the organization\'s operational policies and procedures).\"},{\"title\":\" f. Explain how engagement with stakeholders affects the organization\'s action plans and how the effectiveness of these actions is demonstrated.\"}],\"cols\":[{\"title\":\"Economy\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Environment\"},{\"type\":\"2\",\"title\":\"Social\"}]}','1',11,1696998964,1696999508,'0'),(24449,195,2231,3,'Please describe the organizational structure and responsibilities of sustainable environmental management.','TextLong','0','',NULL,'[]','1',10,1696998964,1696999508,'0'),(24450,195,2231,4,'Please describe your company\'s sustainable environmental management policy','TextLong','0','Here is the translated version of the example you provided:\n\n\"Our company recognizes that one of the key factors for sustainable business operations is the responsible management and efficient use of energy. Therefore, we are committed to energy conservation and carbon reduction efforts to fulfill our responsibilities as global citizens and contributors to corporate social responsibility. We adhere to relevant regulations, implement pollution prevention measures, and continuously work towards energy-saving improvements. Our goal is to create an environmentally sustainable, safe, and pollution-free work environment as we progress towards the aim of sustainable corporate development.\n\nEnvironmental Policy (ISO 14001):\n\nStrict compliance with regulations and continuous environmental improvement.\nPromoting environmental awareness through education and training.\nEnhancing production efficiency and pollution prevention.\nFulfilling corporate responsibilities for a win-win situation in both economic and environmental aspects.\"',NULL,'[]','1',9,1696998964,1696999508,'0'),(24451,195,2231,5,'Please explain the environmental management process. ','TextLong','0','The process includes the following steps:\nOperational Accessment\nEnvironmental Impact Assessment\nRisk and Opportunity Identification\nPlanning and Implementation\nContinuous Improvement Plans',NULL,'[]','1',8,1696998964,1696999508,'0'),(24452,195,2231,6,'Please explain the commitment objectives and communication responses regarding environmental issues (preferably with the signature of the Chairman).','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Water Pollution Control: Water Recycling Rate (%)\"},{\"title\":\"Water Pollution Control: Wastewater Treatment Compliance Rate (%)\"},{\"title\":\"Water Pollution Control: Water Intensity\"},{\"title\":\"Water Pollution Control: otal Water Consumption (ML)\"},{\"title\":\"Air Pollution Control:  Emission Output Reduction Rate (%)\"},{\"title\":\"Waste Management: Waste recovery rate (%)\"},{\"title\":\"Waste Management: Proper Disposal Rate of Hazardous Industrial Waste (%)\"},{\"title\":\"Waste Management: Hazardous Industrial Waste Recycling and Treatment Rate (%)\"},{\"title\":\"Resource Utilization Rate (%)\"},{\"title\":\"GHG Inventory and Energy Usage: Energy Saving Rate (%)\"},{\"title\":\"GHG Inventory and Energy Usage: Energy Intensity (GJ\\/million out)\"},{\"title\":\"GHG Inventory and Energy Usage: GHG Emission Intensity (GJ\\/million out)\"}],\"cols\":[{\"title\":\"2022 (actual)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2023 (actual)\"},{\"type\":\"1\",\"title\":\"2023 (target)\"},{\"type\":\"3\",\"title\":\"Short term goal (2023)\"},{\"type\":\"3\",\"title\":\"Mid term goal (2025)\"},{\"type\":\"3\",\"title\":\"Long term goal (2030)\"}]}','1',7,1696998964,1696999508,'0'),(24453,195,2231,7,'Please describe the allocation of environmental cost inputs and the benefits generated after allocation.','TextLong','0','Here\'s an example of how you can explain the concept of positive/negative impacts, their primary sources, management policies, indicators, and goals:\n\n\"In our company, the primary production activity is XXXX, and within the manufacturing process, there may be various environmental impacts, both positive and negative, that we need to address. These impacts include:\n\nAir Pollution (Volatile Organic Compounds - VOCs, PM2.5)\nWater Resource Usage and Pollution (specifically XXXXX)\n...\nGiven the significance of these environmental impacts, we have dedicated resources and efforts to manage the sources of these impacts. This chapter elaborates on how environmental costs are allocated to manage the potential sources of impacts, such as:\n\nAir Pollution (VOCs, PM2.5)\nWater Resource Usage and Pollution (specifically XXXXX)\n...\nOur management policy is focused on achieving the following objectives:\n\nGoal: Minimize Negative Impacts (Score: 60 points) - We aim to reduce our negative environmental impacts continuously, with a target score of at least 60 points.\nExcellence (Score: Above 90 points) - For areas where we excel (e.g., achieving a score of 90 points or higher), we consider becoming a benchmark for other companies, particularly in areas like circular economy practices.\"\nThis example outlines the concept, identifies the primary sources of impact, discusses management policies, and sets goals and indicators for environmental performance.',NULL,'[]','1',6,1696998964,1696999508,'0'),(24454,195,2231,8,'Please Provide Environmental Cost Expenditure Statistics for 2020-2023\nUnit: USD','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Pollution Control Research and Development\"},{\"title\":\"Investment in Pollution Control Equipment\"},{\"title\":\"Pollution Control Costs\"},{\"title\":\"Waste Disposal Cost\"},{\"title\":\"Management Activity Expenses\"},{\"title\":\"Total Cost\"},{\"title\":\"Environmental Costs as a Percentage of Total Revenue (%)\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',5,1696998964,1696999508,'0'),(24455,195,2231,9,'Impact Assessment and Management Policies for Significant Topics (GRI 3-3) (RT-CH-530a.1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"a. Please explain the organization\'s actual and potential, both negative and positive, impacts on the economy, the environment, and populations (including their human rights).\"},{\"title\":\"b. If negative impacts are involved, please explain the activities of the organization that cause these negative effects (why they occur, assess the likelihood of recurrence in the future, and the probability of occurrence).\"},{\"title\":\"c. Describe the organization\'s policies or commitments related to significant topics.\"},{\"title\":\"d. Explain the actions taken by the organization to manage significant topics and related impacts (preventing, mitigating potential impacts, and managing actual impacts).\"},{\"title\":\"e. Provide an explanation of how the effectiveness of these actions is tracked (process, objectives, indicators, and how they are integrated into the organization\'s operational policies and procedures).\"},{\"title\":\"f. Explain how engagement with stakeholders affects the organization\'s action plans and how the effectiveness of these actions is demonstrated.\"}],\"cols\":[{\"title\":\"Economy\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Environment\"},{\"type\":\"2\",\"title\":\"Social\"}]}','1',4,1696998964,1696999508,'0'),(24456,195,2232,1,'Please explain the total weight or volume of materials used for the production and packaging of primary products and services from 2020 to 2023 (GRI 301-1).\n','DynamicForm','0','a. Total Weight or Volume of Non-renewable Materials Used in the Production and Packaging of Primary Products or Services (GRI 301-1)\nb. Total Weight or Volume of Renewable Materials Used in the Production and Packaging of Key Products or Services (GRI 301-1)',NULL,'{\"cols\":[{\"title\":\"Year\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Renewable Materials\"},{\"type\":\"3\",\"title\":\"Total Weight of Renewable Materials (ton)\"},{\"type\":\"1\",\"title\":\"Non- Renewable Materials\"},{\"type\":\"3\",\"title\":\"Total Weight of Non- Renewable Materials (ton)\"}]}','1',3,1696998964,1696999508,'0'),(24457,195,2232,2,'Please explain the percentage of recycled and reused materials used from 2020 to 2023 (GRI 301-2).\n\n','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Year\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Key Products\"},{\"type\":\"1\",\"title\":\"Name of Material\"},{\"type\":\"3\",\"title\":\"Total Amount (metric tons) of Recycled and Reused Materials Used\"},{\"type\":\"3\",\"title\":\"Total Amount of Materials Used (Metric Tons)\"},{\"type\":\"3\",\"title\":\"Percentage of Renewable Materials (%)\"}]}','1',2,1696998964,1696999508,'0'),(24458,195,2232,3,'Please explain the percentage of recycled products and packaging materials for the main product categories from 2020 to 2022 (GRI 301-3).','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Year\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Product\"},{\"type\":\"1\",\"title\":\"Packaging Category\"},{\"type\":\"3\",\"title\":\"Total Volume of Product Sale (Metric Tons)\"},{\"type\":\"3\",\"title\":\"Quantity of Recycled Products and Packaging Materials used (Metric Tons) \"},{\"type\":\"3\",\"title\":\"Recycling Rate (%)\"}]}','1',1,1696998964,1696999508,'0'),(24459,195,2233,1,'Energy Use Analysis (GRI 302-1, 302-3)\nPlease provide usage summary for Internal Energy Consumption\n','TextLong','0','','/static/upload/image/7/a6/d2/8df39b8c1f16d689e3c440095245ab6d.png','[]','1',3,1696998964,1696999508,'0'),(24460,195,2233,2,'Please disclose your energy consumption for the past 4 years using the following table: \n(GRI 302-1, 302-2, 302-3, 302-4)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Purchased electricity: Renewable energy use (GJ)\"},{\"title\":\"Purchased electricity: Non-Renewable energy use (GJ)\"},{\"title\":\"Natural gas (GJ)\"},{\"title\":\"Petroleum (GJ)\"},{\"title\":\"Total (GJ)\"},{\"title\":\"Intensity: Energy intensity (GJ\\/g)\"},{\"title\":\"Comparison with the previous year (% changed)\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',2,1696998964,1696999508,'0'),(24461,195,2233,3,'Please describe Reductions in energy used for products and services (GRI 302-4, GRI 302-5)','UploadFile','0','Example from 2022:\nPharmaEssentia has implemented multiple energy-saving measures to reduce operational and production energy\nconsumption and greenhouse gas emissions, and continues to better energy conservation and carbon reduction\nin administrative areas. These measures include advocating for the unplugging of unused electrical appliances,\nturning off electrical power during long vacations, and using public transportation for business trips. Using 2021 as\nthe basis, despite laboratory expansion and an increase in the number of employees, electricity consumption was\nreduced by 3.91%, and water consumption was reduced by 4.72%. In the Taichung Plant, adjusting the cooling\ntower water level and increasing the use of recycled water in water cooling towers have increased water usage\nefficiency, resulting in a reduction in water consumption by 8 tons per day and a decrease in overall water usage at\nthe Taichung Plant by approximately 14.8%. Furthermore, PharmaEssentia plans to complete the installation of a\nvariable frequency air compressor by March 2023 and a magnetic levitation ice water machine by June 2023. The\ncompany is also evaluating the adoption of an energy monitoring system to reduce electricity consumption as well\nas improve task force process control/optimization and waste heat recovery, so that the usage of natural gas can\nbe reduced and energy efficiency can be improved.',NULL,'[]','1',1,1696998964,1696999508,'0'),(24462,195,2234,1,'Please describe your policy on water stewardship, impact assessment mechanism, and actions taken (GRI 303-1, GRI 303-2, GRI 3-3).','ColumnInput','0','An example from 2022\'s report:\nOur company does not consume a large amount of water resources in its operations, and we\nactively implement water conservation measures. Regarding our Taichung plant, which uses the\nmost water resources, the source of the water intake is all third-party freshwater, and the wastewater\nis discharged through the third-party Central Taiwan Science Park Taichung Park Wastewater\nTreatment Plant. The water quality of the discharged water is monitored annually in accordance\nwith the regulations of the Environmental Protection Administration. A third-party testing organization\naccredited by the Environmental Protection Administration conducts testing every six months\nto ensure compliance with management standards and discharge standards set by the Central\nTaiwan Science Park Administration. The process of wastewater treatment is detailed in our 2020\nSustainability Report on page 113.',NULL,'{\"rows\":[{\"title\":\"Please explain the organization\'s actual and potential, both negative and positive, impacts on the economy, the environment, and populations (including their human rights).\"},{\"title\":\"If negative impacts are involved, please explain the activities of the organization that cause these negative effects (why they occur, assess the likelihood of recurrence in the future, and the probability of occurrence).\"},{\"title\":\"Describe the organization\'s policies or commitments related to significant topics.\"},{\"title\":\"Explain the actions taken by the organization to manage significant topics and related impacts (preventing, mitigating potential impacts, and managing actual impacts).\"},{\"title\":\"Provide an explanation of how the effectiveness of these actions is tracked (process, objectives, indicators, and how they are integrated into the organization\'s operational policies and procedures).\"},{\"title\":\"Explain how engagement with stakeholders affects the organization\'s action plans and how the effectiveness of these actions is demonstrated.\"}],\"cols\":[{\"title\":\"Please provide answers on Economic, Environment & Social perspective.\",\"type\":\"1\"}]}','1',6,1696998964,1696999508,'0'),(24463,195,2234,2,'Water Withdrawal (GRI 303-3)\nPlease input the following data.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Surface Water\"},{\"title\":\"Groundwater\"},{\"title\":\"Seawater\"},{\"title\":\"Effluent Water\"},{\"title\":\"Other\"},{\"title\":\"Total Water Withdrawal\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',5,1696998964,1696999508,'0'),(24464,195,2234,3,'Water Discharge Management Indicators (GRI 303-4)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Please describe the minimum water quality standards for discharges, as well as how these minimum standards are determined.\"}],\"cols\":[{\"title\":\"Discharge Treatment Method\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Discharge Standards, Source of Standards (Environmental Indicators, Compliant Regulations)\"},{\"type\":\"1\",\"title\":\"Discharge Location\"}]}','1',4,1696998964,1696999508,'0'),(24465,195,2234,4,'Please provide detailed discharge volume statistics for the past three years. (in million liters)  (GRI 303-4)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Water Discharge Volume\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',3,1696998964,1696999508,'0'),(24466,195,2234,5,'Please provide detailed water consumption volume statistics for the past 4 years. (in million liters)  (GRI 303-5) 複製','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total Water Withdrawal\"},{\"title\":\"Total Water Discharged\"},{\"title\":\"Water Consumption\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',2,1696998964,1696999508,'0'),(24467,195,2234,6,'Please describe your Water Conservation Initiatives.','TextLong','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24468,195,2235,1,'Please report if there are any Significant impacts of activities, products and services on biodiversity. (GRI 304)','UploadFile','0','You should report the following information: REQUIREMENTS\nNature of significant direct and indirect impacts on biodiversity with reference to one or\nmore of the following:\ni. Construction or use of manufacturing plants, mines, and transport infrastructure;\nPollution (introduction of substances that do not naturally occur in the habitat from\npoint and non-point sources);\nii.\niii. Introduction of invasive species, pests, and pathogens;\niv. Reduction of species;\nv. Habitat conversion;\nChanges in ecological processes outside the natural range of variation (such as\nsalinity or changes in groundwater level).\nvi.\na.\nSignificant direct and indirect positive and negative impacts with reference to the\nfollowing:\ni. Species affected;\nii. Extent of areas impacted;\niii. Duration of impacts;\niv. Reversibility or irreversibility of the impacts.',NULL,'[]','1',1,1696998964,1696999508,'0'),(24469,195,2236,1,'Greenhouse Gas (GHG) emissions Policy (GRI 305-1, GRI 305-2, GRI 305-3 GRI 305-4, GRI 305-5 )\nPlease explain the GHG emission policy and target values. ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Please explain the organization\'s actual and potential, both negative and positive, impacts on the economy, the environment, and populations (including their human rights).\"},{\"title\":\"If negative impacts are involved, please explain the activities of the organization that cause these negative effects (why they occur, assess the likelihood of recurrence in the future, and the probability of occurrence).\"},{\"title\":\"Describe the organization\'s policies or commitments related to significant topics.\"},{\"title\":\"Explain the actions taken by the organization to manage significant topics and related impacts (preventing, mitigating potential impacts, and managing actual impacts).\"},{\"title\":\"Provide an explanation of how the effectiveness of these actions is tracked (process, objectives, indicators, and how they are integrated into the organization\'s operational policies and procedures).\"},{\"title\":\"Explain how engagement with stakeholders affects the organization\'s action plans and how the effectiveness of these actions is demonstrated.\"}],\"cols\":[{\"title\":\"Please provide answers on Economic, Environment & Social perspective.\",\"type\":\"1\"}]}','1',5,1696998964,1696999508,'0'),(24470,195,2236,2,'Greenhouse Gas (GHG) emissions Statistics for the past 4 years\n(GRI 305-1, 305-2, 305-3, 305-4)\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"GHG Emissions (Scope 1)  (on-CO2e)\"},{\"title\":\"GHG Emissions (Scope 2)  (on-CO2e)\"},{\"title\":\"GHG Emissions (Scope 3)  (on-CO2e)\"},{\"title\":\"Intensity (CO2e\\/g)\"},{\"title\":\"Intensity compared with previous year\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',4,1696998964,1696999508,'0'),(24471,195,2236,3,'Air Pollution Control (GRI 305-6, 305-7)\nPlease explain the air pollution control policy and target values.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Please explain the organization\'s actual and potential, both negative and positive, impacts on the economy, the environment, and populations (including their human rights).\"},{\"title\":\"If negative impacts are involved, please explain the activities of the organization that cause these negative effects (why they occur, assess the likelihood of recurrence in the future, and the probability of occurrence).\"},{\"title\":\"Describe the organization\'s policies or commitments related to significant topics.\"},{\"title\":\"Explain the actions taken by the organization to manage significant topics and related impacts (preventing, mitigating potential impacts, and managing actual impacts).\"},{\"title\":\"Provide an explanation of how the effectiveness of these actions is tracked (process, objectives, indicators, and how they are integrated into the organization\'s operational policies and procedures).\"},{\"title\":\"Explain how engagement with stakeholders affects the organization\'s action plans and how the effectiveness of these actions is demonstrated.\"}],\"cols\":[{\"title\":\"Please provide answers on Economic, Environment & Social perspective.\",\"type\":\"1\"}]}','1',3,1696998964,1696999508,'0'),(24472,195,2236,4,'Air Pollutants Emission Statistics for 2020-2023 (GRI 305-7)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Nitrogen Oxides (NOx)\"},{\"title\":\"Sulfur Oxides (SOx) \"},{\"title\":\"Volatile Organic Compounds (VOCs)\"},{\"title\":\"Hazardous Air Pollutants (HAPs)\"},{\"title\":\"Particulate Matter (PM)\"},{\"title\":\"Hydrochloric Acid\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"}]}','1',2,1696998964,1696999508,'0'),(24473,195,2236,5,'Please descible your Carbon Reduction Initatives.','TextLong','0','This is an example from previous year','/static/upload/image/5/4c/70/48d451a9e782c6a71c173bbaded08887.png','[]','1',1,1696998964,1696999508,'0'),(24474,195,2237,1,'Waste generation and significant waste-related impacts (GRI 306-1)\nPlease explain the waste maangement policy and target values. ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Please explain the organization\'s actual and potential, both negative and positive, impacts on the economy, the environment, and populations (including their human rights).\"},{\"title\":\"If negative impacts are involved, please explain the activities of the organization that cause these negative effects (why they occur, assess the likelihood of recurrence in the future, and the probability of occurrence).\"},{\"title\":\"Describe the organization\'s policies or commitments related to significant topics.\"},{\"title\":\"Explain the actions taken by the organization to manage significant topics and related impacts (preventing, mitigating potential impacts, and managing actual impacts).\"},{\"title\":\"Provide an explanation of how the effectiveness of these actions is tracked (process, objectives, indicators, and how they are integrated into the organization\'s operational policies and procedures).\"},{\"title\":\"Explain how engagement with stakeholders affects the organization\'s action plans and how the effectiveness of these actions is demonstrated.\"}],\"cols\":[{\"title\":\"Please provide answers on Economic, Environment & Social perspective.\",\"type\":\"1\"}]}','1',4,1696998964,1696999508,'0'),(24475,195,2237,2,'Greenhouse Gas (GHG) emissions Statistics for the past 4 years\n(GRI 305-1, 305-2, 305-3, 305-4)\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total General Waste (metric tons)\"},{\"title\":\"Total Hazardous Waste (metric tons)\"},{\"title\":\"Annual Waste Generated  (metric tons)\"},{\"title\":\"Waste Intensity (%)\"}],\"cols\":[{\"title\":\"2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"2021\"},{\"type\":\"3\",\"title\":\"2022\"},{\"type\":\"3\",\"title\":\"2023\"},{\"type\":\"1\",\"title\":\"Remarks\"}]}','1',3,1696998964,1696999508,'0'),(24476,195,2237,3,'Please provide detailed waste disposal information for the past three years (GRI 306-3, GRI 306-4, GRI 306-5).','DynamicForm','0','Disposal Methods:\nIncineration (with energy recovery)\nIncineration (without energy recovery)\nLandfilling\nOther disposal operations',NULL,'{\"cols\":[{\"title\":\"Name of Waste\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Waste Category (Hazardous \\/ Non-Hazardous)\"},{\"type\":\"1\",\"title\":\"Disposal Method\"},{\"type\":\"3\",\"title\":\"Volume (metric ton)\"}]}','1',2,1696998964,1696999508,'0'),(24477,195,2237,4,'Classification and Control of Toxic Substances and Management Measures','TextLong','0','','/static/upload/image/5/bf/23/45c8d84ea344d36c9f44dbe547d95b43.png','[]','1',1,1696998964,1696999508,'0'),(24478,195,2239,1,'Commitment\n\nE1. Does the company have a policy commitment on the following environmental topics?','Scale','0','- CDP C4.1 2022, CDP F6.1 2022, CDP W6.1 2022; GRI Disclosure 3-3-c (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"No, and we have no plans to develop a policy\"},{\"title\":\"No, but we plan to within the next two years\"},{\"title\":\"Yes, included within a broader policy or as a stand-alone policy [Prompts E1.1]\"},{\"title\":\"(Please provide additional information in the mandatory text box)\"}]}','1',51,1696998964,1696999508,'0'),(24479,195,2239,2,'Please provide additional explanation:','TextItem','0','',NULL,'[]','1',50,1696998964,1696999508,'0'),(24480,195,2239,3,'Please input the year the relevant environment policy was last reviewed','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"Year (YYYY)\",\"type\":\"3\"}]}','1',49,1696998964,1696999508,'0'),(24481,195,2239,4,'If respondent answers ‘Yes’ in E1, the below question will be displayed for each relevant topic.\n\nE1.1. For each environmental policy, is it:','ColumnInput','0','- CDP C4.1 2022, CDP F6.1 2022, CDP W6.1 2022; GRI Disclosures 2-23-c, 2-23-d, 2-23-e (2021)\n- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"Aligned with international environmental standards\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Publicly available\"},{\"type\":\"2\",\"title\":\"Approved at most senior level of the company\"},{\"type\":\"2\",\"title\":\"Applied to the company\\u2019s own operations\"},{\"type\":\"2\",\"title\":\"Applied to the company\'s own operations and the value chain (e.g., suppliers, consumers, communities, other business relationships)\"},{\"type\":\"2\",\"title\":\"Developed involving environmental expertise from inside and outside the company\"},{\"type\":\"2\",\"title\":\"* Other (Please provide additional information)\"}]}','1',48,1696998964,1696999508,'0'),(24482,195,2239,5,'* Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',47,1696998964,1696999508,'0'),(24483,195,2239,6,'Prevention\n\nE2. In the course of the reporting period, has the company engaged with affected stakeholders or their legitimate representatives in relation to the following environmental topics?','Scale','0','- GRI Disclosures 3-1-b and 3-3-f (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016), and GRI Disclosure 201-2-a-iv (2016)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"No engagement on this topic\"},{\"title\":\"To better understand the risks\\/impacts in question\"},{\"title\":\"To discuss potential ways to prevent\\/mitigate the risks\\/impacts in question\"},{\"title\":\"To agree on a way to prevent\\/mitigate the risks\\/impacts in question\"},{\"type\":\"5\",\"title\":\"To assess progress in preventing\\/ mitigating the risks\\/ impacts in question\"},{\"type\":\"6\",\"title\":\"To collaborate in the prevention\\/mitigation of the risks\\/impacts in question\"},{\"type\":\"7\",\"title\":\"* Other (Please provide additional information in the mandatory text box)\"}]}','1',46,1696998964,1696999508,'0'),(24484,195,2239,7,'* Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',45,1696998964,1696999508,'0'),(24485,195,2239,8,'E3. What type of action has the company taken in the reporting period with the aim of preventing/mitigating the risks/impacts associated with these environmental topics?','ColumnInput','0','- GRI Disclosure 3-3-d (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016), and GRI Disclosure 201-2-iv (2016)\n- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"Provided internal training\\/ capacity building for the direct workforce\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Built capacity among relevant business relationships (e.g., suppliers, consumers, communities)\"},{\"type\":\"2\",\"title\":\"Conducted an audit process and\\/or corrective action plan\"},{\"type\":\"2\",\"title\":\"Collective Action with peers or other stakeholders to address the issue\"},{\"type\":\"2\",\"title\":\"Collaborated with governmental or regulatory bodies\"},{\"type\":\"2\",\"title\":\"(Please provide additional information) [Makes text box mandatory]\"},{\"type\":\"2\",\"title\":\"No action within reporting period\"}]}','1',44,1696998964,1696999508,'0'),(24486,195,2239,9,'Please provide additional explanation:','TextItem','0','',NULL,'[]','1',43,1696998964,1696999508,'0'),(24487,195,2239,10,'E4. How does the company assess progress in preventing/mitigating the risks/impacts associated with the following environmental topics?','Scale','0','- GRI Disclosure 3-3-e (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016), and GRI Disclosure 201-2-a-iv (2016)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"No monitoring of progress\"},{\"title\":\"Review topics on ad hoc basis\"},{\"title\":\"Set annual targets\\/ goals, track progress over time (internal programmes only)  [Prompts E4.1 and E4.2]\"},{\"type\":\"5\",\"title\":\"Set annual targets\\/ goals, track progress over time (internal and external programmes)  [Prompts E4.1 and E4.2]\"},{\"type\":\"6\",\"title\":\"Other (Please provide additional information in the mandatory text box)\"}]}','1',42,1696998964,1696999508,'0'),(24488,195,2239,11,'If respondent answers in E4 that they set annual targets, the below question will be displayed for each relevant topic.\nE4.1. For each environmental topic for which the company sets timebound goals/targets, what kind of targets has the company set? Please give a description of targets (e.g., what is the target, absolute vs. intensity, externally verified, on track, etc.)','TextLong','0',' CDP F6.1 2022; GRI Disclosure 3-3-e (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016), and GRI Disclosure 201-2-a-iv (2016)',NULL,'[]','1',41,1696998964,1696999508,'0'),(24489,195,2239,12,'If respondent answers in E4 that they set annual targets, the below question will be displayed for each relevant topic.\nE4.2. For each environmental topic in which the company sets timebound goals/targets, how is progress against target/goal tracked?','ColumnInput','0','-  CDP F6.1 2022; GRI Disclosure 3-3-e (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016), and GRI Disclosure 201-2-a-iv (2016)\n- (Matrix – Select all that apply for each line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"Progress is reviewed against goals annually or more frequently\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Progress is reported internally to the most senior level\"},{\"type\":\"2\",\"title\":\"Progress is reported externally\"},{\"type\":\"2\",\"title\":\"* Other (Please provide additional information in the mandatory text box)\"}]}','1',40,1696998964,1696999508,'0'),(24490,195,2239,13,'* Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',39,1696998964,1696999508,'0'),(24491,195,2239,14,'E5. In the course of the reporting period, has the company been involved in providing or enabling remedy for any impacts associated with the following environmental topic(s)?','Scale','0','- GRI Disclosure 3-3-d-ii (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016), and GRI Disclosure 201-2-a-iv (2016)\n- (Matrix – Select one answer option per line)\n',NULL,'{\"rows\":[{\"title\":\"Climate change\"},{\"title\":\"Water\"},{\"title\":\"Oceans\"},{\"title\":\"Forests\\/Biodiversity\\/Land use\"},{\"title\":\"Air pollution\"},{\"title\":\"Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.)\"},{\"title\":\"Energy & resource use\"}],\"cols\":[{\"title\":\"Yes, remedy provided\\/enabled\"},{\"title\":\"No remedy provided\\/enabled\"},{\"title\":\"No adverse impact identified or caused\"},{\"type\":\"5\",\"title\":\"Choose to not disclose\"}]}','1',38,1696998964,1696999508,'0'),(24492,195,2239,15,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',37,1696998964,1696999508,'0'),(24493,195,2239,16,'Climate Action\nE6. What were the company’s gross Scope 1 and Scope 2 global greenhouse gas emissions for the reporting period?','ColumnInput','0','- CDP C6.1 2022, CDP C6.3 2022, CDP C6.5 2022; GRI Disclosures 305-1, 305-2, 305-3 (2016); ISAR B.3.1; ISAR B.3.2\n(Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Scope 1 emissions\"},{\"title\":\"Scope 2 emissions\"}],\"cols\":[{\"title\":\"Measured Total Emissions (tCO2e)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"We did not measure our gross emissions [Please explain in the mandatory text box]\"}]}','1',36,1696998964,1696999508,'0'),(24494,195,2239,17,'We did not measure our gross emissions [Please explain]','TextLong','0','',NULL,'[]','1',35,1696998964,1696999508,'0'),(24495,195,2239,18,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',34,1696998964,1696999508,'0'),(24496,195,2239,19,'E7. What were the company’s gross Scope3 global greenhouse gas (GHG) emissions for the reporting period?','ChoiceOne','0','- CDP C6.5 2022; GRI Disclosure 305-3 (2016)\n- (Multiple Choice – Select one)',NULL,'{\"values\":[\"We fully measured Scope 3 GHG emissions [Please input the measured tCO2e in the text box below]\",\"We partially measured Scope 3 GHG emissions [Please input the measured tCO2e in the text box below] [Prompts E7.1]\",\"We did not measure Scope 3 GHG emissions \"],\"last\":null}','1',33,1696998964,1696999508,'0'),(24497,195,2239,20,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',32,1696998964,1696999508,'0'),(24498,195,2239,21,'If respondent answers \'Partial\' for Scope 3 emissions in E7, the below question will be displayed.\nE7.1. Which Scope 3 categories are included in the organization’s scope 3 emissions calculation?','ChoiceMultiple','0','- GRI Disclosure 305-3 (2016); CDP C6.5 2022\n- (Select all that apply)',NULL,'{\"values\":[\"Purchased goods and services\",\"Capital goods\",\"Fuel- and energy-related activities\",\"Upstream transportation and distribution\",\"Waste generated in operations\",\"Business travel\",\" Employee commuting\",\"Upstream leased assets\",\"Downstream transportation and distribution\",\"Processing of sold products\",\"Use of sold products\",\"End-of-life treatment of sold products\",\"Downstream leased assets\",\"Franchises\",\"Investments\",\"Other - upstream\",\"Other - downstream\",\" Unknown\"],\"last\":null}','1',31,1696998964,1696999508,'0'),(24499,195,2239,22,'E8. What percentage of the company\'s revenue was invested in R&D of low-carbon products/services during this reporting period?','ColumnInput','0','- CDP C4.3c 2022; CDP C4.2b 2022; (partially linked to) ISAR A.3.3\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"R&D for low-carbon products\\/services\"}],\"cols\":[{\"title\":\"Percent of revenue (%) (Please input a whole number (e.g., 50% = 50))\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',30,1696998964,1696999508,'0'),(24500,195,2239,23,'* Not applicable (Please provide additional information)','TextLong','0','',NULL,'[]','1',29,1696998964,1696999508,'0'),(24501,195,2239,24,'E9. Has the organization acted to support climate change adaptation and resilience?','ChoiceMultiple','0','- GRI Disclosure 201-2-a-iv (2016)\n- (Select all that apply)',NULL,'{\"values\":[\"We have taken action to increase organization-wide resilience to climate change\",\"We have taken action to increase resilience in our supply chains\",\"We have taken action to increase resilience in the communities in which we operate\",\"We have provided funding for climate change adaptation and resilience initiatives and projects\",\"We have not taken actions to build climate change resilience in the reporting period\",\"Unknown\"]}','1',28,1696998964,1696999508,'0'),(24502,195,2239,25,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',27,1696998964,1696999508,'0'),(24503,195,2239,26,'Energy / Resource Use\nE10. Please report the company\'s renewable energy consumption as a percentage of total energy consumption in the reporting period.','ColumnInput','0','- E10. Please report the company\'s renewable energy consumption as a percentage of total energy consumption in the reporting period.\n- (Matrix – Text Box with option for Unknown)',NULL,'{\"rows\":[{\"title\":\"Renewable energy consumption as % of total energy consumption:\"}],\"cols\":[{\"title\":\"% of total energy consumption (Please input a whole number (e.g., 50% = 50))\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"}]}','1',26,1696998964,1696999508,'0'),(24504,195,2239,27,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',25,1696998964,1696999508,'0'),(24505,195,2239,28,'Technology\nE11. What percent of the company\'s revenue came from low-carbon products/services during this reporting period? If applicable, please give a description of the products/services included in your calculation (e.g., relevant certifications)','ColumnInput','0','- SASB CG-MR-410a.1a; WEF Common Metrics\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Low-carbon products and services\\/total revenue for the reporting period\"}],\"cols\":[{\"title\":\"Percent of total revenue (%) (Please input a whole number (e.g., 50%=50))\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',24,1696998964,1696999508,'0'),(24506,195,2239,29,'* Not applicable (Please provide additional information)','TextLong','0','',NULL,'[]','1',23,1696998964,1696999508,'0'),(24507,195,2239,30,'Materiality-specific Questions\nE12. Which of the following has the company identified as material environmental topics connected with its operations and/or value chain (e.g. based on the most severe actual or potential negative impacts on people and/or the environment)?','ChoiceMultiple','0','- GRI Disclosure 2-6-a (2021)\n- (Select all that apply)',NULL,'{\"values\":[\"Water [Prompts Questions E13; E14]\",\"Forests\\/Biodiversity\\/Land use [Prompts Questions E15-E17]\",\"Air pollution [Prompts Question E18]\",\" Waste (e.g., chemical spills, solid waste, hazardous, plastic, etc.) [Prompts Questions E19-E21]\",\" None of the topics have been identified as material by the company\"]}','1',22,1696998964,1696999508,'0'),(24508,195,2239,31,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',21,1696998964,1696999508,'0'),(24509,195,2239,32,'Materiality-specific: Water\nE13.1 Please provide details regarding the company\'s water W (own operations) during the reporting period.\n','ColumnInput','0','- SAR B.1.3; CDP W1.2b 2022, CDP W1.2d 2022; SASB CG-HP-140a.1; GRI Disclosures 303-3, 303-5 (2018)\n- (Matrix – Text Boxes with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Total water WITHDRAWAL by source:\"},{\"title\":\"Fresh surface water withdrawal:\"},{\"title\":\"Groundwater withdrawal:\"},{\"title\":\"Brackish surface water\\/seawater withdrawal:\"},{\"title\":\"Produced water withdrawal:\"},{\"title\":\"Third-party water withdrawal:\"},{\"title\":\"Percentage of water withdrawn in regions with high or extremely high water stress(%):\"}],\"cols\":[{\"title\":\"Volume of water in megaliters\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information)\"}]}','1',20,1696998964,1696999508,'0'),(24510,195,2239,33,'Materiality-specific: Water\nE13.2 Please provide details regarding the company\'s water consumption (own operations) during the reporting period.','ColumnInput','0','- SAR B.1.3; CDP W1.2b 2022, CDP W1.2d 2022; SASB CG-HP-140a.1; GRI Disclosures 303-3, 303-5 (2018)\n- (Matrix – Text Boxes with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Total water CONSUMPTION by source:\"},{\"title\":\"Fresh surface water withdrawal:\"},{\"title\":\"Groundwater withdrawal:\"},{\"title\":\"Brackish surface water\\/seawater withdrawal:\"},{\"title\":\"Produced water withdrawal:\"},{\"title\":\"Third-party water withdrawal:\"},{\"title\":\"Percentage of water withdrawn in regions with high or extremely high water stress(%):\"}],\"cols\":[{\"title\":\"Volume of water in megaliters\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information)\"}]}','1',19,1696998964,1696999508,'0'),(24511,195,2239,34,'Please provide additional explanation: ','TextLong','0','',NULL,'[]','1',18,1696998964,1696999508,'0'),(24512,195,2239,35,'E14. Please provide details about the company’s water intensity of products in regions with high or extremely high water stress.','ColumnInput','0','- CDP 1.3 2022; CDP 1.3a 2022\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Water intensity of products:\"}],\"cols\":[{\"title\":\"Cubic meter\\/$ OR cubic meter\\/product type (Please input a number e.g., 50)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',17,1696998964,1696999508,'0'),(24513,195,2239,36,'* Not applicable (Please provide additional information in the mandatory text box)','TextLong','0','',NULL,'[]','1',16,1696998964,1696999508,'0'),(24514,195,2239,37,'E15. Please report the number and area (in hectares) of sites owned, leased, or managed by the company in or adjacent to protected areas and/or key biodiversity areas (KBA).','ColumnInput','0','- GRI Disclosure 304-1 (2016)\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Sites\"},{\"title\":\"Hectares\"}],\"cols\":[{\"title\":\"Number\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',15,1696998964,1696999508,'0'),(24515,195,2239,38,'* Not applicable (Please provide additional information in the mandatory text box) ','TextLong','0','',NULL,'[]','1',14,1696998964,1696999508,'0'),(24516,195,2239,39,'E16. What area (in hectares) of natural ecosystems was converted during the reporting period in areas owned, leased, or managed by the company?','ColumnInput','0','- CDP F1.3 2022; GRI Disclosure 304-1 (2016)\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Conversion of natural resources\"}],\"cols\":[{\"title\":\"Area (hecvtares)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',13,1696998964,1696999508,'0'),(24517,195,2239,40,'E17. Is the company supporting or implementing project(s) focused on ecosystem restoration and protection?','ColumnInput','0','- CDP F6.11 2022; GRI Disclosure 304-3 (2016)\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Forest ecosystem restoration\"},{\"title\":\"Other ecosystem restoration\"},{\"title\":\"Reforestation\"},{\"title\":\"Natural regeneration\"},{\"title\":\"Agroforestry\"},{\"title\":\"Set-aside land\"},{\"title\":\"Biodiversity offsetting\"},{\"title\":\"* Other (Please provide additional information)\"}],\"cols\":[{\"title\":\"No\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"No, but we plan to within the next 2 years\"},{\"type\":\"3\",\"title\":\"Yes, Project(s) area to date (hectares)\"}]}','1',12,1696998964,1696999508,'0'),(24518,195,2239,41,'* Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',11,1696998964,1696999508,'0'),(24519,195,2239,42,'Materiality-specific: Air Pollution\nE18. Where applicable, please report the company\'s emissions of the following pollutants during the reporting period.','ColumnInput','0','-  GRI Disclosure 305-7 (2016); ISAR B.1.4\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"NOx\"},{\"title\":\"SOx\"},{\"title\":\"Volatile Organic Compounds (VOCs)\"},{\"title\":\"Hazardous air pollutants (HAPs)\"},{\"title\":\"Particulate matter (PM10)\"},{\"title\":\"Persistent organic pollutants (POPs)\"},{\"title\":\"* Other (Please provide additional information)\"}],\"cols\":[{\"title\":\"Emissions (tonnes)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown (Please provide additional information in the mandatory text box)\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',10,1696998964,1696999508,'0'),(24520,195,2239,43,'* Other (Please provide additional information)','TextLong','0','',NULL,'[]','1',9,1696998964,1696999508,'0'),(24521,195,2239,44,'Additional Topic-specific Questions: Waste\nE19. In metric tonnes, please report the company\'s total weight of waste generated during the reporting period.','ColumnInput','0','- GRI Disclosure 306-3 (2020); (partially linked to) ISAR B.2.1\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Solid Waste\"}],\"cols\":[{\"title\":\"Waste Generated (t)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',8,1696998964,1696999508,'0'),(24522,195,2239,45,'* Not applicable (Please provide additional information) ','TextLong','0','',NULL,'[]','1',7,1696998964,1696999508,'0'),(24523,195,2239,46,'E20. Please report the percentage of the company\'s waste that was hazardous waste (e.g., hazardous waste ratio) during the reporting period.','ColumnInput','0','- GRI Disclosures 306-4, 306-5 (2020); ISAR B.2.3\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Hazardous waste\"}],\"cols\":[{\"title\":\"Hazardous Waste Ratio (%) (Please input a whole number e.g., 50%=50))\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',6,1696998964,1696999508,'0'),(24524,195,2239,47,'* Not applicable (Please provide additional information) ','TextLong','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24525,195,2239,48,'E21. Please report the company\'s estimated metric tonnes of single-use plastic consumed wherever material along the value chain during the reporting period.','ColumnInput','0','- WEF Common Metrics\n- (Matrix – Text Box with option for Unknown or N/A)',NULL,'{\"rows\":[{\"title\":\"Single-use plastics\"}],\"cols\":[{\"title\":\"Single-use plastics (t)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"* Not applicable (Please provide additional information in the mandatory text box)\"}]}','1',4,1696998964,1696999508,'0'),(24526,195,2239,49,'* Not applicable (Please provide additional information)  ','TextLong','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24527,195,2239,50,'Overall Environment\nE22. Briefly describe additional relevant practical actions the company has taken during the reporting period and/or plans to take to implement the environment principles, including any challenges faced and actions taken towards prevention and/or remediation.','TextLong','0','GRI Disclosures 3-3-c and 3-3-d (2021) for topics GRI 303 (2018), GRI 304 (2016), GRI 305 (2016), GRI 306 (2020), GRI 302 (2016)',NULL,'[]','1',2,1696998964,1696999508,'0'),(24528,195,2239,51,'What is the time period covered by your questionnaire?','TextItem','0','(MM/YYYY - MM/YYYY)',NULL,'[]','1',1,1696998964,1696999508,'0'),(24529,195,2240,1,'Please provide your company\'s total net fresh water consumption, including data for fresh water extraction and consumption. For each row in the table, it is mandatory that the values are provided in the same unit. \n\nBoundary: PEC Japan office (Units: Million cubic meters)\n','ColumnInput','0','','','{\"rows\":[{\"title\":\"Withdrawal: Total municipal water supplies (or from other water utilities)\"},{\"title\":\"Withdrawal: Fresh surface water (lakes, rivers, etc.)\"},{\"title\":\"Withdrawal: Fresh groundwater\"},{\"title\":\"Discharge: Water returned to the source of extraction at similar or higher quality as raw water extracted (only applies to B and C)\"},{\"title\":\"TOTAL NET FRESH WATER CONSUMPTION (A+B+C-D)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"},{\"type\":\"3\",\"title\":\"What was your target for FY 2022?\"}]}','1',2,1696998964,1696999508,'0'),(24530,195,2240,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24531,195,2241,1,'Does your company have a group-wide strategy that provides guidance to your corporate citizenship/ philanthropic activities? Please indicate how this strategy aligns with your overall corporate strategy and the 17 UN Sustainable Development Goals.','DynamicForm','0','Please specify and provide supporting documents:\nPriorities & KPIs\n- Please indicate the three main voluntary or charitable priorities as outlined in your group-wide corporate citizenship/philanthropy strategy specified above and whether the priority is publicly available. \n- For each priority, please indicate which UN Sustainable Development Goal the priority is aligned with. Furthermore, please provide a short description of how the priority is aligned with your business drivers. In addition, please indicate which KPIs your company uses to measure the benefits of the three main priorities. \n- The KPIs need to be measurable and you should provide quantitative results wherever possible. Please clearly describe the benefit KPIs as well as the activity in the provided text boxes.\nBelow is an example from the HQ','/static/upload/image/d/d7/7b/8dce2ca9eb86e90f9228e1e64f2889da.6','{\"cols\":[{\"title\":\"Priorities\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Description of alignment between priority and your business drivers.\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',7,1696998964,1696999508,'0'),(24532,195,2241,2,'Please provide ONE examples from the JP team which focus on (A) R&D innovation','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"R&D innovation programs \"}],\"cols\":[{\"title\":\"Description of alignment between priority and your business drivers.\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',6,1696998964,1696999508,'0'),(24533,195,2241,3,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',5,1696998964,1696999508,'0'),(24534,195,2241,4,'Please provide ONE examples from the JP team which focus on (B) Quality drugs','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Quality drugs\"}],\"cols\":[{\"title\":\"Description of alignment between priority and your business drivers.\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',4,1696998964,1696999508,'0'),(24535,195,2241,5,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',3,1696998964,1696999508,'0'),(24536,195,2241,6,'Please provide ONE examples from the JP team which focus on (C) Access to Medicine ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Access to Medicine \"}],\"cols\":[{\"title\":\"Description of alignment between priority and your business drivers.\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Business Benefit KPI\"},{\"type\":\"1\",\"title\":\"Social \\/ Environmental Benefit KPI\"}]}','1',2,1696998964,1696999508,'0'),(24537,195,2241,7,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24538,195,2242,1,'For the last fiscal year (2022), please indicate on a consolidated group-wide basis what percentage of your corporate citizenship and/or philanthropic contributions falls within each category. Please refer to the information button for definitions and explanations of the categories.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Charitable Donations\"},{\"title\":\"Community Investments\"},{\"title\":\"Commercial Initiatives\"},{\"title\":\"Other \"},{\"title\":\"Total \"}],\"cols\":[{\"title\":\"Type or Name of activities \",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Please describe your contribution (e.g. intangible or tangible)\"}]}','1',2,1696998964,1696999508,'0'),(24539,195,2242,2,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999508,'0'),(24540,195,2244,1,'風險管理與因應相關問題','Scale','0','',NULL,'{\"rows\":[{\"title\":\"\\u8acb\\u554f\\u516c\\u53f8\\u662f\\u5426\\u6709\\u8a2d\\u7acb\\u98a8\\u96aa\\u7ba1\\u7406\\u8207\\u56e0\\u61c9\\u7684\\u59d4\\u54e1\\u6703\\u53ca\\u6c7a\\u7b56\\u7ba1\\u7406\\u5c64\\u7d1a?\"},{\"title\":\"\\u96b8\\u5c6c\\u65bc\\u8463\\u4e8b\\u6703\\u9084\\u662f\\u71df\\u904b\\u7ba1\\u7406\\u5c64\\u7d1a? \"}],\"cols\":[{\"title\":\"\\u662f\"},{\"title\":\"\\u5426\"}]}','1',9,1696998964,1696999509,'0'),(24541,195,2244,2,'請提供風險管理與因應委員會及決策管理層級的說明','TextLong','0','',NULL,'[]','1',8,1696998964,1696999509,'0'),(24542,195,2244,3,'請問公司多久進行一次風險辨識與風險管理? ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u98a8\\u96aa\\u8fa8\\u8b58\"},{\"title\":\"\\u98a8\\u96aa\\u7ba1\\u7406\"}],\"cols\":[{\"title\":\"\\u57f7\\u884c\\u9031\\u671f\",\"type\":\"1\"}]}','1',7,1696998964,1696999509,'0'),(24543,195,2244,4,'請問與公司本業有關最重大的前3項風險為何？（至多勾選3項）並說明公司針對上述3大風險的管理與因應。','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u50b3\\u67d3\\u75c5\\u6216\\u5176\\u4ed6\\u5065\\u5eb7\\u5371\\u6a5f\"},{\"title\":\"\\u5730\\u7de3\\u653f\\u6cbb\\u98a8\\u96aa\"},{\"title\":\"\\u4f9b\\u61c9\\u93c8\\u4e2d\\u65b7\"},{\"title\":\"\\u7db2\\u8def\\u5a01\\u8105\\uff08\\u8cc7\\u5b89\\u98a8\\u96aa\\uff09\"},{\"title\":\"\\u6c23\\u5019\\u8b8a\\u9077\"},{\"title\":\"\\u80fd\\u6e90\\u53ca\\u8cc7\\u6e90\\u77ed\\u7f3a\"},{\"title\":\"\\u85e5\\u7269\\u56de\\u6536\"},{\"title\":\"\\u4eba\\u624d\\u53ca\\u52de\\u52d5\\u529b\\u77ed\\u7f3a\"},{\"title\":\"\\u5176\\u4ed6\\uff0c\\u8acb\\u8aaa\\u660e                                               \"}],\"cols\":[{\"title\":\"\\u52fe\\u9078\\u6392\\u5e8f\\u524d\\u4e09\\u9805\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\\u516c\\u53f8\\u91dd\\u5c0d\\u4e0a\\u8ff03\\u5927\\u98a8\\u96aa\\u7684\\u7ba1\\u7406\\u8207\\u56e0\\u61c9\"}]}','1',6,1696998964,1696999509,'0'),(24544,195,2244,5,'董事會組成席次','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u8463\\u4e8b\\u6703\\u7e3d\\u5e2d\\u6b21\"},{\"title\":\"\\u7368\\u7acb\\u8463\\u4e8b\\u5e2d\\u6b21\"},{\"title\":\"\\u5973\\u6027\\u8463\\u4e8b\\u5e2d\\u6b21\"},{\"title\":\"\\u5177\\u6709\\u914d\\u5076\\u6216\\u4e8c\\u7b49\\u89aa\\u4ee5\\u5167\\u89aa\\u5c6c\\u95dc\\u4fc2\\u4e4b\\u8463\\u4e8b\\u5e2d\\u6b21\"},{\"title\":\"\\u517c\\u4efb\\u516c\\u53f8\\u7d93\\u7406\\u4eba\\u4e4b\\u8463\\u4e8b\\u5e2d\\u6b21\"}],\"cols\":[{\"type\":\"1\",\"title\":\"\\u7e3d\\u5e2d\\u6578\"}]}','1',5,1696998964,1696999509,'0'),(24545,195,2244,6,'請說明董事會績效評估作法? 如何強化董事會績效? ','TextLong','0','',NULL,'[]','1',4,1696998964,1696999509,'0'),(24546,195,2244,7,'請問藥華董事會在2023年度是否有效發揮董事職能？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u6709\",\"\\u6c92\\u6709\"]}','1',3,1696998964,1696999509,'0'),(24547,195,2244,8,'藥華2023全年召開董事會次數','NumberInput','0','',NULL,'[]','1',2,1696998964,1696999509,'0'),(24548,195,2244,9,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696998964,1696999509,'0'),(24549,196,2245,1,'Please indicate the breakout in R&D investments (% of total R&D spend), duration (months), and success rates (%) for each of the three phases of the healthcare innovation process below','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Pre-clinical Research\"},{\"title\":\"Clinical Research\\/ Pathway to Approval\"},{\"title\":\"Launch\"},{\"title\":\"Total (must equal 100%)\"}],\"cols\":[{\"type\":\"3\",\"title\":\"Share of R&D budget invested (%)\"},{\"type\":\"1\",\"title\":\"Average duration\"},{\"type\":\"3\",\"title\":\"Average success rate (% of products that move to next phase)\"}]}','1',2,1696998983,1696998983,'0'),(24550,196,2245,2,'If the data cannot be aggregated at the company level, indicate which business unit you have chosen to represent in the table above, as well as the revenues generated by that unit (in % of total revenues):','TextLong','0','',NULL,'[]','1',1,1696998983,1696998983,'0'),(24551,196,2246,1,'Please provide us with your R&D spending for the last four fiscal years in the table below: Supporting evidence','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total R&D spending\"},{\"title\":\"Number of R&D positions\"},{\"title\":\"R&D Spending as % of sales\"}],\"cols\":[{\"title\":\"Unit\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"FY 2020   \"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',1,1696998983,1696998983,'0'),(24552,196,2247,1,'Please indicate three approaches you have adopted to profit from or contribute to external knowledge to complement in-house R&D. Please select three different approaches from the provided drop-down menus.','ColumnInput','0','•Example of approach: Please provide an example and attach supporting documents\n•Efficiency gains: Please provide description and impact assessment\n•Cost reduction/ Revenue generation: Please provide a description as well as the quantified impact on R&D costs/benefits\n•Access to human capital, technologies, inventions, etc.: Please provide a description of how this approach.\n•Other impact: Please provide an example and attach supporting documents',NULL,'{\"rows\":[{\"title\":\"Approach 1 \\u2022R&D Collaborations with external business partners \\u2022Corporate Venture Capital \\u2022Spin-offs, start-ups \\u2022Technology licensing \\u2022Open source \\u2022Suppliers \\u2022Other approach, please specify \\u2022Distributed creativity\"},{\"title\":\"Approach 2 \\u2022R&D Collaborations with external business partners \\u2022Corporate Venture Capital \\u2022Spin-offs, start-ups \\u2022Technology licensing \\u2022Open source \\u2022Suppliers \\u2022Other approach, please specify \\u2022Distributed creativity\"},{\"title\":\"Approach 3 \\u2022R&D Collaborations with external business partners \\u2022Corporate Venture Capital \\u2022Spin-offs, start-ups \\u2022Technology licensing \\u2022Open source \\u2022Suppliers \\u2022Other approach, please specify \\u2022Distributed creativity\"}],\"cols\":[{\"title\":\"Example of approach\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Efficiency gains (e.g. reduction of cycle time\\/ time to market, etc.)\"},{\"type\":\"1\",\"title\":\"Cost reduction\\/ Revenue generation\"},{\"type\":\"1\",\"title\":\"Access to human capital, technologies, inventions, etc.\"},{\"type\":\"1\",\"title\":\"Other impact\"}]}','1',2,1696998983,1696998983,'0'),(24553,196,2247,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696998983,1696998983,'0'),(24554,196,2248,1,'Safety of Clinical Trial Participants\nPlease describe company\'s  management process for ensuring quality and patient safety during clinical trials\nHC-BP-210a.1.','TextLong','0','',NULL,'[]','1',3,1696998983,1696998983,'0'),(24555,196,2248,2,'Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI) (HC-BP-210a.2.)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\" Clinical trial management\"},{\"title\":\"Pharmacovigilance\"}],\"cols\":[{\"title\":\"Yes (please answer the next question)\",\"type\":\"2\"},{\"type\":\"3\",\"title\":\"Number of incidents resulted in: Voluntary Action Indicated (VAI)\"},{\"type\":\"3\",\"title\":\"Number of incidents resulted in:  Official Action Indicated (OAI)\"},{\"type\":\"1\",\"title\":\"Please provide more details\"}]}','1',2,1696998983,1696998983,'0'),(24556,196,2248,3,'Please provide Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries (HC-BP-210a.3)','TextLong','0','',NULL,'[]','1',1,1696998983,1696998983,'0'),(24557,197,2250,1,'Does your company have a Supplier Code of Conduct and is it publicly available? ','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, our company has a Supplier Code of Conduct and it is publicly available.\",\"No, our company does not have a Supplier Code of Conduct OR this Code is not publicly available\"],\"last\":null}','1',4,1696999010,1696999798,'0'),(24558,197,2250,2,'If yes, the Code covers the following issues:','ChoiceMultiple','0','Please provide a weblink and indicate which of the listed issues are covered in the Code and applied to all operations across all countries.',NULL,'{\"values\":[\"Forced labor\",\"Child labor\",\"Working conditions (e.g., working hours, physical\\/mental demands of the workplace, wages, benefits)\",\"Occupational health and safety\",\"Discrimination and harassment\",\"Freedom of associations and collective bargaining\",\"Greenhouse gas emissions and energy consumption\",\"Pollution prevention and waste management\",\"Resource efficiency\",\"Biodiversity, no deforestation, or land conservation\",\"Anti-corruption and conflict of interest\",\"Anti-competitiveness\"],\"last\":null}','1',3,1696999010,1696999798,'0'),(24559,197,2250,3,'Please provide a weblink and indicate which of the listed issues are covered in the Code and applied to all operations across all countries.','UploadFile','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24560,197,2250,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24561,197,2251,1,'Does your company identify critical suppliers?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company identifies critical suppliers\",\"No, we do not identify critical suppliers.\"]}','1',7,1696999010,1696999798,'0'),(24562,197,2251,2,'If yes, Please indicate which of the following elements are considered in your definition of critical suppliers.\n','ChoiceMultiple','0','Please attach supporting evidence describing the process of identifying critical suppliers and the elements considered in the definition:',NULL,'{\"values\":[\"High-volume suppliers or similar\",\"Critical component suppliers or similar \",\" Non-substitutable suppliers or similar \",\"Other\"],\"last\":null}','1',6,1696999010,1696999798,'0'),(24563,197,2251,3,'If select other, please specify: Strategic materials','TextLong','0','',NULL,'[]','1',5,1696999010,1696999798,'0'),(24564,197,2251,4,'Please attach supporting evidence describing the process of identifying critical suppliers and the elements considered in the definition:','UploadFile','0','',NULL,'[]','1',4,1696999010,1696999798,'0'),(24565,197,2251,5,'Please indicate how many critical tier 1 and critical non-tier 1 suppliers you have identified. ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total tier 1 suppliers\"},{\"title\":\"Critical tier 1 suppliers\"},{\"title\":\"Critical non-tier 1 suppliers\"}],\"cols\":[{\"title\":\"Absolute number of suppliers\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Share of total procurement spent (%)\"}]}','1',3,1696999010,1696999798,'0'),(24566,197,2251,6,'If you did not identify any suppliers in one of the categories, please provide an explanation in the comment box at the end of the question.','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24567,197,2251,7,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24568,197,2252,1,'Does your company have a formalized process in place to identify potential sustainability risks in the supply chain?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we have a formalized process in place.\",\"No, we do not have a formalized process to assess sustainability risks in the supply chain\"]}','1',8,1696999010,1696999798,'0'),(24569,197,2252,2,'If Yes, Please describe the risk identification process: ','TextLong','0','',NULL,'[]','1',7,1696999010,1696999798,'0'),(24570,197,2252,3,'If Yes, How do you define high risks versus low risks?','TextLong','0','',NULL,'[]','1',6,1696999010,1696999798,'0'),(24571,197,2252,4,'If Yes, Number of suppliers evaluated in the last 3 years (2020-2023）\n','TextLong','0','',NULL,'[]','1',5,1696999010,1696999798,'0'),(24572,197,2252,5,'If Yes, Please fill in the following ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Critical suppliers\"},{\"title\":\"Tier 1 suppliers\"},{\"title\":\"Non-tier 1 suppliers \"},{\"title\":\"Non-critical suppliers\"}],\"cols\":[{\"title\":\"Definition\",\"type\":\"1\"}]}','1',4,1696999010,1696999798,'0'),(24573,197,2252,6,'Please indicate the number of suppliers in the following table ','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Critical supplier\"},{\"title\":\"Tier 1\"},{\"title\":\"Non Tier 1\"},{\"title\":\"Non-critical suppliers\"},{\"title\":\"Total suppliers\"}],\"cols\":[{\"title\":\"Number of suppliers *(total) \",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of suppliers assessed in FY 2020\"},{\"type\":\"3\",\"title\":\"Number of suppliers assessed in FY 2021\"},{\"type\":\"3\",\"title\":\"Number of suppliers assessed in FY 2022\"},{\"type\":\"3\",\"title\":\"Number of suppliers assessed in 2023 YTD\"}]}','1',3,1696999010,1696999798,'0'),(24574,197,2252,7,'Please indicate the number of suppliers classified as high-risk in the following table','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Critical supplier\"},{\"title\":\"Tier 1\"},{\"title\":\"Non Tier 1\"},{\"title\":\"Non-critical suppliers\"},{\"title\":\"Total suppliers\"}],\"cols\":[{\"type\":\"3\",\"title\":\"Number of suppliers classified as high-risk in FY 2020\"},{\"type\":\"3\",\"title\":\"Number of suppliers classified as high-risk in FY 2021\"},{\"type\":\"3\",\"title\":\"Number of suppliers classified as high-risk in FY 2022\"},{\"type\":\"3\",\"title\":\"Number of suppliers classified as high-risk in 2023 YTD\"}]}','1',2,1696999010,1696999798,'0'),(24575,197,2252,8,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24576,197,2253,1,'Please indicate which measures your company has taken in order to manage sustainability risks amongst your critical suppliers (tier 1 and non-tier 1) and your high sustainability risk suppliers. Please indicate the scope and attach supporting evidence or specify where requested.','TextLong','0','• Measures to manage “critical suppliers (tier 1）” \n• Measures to manage “critical suppliers (non-tier 1）”\n• Measures to manage “high sustainability risk suppliers”',NULL,'[]','1',7,1696999010,1696999798,'0'),(24577,197,2253,2,'Please indicate the standard frequency of a more comprehensive assessment of your suppliers and attach supporting documents (for example a process describing the system that tracks assessments\' frequency)','TextLong','0','',NULL,'[]','1',6,1696999010,1696999798,'0'),(24578,197,2253,3,'Please attach supporting documents (for example a process describing the system that tracks assessments\' frequency)','UploadFile','0','',NULL,'[]','1',5,1696999010,1696999798,'0'),(24579,197,2253,4,'By \"more comprehensive,\" we mean an assessment including at least a company visit either by your company\'s own personnel or by external third parties, for instance sustainability agencies.\n\nPlease note that the percentage of suppliers assessed at least once every three years should NOT include the companies assessed annually. Please also note that it is possible that there is some overlap between critical suppliers and suppliers with high sustainability risk.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Critical suppliers  (tier 1 and non-tier 1)\"},{\"title\":\"Suppliers with high sustainability risk. If you have not identified any suppliers with high sustainability risks, please ensure that \\\"0\\\" is marked \"}],\"cols\":[{\"title\":\"Number of suppliers assessed annually\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of suppliers assessed at least once every 3 years\"},{\"type\":\"3\",\"title\":\"Total number \"}]}','1',4,1696999010,1696999798,'0'),(24580,197,2253,5,'Corrective action plans for suppliers','TextLong','0','For suppliers with high sustainability risk, please indicate the number of suppliers assessed/audited for which corrective action plans have been developed:',NULL,'[]','1',3,1696999010,1696999798,'0'),(24581,197,2253,6,'Corrective action plans for suppliers ','TextLong','0','For suppliers with high sustainability risk, please indicate the number of suppliers with a corrective action plan which has improved their ESG performance since the action plan was launched.',NULL,'[]','1',2,1696999010,1696999798,'0'),(24582,197,2253,7,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24583,197,2254,1,'General supply chain strategy\n\nPlease provide a brief description of your supply chain management strategy, as well as the top five priorities of your company\'s general supply chain management strategy\n• Supply chain management strategy\n• Top 5 priorities (e.g. cost, time, quality, continuity of supply, etc)\n','TextLong','0','Please note that this should refer to the general approach that the company is taking in order to manage the supply chain with regards to aspects such as cost, time, quality and continuity of supply and not to a sustainable sourcing or a sustainable supply chain strategy.',NULL,'[]','1',10,1696999010,1696999798,'0'),(24584,197,2254,2,'Sustainability Declaration \nDoes your company have a Sustainability Declaration?','TextLong','0','',NULL,'[]','1',9,1696999010,1696999798,'0'),(24585,197,2254,3,'Strengthen Supply Chain Management and Resilience\nDoes your company have a Sustainability Declaration?','TextLong','0','',NULL,'[]','1',8,1696999010,1696999798,'0'),(24586,197,2254,4,'Integration of ESG objectives\n\nPlease indicate which formalized ESG objectives have been identified for your supply chain management strategy.\n','TextLong','0','',NULL,'[]','1',7,1696999010,1696999798,'0'),(24587,197,2254,5,'Integration of ESG objectives\n\nFurther, indicate how these are connected to the overall supply chain strategy:','TextLong','0','',NULL,'[]','1',6,1696999010,1696999798,'0'),(24588,197,2254,6,'Integration of ESG objectives\n\nPlease note that in this section you can refer to a sustainable sourcing strategy or a sustainable supply chain strategy as well as to objectives relating to ESG factors already integrated in the strategy above.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Key ESG Objective 1\"},{\"title\":\"Key ESG Objective 2\"}],\"cols\":[{\"title\":\"Description of ESG objective\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Link to overall supply chain strategy\"}]}','1',5,1696999010,1696999798,'0'),(24589,197,2254,7,'Integration of ESG factors into supplier selection\n\nPlease complete the table below, indicating how ESG factors impact your supplier selection and retention process.\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"New suppliers \"},{\"title\":\"Existing suppliers\"},{\"title\":\"New and existing suppliers\"}],\"cols\":[{\"type\":\"1\",\"title\":\"Minimum number of (i.e. certified management systems in place, requiring to replicate own standards down the supply chain, minimum score at ESG assessment, etc.):\"}]}','1',4,1696999010,1696999798,'0'),(24590,197,2254,8,'Does your company use a % (weight) of ESG in the overall assessment of suppliers (compared to other factors such as price, quality and delivery time), as a tool to ensure integration of sustainability into supplier selection and retention decisions? \nand indicate for which supplier categories (tier 1, critical tier 1, etc.) this weight factor is being applied:\n','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\"No\"]}','1',3,1696999010,1696999798,'0'),(24591,197,2254,9,'If yes, please indicate for which supplier categories (tier 1, critical tier 1, etc.) this weight factor is being applied','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24592,197,2254,10,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24593,197,2255,1,'Which of the following supply chain approaches do you have in place? Selet all that applies','ChoiceMultiple','0','',NULL,'{\"values\":[\"Supply chain spend analysis (containing basic spend analysis information such as: number of suppliers, category, spend value and geographical spread)\",\"Supply chain awareness (identification of critical suppliers)\",\"Supply chain risk assessment and corrective actions (e.g. supplier sustainability assessment)\",\"ESG integration in supply chain management strategy (e.g. minimum thresholds or alignment of overall supply chain management strategy with ESG objectives)\"]}','1',3,1696999010,1696999798,'0'),(24594,197,2255,2,'Reporting quantitative KPIs and targets\n\nIf available, please select KPIs with at least three years of history, well defined targets and clear reporting on progress towards these targets.\n','ColumnInput','0','The KPIs of supply chain management indicators e.g. Code of Conduct for suppliers \nThe target that is linked to the KPI of supply chain indicators e.g. 100% ',NULL,'{\"rows\":[{\"title\":\"Example\"},{\"title\":\"KPI 1\"},{\"title\":\"KPI 2\"},{\"title\":\"KPI 3\"}],\"cols\":[{\"title\":\"Please specify the KPIs of supply chain management indicators\",\"type\":\"1\"},{\"type\":\"3\",\"title\":\"What are the target that is linked to the KPI of supply chain indicators\"}]}','1',2,1696999010,1696999798,'0'),(24595,197,2255,3,'Please provide supporting document','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24596,197,2256,1,'Does your company have systems/procedures in place to ensure effective implementation of company’s supplier ESG programs required to identify and address material risks and impacts?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, we publicly disclose the measures below related to supplier ESG programs.\",\"No, we do not publicly report this information.\"]}','1',5,1696999010,1696999798,'0'),(24597,197,2256,2,'If yes, please answer this question：','ChoiceMultiple','0','',NULL,'{\"values\":[\"Oversight of implementation of the supplier ESG program is defined. Please select the highest accountable decision-making body\",\"Purchasing practices towards suppliers are continuously reviewed to ensure alignment with the Supplier Code of Conduct and to avoid potential conflicts with ESG requirements.\",\"Suppliers are excluded from contracting if they cannot achieve minimum ESG requirements within a set timeframe.\",\"Suppliers with better ESG performance are preferred by applying a minimum weight to ESG criteria in supplier selection and contract awarding.\",\"Training for company\\u2019s buyers and\\/or internal stakeholders on their roles in the supplier ESG program.\"]}','1',4,1696999010,1696999798,'0'),(24598,197,2256,3,'Oversight of implementation of the supplier ESG program is defined. Please select the highest accountable decision-making body:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Board of directors\",\"Executive management\"]}','1',3,1696999010,1696999798,'0'),(24599,197,2256,4,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24600,197,2256,5,'Please provide supporting document','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24601,197,2257,1,'Does your company apply supplier screening to systematically identify significant suppliers (Please see infotext for the definition)?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company has a systematic supplier screening approach to identify significant suppliers. Please provide public supporting evidence with reference to the description of selected options.\",\"No, we do not publicly disclose our supplier screening approach to identify significant suppliers.\"]}','1',5,1696999010,1696999798,'0'),(24602,197,2257,2,'Aspects of suppliers screening\nPlease indicate which of the following aspects are considered in your screening process for significant suppliers.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Environmental\",\"Social\",\"Governance\",\"Business relevance\"]}','1',4,1696999010,1696999798,'0'),(24603,197,2257,3,'Methodology for suppliers screening\nPlease indicate which of the following risks are considered in your screening process for significant suppliers.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Country-specific risk\",\"Sector-specific risk\",\"Commodity-specific risk\"]}','1',3,1696999010,1696999798,'0'),(24604,197,2257,4,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24605,197,2257,5,'Please provide supporting document','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24606,197,2258,1,'Does your company have a publicly available supplier assessment and development process in place?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, our company has a publicly available supplier assessment and development process in place\",\"No, we do not have a publicly available supplier assessment process in place\"]}','1',5,1696999010,1696999798,'0'),(24607,197,2258,2,'Supplier assessment\nYes, our company has a publicly available supplier assessment process in place which includes the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Supplier desk assessments with systematic verification of evidence\",\"Supplier on-site assessments carried out by purchasing company employees or contracted consultant (2nd party assessment)\",\"Supplier on-site assessments carried out by an independent accredited auditing body (3rd party assessment).\",\"Supplier assessments (desk or on-site) are carried out using standards and methodologies of a recognized industry or multi-stakeholder initiative. Please provide name\\/description:\",\"Supplier corrective action\\/improvement plans\"]}','1',4,1696999010,1696999798,'0'),(24608,197,2258,3,'Supplier Development\nYes, our company has a publicly available supplier development process in place which includes the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Supplier information\\/trainings on company\'s supplier ESG program, process and requirements\",\"Supplier access to ESG benchmarks against peers\",\"Supplier support (remote\\/on-site) on implementation of corrective\\/improvement actions\",\"In-depth technical support programs to build capacity and ESG performance in suppliers\"]}','1',3,1696999010,1696999798,'0'),(24609,197,2258,4,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe\nsignificant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit\nor format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24610,197,2258,5,'Please provide supporting document','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24611,197,2259,1,'Does your company monitor and report on coverage and progress of your supplier screening program?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, we monitor and report on coverage and progress of our supplier screening program\",\"Our data is publicly available. Please provide supporting evidence or web link.\",\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\",\"No, we do not monitor and report on coverage and progress of our supplier screening program.\"]}','1',4,1696999010,1696999798,'0'),(24612,197,2259,2,'Supplier Screening','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"1.1 Total number of Tier-1 suppliers\"},{\"title\":\"1.2 Total number of significant suppliers in Tier-1\"},{\"title\":\"1.3 % of total spend on significant suppliers in Tier-1\"},{\"title\":\"1.4 Total number of significant suppliers in non Tier-1\"},{\"title\":\"1.5 Total number of significant suppliers (Tier-1 and non Tier-1)\"}],\"cols\":[{\"title\":\"FY 2022\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"2023 YTD\"}]}','1',3,1696999010,1696999798,'0'),(24613,197,2259,3,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24614,197,2259,4,'Please provide supporting document','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24615,197,2260,1,'Does your company monitor and report on the coverage and progress of your supplier assessment and development program?\nPlease report the number of unique suppliers, which were identified as significant in the supplier screening process. These are unique significant suppliers assessed during the reporting period (not number of assessments realized, i.e. no multiple count of suppliers if they were assessed more than once during the reporting period).','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, our company monitors and reports on the coverage and progress of our supplier assessment and development program. It includes the following:\",\"Our data is publicly available. Please provide supporting evidence or web link\",\"Our data has been third-party verified in the most recent financial year reported. Please provide supporting evidence.\",\"No, we do not monitor and report on coverage and progress of our supplier assessment and development program\",\"Not known\"]}','1',6,1696999010,1696999798,'0'),(24616,197,2260,2,'Coverage and progress of our supplier assessment program\nSupplier Assessment','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"1.1 Total number of suppliers assessed via desk assessments\\/ on-site assessments\"},{\"title\":\"1.2 % of significant suppliers assessed\"},{\"title\":\"1.3 Number of suppliers assessed with substantial actual\\/ potential negative impacts\"},{\"title\":\"1.4 % of suppliers with substantial actual\\/potential negative impacts with agreed corrective action\\/improvement plan\"},{\"title\":\"1.5 Number of suppliers with substantial actual\\/potential negative impacts that were terminated\"}],\"cols\":[{\"title\":\"FY 2023\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Target for FY 2023\"}]}','1',5,1696999010,1696999798,'0'),(24617,197,2260,3,'Coverage and progress of suppliers with corrective action plans\nCorrective action plan support','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"2.1 Total number of suppliers supported in corrective action plan implementation\"},{\"title\":\"2.2. % of suppliers assessed with substantial actual\\/potential negative impacts supported in corrective action plan implementation\"}],\"cols\":[{\"title\":\"FY 2023\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Target for FY 2023\"}]}','1',4,1696999010,1696999798,'0'),(24618,197,2260,4,'Coverage and progress of suppliers in capacity building programs\nCapacity building programs','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"3.1 Total number of suppliers in capacity building programs\"},{\"title\":\"3.2 % of significant suppliers in capacity building programs\"}],\"cols\":[{\"title\":\"FY 2023\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Target for FY 2023\"}]}','1',3,1696999010,1696999798,'0'),(24619,197,2260,5,'Confidential additional comments: Use the text field below only in the following cases: (i) to describe significant changes in data or calculation methodology compared to last year\'s submission, (ii) to explain why a\nquestion is not applicable to your company\'s business model, (iii) to explain if your data deviates from the unit or format requested, or (iv) to provide supporting notes on translations of non-English references.','TextLong','0','',NULL,'[]','1',2,1696999010,1696999798,'0'),(24620,197,2260,6,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24621,197,2261,1,'New suppliers that were screened\nusing environmental criteria','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"The percentage of new suppliers that are screened using energy criteria (energy consumption, intensity, reduced energy demand for a product or service)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Percentage of new suppliers screened using water intake criteria (source vs. water consumption \\u2013 surface water, groundwater, seawater, produced water, third-party water, freshwater)\"},{\"type\":\"3\",\"title\":\"Percentage of new suppliers screened using emission criteria (Scope I, II, III, INTENSITY, REDUCTION, ODS, NOx, SOx).\"}]}','1',3,1696999010,1696999798,'0'),(24622,197,2261,2,'Negative environmental impacts in the supply chain and actions taken','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Number of suppliers assessed for environmental impacts. \",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of suppliers identified as having significant actual and potential negative environmental impacts. b.\"},{\"type\":\"3\",\"title\":\"Significant actual and potential negative environmental impacts identified in the supply chain.\"},{\"type\":\"3\",\"title\":\"Percentage of suppliers identified as having significant actual and potential negative environmental impacts with which improvements were agreed upon as a result of assessment. d.\"},{\"type\":\"3\",\"title\":\"Percentage of suppliers identified as having significant actual and potential negative environmental impacts with which relationships were terminated as a result of assessment\"}]}','1',2,1696999010,1696999798,'0'),(24623,197,2261,3,'Present the above question (suppliers identified as having significant actual and potential negative environmental impacts with which relationships were terminated as a result of assessment), please indicate why','TextLong','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24624,197,2262,1,'Percentage of new suppliers that were screened using social criteria','NumberInput','0','',NULL,'[]','1',3,1696999010,1696999798,'0'),(24625,197,2262,2,'Negative social impacts in the supply\nchain and actions taken','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Number of suppliers assessed for social impacts. \",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of suppliers identified as having significant actual and potential negative social impacts.\"},{\"type\":\"3\",\"title\":\"Significant actual and potential negative social impacts identified in the supply chain. \"},{\"type\":\"3\",\"title\":\"Percentage of suppliers identified as having significant actual and potential negative social impacts with which improvements were agreed upon as a result of assessment.\"},{\"type\":\"3\",\"title\":\"Percentage of suppliers identified as having significant actual and potential negative social impacts with which relationships were terminated as a result of assessment\"}]}','1',2,1696999010,1696999798,'0'),(24626,197,2262,3,'Present the above question (ercentage of suppliers identified as having significant actual and potential negative social impacts with which relationships were terminated as a result of assessment), please indicate why','TextLong','0','',NULL,'[]','1',1,1696999010,1696999798,'0'),(24627,197,2263,1,'Suppliers in which the right to freedom of association and collective bargaining may be at risk (407-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"the workers\\u2019 rights to exercise freedom of association\"},{\"title\":\" collective bargaining \"}],\"cols\":[{\"title\":\"type of Supplier (such as manufacturing plant)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"countries or geographic areas with suppliers considered at risk\"},{\"type\":\"1\",\"title\":\"Measures taken by the organization in the reporting period intended to support rights to exercise freedom of association and collective bargaining\"}]}','1',4,1696999010,1696999798,'0'),(24628,197,2263,2,'Suppliers  at significant risk for incidents of child labor (GRI 408-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"child labor\"},{\"title\":\"young workers exposed to hazardous work. \"}],\"cols\":[{\"title\":\"type of Supplier (such as manufacturing plant) \",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"countries or geographic areas with Supplier considered at risk. \"},{\"type\":\"1\",\"title\":\"Measures taken by the organization in the reporting period intended to contribute to the effective abolition of child labor\"}]}','1',3,1696999010,1696999798,'0'),(24629,197,2263,3,'Forced or Compulsory Labor (GRI 409-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Forced or Compulsory Labo\"}],\"cols\":[{\"title\":\"type of supplier (such as manufacturing plant) \",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"countries or geographic areas with suppliers considered at risk\"},{\"type\":\"1\",\"title\":\"Measures taken by the organization in the reporting period intended to contribute to the effective abolition of child labor\"}]}','1',2,1696999010,1696999798,'0'),(24630,197,2263,4,'The supplier of Security personnel trained in human rights policies or procedures (410-1)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"state whether employees of third-party organizations are also included in the calculation\"}],\"cols\":[{\"title\":\"If the Surecity provided by the supplier, please indicate the percentage of security personnel who have received formal training in the organization\\u2019s human rights policies\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"If the Surecity provided by the supplier, please indicate the specific procedures and their application to security\"},{\"type\":\"2\",\"title\":\"If the Surecity provided by the supplier, whether training requirements also apply to third-party organizations providing security personnel\"}]}','1',1,1696999010,1696999798,'0'),(24631,198,2264,1,'Please indicate three approaches you have adopted to profit from or contribute to external knowledge to complement in-house R&D. For each approach selected, please provide examples, add supporting evidence and describe/quantify the impacts of the open innovation approach.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\" No such approaches are in place\",\"Not applicable. Please provide an explanation in the comment box below.\",\"Not known\"]}','1',4,1696999023,1696999781,'0'),(24632,198,2264,2,'If yes, Please indicate three approaches you have adopted to profit from or contribute to external knowledge to complement in-house R&D. For each approach selected, please provide examples, add supporting evidence and describe/quantify the impacts of the open innovation approach.','DynamicForm','0','Please select three different approaches from the provided drop-down menus. Duplicate approaches will not be accepted: \n\nExample of open innovation approach(please specify if other)\nApproach 1 focuses on Licensing Out - mainly refers to our partnership with AOP to obtain marketing authorization\n1) R&D - Collaborations with external business partners\n2) Corporate Venture Capital\n3) Spin-offs, start-ups\n4) Technology licensing\n5) Open source\n6) Suppliers\n7) Other approach, please specify\n8) Distributed creativity\n\nApproach 2 focuses on Licensing In - mainly refers to PharmaEssentia\'s collaboration with Axis Therapeutics and Athenex\n1) R&D - Collaborations with external business partners\n2) Corporate Venture Capital\n3) Spin-offs, start-ups\n4) Technology licensing\n5) Open source\n6) Suppliers\n7) Other approach, please specify\n8) Distributed creativity\n\nApproach \n1) R&D - Collaborations with external business partners\n2) Distributed creativity\n3) Corporate Venture Capital\n4) Spin-offs, start-ups\n5) Technology licensing\n6) Open source\n7) Suppliers\n8) Other approach, please specify',NULL,'{\"cols\":[{\"title\":\"Example of open innovation approach (please specify if other)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Example of approach \"},{\"type\":\"1\",\"title\":\"Efficiency gains (e.g. reduction of cycle time\\/ time to market, etc.) Please provide description and impact assessment\"},{\"type\":\"1\",\"title\":\"Cost reduction\\/ Revenue generation.\"},{\"type\":\"1\",\"title\":\"Access to human capital, technologies, inventions, etc. \"},{\"type\":\"1\",\"title\":\"Other impact.\"}]}','1',3,1696999023,1696999781,'0'),(24633,198,2264,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',2,1696999023,1696999781,'0'),(24634,198,2264,4,'If Not applicable. Please provide an explanation in the comment box below.','TextLong','0','',NULL,'[]','1',1,1696999023,1696999781,'0'),(24635,199,2265,1,'Please indicate three approaches you have adopted to profit from or contribute to external knowledge to complement in-house R&D. For each approach selected, please provide examples, add supporting evidence and describe/quantify the impacts of the open innovation approach.','ChoiceOne','0','',NULL,'{\"values\":[\"Yes\",\" No such approaches are in place\",\"Not applicable. Please provide an explanation in the comment box below.\",\"Not known\"]}','1',4,1696999037,1696999037,'0'),(24636,199,2265,2,'If yes, Please indicate three approaches you have adopted to profit from or contribute to external knowledge to complement in-house R&D. For each approach selected, please provide examples, add supporting evidence and describe/quantify the impacts of the open innovation approach.','DynamicForm','0','Please select three different approaches from the provided drop-down menus. Duplicate approaches will not be accepted: \n\nExample of open innovation approach(please specify if other)\nApproach 1 focuses on Licensing Out - mainly refers to our partnership with AOP to obtain marketing authorization\n1) R&D - Collaborations with external business partners\n2) Corporate Venture Capital\n3) Spin-offs, start-ups\n4) Technology licensing\n5) Open source\n6) Suppliers\n7) Other approach, please specify\n8) Distributed creativity\n\nApproach 2 focuses on Licensing In - mainly refers to PharmaEssentia\'s collaboration with Axis Therapeutics and Athenex\n1) R&D - Collaborations with external business partners\n2) Corporate Venture Capital\n3) Spin-offs, start-ups\n4) Technology licensing\n5) Open source\n6) Suppliers\n7) Other approach, please specify\n8) Distributed creativity\n\nApproach \n1) R&D - Collaborations with external business partners\n2) Distributed creativity\n3) Corporate Venture Capital\n4) Spin-offs, start-ups\n5) Technology licensing\n6) Open source\n7) Suppliers\n8) Other approach, please specify',NULL,'{\"cols\":[{\"title\":\"Example of open innovation approach (please specify if other)\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Example of approach \"},{\"type\":\"1\",\"title\":\"Efficiency gains (e.g. reduction of cycle time\\/ time to market, etc.) Please provide description and impact assessment\"},{\"type\":\"1\",\"title\":\"Cost reduction\\/ Revenue generation.\"},{\"type\":\"1\",\"title\":\"Access to human capital, technologies, inventions, etc. \"},{\"type\":\"1\",\"title\":\"Other impact.\"}]}','1',3,1696999037,1696999037,'0'),(24637,199,2265,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',2,1696999037,1696999037,'0'),(24638,199,2265,4,'If Not applicable. Please provide an explanation in the comment box below.','TextLong','0','',NULL,'[]','1',1,1696999037,1696999037,'0'),(24639,200,2266,1,'Overview of substantiated complaints concerning breaches of customer privacy and losses of customer data. (GRI 418-1)','TextLong','0','Example from previous year\'s report:\nThe privacy policy of PharmaEssentia focuses on protecting personal information, including\nthat of patients, healthcare professionals and other individuals involved in business transactions.\nPrivacy protection is divided into two stages: clinical trial and drug launch. All of\nour partner research institution and hospitals for clinical trials are required to strictly follow\nour internal policy and national regulations, such as the General Data Protection Regulation\n(GDPR) in the European Union, Good Clinical Practice (GCP), the Helsinki Declaration and\nTaiwan\'s guidelines on ethical human research to ensure the protection of personal data.\nIn 2022, there were no complaints of privacy violations or loss of customer data.',NULL,'[]','1',4,1696999056,1696999762,'0'),(24640,200,2266,2,'Global Cybersecurity Strategy\nPlease provide information on the following topics:','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Governance Responsibility\"},{\"title\":\"Risk Prevention Monitoring\"},{\"title\":\"Management Measures\"},{\"title\":\"Education & Training on data privacy\"}],\"cols\":[{\"title\":\"Is this available?\",\"type\":\"2\"},{\"type\":\"1\",\"title\":\"Please provide details\"}]}','1',3,1696999056,1696999762,'0'),(24641,200,2266,3,'Confirmed Privacy Violations or Loss of Customer Data Complaints (GRI 418)','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Please provide the total number of confirmed external complaints related to privacy violations.\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Please provide the total number of confirmed complaints related to privacy violations from regulatory authorities.\"},{\"type\":\"3\",\"title\":\"Please provide the total number of confirmed incidents of information disclosure, data breaches, or loss of customer data.\"},{\"type\":\"1\",\"title\":\"If the organization has not identified any complaints, simply state this fact briefly.\"}]}','1',2,1696999056,1696999762,'0'),(24642,200,2266,4,'Please provide supporting documents.','UploadFile','0','',NULL,'[]','1',1,1696999056,1696999762,'0'),(24643,200,2267,1,'Are the board of directors and executive management engaged in the information security /cybersecurity strategy and review process?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we have a director on the board with relevant background in IT engaged on the cybersecurity strategy process and someone in the Executive Management team who oversees the company\\u2019s cybersecurity strategy.\",\"No, we don\'t have a director on the board with relevant background in IT engaged on the cybersecurity strategy process and someone in the Executive Management team who oversees the company\\u2019s cybersecurity strategy.\"],\"last\":null}','1',5,1696999056,1696999762,'0'),(24644,200,2267,2,'If Yes, please indicate the Board member who oversees the cybersecurity strategy together with his/her experience and indicate this person’s membership in the committee responsible for the oversight of cybersecurity.\nBoard Responsibility','DynamicForm','0','Please indicate the Board member’s membership in the committee which oversees cyber security strategy\n❏ If publicly available, please indicate where this information can be found in your public reporting or corporate website.\n❍ Cybersecurity / information security committee\n❍ Risk committee\n❍ Audit committee\n❍ Not known',NULL,'{\"cols\":[{\"title\":\"Name of board member\",\"type\":\"1\"},{\"type\":\"1\",\"title\":\"Relevant experience and previously held positions:\"},{\"type\":\"1\",\"title\":\"Please indicate the Board member\\u2019s membership in the committee which oversees cyber security strategy\"}]}','1',4,1696999056,1696999762,'0'),(24645,200,2267,3,'If Yes, please indicate which role or function within or reporting directly to the Executive Management team is responsible for overseeing cybersecurity within the company.\n\nExecutive Management Responsibility','ChoiceOne','0','',NULL,'{\"values\":[\"Chief Information Security Officer (CISO) \\/ Chief Security Officer (CSO)\",\"Chief Technology Officer (CTO) \\/ Chief Information Officer (CIO) or similar\",\"CEO \\/ COO \\/ CRO or similar with clear responsibility for IT security\\/cybersecurity.\",\"We do not have anyone who oversees cybersecurity in the executive management team.\"]}','1',3,1696999056,1696999762,'0'),(24646,200,2267,4,'If publicly available, please indicate where this information can be found in your public reporting or corporate website.','TextItem','0','',NULL,'[]','1',2,1696999056,1696999762,'0'),(24647,200,2267,5,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999056,1696999762,'0'),(24648,200,2268,1,'Have you implemented policies and procedures for all employees in order to ensure that they are aware of threat issues and the importance of information security/cybersecurity?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, we have implemented policies and procedures for all employees\",\"A clear escalation process which employees can follow in the event an employee notices something suspicious is in place.\",\"Information security\\/cybersecurity is part of the employee performance evaluation (e.g. disciplinary actions).\",\"No, we have not  implemented any policies and procedures on security\\/cybersecurity.\"]}','1',3,1696999056,1696999762,'0'),(24649,200,2268,2,'Are the following policies and procedures available to all employees?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Information security\\/cybersecurity policy is internally available to all employees. Please provide the relevant document:\",\"Information security\\/cybersecurity awareness training. Please explain and provide supporting evidence:\"]}','1',2,1696999056,1696999762,'0'),(24650,200,2268,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999056,1696999762,'0'),(24651,200,2269,1,'Incident Response\nDo you have business continuity / contingency plans and incident response procedures in place and how often do you test them? ','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, and we test them at least semi-annually\",\"Yes, and we test them at least annually\",\"Yes, but frequency is less than yearly or not specified\",\"No, we do not have any business continuity \\/ contingency plans and incident response procedures in place.\"]}','1',8,1696999056,1696999762,'0'),(24652,200,2269,2,'Please provide supporting evidence of how often these plans/procedures are tested.','UploadFile','0','',NULL,'[]','1',7,1696999056,1696999762,'0'),(24653,200,2269,3,'Certification\nIs your IT infrastructure and information security management system certified to ISO 27001, NIST or similar?','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, the following percentage of our IT infrastructure has been certified\",\"No, our IT infrastructure has not been certified.\"]}','1',6,1696999056,1696999762,'0'),(24654,200,2269,4,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',5,1696999056,1696999762,'0'),(24655,200,2269,5,'External Verification and Vulnerability Analysis\nPlease indicate if there are other additional procedures implemented to assure the security of the IT infrastructure / information security management systems.\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Our IT infrastructure and information security management systems have been audited by external auditors in the last fiscal year. Please provide letter of opinion from the external auditor.\",\"We conduct third-party vulnerability analysis including simulated hacker attacks. Please provide supporting evidence.\",\"We do not have processes and infrastructure in place to prevent and\\/or respond to cyberattacks.\"]}','1',4,1696999056,1696999762,'0'),(24656,200,2269,6,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',3,1696999056,1696999762,'0'),(24657,200,2269,7,'Breaches\nHas your company experienced breaches of information security?','ChoiceMultiple','0','',NULL,'{\"values\":[\"We collect data on information security\\/cybersecurity breaches. Please note that if you did not have any information breaches, 0 should be entered in the corresponding box in the table. If you do not know the information, please leave the box empty. See the information text for more information.\",\"We do not collect data on information security\\/cybersecurity breaches.\",\"We do not have processes and infrastructure in place to prevent and\\/or respond to cyberattacks.\"]}','1',2,1696999056,1696999762,'0'),(24658,200,2269,8,'Supporting evidence:','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Total number of information security breaches\"},{\"title\":\"Total number of clients, customers and employees affected by the breaches\"}],\"cols\":[{\"title\":\"2022\",\"type\":\"1\"}]}','1',1,1696999056,1696999762,'0'),(24659,201,2270,1,'Regulatory Compliance (GRI 2-27, GRI 417-3)\n\nPlease describe the total number of significant regulatory compliance incidents that occurred during the reporting period. This includes non-monetary sanction incidents, such as warnings, corrections, etc. (Please break down as follows: incidents resulting in fines, incidents subject to non-monetary sanctions).','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Corporate Governance Related: Integrity and Corruption-Related Issues\"},{\"title\":\"Corporate Governance Related: Competition (Antitrust) and Monopoly-Related Behaviors\"},{\"title\":\"Environmental Related: Air Pollution Emissions\"},{\"title\":\"Environmental Related: Water Pollution Emissions\"},{\"title\":\"Environmental Related: Waste Management\"},{\"title\":\"Environmental Related: Other\"},{\"title\":\"Social Related: Labor Standards Act Related\"},{\"title\":\"Social Related: Occupational Health and Safety Related\"},{\"title\":\"Marketing and Communication\"},{\"title\":\"Other (Please specify)\"}],\"cols\":[{\"title\":\"Number of Incidents Subject to Fines in 2023\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of Incidents Subject to Non-Monetary Sanctions in 2023\"},{\"type\":\"1\",\"title\":\"Please provide details.\"}]}','1',9,1696999081,1696999724,'0'),(24660,201,2270,2,'Other (Please specify)','TextLong','0','',NULL,'[]','1',8,1696999081,1696999724,'0'),(24661,201,2270,3,'Total Number and Amount of Regulatory Fines Paid During the Reporting Period (Please break down as follows: fines for violations that occurred during the reporting period, fines for violations that occurred in previous reporting periods).\nIf there are such incidents, please provide details in the following table:','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"Fines for Violations That Occurred During the Reporting Period (2023)(USD))\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Fines for Violations That Occurred in Previous Reporting Periods (2020-2022) (NTD)\"},{\"type\":\"1\",\"title\":\"Please provide explanations.\"}]}','1',7,1696999081,1696999724,'0'),(24662,201,2270,4,'GRI 205-1 (Anti-Corruption) and GRI 206-1 (Anti-Competitive Behavior and Anti-Trust and Monopoly Behavior)\nPlease describe relevant policies and implementation status regarding \'no corruption events, no anti-competitive behavior, and no anti-trust and monopoly behavior.','TextLong','0','',NULL,'[]','1',6,1696999081,1696999724,'0'),(24663,201,2270,5,'Please explain whether your company has received financial assistance from the government, and if so, what is the amount of the assistance? (GRI 201-4)','TextLong','0','',NULL,'[]','1',5,1696999081,1696999724,'0'),(24664,201,2270,6,'Please explain company\'s tax policy and describe the tax governance and control framework. (GRI 207-1, GRI 207-2)','TextLong','0','',NULL,'[]','1',4,1696999081,1696999724,'0'),(24665,201,2270,7,'Please explain how your company communicates its tax issues with stakeholders. (GRI 207-3)','TextLong','0','',NULL,'[]','1',3,1696999081,1696999724,'0'),(24666,201,2270,8,'Please fill out the following table regarding tax jurisdiction disclosures (GRI 207-4).','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Names of the resident entities\"},{\"title\":\"Primary activities of the organization\"},{\"title\":\"Number of employees, and the basis of calculation of this number\"},{\"title\":\"Revenues from third-party sales\"},{\"title\":\"Revenues from intra-group transactions with other tax jurisdictions\"},{\"title\":\"Profit\\/loss before tax\"},{\"title\":\"Tangible assets other than cash and cash equivalents\"},{\"title\":\"Corporate income tax paid on a cash basis\"},{\"title\":\"Corporate income tax accrued on profit\\/loss\"},{\"title\":\"Reasons for the difference between corporate income tax accrued on profit\\/loss and the tax due if the statutory tax rate is applied to profit\\/loss before tax\"},{\"title\":\"The time period covered in this report\"}],\"cols\":[{\"title\":\"Please provide information\",\"type\":\"1\"}]}','1',2,1696999081,1696999724,'0'),(24667,201,2270,9,'Please provide supporting documents.','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24668,201,2271,1,'Which of the following aspects are covered by your codes of conduct? \nOur codes of conduct specifically include the following:\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Corruption and bribery\",\"Discrimination\",\"Confidentiality of information\",\"Conflicts of interest\",\"Antitrust\\/anti-competitive practices\",\"Money-laundering and\\/or insider trading\\/dealing\",\"Environment, health and safety\",\"Whistleblowing\"]}','1',2,1696999081,1696999724,'0'),(24669,201,2271,2,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24670,201,2272,1,'Please complete the following table related to coverage of your codes of conduct, and whether or not written or digital acknowledgement has been obtained and training has been provided in the past three years.','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Employees\"},{\"title\":\"Contractors \\/ Suppliers \\/ Service Providers\"},{\"title\":\"Other organizations (including subsidiaries and joint ventures)\"}],\"cols\":[{\"title\":\"Digital acknowledgement been obtained in the past 3 years\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"Training has been provided in the past 3 years\"},{\"type\":\"3\",\"title\":\"Coverage (%)\"},{\"type\":\"3\",\"title\":\"Written\\/Digital Acknowledgement (%)\"},{\"type\":\"3\",\"title\":\"Training Provided (%)\"}]}','1',2,1696999081,1696999724,'0'),(24671,201,2272,2,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24672,201,2273,1,'Which of the following aspects are covered by your anti-corruption and bribery policy?\n\nOur anti-corruption and bribery policy includes the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Bribes in any form (including kickbacks) on any portion of contract payments or soft dollar practices\",\"Direct or indirect political contributions\",\"Charitable contributions and sponsorship\",\"Other\",\"No, we do not have any of the above\"]}','1',3,1696999081,1696999724,'0'),(24673,201,2273,2,'Other (please specify) ','TextItem','0','',NULL,'[]','1',2,1696999081,1696999724,'0'),(24674,201,2273,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24675,201,2274,1,'Anti-corruptionCommitment\nAC1. Does the company have an anti-corruption compliance programme?\n','ChoiceOne','0','- GRI Disclosure 3-3-c (2021) for the topic GRI 205 (2016)\n(Select One)\n',NULL,'{\"values\":[\"No, it is not an immediate business priority\",\"No, but we plan to within the next two years\",\"Yes  [Please answer AC1.1]\"],\"last\":null}','1',17,1696999081,1696999724,'0'),(24676,201,2274,2,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',16,1696999081,1696999724,'0'),(24677,201,2274,3,'If respondent answers \'yes\' in AC1, the below question will be displayed.				\nAC1.1. If yes, in what year was this programme last reviewed? (YYYY)				\n','NumberInput','0','',NULL,'[]','1',15,1696999081,1696999724,'0'),(24678,201,2274,4,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',14,1696999081,1696999724,'0'),(24679,201,2274,5,'AC2. Does your company have policies and recommendations for employees on how to act in case of doubt and/or in situations that may represent a conflict of interest, e.g. with regard to gifts and hospitality, donations, sponsorship, or interactions with public officials?','ChoiceOne','0','- (Select One)',NULL,'{\"values\":[\"No, but we plan to within the next two years\",\"No, and we have no plans to develop a policy \",\"Yes, included within a broader policy or as a stand-alone policy\"],\"last\":null}','1',13,1696999081,1696999724,'0'),(24680,201,2274,6,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',12,1696999081,1696999724,'0'),(24681,201,2274,7,'Prevention\nAC3. Who receives training on anti-corruption and integrity?\n','ChoiceMultiple','0','WEF Common Metrics; GRI Disclosure 205-2 (2016)\n(Select all that apply)\n',NULL,'{\"values\":[\" Select employees\",\"All employees\",\"Contractors\",\"Direct suppliers of the organization\",\"Indirect suppliers of the organization \",\" Other \\u2013 such as partners, clients, etc.\",\"No training provided\"]}','1',11,1696999081,1696999724,'0'),(24682,201,2274,8,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',10,1696999081,1696999724,'0'),(24683,201,2274,9,'If respondent answers any option in AC3 besides \'No training provided\', the below question will be displayed for each chosen category. For the user, options would be visible only for the categories selected in AC3.\nAC3.1. How often is such training provided?\n','Scale','0','- (Matrix – Select one answer option per line)',NULL,'{\"rows\":[{\"title\":\"Select employees\"},{\"title\":\"All employees\"},{\"title\":\"Contractors\"},{\"title\":\"Direct suppliers of the organization\"},{\"title\":\"Indirect suppliers of the organization \"},{\"title\":\"Other \\u2013\\u00a0such as partners, clients, etc.\"}],\"cols\":[{\"title\":\"One time only\"},{\"title\":\"Every two or more years\"},{\"title\":\"Every year\"},{\"title\":\"We do not collect this data\"}]}','1',9,1696999081,1696999724,'0'),(24684,201,2274,10,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',8,1696999081,1696999724,'0'),(24685,201,2274,11,'Performance\nAC5. Please report the company\'s total number and nature of incidents of corruption during the reporting year.\n','ColumnInput','0','- GRI Disclosure 205-3 (2016); WEF Common Metrics; ISAR D.2.1\n- (Matrix – Text Boxes with option for Unknown or N/A)\n',NULL,'{\"rows\":[{\"title\":\"Confirmed during the current year, but related to previous years \"},{\"title\":\"Confirmed during the current year, and related to this year \"}],\"cols\":[{\"title\":\"Number of incident(s) (Please describe the nature of the incidents in the text box below)\",\"type\":\"3\"},{\"type\":\"2\",\"title\":\"Unknown\"},{\"type\":\"2\",\"title\":\"Choose to not disclose\"}]}','1',7,1696999081,1696999724,'0'),(24686,201,2274,12,'Please provide additional explanation:','TextLong','0','',NULL,'[]','1',6,1696999081,1696999724,'0'),(24687,201,2274,13,'Response and Reporting\nAC6. Within the reporting period, what measures has the company taken to address suspected incidents of corruption independently or in response to a dispute or investigation by a government regulator?\n','ChoiceMultiple','0','- GRI Disclosure 3-3-d (2021) for the topic GRI 205 (2016).; Reporting Guidance on the10th Principle Against Anti-corruption – B3\n- (Select all that apply)\n',NULL,'{\"values\":[\"Initial case assessment\",\" Internal investigation\",\"Review by risk\\/ethics committee\",\"Review by board of directors\",\"External audit\\/review\",\" Other (Please provide additional information) \",\"Not applicable\\/no incidents in the reporting period\"]}','1',5,1696999081,1696999724,'0'),(24688,201,2274,14,' Other (Please provide additional information) ','TextLong','0','',NULL,'[]','1',4,1696999081,1696999724,'0'),(24689,201,2274,15,'AC7. Does your company engage in collective action against corruption?\n','ChoiceOne','0','- GRI Disclosure 3-3-d (2021) for the topic GRI 205 (2016)\n- (Select One)',NULL,'{\"values\":[\"No, but we plan to in the next two years\",\"No, it is not an immediate business priority\",\"Yes (Please explain) \"]}','1',3,1696999081,1696999724,'0'),(24690,201,2274,16,'Yes (Please explain) ','TextLong','0','',NULL,'[]','1',2,1696999081,1696999724,'0'),(24691,201,2274,17,'AC8. Briefly describe additional relevant practical actions the company has taken during the reporting period and/or plans to take to implement the anti-corruption principle, including any challenges faced and actions taken towards prevention and/or remediation.\n','TextLong','0','GRI Disclosures 3-3-c and 3-3-d (2021) for the topic GRI 205 (2016)\n',NULL,'[]','1',1,1696999081,1696999724,'0'),(24692,201,2275,1,'What mechanisms are in place to assure effective implementation of your company\'s codes of conduct (e.g. compliance system)? Please provide supporting evidence.','ChoiceMultiple','0','',NULL,'{\"values\":[\"Responsibilities, accountabilities and reporting lines are systemically defined in all divisions and group companies\",\"Dedicated help desks, focal points, ombudsman, hotlines\",\"Compliance linked to employee remuneration\",\"Employee performance appraisal systems integrates compliance\\/codes of conduct\",\"Disciplinary actions in case of breach, i.e. warning, dismissal, zero tolerance policy\",\"Compliance system is certified\\/auditedverified by third party. Please review the additional information and question guidance banner for further detail.\"],\"last\":null}','1',2,1696999081,1696999724,'0'),(24693,201,2275,2,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24694,201,2276,1,'Please indicate the amount of fines and settlements (excluding legal fees) incurred in the last 4 fiscal years related to anti-trust/anti-competitive practices and the number of currently pending investigations against your company. For past cases, if you did not incur any fines in a given year, please enter a value of \"0.\" \n\nPast Cases','ColumnInput','0','Fines and settlements (USD)',NULL,'{\"rows\":[{\"title\":\"Total amount\"},{\"title\":\"% of revenues (as provided in the\\\"Denominator\\\" question)\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',3,1696999081,1696999724,'0'),(24695,201,2276,2,'Ongoing Cases and Contingent Liabilities\nIs your company currently involved in any ongoing investigations related to anti-competitive practices?\n','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we are currently the subject of ongoing investigations.\",\"No, we are not involved in any ongoing investigations related to anti-competitive practices.\"]}','1',2,1696999081,1696999724,'0'),(24696,201,2276,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24697,201,2277,1,'Please indicate the number of substantiated cases of corruption and bribery in the last four fiscal years as well as the number of ongoing external investigations by local or international authorities. For past cases, if you did not incur any fines and settlements in a given year, please enter a value of \"0.\" For ongoing cases, if you do not have any ongoing external investigation, please select the appropriate \"no\" option.\n\nPast Cases','ColumnInput','0','Corruption & bribery cases',NULL,'{\"rows\":[{\"title\":\"Total number of substantiated corruption & bribery cases\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',3,1696999081,1696999724,'0'),(24698,201,2277,2,'Ongoing Cases \nIs your company currently involved in any ongoing external investigations related to corruption & bribery?\n','ChoiceOne','0','',NULL,'{\"values\":[\"Yes, we currently have ongoing investigations against us. Supporting evidence.\",\"No, we are not currently involved in any ongoing corruption & bribery cases.\"],\"last\":null}','1',2,1696999081,1696999724,'0'),(24699,201,2277,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24700,201,2278,1,'Does your company publicly report on breaches (e.g. Corruption, Discrimination etc.) against your codes of conduct/ethics?','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, we publicly report breaches of the Codes of Conduct\",\"We report breaches on a combined basis for all areas in the Code of conduct\",\"We report breaches on a combined basis, but only for some areas in the Code of conduct\",\"We report that no Codes of Conduct related breaches have occurred during the most recent reporting cycle\",\"No, we do not publicly report on breaches.\"],\"last\":null}','1',3,1696999081,1696999724,'0'),(24701,201,2278,2,'We report on following areas:','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Corruption or Bribery\"},{\"title\":\"Discrimination or Harassment\"},{\"title\":\"Customer Privacy Data\"},{\"title\":\"Conflicts of Interest\"},{\"title\":\"Money Laundering or Insider trading\"}],\"cols\":[{\"title\":\"Number of breaches in FY 2022\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"Number of breaches in FY 2023\"}]}','1',2,1696999081,1696999724,'0'),(24702,201,2278,3,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24703,201,2279,1,'Has your company been subject to inspection by regulators and/or received any FDA Form 483 notices or FDA Warning Letters (or equivalent notices from other agencies) as a result of production plant inspections by regulatory authorities in the last four fiscal years (2020-2023)?\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"Yes, we have been subjected to inspections by regulatory agencies in the last four years\",\"Yes, we received Form 483s Observations (or equivalent) in the last four years\",\"Yes, we received FDA Warning Letters (or equivalent)\",\"No, we did not receive any Form 483s (or equivalent) in the last four years.\"],\"last\":null}','1',5,1696999081,1696999724,'0'),(24704,201,2279,2,'Regulatory Agency Inspections (if any).','ColumnInput','0','Yes, we have been subject to inspections by regulatory agencies in the last four years',NULL,'{\"rows\":[{\"title\":\"Number of inspections\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',4,1696999081,1696999724,'0'),(24705,201,2279,3,'Form 483 Observations\nPlease specify the type of warnings received, the revenues generated by the impacted facilities and the financial impact of production stoppages. If you did not have any Form 483 Observations, choose \"No\" at the appropriate level..\n','ColumnInput','0','Yes, we have been subject to inspections by regulatory agencies in the last four years',NULL,'{\"rows\":[{\"title\":\"Number of Form 483 Observations (or equivalent)\"},{\"title\":\"Annual revenues generated from the affected facilities. Please report this in USD millions.\"},{\"title\":\"Annual revenues impacted by production stoppages. Please report this in USD millions.\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',3,1696999081,1696999724,'0'),(24706,201,2279,4,'FDA Warning Letters\nPlease specify the type of warnings received, the revenues generated by the impacted facilities and the financial impact of production stoppages. If you did not have any FDA Warning Letters, choose \"No\" at the appropriate level..','ColumnInput','0','Yes, we received FDA Warning Letters (or equivalent)',NULL,'{\"rows\":[{\"title\":\"Number of FDA Warning Letters (or equivalent)\"},{\"title\":\"Annual revenues generated from the affected facilities. Please report this in USD millions.\"},{\"title\":\"Annual revenues impacted by production stoppages. Please report this in USD millions.\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',2,1696999081,1696999724,'0'),(24707,201,2279,5,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24708,201,2280,1,'Does your company agree not to file or enforce patents for products used to treat diseases in scope of the Access to Medicines Index (ATMI) in Least Developed Countries (LDCs, as defined by the United Nations), Low Income Countries (LICs, as defined by the World Bank) and Lower-Middle-Income Countries (LMICs, as defined by the World Bank)?','ChoiceOne','0','',NULL,'{\"values\":[\"We commit not to patent or enforce patents on all Intellectual Property related to all products for diseases in scope of ATMI 2022.\",\"We commit not to patent or enforce patents on Intellectual Property for a sub-set of products. \"]}','1',6,1696999081,1696999724,'0'),(24709,201,2280,2,'We commit not to patent or enforce patents on all Intellectual Property related to all products for diseases in scope of ATMI 2022.','ChoiceOne','0','',NULL,'{\"values\":[\"Least Developed Countries, Low Income Countries and Lower-Middle-Income Countries\",\"Least Developed Countries or Low Income Countries, but not in Lower-Middle-Income Countries\",\"Least Developed Countries, Low Income Countries and most Lower-Middle-Income Countries. (please refer to list of the LMIC countries in which we retain the right to enforce patents )\"],\"last\":null}','1',5,1696999081,1696999724,'0'),(24710,201,2280,3,'* Please provide a list of the LMIC countries in which you retain the right to enforce patents:','TextLong','0','',NULL,'[]','1',4,1696999081,1696999724,'0'),(24711,201,2280,4,'We commit not to patent or enforce patents on Intellectual Property for a sub-set of products. Please indicate which regions fall under this commitment and provide supporting evidence:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Least Developed Countries and Low Income Countries. \",\"Certain regions only.\"]}','1',3,1696999081,1696999724,'0'),(24712,201,2280,5,'Please list the products you retain the right to enforce patents:','TextLong','0','',NULL,'[]','1',2,1696999081,1696999724,'0'),(24713,201,2280,6,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24714,201,2281,1,'Has your company implemented a publicly available worldwide Marketing and Sales Practices code? Please indicate where this information is available in your public reporting or corporate website.','TextItem','0','',NULL,'[]','1',4,1696999081,1696999724,'0'),(24715,201,2281,2,'Yes, we have a publicly available policy for our commitments to ethical marketing, advertising and sales practices. The policy covers/contains the following:','ChoiceMultiple','0','',NULL,'{\"values\":[\"Commitment to providing accurate and balanced information about our company\\u2019s products\\/services\",\"Provision to ensure ethical interactions with customers and\\/or health care professionals\"]}','1',3,1696999081,1696999724,'0'),(24716,201,2281,3,'Please list the commitments and describe what they are .','TextLong','0','',NULL,'[]','1',2,1696999081,1696999724,'0'),(24717,201,2281,4,'Please provide supporting document: ','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24718,201,2282,1,'Please provide the number of upheld regulatory and self-regulatory complaints concerning marketing and selling practices worldwide in the table below. If your company hasn’t received any regulatory or non- regulatory complaints in the last financial year, please fill in the table with \"0\".','ColumnInput','0','Yes, we record the number and nature of upheld regulatory and self-regulatory complaints concerning marketing and selling practices worldwide.',NULL,'{\"rows\":[{\"title\":\"Upheld regulatory complaints\"},{\"title\":\"Upheld self-regulatory complaints\"}],\"cols\":[{\"title\":\"Number of complaints in FY 2022\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"Number of complaints in 2023 YTD\"}]}','1',2,1696999081,1696999724,'0'),(24719,201,2282,2,'Please provide supporting document:','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24720,201,2283,1,'Please indicate your annual Direct-to-Consumer Marketing budget (USD)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"Direct-to-Consumer Marketing budget\"}],\"cols\":[{\"type\":\"3\",\"title\":\"FY 2020\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',2,1696999081,1696999724,'0'),(24721,201,2283,2,'Please provide supporting evidence:','UploadFile','0','',NULL,'[]','1',1,1696999081,1696999724,'0'),(24722,202,2284,1,'1. 誠信經營與企業倫理  \n1-1 誠信經營與企業倫理之政策 (GRI 3-3)\n\n請說明\n','TextLong','0','參考範例\n❖ 重視道德廉潔\nOO遵守公司法、證券交易法、商業會計法、政治獻金法、貪污治罪條例、政府採購法、公職人員利益衝突迴避法、上市上櫃相關規章或其他商業行為有關法令，以作為落實誠信經營之基本前提。\n為進一步落實企業誠信經營，滿足投資人及其他利害關係人的期待，OO已於2011年董事會正式通過「誠信經營守則」與「道德行為準則」，並對OO所有營運據點之員工進行教育訓練，訂定詳細的作業程序、行為指南與獎懲制度，確保所有員工皆理解及落實誠信經營及職業道德的重要性。\n「誠信經營守則」規範OO之董事、經理人及所有受雇員工在商業行為中不得接受任何不正當之利益，或從事違反法律及不誠信的行為。涵蓋範疇包括禁止行賄與收賄、提供非法政治獻金、不當慈善捐贈或活動、不當禮物或款待的收受等。該守則亦規範董事、監察單位及經理人應避免利益衝突，並針對不誠信行為或潛在風險高的營業活動，建立完善的內控制度。\n「道德行為準則」規範OO之董事、經理人及所有受雇員工在履行工作職務時的道德行為，涵蓋範疇包括迴避利益衝突與不當利益之輸送、不得圖己私利、落實公司及客戶保密、公平交易與交易情形真實呈報、公司資產之妥善運用及維護等。除此之外，OO另外訂有「績效考核辦法」，考核項目除了工作績效外，也包括工作態度、品德操守等，期望透過選、用、育、留的結合並輔以有效的目標管理與績效考核制度，提升管\n理績效。\n「防範內線交易機制」為防範內線交易，避免不當洩漏，並確保對外界發表之一致性與正確性，特制定「內部重大處理作業程序」。適用對象為本公司董事、經理人及全體員工，並規定對於知悉重大訊息者，不得洩露予他人，亦不得探詢或蒐集與個人職務不相關之公司未公開重大，以落實防範內線交易管理作業。\n「誠信經營及道德行為訓練」OO員工於新進人員職前訓練時，均安排誠信及道德行為宣導課程，新進人員受訓比例達100%；並於每兩年安排一次誠信、道德相關教育訓練，另透過 不定期會議或教育訓練場合，向全體同仁宣達誠信經營理念，徹底杜絕貪腐事件發生。\n我們除了透過制訂組織規章、設置專責單位、加強誠信教育宣導之外、並建立懲處制度，另提供內外部申訴與檢舉管道，全面落實不誠信行為之防範指施，據以嚴加防範不誠信行為發生。',NULL,'[]','1',5,1696999119,1696999709,'0'),(24723,202,2284,2,'2. 內線交易與利益衝突防範措施(GRI 2-15)\n2-1 說明最高治理單位如何避免及減緩利益衝突（請描述流程）；並說明是否有向利害關係人揭露利益衝突，至少應包括與以下項目有關的利益衝突：於其他董事會任職、對供應商或其他利害關係人的交叉持股情況、控股股東 (controlling shareholders)、利害關係群體 (related parties) 及其關係、交易和未清餘額 (outstanding balances) \n\n請說明流程: \n利益衝突揭露: ','TextLong','0','參考範例\n❖ 利益衝突迴避：本公司董事會議事規範亦明文規定董事對於會議事項，與其自身或其代表之法人有利害關係，致有害於公司利益之虞者，得陳述意見及答詢，不得加入討論及表決，且討論及表決時應予迴避，並不得代理其他董事行使其表決權。本公司董事會之決議，對依前項規定不得行使表決之董事，依《公司法》第二百零六條第二項準用第一百八十條第二項規定辦理。2021年度董事因其本身之利害關係衝突而迴避投票者有何基丞董事，共計5次迴避投票；OOO董事，共計1次迴避投票；OOO董事，共計4次迴避投票。\nOO之董事對於董事會中所列之各項議案均逐項仔細審議，並確切評估可能造成公司之營運風險，以追求客戶及本公司股東、員工之最大利益為目標。董事的選任，係依相關法令及章程規定，採候選人提名制度，由董事會及符合法定持股比例要求的股東提名，依法定程序辦理董事提名公告及審查作業，為避免最高治理機構的利益衝突，我們用下列程序來進行嚴謹的控管，包括：\n● 新任董事均須簽署願任同意書，遵守公司法第23條的規定，忠實執行業務及盡善良\n管理人的注意義務。\n●所有董事均須簽署聲明書，聲明已確知公司法第206條有關表決權行使的迴避內容及\n其違反的法律效果。\n●董事會議事規範已明定董事利益迴避制度。\n在董事的高道德自律標準，及完整機制的運作下，董事會成立迄今並未有任何利益衝\n突事件發生。',NULL,'[]','1',4,1696999119,1696999709,'0'),(24724,202,2284,3,'3. 補救負面衝擊的程序 (GRI2-25) \n3-1 請描述：針對造成或促成的負面衝擊提供（或以合作方式進行）補救措施的承諾；鑑別與處理申訴 (complaints) 的方法（包括已建立或參與的申訴機制）；針對造成/促成的負面衝擊，提供（或合作進行）補救的程序；使用申訴機制的潛在利害關係人如何參與這些機制的設計/檢視/操作和改善；如何追蹤申訴機制和補救程序的有效性，提供有效性的例子（包括利害關係人的意見回饋）','TextLong','0','請說明: \n例如: \n除了防範負面衝擊之外，本公司也訂定補救負面衝擊的機制，提供內外部利害關係人進行申訴以及處理相關補救事宜。',NULL,'[]','1',3,1696999119,1696999709,'0'),(24725,202,2284,4,'4. 尋求建議和提出疑慮的機制 (GRI 2-26) \n4-1 描述下列事項的機制：讓個人可尋求關於「責任商業行為政策和實務之實踐」的意見；讓個人可對組織的商業行為 (business conduct) 提出疑慮 (raise concerns)\n','TextLong','0','參考範例\n❖ 道德倫理、誠信之內外部諮詢及舉報機制：本公司及本公司董事、獨立董事、經理人、員工與實質控制者，於執行業務時，不得直接或間接提供、承諾、要求或收受任何形式之不正當利益，包括回扣、佣金、疏通費或透過其他途徑向客戶、代理商、承包商、供應商、公職人員或其他利害關係人提供或收受不正當利益。但符合營運所在地法律者，不在此限。我們為健全公司治理之監督功能，內外部均設有相關諮詢，並透過年度員工訪談機制宣導告知同仁諮詣及舉報管道，作為員工及利害關係人於對倫理及誠信相關情事徵詢意見，並可為權益受侵害時之申訴管道，以促進本公司與員工、顧客、供應商、投資人對利害關係之充分溝通。',NULL,'[]','1',2,1696999119,1696999709,'0'),(24726,202,2284,5,'5. 內部組織及運作\n5-1 請說明內部機制的運作 \n','TextLong','0','參考範例\n❖ 室：為獨立之單位，隸屬於董事會；其主要工作為內部控制制度之規劃、推行及修訂、年度計劃之擬定及執行、各單位及子公司之自行檢查作業計劃擬定及執行以及其他依據法令規定執行事項，並及時提供管理階層以便了解存在或潛在缺失的管道。除了需於董事會例行會議中進行報告，每月或必要時得以隨時向董事長或總經理報告。\n❖ 公開透明化：OO依照規定定期及不定期於公開觀測站申報各項財務業務，並於本公司網站設置投資人服務。並設有專人負責公司之蒐集及揭露，並依規定落實發言人制度。股權的部分，由專業之股務代理機構負責股份相關事宜，並透過每月申報來了解內部人股權異動情形。\n❖ 會計與內部控制：OO對於具較高不誠信行為風險之營業活動，建立有效之會計制度及內部控制制度，不得有外帳或保留秘密帳戶，並應隨時檢討，以確保該制度之設計及執行持續有效。\n內部人員應定期查核前項制度遵循情形，並作成報告提報董事會。\n本公司已制定內部控制制度、內部制度、各項管理辦法，並由及外部專業人員(券商、會計師)不定期抽查其執行狀況，可充分降低相關人員執行職務對公司風險，保障投資人權益。2021年OO並無發生依法被處罰及違反內部控制制度規章之處罰、主要缺失及改善情形。',NULL,'[]','1',1,1696999119,1696999709,'0'),(24727,202,2285,1,'法規遵循  (GRI 2-27, GRI 417-3) \n1. 請說明報導期間發生的重大違反法規事件總數 #非金錢制裁事件：例如沒有罰款但被警告. 糾正等\n（請按以下細分：被罰款的事件、受到非金錢制裁的事件）\n\n2. 在報導期間內支付違反法規罰款的總數和金額\n（請按以下方式細分：在報導期間內發生的違規行為事件之罰款、過往報導期間發生的違規行為事件之罰款）\n\n3.  描述重大違規事件\n（請說明 2022年發生的重大違反法規事件總數；並說明如何判定何謂重大違規事件）\n','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u516c\\u53f8\\u6cbb\\u7406\\u76f8\\u95dc\\uff1a\\u8aa0\\u4fe1\\u8207\\u8caa\\u8150\\u76f8\\u95dc\\u8b70\\u984c \"},{\"title\":\"\\u516c\\u53f8\\u6cbb\\u7406\\u76f8\\u95dc\\uff1a\\u7af6\\u722d(\\u6258\\u62c9\\u65af)\\u8207\\u58df\\u65b7\\u884c\\u70ba\\u76f8\\u95dc\"},{\"title\":\"\\u516c\\u53f8\\u6cbb\\u7406\\u76f8\\u95dc\\uff1a\\u8cc7\\u5b89\\u4e8b\\u4ef6\"},{\"title\":\"\\u516c\\u53f8\\u6cbb\\u7406\\u76f8\\u95dc\\uff1a\\u7d93\\u8b49\\u5be6\\u4fb5\\u72af\\u5ba2\\u6236\\u96b1\\u79c1\\u6216\\u907a\\u5931\\u5ba2\\u6236\\u8cc7\\u6599\"},{\"title\":\"\\u74b0\\u5883\\u76f8\\u95dc\\uff1a\\u7a7a\\u6c23\\u6c61\\u67d3\\u6392\\u653e\"},{\"title\":\"\\u74b0\\u5883\\u76f8\\u95dc\\uff1a\\u6c34\\u6c61\\u67d3\\u6392\\u653e\"},{\"title\":\"\\u74b0\\u5883\\u76f8\\u95dc\\uff1a\\u5ee2\\u68c4\\u7269\\u7ba1\\u7406\"},{\"title\":\"\\u74b0\\u5883\\u76f8\\u95dc\\uff1a\\u5176\\u4ed6\"},{\"title\":\"\\u793e\\u6703\\u76f8\\u95dc\\uff1a\\u52de\\u52d5\\u57fa\\u6e96\\u6cd5\\u76f8\\u95dc\"},{\"title\":\"\\u793e\\u6703\\u76f8\\u95dc\\uff1a\\u8077\\u696d\\u5b89\\u5168\\u885b\\u751f\\u76f8\\u95dc\"},{\"title\":\"\\u884c\\u92b7\\u50b3\\u64ad\"},{\"title\":\"\\u5176\\u4ed6\\uff08\\u8acb\\u8aaa\\u660e\\uff09\"},{\"title\":\"\\u5176\\u4ed6\\uff08\\u8acb\\u8aaa\\u660e\\uff09\"}],\"cols\":[{\"title\":\"2023 \\u5e74\\u88ab\\u7f70\\u6b3e\\u7684\\u4e8b\\u4ef6\",\"type\":\"3\"},{\"type\":\"1\",\"title\":\"\\u53d7\\u5230\\u975e\\u91d1\\u9322\\u5236\\u88c1\\u7684\\u4e8b\\u4ef6\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\"}]}','1',8,1696999119,1696999709,'0'),(24728,202,2285,2,'若有相關事件，說明於下方表格\n在報導期間內支付違反法規罰款的總數和金額（請按以下方式細分：在報導期間內發生的違規行為事件之罰款、過往報導期間發生的違規行為事件之罰款）','DynamicForm','0','',NULL,'{\"cols\":[{\"title\":\"2023 \\u5728\\u5831\\u5c0e\\u671f\\u9593\\u5167\\u767c\\u751f\\u7684\\u9055\\u898f\\u884c\\u70ba\\u4e8b\\u4ef6\\u4e4b\\u7f70\\u6b3e (NTD)\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"\\u904e\\u5f80\\u5831\\u5c0e\\u671f\\u9593\\u767c\\u751f\\u7684\\u9055\\u898f\\u884c\\u70ba\\u4e8b\\u4ef6\\u4e4b\\u7f70\\u6b3e (2020-2022) (NTD)\"},{\"type\":\"1\",\"title\":\"\\u8aaa\\u660e\"}]}','1',7,1696999119,1696999709,'0'),(24729,202,2285,3,'5. 無貪腐，反競爭，反托拉斯與壟斷行為 (GRI 205-1) (GRI 206-1)\n5-1 請說明藥華在「無貪腐事件，無反競爭行為、反托拉斯和壟斷行為」的相關政策和執行情形','TextLong','0','',NULL,'[]','1',6,1696999119,1696999709,'0'),(24730,202,2285,4,'6. 請說明藥華是否有接受政府的財務補助，如有的話，補助金額是多少？(GRI 201-4)','TextLong','0','',NULL,'[]','1',5,1696999119,1696999709,'0'),(24731,202,2285,5,'7. 請說明藥華的稅務方針，並描述稅務治理與管控架構 (GRI 207-1, GRI 207-2)','TextLong','0','',NULL,'[]','1',4,1696999119,1696999709,'0'),(24732,202,2285,6,'8. 請說明藥華的稅務議題如何與利害關係人溝通 (GRI 207-3)','TextLong','0','',NULL,'[]','1',3,1696999119,1696999709,'0'),(24733,202,2285,7,'9. 請填寫以下表格關於稅務管轄區的揭露 (GRI 207-4)','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u5c45\\u4f4f\\u8005\\u5be6\\u9ad4\\u540d\\u7a31\"},{\"title\":\"\\u7d44\\u7e54\\u4e3b\\u8981\\u6d3b\\u52d5\"},{\"title\":\"\\u54e1\\u5de5\\u4eba\\u6578\\u3001\\u53ca\\u8a08\\u7b97\\u4eba\\u6578\\u7684\\u57fa\\u790e\"},{\"title\":\"\\u4f86\\u81ea\\u7b2c\\u4e09\\u65b9\\u92b7\\u552e\\u4e4b\\u6536\\u5165\"},{\"title\":\"\\u8207\\u5176\\u4ed6\\u7a05\\u52d9\\u7ba1\\u8f44\\u5340\\u7684\\u96c6\\u5718\\u5167\\u90e8\\u4ea4\\u6613\\u6536\\u5165\"},{\"title\":\"\\u7a05\\u524d\\u6536\\u76ca\\uff0f\\u640d\\u5931\"},{\"title\":\"\\u73fe\\u91d1\\u53ca\\u7d04\\u7576\\u73fe\\u91d1\\u4ee5\\u5916\\u7684\\u6709\\u5f62\\u8cc7\\u7522\"},{\"title\":\"\\u4ee5\\u73fe\\u91d1\\u652f\\u4ed8\\u7684\\u4f01\\u696d\\u6240\\u5f97\\u7a05\"},{\"title\":\"\\u61c9\\u8a08\\u4f01\\u696d\\u6240\\u5f97\\u7a05\\u7684\\u6536\\u76ca\\uff0f\\u640d\\u5931\"},{\"title\":\"\\u5982\\u679c\\u7a05\\u524d\\u640d\\u76ca\\u63a1\\u7528\\u6cd5\\u5b9a\\u7a05\\u7387\\uff0c\\u8aaa\\u660e\\u9020\\u6210\\u61c9\\u8a08\\u4f01\\u696d\\u6240\\u5f97\\u7a05\\u6536\\u76ca\\uff0f\\u640d\\u5931\\u8207\\u61c9\\u4ed8\\u7a05\\u6b3e\\u5dee\\u7570\\u7684\\u539f\\u56e0\"}],\"cols\":[{\"title\":\"\\u8aaa\\u660e\",\"type\":\"1\"}]}','1',2,1696999119,1696999709,'0'),(24734,202,2285,8,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24735,202,2286,1,'您的行為準則涵蓋了以下哪些方面？\n我們的行為準則明確包括以下内容：\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u8caa\\u6c61\\u8207\\u8cc4\\u8cc2\",\"\\u6b67\\u8996\",\"\\u8a0a\\u606f\\u4fdd\\u5bc6\\u6027\",\"\\u5229\\u76ca\\u885d\\u7a81\",\"\\u53cd\\u58df\\u65b7\\u3001\\u53cd\\u7af6\\u722d\\u884c\\u70ba\",\"\\u6d17\\u9322\\u548c\\/\\u6216\\u5167\\u5e55\\u4ea4\\u6613\\/\\u4ea4\\u6613\",\"\\u74b0\\u5883\\u3001\\u5065\\u5eb7\\u548c\\u5b89\\u5168\",\"\\u8209\\u5831\"],\"last\":null}','1',2,1696999119,1696999709,'0'),(24736,202,2286,2,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24737,202,2287,1,'請填寫下表，以了解您的行為準則的涵蓋範圍，並且在過去三年中是否已獲得書面或數字確認以及是否提供了培訓：','ColumnInput','0','',NULL,'{\"rows\":[{\"title\":\"\\u54e1\\u5de5\"},{\"title\":\"\\u627f\\u5305\\u5546\\/\\u4f9b\\u61c9\\u5546\\/\\u670d\\u52d9\\u63d0\\u4f9b\\u8005\"},{\"title\":\"\\u5176\\u4ed6\\u7d44\\u7e54\\uff08\\u5305\\u62ec\\u5b50\\u516c\\u53f8\\u548c\\u5408\\u8cc7\\u4f01\\u696d\\uff09\"}],\"cols\":[{\"title\":\"\\u5df2\\u5728\\u904e\\u53bb\\u4e09\\u5e74\\u4e2d\\u7372\\u5f97\\u66f8\\u9762\\u6216\\u6578\\u4f4d\\u78ba\\u8a8d\",\"type\":\"2\"},{\"type\":\"2\",\"title\":\"\\u5df2\\u5728\\u904e\\u53bb\\u4e09\\u5e74\\u4e2d\\u63d0\\u4f9b\\u4e86\\u57f9\\u8a13\"},{\"type\":\"3\",\"title\":\"\\u6db5\\u84cb\\u7387(%)\"},{\"type\":\"3\",\"title\":\"\\u66f8\\u9762\\/\\u6578\\u4f4d\\u78ba\\u8a8d(%)\"},{\"type\":\"3\",\"title\":\"\\u63d0\\u4f9b\\u7684\\u57f9\\u8a13\\uff08%\\uff09\"}]}','1',2,1696999119,1696999709,'0'),(24738,202,2287,2,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24739,202,2288,1,'您的反腐敗和反賄賂政策涵蓋下列哪些面向？\n\n我們的反貪腐和反賄賂政策包括以下內容：','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u5c0d\\u5408\\u7d04\\u4ed8\\u6b3e\\u7684\\u4efb\\u4f55\\u90e8\\u5206\\u9032\\u884c\\u4efb\\u4f55\\u5f62\\u5f0f\\u7684\\u8cc4\\u8cc2\\uff08\\u5305\\u62ec\\u56de\\u6263\\uff09\\u6216\\u8edf\\u7f8e\\u5143\\u505a\\u6cd5\",\"\\u76f4\\u63a5\\u6216\\u9593\\u63a5\\u653f\\u6cbb\\u6350\\u6b3e\",\"\\u6148\\u5584\\u6350\\u6b3e\\u548c\\u8d0a\\u52a9\",\"\\u5176\\u4ed6\",\"\\u4ee5\\u4e0a\\u90fd\\u6c92\\u6709\"],\"last\":null}','1',3,1696999119,1696999709,'0'),(24740,202,2288,2,'其他（請註明）','TextItem','0','',NULL,'[]','1',2,1696999119,1696999709,'0'),(24741,202,2288,3,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24742,202,2289,1,'有哪些機制來確保有效實施貴公司的行為準則（例如合規制度）？ 請提供佐證資料。','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u6240\\u6709\\u90e8\\u9580\\u548c\\u96c6\\u5718\\u516c\\u53f8\\u90fd\\u7cfb\\u7d71\\u5730\\u5b9a\\u7fa9\\u4e86\\u8cac\\u4efb\\u3001\\u7fa9\\u52d9\\u548c\\u5831\\u544a\\u8def\\u5f91\\u3002\",\"\\u6240\\u6709\\u90e8\\u9580\\u548c\\u96c6\\u5718\\u516c\\u53f8\\u90fd\\u7cfb\\u7d71\\u5730\\u5b9a\\u7fa9\\u4e86\\u8cac\\u4efb\\u3001\\u7fa9\\u52d9\\u548c\\u5831\\u544a\\u8def\\u5f91\\u3002(\\u5c08\\u9580\\u7684\\u670d\\u52d9\\u53f0\\u3001\\u806f\\u7d61\\u9ede\\u3001\\u76e3\\u5bdf\\u54e1\\u3001\\u71b1\\u7dda)\",\"\\u5408\\u898f\\u6027\\u8207\\u54e1\\u5de5\\u85aa\\u8cc7\\u639b\\u9264\",\"\\u54e1\\u5de5\\u7e3e\\u6548\\u8a55\\u4f30\\u7cfb\\u7d71\\u6574\\u5408\\u4e86\\u5408\\u898f\\u6027\\/\\u884c\\u70ba\\u6e96\\u5247\",\"\\u9055\\u53cd\\u898f\\u5b9a\\u7684\\u7d00\\u5f8b\\u8655\\u5206\\uff0c\\u5373\\u8b66\\u544a\\u3001\\u89e3\\u50f1\\u3001\\u96f6\\u5bb9\\u5fcd\\u653f\\u7b56\",\"\\u5408\\u898f\\u7cfb\\u7d71\\u7531\\u7b2c\\u4e09\\u65b9\\u8a8d\\u8b49\\/\\u5be9\\u6838\\/\\u9a57\\u8b49\\u3002 \\u8acb\\u67e5\\u770b\\u9644\\u52a0\\u8cc7\\u8a0a\\u548c\\u554f\\u984c\\u6307\\u5357\\u4ee5\\u4e86\\u89e3\\u66f4\\u591a\\u8a73\\u7d30\\u8cc7\\u8a0a\\u3002\"],\"last\":null}','1',2,1696999119,1696999709,'0'),(24743,202,2289,2,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24744,202,2290,1,'請說明過去 4 個會計年度中與反壟斷/反競爭行為相關的罰款和和解金額（不包括律師費）以及目前針對貴公司的待處理調查的數量。 對於過去的案例，如果您在某一年沒有受到任何罰款，請輸入「0」。\n\n過往案例','ColumnInput','0','罰款和和解 (USD)',NULL,'{\"rows\":[{\"title\":\"\\u7e3d\\u91d1\\u984d\"},{\"title\":\"\\u4f54\\u6536\\u5165\\u7684\\u767e\\u5206\\u6bd4\\uff08\\u5982\\u201c\\u5206\\u6bcd\\u201d\\u70ba\\u7e3d\\u91d1\\u984d\\uff09\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',3,1696999119,1696999709,'0'),(24745,202,2290,2,'正在進行的案件和或有負債\n貴公司目前是否參與任何與反競爭行為相關的持續調查？\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\u7684\\uff0c\\u6211\\u5011\\u76ee\\u524d\\u6b63\\u5728\\u63a5\\u53d7\\u8abf\\u67e5\\u3002\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u4e0d\\u53c3\\u8207\\u4efb\\u4f55\\u6b63\\u5728\\u9032\\u884c\\u7684\\u8207\\u53cd\\u7af6\\u722d\\u884c\\u70ba\\u76f8\\u95dc\\u7684\\u8abf\\u67e5\\u3002\"],\"last\":null}','1',2,1696999119,1696999709,'0'),(24746,202,2290,3,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24747,202,2291,1,'請說明過去四個會計年度經證實的腐敗和賄賂案件數量以及地方或國際當局正在進行的外部調查的數量。 對於過去的案例，如果您在某一年沒有遭受任何罰款和和解，請輸入「0」。 對於正在進行的案件，如果您沒有任何正在進行的外部調查，請選擇適當的「否」選項。\n\n過往案例','ColumnInput','0','腐敗和賄賂案件',NULL,'{\"rows\":[{\"title\":\"\\u5df2\\u8b49\\u5be6\\u7684\\u8150\\u6557\\u548c\\u8cc4\\u8cc2\\u6848\\u4ef6\\u7e3d\\u6578\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',3,1696999119,1696999709,'0'),(24748,202,2291,2,'正在進行的案例\n貴公司目前是否參與任何與腐敗和賄賂相關的持續外部調查？\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u662f\\u7684\\uff0c\\u6211\\u5011\\u76ee\\u524d\\u6b63\\u5728\\u9032\\u884c\\u91dd\\u5c0d\\u6211\\u5011\\u7684\\u8abf\\u67e5\\u3002 \\u4f50\\u8b49\\uff1a\",\"\\u4e0d\\uff0c\\u6211\\u5011\\u76ee\\u524d\\u6c92\\u6709\\u6d89\\u53ca\\u4efb\\u4f55\\u6b63\\u5728\\u9032\\u884c\\u7684\\u8150\\u6557\\u548c\\u8cc4\\u8cc2\\u6848\\u4ef6\\u3002\"],\"last\":null}','1',2,1696999119,1696999709,'0'),(24749,202,2291,3,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24750,202,2292,1,'2022 年和 2023 年是否有違反行為/道德準則的情況（例如違規數量、案例等）？\n請選擇領域數量（例如隱私、賄賂、歧視）以及發生的資訊類型：\n','ChoiceOne','0','',NULL,'{\"values\":[\"\\u4e00\\u7a2e\\u9818\\u57df\\/\\u6c92\\u6709\\u8a73\\u7d30\\u62c6\\u5206\",\"\\u5169\\u500b\\/\\u4e09\\u500b\\u9818\\u57df\",\"\\u4e09\\u500b\\u4ee5\\u4e0a\\u9818\\u57df\",\"\\u8209\\u5831\\u7e3d\\u6578 caat \\u8209\\u5831\\u7684\\u9055\\u898f\\u60c5\\u6cc1\\/\\u9032\\u5c55\\uff08\\u5df2\\u8b49\\u5be6\\u7684\\u6848\\u4ef6\\u6578\\u91cf\\uff0c\\u6216\\u6b63\\u5728\\u8abf\\u67e5\\u7684\\u6848\\u4ef6\\u6578\\u91cf\\u7b49\\uff09 \",\"\\u7121\\u4efb\\u4f55\\u9055\\u53cd\\u884c\\u70ba\\/\\u9053\\u5fb7\\u6e96\\u5247\\u7684\\u60c5\\u6cc1\"],\"last\":null}','1',3,1696999119,1696999709,'0'),(24751,202,2292,2,'請描述已確認的案件所採取行動的詳情','TextLong','0','',NULL,'[]','1',2,1696999119,1696999709,'0'),(24752,202,2292,3,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24753,202,2293,1,'貴公司在過去四個會計年度（2020-2023 年）是否因監管機構對生產工廠進行檢查而受到監管機構的檢查和/或收到任何FDA 483 表格通知或FDA 警告信（或其他機構的同等通知）？\n','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u662f\\u7684\\uff0c\\u6211\\u5011\\u5728\\u904e\\u53bb\\u56db\\u5e74\\u4e2d\\u4e00\\u76f4\\u63a5\\u53d7\\u76e3\\u7ba1\\u6a5f\\u69cb\\u7684\\u6aa2\\u67e5\",\"\\u662f\\u7684\\uff0c\\u6211\\u5011\\u6536\\u5230\\u4e86 483 \\u89c0\\u5bdf\\u8868\\uff08\\u6216\\u540c\\u7b49\\u6587\\u4ef6\\uff09\",\"\\u662f\\u7684\\uff0c\\u6211\\u5011\\u6536\\u5230\\u4e86 FDA \\u8b66\\u544a\\u4fe1\\uff08\\u6216\\u540c\\u7b49\\u6587\\u4ef6\\uff09\",\"\\u6c92\\u6709\\uff0c\\u6211\\u5011\\u5728\\u904e\\u53bb\\u56db\\u5e74\\u4e2d\\u6c92\\u6709\\u6536\\u5230\\u4efb\\u4f55 483 \\u8868\\u683c\\uff08\\u6216\\u540c\\u7b49\\u8868\\u683c\\uff09\\u3001FDA \\u8b66\\u544a\\u4fe1\\u6216\\u53d7\\u5230\\u76e3\\u7ba1\\u6a5f\\u69cb\\u7684\\u4efb\\u4f55\\u6aa2\\u67e5\\u3002\"],\"last\":null}','1',5,1696999119,1696999709,'0'),(24754,202,2293,2,'監理機構檢查 (如有).','ColumnInput','0','是的，我們在過去四年中一直接受監管機構的檢查',NULL,'{\"rows\":[{\"title\":\"\\u6aa2\\u67e5\\u6b21\\u6578\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',4,1696999119,1696999709,'0'),(24755,202,2293,3,'483 表觀察結果\n請具體說明收到的警告類型、受影響設施產生的收入以及停產的財務影響。 如果您沒有任何 483 表格觀察結果，請在適當的層級選擇「否」。\n','ColumnInput','0',' 是的，我們收到了 483 觀察表（或同等文件）',NULL,'{\"rows\":[{\"title\":\"483 \\u8868\\u683c\\u89c0\\u5bdf\\u7d50\\u679c\\uff08\\u6216\\u540c\\u7b49\\u5167\\u5bb9\\uff09\\u7684\\u6578\\u91cf\"},{\"title\":\"\\u53d7\\u5f71\\u97ff\\u8a2d\\u65bd\\u7522\\u751f\\u7684\\u5e74\\u6536\\u5165\\u3002 \\u8acb\\u4ee5\\u767e\\u842c\\u7f8e\\u5143\\u70ba\\u55ae\\u4f4d\\u5831\\u544a\\u3002\"},{\"title\":\"\\u5e74\\u6536\\u5165\\u53d7\\u5230\\u505c\\u7522\\u7684\\u5f71\\u97ff\\u3002 \\u8acb\\u4ee5\\u767e\\u842c\\u7f8e\\u5143\\u70ba\\u55ae\\u4f4d\\u5831\\u544a\\u3002\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',3,1696999119,1696999709,'0'),(24756,202,2293,4,'FDA Warning Letters\n請具體說明收到的警告類型、受影響設施產生的收入以及停產的財務影響。 如果您沒有任何 FDA 警告信，請在適當的層級選擇「否」。','ColumnInput','0','是的，我們收到了 FDA 警告信（或同等文件）',NULL,'{\"rows\":[{\"title\":\"FDA \\u8b66\\u544a\\u4fe1\\uff08\\u6216\\u540c\\u7b49\\u6587\\u4ef6\\uff09\\u7684\\u6578\\u91cf\"},{\"title\":\"\\u53d7\\u5f71\\u97ff\\u8a2d\\u65bd\\u7522\\u751f\\u7684\\u5e74\\u6536\\u5165\\u3002 \\u8acb\\u4ee5\\u767e\\u842c\\u7f8e\\u5143\\u70ba\\u55ae\\u4f4d\\u5831\\u544a\\u3002\"},{\"title\":\"\\u5e74\\u6536\\u5165\\u53d7\\u5230\\u505c\\u7522\\u7684\\u5f71\\u97ff\\u3002 \\u8acb\\u4ee5\\u767e\\u842c\\u7f8e\\u5143\\u70ba\\u55ae\\u4f4d\\u5831\\u544a\\u3002\"}],\"cols\":[{\"title\":\"FY 2020\",\"type\":\"3\"},{\"type\":\"3\",\"title\":\"FY 2021\"},{\"type\":\"3\",\"title\":\"FY 2022\"},{\"type\":\"3\",\"title\":\"2023 YTD\"}]}','1',2,1696999119,1696999709,'0'),(24757,202,2293,5,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24758,202,2294,1,'1. 請說明貴公司之智慧財產管理方針','TextLong','0','',NULL,'[]','1',6,1696999119,1696999709,'0'),(24759,202,2294,2,'2. 請說明貴公司之智慧財產管理制度/系統','TextLong','0','例如：本公司設置專利管理委員會，透過評審機制、獎勵制度和宣導教育等執行層面的落實，鼓勵同仁踴躍參與發明事務，並保護公司研發成果；對於獲證專利，定期評估維護，使公司專利獲得有效管理和保護。',NULL,'[]','1',5,1696999119,1696999709,'0'),(24760,202,2294,3,'3.	請說明貴公司之專利保護措施','TextLong','0','',NULL,'[]','1',4,1696999119,1696999709,'0'),(24761,202,2294,4,'4. 2023年執行成果與具體作為？','TextLong','0','',NULL,'[]','1',3,1696999119,1696999709,'0'),(24762,202,2294,5,'5. 目前貴公司累計之智慧財產數量為？','TextLong','0','',NULL,'[]','1',2,1696999119,1696999709,'0'),(24763,202,2294,6,'6. 2023年是否有重大智慧財產違失事件？','TextLong','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24764,202,2295,1,'貴公司是否同意不對最不發達國家（LDCs，根據聯合國的定義）、低收入國家（LICs，根據定義）藥物近用指數（ATMI）範圍內用於治療疾病的產品申請或執行專利？由世界銀行定義）和中低收入國家（LMICs，由世界銀行定義）？','ChoiceOne','0','',NULL,'{\"values\":[\"\\u6211\\u5011\\u627f\\u8afe\\u4e0d\\u5c0d 2022\\u85e5\\u7269\\u8fd1\\u7528\\u7bc4\\u570d\\u5167\\u6240\\u6709\\u75be\\u75c5\\u7522\\u54c1\\u76f8\\u95dc\\u4e4b\\u6240\\u6709\\u667a\\u6167\\u8ca1\\u7522\\u6b0a\\u7533\\u8acb\\u5c08\\u5229\\u6216\\u5f37\\u5236\\u57f7\\u884c\\u5c08\\u5229\\u3002\\u8acb\\u6307\\u51fa\\u54ea\\u4e9b\\u5730\\u5340\\u5c6c\\u65bc\\u6b64\\u627f\\u8afe\\u4e26\\u63d0\\u4f9b\\u4f50\\u8b49\\u8cc7\\u6599\\uff1a\",\"\\u6211\\u5011\\u627f\\u8afe\\u4e0d\\u6703\\u70ba\\u9644\\u5c6c\\u7522\\u54c1\\u7533\\u8acb\\u667a\\u6167\\u8ca1\\u7522\\u6b0a\\u5c08\\u5229\\u6216\\u5f37\\u5236\\u57f7\\u884c\\u667a\\u6167\\u8ca1\\u7522\\u6b0a\\u5c08\\u5229\\u3002 \\u8acb\\u6307\\u51fa\\u54ea\\u4e9b\\u5730\\u5340\\u5c6c\\u65bc\\u6b64\\u627f\\u8afe\\u4e26\\u63d0\\u4f9b\\u652f\\u6301\\u8b49\\u64da\\uff1a\"],\"last\":null}','1',6,1696999119,1696999709,'0'),(24765,202,2295,2,'我們承諾不對 2022藥物近用範圍內所有疾病產品相關之所有智慧財產權申請專利或強制執行專利。請指出哪些地區屬於此承諾並提供佐證資料：','ChoiceOne','0','',NULL,'{\"values\":[\"\\u6700\\u4e0d\\u767c\\u9054\\u570b\\u5bb6\\u3001\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\\u53ca\\u4e2d\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\",\"\\u6700\\u4e0d\\u767c\\u9054\\u570b\\u5bb6\\u3001\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\\u548c\\u5927\\u591a\\u6578\\u4e2d\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\\u3002 *\",\"\\u6700\\u4e0d\\u767c\\u9054\\u570b\\u5bb6\\u6216\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\\uff0c\\u4f46\\u4e0d\\u5305\\u62ec\\u4e2d\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\"],\"last\":null}','1',5,1696999119,1696999709,'0'),(24766,202,2295,3,'*  請提供您保留專利執行權的中低收入國家名單:','TextLong','0','',NULL,'[]','1',4,1696999119,1696999709,'0'),(24767,202,2295,4,'我們承諾不會為附屬產品申請智慧財產權專利或強制執行智慧財產權專利。 ','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u6700\\u4e0d\\u767c\\u9054\\u570b\\u5bb6\\u548c\\u4f4e\\u6536\\u5165\\u570b\\u5bb6\\u3002\",\"\\u50c5\\u9650\\u67d0\\u4e9b\\u5730\\u5340\\u3002 \"],\"last\":null}','1',3,1696999119,1696999709,'0'),(24768,202,2295,5,'請備註您保留對哪些產品實施專利的權利：','TextLong','0','',NULL,'[]','1',2,1696999119,1696999709,'0'),(24769,202,2295,6,'請提供佐證文件：','UploadFile','0','',NULL,'[]','1',1,1696999119,1696999709,'0'),(24770,202,2296,1,'貴公司是否實施了公開的全球行銷和銷售實務代碼？ 請指出您的公開報告或公司網站上哪裡可以找到此資訊。','TextItem','0','',NULL,'[]','1',4,1696999119,1696999709,'0'),(24771,202,2296,2,'是的，我們有一個公開政策來承諾我們對道德行銷、廣告和銷售實踐的承諾。 該保單涵蓋/包含以下內容：','ChoiceMultiple','0','',NULL,'{\"values\":[\"\\u81f4\\u529b\\u65bc\\u63d0\\u4f9b\\u6709\\u95dc\\u6211\\u5011\\u516c\\u53f8\\u7522\\u54c1\\/\\u670d\\u52d9\\u7684\\u6e96\\u78ba\\u4e14\\u5e73\\u8861\\u7684\\u8a0a\\u606f\",\"\\u78ba\\u4fdd\\u8207\\u5ba2\\u6236\\u548c\\/\\u6216\\u91ab\\u7642\\u4fdd\\u5065\\u5c08\\u696d\\u4eba\\u54e1\\u7684\\u9053\\u5fb7\\u4e92\\u52d5\\u7684\\u898f\\u5b9a\"],\"last\":null}','1',3,1696999119,1696999709,'0'),(24772,202,2296,3,'請列出承諾並描述其內容。','TextLong','0','',NULL,'[]','1',2,1696999119,1696999709,'0'),